Evidence Report/Technology Assessment 

Number 125 

Manifestations and Management of Chronic Insomnia 

in Adults 

Prepared for: 

Agency for Healthcare Research and Quality 

U.S. Department of Health and Human Services 

540 Gaither Road 

Rockville, MD 20850 

www.ahrq.gov 

Contract No. C400000021

Prepared by: 

University of Alberta Evidence-based Practice Center 

Edmonton, Alberta, Canada 

Investigators: 

Nina Buscemi, PhD

Ben Vandermeer, MSc 

Carol Friesen, MA, MLIS 

Liza Bialy, BSc 

Michelle Tubman, BSc 

Maria Ospina, MSc 

Terry P. Klassen, MD, MSc, FRCPC 

Manisha Witmans, MD, FRCPC, Dip. ABSM 

AHRQ Publication No. 05-E021-2 

June 2005
This report may be used, in whole or in part, as the basis for development of clinical practice 

guidelines and other quality enhancement tools, or a basis for reimbursement and coverage 

policies. AHRQ or U.S. Department of Health and Human Services endorsement of such 

derivative products may not be stated or implied. 

AHRQ is the lead Federal agency charged with supporting research designed to improve the 

quality of health care, reduce its cost, address patient safety and medical errors, and broaden access 

to essential services. AHRQ sponsors and conducts research that provides evidence-based 

information on health care outcomes; quality; and cost, use, and access. The information helps 

health care decisionmakers—patients and clinicians, health system leaders, and policymakers—

make more informed decisions and improve the quality of health care services. 
ii

This document is in the public domain and may be used and reprinted without permission except 

those copyrighted materials noted for which further reproduction is prohibited without the 

specific permission of copyright holders. 

Suggested Citation: 

Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, Klassen TP, Witmans M. 

Manifestations and Management of Chronic Insomnia in Adults. Evidence Report/Technology 

Assessment No. 125. (Prepared by the University of Alberta Evidence-based Practice Center, 

under Contract No. C400000021.) AHRQ Publication No. 05-E021-2. Rockville, MD: Agency 

for Healthcare Research and Quality. June 2005. 
iii

Preface 

 The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-Based 

Practice Centers (EPCs), sponsors the development of evidence reports and technology 

assessments to assist public- and private-sector organizations in their efforts to improve the 

quality of health care in the United States. This report was requested and funded by the Office of 

Medical Applications of Research (OMAR), National Institutes of Health (NIH). The reports and 

assessments provide organizations with comprehensive, science-based information on common, 

costly medical conditions and new health care technologies. The EPCs systematically review the 

relevant scientific literature on topics assigned to them by AHRQ and conduct additional 

analyses when appropriate prior to developing their reports and assessments. 

 To bring the broadest range of experts into the development of evidence reports and health 

technology assessments, AHRQ encourages the EPCs to form partnerships and enter into 

collaborations with other medical and research organizations. The EPCs work with these partner 

organizations to ensure that the evidence reports and technology assessments they produce will 

become building blocks for health care quality improvement projects throughout the Nation. The 

reports undergo peer review prior to their release. 

 AHRQ expects that the EPC evidence reports and technology assessments will inform 

individual health plans, providers, and purchasers as well as the health care system as a whole by 

providing important information to help improve health care quality. 

 We welcome comments on this evidence report. They may be sent by mail to the Task Order 

Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, 

Rockville, MD 20850, or by email to epc@ahrq.gov. 

Carolyn M. Clancy, M.D. Jean Slutsky, P.A., M.S.P.H. 

Director Director, Center for Outcomes and Evidence 

Agency for Healthcare Research and Quality Agency for Healthcare Research and Quality 

The authors of this report are responsible for its content. Statements in the report should 

not be construed as endorsement by the Agency for Healthcare Research and Quality or the 

U.S. Department of Health and Human Services of a particular drug, device, test, treatment, 

or other clinical service. 

Ernestine W. Murray, B.S.N., R.N., M.A.S. 

EPC Program Task Order Officer 

Agency for Healthcare Research and Quality 

Kenneth S. Fink, M.D., M.G.A., M.P.H. 

Director, EPC Program 

Agency for Healthcare Research and Quality 

Barnett S. Kramer, M.P.H., M.D. 

Director 

Office of Medical Applications of Research
iv

Acknowledgments 

We are grateful to members of the technical expert panel for providing input on the direction 

of the review. The members of the panel include J. Todd Arnedt, Ph.D., Richard Bootzin, Ph.D., 

Irvin Mayers, M.D., Parameswaran Nair, M.D., Ph.D., Larry Pawluk, M.D., and Arthur 

Spielman, Ph.D. 

We thank the NIH Office of Medical Applications of Research for their support of this work. 

We are grateful to the Agency for Healthcare Research and Quality for granting the contract for 

this work and the Task Order Officer, CAPT Tina Murray, for facilitating the process. We also 

thank Alan I. Leshner, Ph.D., for his input on the direction of the review and for chairing the preconference panel meeting for the State-of-the-Science Conference on the “Manifestations and 

Management of Chronic Insomnia in Adults.” 
v

Structured Abstract 

Context: Approximately 40 to 70 million Americans are affected by either intermittent or 

chronic sleep problems, representing approximately 20 percent of the population. 

 

Objectives: To conduct a systematic review of (1) the prevalence, natural history, incidence, 

risk factors and consequences of chronic insomnia in adults and (2) the efficacy and safety of 

treatments used in the management of chronic insomnia in adults.

Data Sources: A systematic search of twenty-one electronic databases was conducted. We 

searched MEDLINE®, EMBASE, CINAHL®, Ovid MEDLINE In-Process & Other Non-Indexed 

Citations, Ovid OLDMEDLINE®, PsycINFO®, EBM Reviews-Cochrane Central Register of 

Controlled Trials, International Pharmaceutical Abstracts, AMED (Allied and Complementary 

Medicine), HealthSTAR/Ovid Healthstar, EBM Reviews-Cochrane Database of Systematic 

Reviews (CDSR), ACP Journal Club (ACPJC), Database of Abstracts of Reviews of Effects 

(DARE), Science Citation Index ExpandedTM, Biological Abstracts, Cochrane Complementary 

Medicine Field Registry, CAB Abstracts, SIGLE, OCLC Proceedings First, Dissertation 

Abstracts, Alt HealthWatch, NLM Gateway and PubMed®. 

Study Selection: Cohort, case-control and cross-sectional studies were eligible for questions on 

manifestations of chronic insomnia. Randomized controlled trials were eligible for the question 

on management of chronic insomnia. 

 

Quality Assessment: One of three instruments was used to assess the quality of studies relevant 

to the manifestations of chronic insomnia. The Jadad Scale was used to assess the quality of 

studies relevant to the management of chronic insomnia. The concealment of treatment 

allocation was also assessed in the latter studies. 

 

Data Analysis: Data were analyzed both qualitatively and quantitatively. The Random Effects 

Model was used for quantitative analyses. 

Main Results: The interquartile range of prevalence of chronic insomnia varied from 8.5-24.3 

percent across high quality studies of general populations, to 19.8-53.7 percent across moderate 

quality studies of outpatient populations, to 27.8-43.0 percent across moderate quality studies of 

clinical populations. Sleep onset latency (SOL) was significantly decreased by benzodiazepines 

(Mean Difference (MD): -16.5, 95% Confidence Interval (CI): [-20.5, -12.5]), nonbenzodiazepines (MD: -18.1, 95% CI: [-22.5, -13.7]), antidepressants (MD: -7.4, 95% CI: [-10.5, 

-4.4]) and melatonin (MD: -8.3, 95% CI: [-14.5, -2.0]). All of the preceding interventions, 

except melatonin, had a significantly higher risk of harm compared to placebo: benzodiazepines 

(Risk Difference [RD]: 0.15, 95% CI: [0.10, 0.20]), non-benzodiazepines (RD 0.05, 95% CI: 

[0.01, 0.09]), antidepressants (RD: 0.09, 95% CI: [0.01, 0.18]) and melatonin (RD: 0.09, 95% 

CI: [-0.11, 0.29]). Wakefulness after sleep onset (WASO) was not significantly reduced by 

melatonin (MD: -9.7, 95% CI: [-33.6, 14.3]). SOL was significantly decreased by relaxation 

therapy with short-term treatment (less than 4 weeks) (MD: -22.0, 95% CI: [-41.0, -2.9]); 

however, WASO was not significantly reduced by relaxation therapy (MD: -1.6, 95% CI: [-14.1, 
vi

10.8]). WASO was significantly decreased by cognitive/behavioral therapy (MD: -18.2, 95% CI: 

[-30.4, -6.0]); however, SOL was not significantly reduced by cognitive/behavioral therapy (MD: 

-4.6, 95% CI: -9.8, 0.6). 

Main Conclusions 

• There is evidence that chronic insomnia is associated with older age, female gender, present 

or past psychiatric illness and psychological problems, medical conditions and poor general 

health, increased healthcare utilization, lower quality of life and social relationships, 

socioeconomic status (marital separation, unemployment, poorer working conditions and 

lower social status), and decrements in memory, mood and cognitive function. 

• There is evidence that benzodiazepines and non-benzodiazepines are effective in the 

management of chronic insomnia. There is some evidence that antidepressants are effective 

in the management of chronic insomnia: more research is required in this area. There is 

evidence that benzodiazepines, non-benzodiazepines and antidepressants pose a risk of harm. 

• There is some evidence that melatonin is effective in the management of chronic insomnia in 

subsets of the chronic insomnia population, and there is no evidence that melatonin poses a 

risk of harm. However, more research is required in this area, given that the results are based 

on a small number of studies. 

• There is evidence that relaxation therapy and cognitive/behavioral therapy are effective in the 

management of chronic insomnia in subsets of the chronic insomnia population. 

• There is evidence that benzodiazepines have a greater risk of harm than nonbenzodiazepines. 
Contents 

Evidence Report.............................................................................................................................1 

Chapter 1. Introduction ...................................................................................................................3 

Prevalence of Insomnia....................................................................................................................3 

Risk Factors for Insomnia................................................................................................................3 

Consequences of Insomnia ..............................................................................................................4 

Management of Insomnia ................................................................................................................4 

Objectives ........................................................................................................................................6 

Analytic Approach...........................................................................................................................6 

Etiology and Population at Risk ..................................................................................................6 

Consequences, Morbidities, Co-morbidities, and Public Health Burden ....................................6 

Treatment .....................................................................................................................................7 

Future Direction...........................................................................................................................7 

Chapter 2. Methods.........................................................................................................................9 

Overview..........................................................................................................................................9 

Literature Search..........................................................................................................................9 

Development of Inclusion Criteria.............................................................................................10 

Study Selection ..........................................................................................................................12 

Assessment of Study Quality.....................................................................................................13 

Data Extraction ..........................................................................................................................13 

Data Analysis.............................................................................................................................14 

Chapter 3. Results.........................................................................................................................19 

Literature Review...........................................................................................................................19 

Data Synthesis................................................................................................................................19 

How is chronic insomnia defined, diagnosed and classified, and what is known about its 

etiology?.....................................................................................................................................19 

What are the prevalence, natural history, incidence and risk factors for chronic insomnia? ....24 

What are the consequences, morbidities, co-morbidities and public health burden associated 

with chronic insomnia? ..............................................................................................................24 

What treatments are used for the management of chronic insomnia in adults and what is the 

evidence regarding their safety, efficacy and effectiveness?.....................................................28 

What are the important future directions for insomnia-related research?..................................39 

Chapter 4. Discussion .................................................................................................................115 

Prevalence, Natural History, Incidence and Factors Associated with Chronic Insomnia .......115 

Efficacy and Safety of Treatments for Chronic Insomnia .......................................................116 

Limitations of the Review and Future Research......................................................................120 

Conclusions..............................................................................................................................121 

References and Included Studies.................................................................................................123 

References................................................................................................................................123 

Included Studies.......................................................................................................................127 

vii
viii

Flow Diagrams 

Flow Diagram 1. Analytic framework............................................................................................8 

Flow Diagram 2. Study retrieval and selection.............................................................................40 

Tables 

Table 1. Databases searched .......................................................................................................17 

Table 2. Subject headings and keywords used in searches.........................................................18 

Table 3a. Prevalence of chronic insomnia in adults: general population .....................................41 

Table 3b. Prevalence of chronic insomnia in adults: outpatients of general practice...................47 

Table 4. Natural history of chronic insomnia in adults...............................................................51 

Table 5. Factors associated with chronic insomnia in adults......................................................52 

Table 6. Sleep onset latency: benzodiazepines versus placebo ..................................................68 

Table 7. Other outcomes: benzodiazepines versus placebo........................................................70 

Table 8. Sleep onset latency: non-benzodiazepines versus placebo...........................................71 

Table 9. Other outcomes: non-benzodiazepines versus placebo ................................................72 

Table 10. Sleep onset latency: antidepressants versus placebo ....................................................73 

Table 11. Other outcomes: antidepressants versus placebo..........................................................74 

Table 12. All outcomes: L-trytophan versus placebo ...................................................................75 

Table 13. All outcomes: melatonin versus placebo ......................................................................76 

Table 14. All outcomes: valerian versus placebo .........................................................................77 

Table 15. Sleep onset latency: relaxation therapy versus placebo................................................78 

Table 17. Sleep onset latency: cognitive/behavioral therapy versus placebo...............................80 

Table 18. Other outcomes: cognitive/behavioral therapy versus placebo ....................................81 

Table 19. Sleep onset latency: indirect comparisons of main pharmacological treatment 

 categories ..............................................................................................................................82 

Table 20. Adverse events: indirect comparisons of main pharmacological treatment categories83 

Table 21. All outcomes: barbiturates versus placebo ...................................................................84 

Table 22. All outcomes: hormones versus placebo ......................................................................85 

Table 23. All outcomes: alcohol versus placebo ..........................................................................86 

Table 24. All outcomes: low energy emission therapy versus placebo ........................................87 

Table 25. All outcomes: relaxation therapy and cognitive/behavioral therapy versus placebo....88 

Table 26. All outcomes: relaxation therapy and cognitive/behavioral therapy versus relaxation 

 therapy...................................................................................................................................89 

Table 27. All outcomes: relaxation therapy and cognitive/behavioral therapy versus 

 cognitive/behavioral therapy.................................................................................................90 

Table 28. All outcomes: relaxation therapy and cognitive/behavioral therapy versus 

benzodiazepines .............................................................................................................................91 

Table 29. All outcomes: benzodiazepine and cognitive/behavioral therapy versus placebo........92 

Table 31. All outcomes: benzodiazepine and cognitive/behavioral therapy versus 

 cognitive/behavioral therapy.................................................................................................94 

Table 33. All outcomes: cognitive/behavioral therapy and modafinil versus cognitive/behavioral 

 therapy...................................................................................................................................96 

Table 34. All outcomes: cognitive/behavioral therapy and modafinil versus modafinil..............97 
ix

Figures 

Figure 1. Meta graph: Sleep onset latency: benzodiazepines versus placebo...............................98 

Figure 2. Funnel Plot: Sleep onset latency: benzodiazepines versus placebo ..............................99 

Figure 3. Meta graph: Wakefulness After Sleep Onset: benzodiazepines versus placebo .........100 

Figure 4. Meta graph: Sleep Onset Latency: non-benzodiazepines versus placebo...................101 

Figure 5. Funnel Plot: Sleep Onset Latency: non-benzodiazepines versus placebo...................102 

Figure 6. Meta graph: Wakefulness After Sleep Onset: non-benzodiazepines versus placebo..103 

Figure 7. Meta graph: Sleep Onset Latency: antidepressants versus placebo ............................104 

Figure 8. Meta graph: Wakefulness After Sleep Onset: antidepressants versus placebo ...........105 

Figure 9. Meta graph: Sleep Onset Latency: complementary and alternative care 

 versus placebo..................................................................................................................106 

Figure 10. Funnel Plot: Sleep Onset Latency: melatonin versus placebo...................................107 

Figure 11. Meta graph: Wakefulness After Sleep Onset: complementary and alternative care 

 versus placebo....................................................................................................................108 

Figure 11. Meta graph: Wakefulness After Sleep Onset: complementary and alternative care 

 versus placebo....................................................................................................................108 

Figure 12. Meta graph: Sleep Onset Latency: relaxation therapy versus placebo......................109 

Figure 13. Funnel Plot: Sleep Onset Latency: relaxation therapy versus placebo......................110 

Figure 14. Meta graph: Wakefulness After Sleep Onset: relaxation therapy versus placebo.....111 

Figure 15. Meta graph: Sleep Onset Latency: cognitive/behavioral therapy versus placebo.....112 

Figure 16. Funnel Plot: Sleep Onset Latency: cognitive/behavioral therapy versus placebo.....113 

Figure 17. Meta graph: Wakefulness After Sleep Onset: cognitive/behavioral therapy versus 

 placebo ...............................................................................................................................114 

Appendices 

Appendix A: Exact Search Strings 

Appendix B: Data Extraction and Quality Assessment Forms 

Appendix C: Evidence Tables 

Appendix D: Technical Expert Panel 

Appendix E: Excluded Studies 

The Appendices and Evidence Tables cited in this report are provided electronically at 

http://www.ahrq.gov/clinic/tp/insomntp.htm
Prevalence of Insomnia

Insomnia, or inability to sleep, is the most

commonly reported sleep problem in the

industrialized world.1 Estimates suggest that

between 40 and 70 million Americans are

affected by either intermittent or chronic sleep

problems, representing approximately 20 percent

of the population.2 The Sleep in America Poll,

conducted by the National Sleep Foundation,

revealed that almost 50 percent of people

surveyed had complaints of frequent insomnia,

but only 6 percent were formally diagnosed.3

Moreover, approximately, 30 to 35 percent of

respondents complained of nightly insomnia.3

The most prevalent symptoms of insomnia,

experienced at least a few nights a week by

people with insomnia, include waking up feeling

unrefreshed (34 percent) and being awake often

during the night (32 percent).3 The symptoms

of difficulty falling asleep and waking up too

early are less common, but still experienced at

least a few nights a week by about one-fourth of

adults with insomnia (23 to 24 percent).3

Risk Factors for Insomnia

Although some risk factors and etiologies of

insomnia have been identified, the nature of the

relationships has not been fully elucidated. Some

risk factors for insomnia that have emerged from

data related to insomnia include female gender3

and old age.4 Additional risks factors include less

education, unemployment, separation or divorce,

and medical illness.1 Insomnia may be primary

or secondary to other sleep problems and may be

associated with a number of co-morbidities. An

association has been found between insomnia

and psychiatric (depression and anxiety) and

psychological disorders.4 There is increasing

evidence that chronic insomnia may predispose

individuals to the development of psychiatric

disorders.5-6 Persistent insomnia increases the risk

of depression, substance abuse, and anxiety

disorders. Environmental factors such as

irregular sleep schedules, use of caffeine or other

stimulants, co-morbid medical conditions,

and/or shift work may also predispose vulnerable

individuals to insomnia. 

Consequences of Insomnia

Insomnia has significant direct and indirect

effects on the health and wellness of affected

individuals. Insomnia has been correlated with

frequent use of medical services,7-8 chronic health

problems, 9-10 increased drug use,7-8 and perceived

poor health,11 and has been associated with

medical problems including heart disease,12

hypertension,13 and musculoskeletal problems.12

The daytime consequences of chronic insomnia

often include increased healthcare utilization,

increased risk of depression,14 poor memory,

reduced concentration, poor work performance,

and perceived or real risk of failure at work.15

The economic implications of insomnia and

Evidence Report/Technology Assessment

Number 125

Manifestations and Management of Chronic

Insomnia in Adults

Summary

Authors: Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, 

Klassen TP, Witmans M

Agency for Healthcare Research and Quality

Advancing Excellence in Health Care • www.ahrq.gov

Agency for Healthcare Research and Quality Evidence-Based

Practice
2

associated morbidity have been described.7,3 The direct costs of

insomnia (insomnia treatments, healthcare services, hospital

and nursing home care) are estimated to be nearly $14

billion.16-17 The indirect costs of insomnia, such as time lost

from work and loss of productivity, are estimated to be nearly

$28 billion. A National Sleep Foundation survey found that

lost productivity from insomnia alone was over $18 billion. 

Management of Insomnia

Management of acute insomnia has traditionally involved

pharmacotherapy. The use of such agents is common practice

for both acute and chronic insomnia, despite the fact that the

Food and Drug Administration (FDA) has approved none of

them for chronic insomnia. Another medication, eszopiclone

(Lunesta), was recently approved by the FDA for treatment of

insomnia, but the duration of use is not explicitly stated. An

estimated 0.5 percent of the population takes sedative

medications for insomnia for more than 1 year.3 More than 1

in 10 people (11 percent) report using prescription (6 percent)

and/or over-the-counter (OTC) medications (6 percent), at

least a few nights a month, to help them sleep, according to a

Sleep in America Poll.3 Individuals reporting symptoms of

medical conditions are more likely to take sleep aids, both

prescription and OTC medications. For example, 14 percent

of people with symptoms of depression report using

prescription medication, and 12 percent of people with

symptoms of depression report using OTC sleep aids.3

Medications commonly used to treat insomnia include

sedating antidepressants,18 antihistamines, anticholinergics,

benzodiazepines, and non-benzodiazepine hypnotics. A side

effect of all hypnotics is to reduce slow wave sleep. Other side

effects of concern are possible daytime residual effects related

to sedation, rebound insomnia, and tolerance, along with

minor side effects specific to each drug class. Many questions

and challenges related to pharmacological therapy for chronic

insomnia remains, such as the appropriate treatment for

different types of primary and secondary insomnia, and the

long-term side effects and daytime consequences of

pharmacotherapy. The evidence for management of chronic

insomnia with pharmacotherapy has not been systematically

evaluated. 

Cognitive/behavioral therapy has been recognized as a valid

and successful treatment approach for insomnia. Cognitive/

behavioral therapy can include any combination of sleep

restriction, sleep hygiene, stimulus control, paradoxical

intention, and cognitive restructuring. Many of these

commonly used clinical tools have not undergone rigorous

testing to determine their efficacy and long-term safety. The

efficacy of these treatments has been evaluated in some

studies,4,19 but differences in the definition of insomnia and

outcome measures make it difficult to compare study results. 

In summary, insomnia is a common complaint with

significant consequences. Significant advancements have been

made in sleep research over the past three decades, yet many

questions related to the treatment of chronic insomnia remain.

Our goal was to review the evidence and state of research in

the area of chronic insomnia.

Objectives

The objectives of this report are to conduct a systematic

review of (1) the prevalence, natural history, incidence, risk

factors, and consequences of chronic insomnia in adults and

(2) the efficacy and safety of treatments used in the

management of chronic insomnia in adults. A population was

considered to suffer from chronic insomnia if the sleep

disturbance persisted for at least 4 weeks, regardless of severity

of symptoms. 

Methods

Literature Search

The research librarian, in collaboration with the TEP

(Technical Expert Panel), developed and implemented search

strategies designed to identify relevant evidence for key

questions of the review. A systematic search of 21 electronic

databases was conducted. We searched MEDLINE®,

EMBASE, CINAHL®, Ovid MEDLINE® In-Process &

Other Non-Indexed Citations, Ovid OLDMEDLINE®,

PsycINFO®, EBM Reviews-Cochrane Central Register of

Controlled Trials, International Pharmaceutical Abstracts,

AMED (Allied and Complementary Medicine) ,

HealthSTAR/Ovid Healthstar, EBM Reviews-Cochrane

Database of Systematic Reviews (CDSR), ACP Journal Club

(ACPJC), Database of Abstracts of Reviews of Effects

(DARE), Science Citation Index ExpandedTM, Biological

Abstracts, Cochrane Complementary Medicine Field Registry,

CAB Abstracts, SIGLE, OCLC Proceedings First, Dissertation

Abstracts, Alt HealthWatch, NLM Gateway, and PubMed®.

Most of the searches were limited to humans, and no age

restrictions were applied to any of the searches. 

For Question 1, which relates to the definition,

classification, diagnosis, and aetiology of chronic insomnia in

adults, we searched for narrative and systematic reviews, book
chapters, diagnostic manuals and standards of practice

parameters, and applied English-language restrictions. For

Question 2, which relates to the prevalence, natural history,

incidence, and risk factors for chronic insomnia in adults, and

Question 3, which relates to the consequences, morbidities,

co-morbidities and public health burden associated with

chronic insomnia in adults, we searched for observational

studies, encompassing a range of designs including crosssectional, case-control, and cohort studies, and applied

English-language restrictions. For Question 4, which relates to

the treatments for chronic insomnia in adults, and the

evidence regarding their safety, efficacy, and effectiveness, we

searched for randomized controlled trials, and no language

restrictions were applied. 

Inclusion Criteria

We did not develop formal inclusion criteria for the

question pertaining to the definition, classification, diagnosis,

and etiology of chronic insomnia (Question 1), nor for the

question pertaining to the future direction of insomnia-related

research (Question 5). The former question was answered by

providing an overview of the literature, and the latter question

was answered by assessing the limitations in the evidence for

the other questions of the review.

Inclusion criteria were developed for three questions of the

review (Questions 2-4). Question-specific inclusion criteria

appear below. In the interest of clarity, questions 2 and 3 will

be referred to as the questions on manifestations of chronic

insomnia, while question 4 will be referred to as the question

on management of chronic insomnia.

2. What are the prevalence, natural history, incidence,

and risk factors for chronic insomnia? Specific risk

factors of interest include age, gender, race/ethnicity,

psychiatric illness and psychological problems, medical

disease, socioeconomic status, and shift work.

A study was considered to be relevant to the portion of

Question 2 pertaining to the prevalence, natural history, and

incidence of chronic insomnia, if it met the following criteria:

• The report was written in English

• Participants were at least 15 years old

• It examined chronic insomnia

• It had a cross-sectional or cohort design

• It assessed the prevalence, natural history, or incidence

of chronic insomnia

A study was considered to be relevant to the portion of

Question 2 pertaining to risk factors for chronic insomnia, if it

met the first three criteria listed above as well as the following:

• It had a cohort, case-control, or cross-sectional design

• It assessed one of the risk factors of interest

3. What are the consequences, morbidities, comorbidities, and public health burden associated with

chronic insomnia? Specific outcomes of interest include

healthcare utilization, psychiatric illness, absenteeism,

work performance, accidents, falls in the elderly, quality

of life and social relationships, memory, cognitive

function, mood, and direct and indirect costs.

A study was considered to be relevant to this question of the

review, if it met the first three criteria outlined for Question 2 as

well as the following:

• It had a cohort or cross-sectional design

• It assessed one of the consequences of interest

For Questions 2 and 3, a study was considered to examine

chronic insomnia if this condition was defined as a sleep

disturbance of four weeks or more or the report explicitly

mentioned that chronic sleep disturbance was examined.

4. What treatments are used for the management of

chronic insomnia and what is the evidence regarding

their safety, efficacy, and effectiveness? Specific

treatments of interest include prescription medication,

over-the-counter medication, alcohol, behavioral therapy,

combination therapy, and complementary and alternative

care.

A study was considered to be relevant to this question of the

review, if it met the following criteria:

• The report was written in English

• Participants were at least 15 years old, and the

majority were at least 18 years old

• Participants suffered from chronic insomnia

• Participants were randomized to intervention or

placebo

• Participants and assessors were blind to treatment

received

• It assessed at least one of the following outcomes,

listed in order of importance in deriving conclusions

of the review:

• sleep onset latency

• wakefulness after sleep onset 

• sleep efficiency

• total sleep time

3
4

• sleep quality

• quality of life

Sleep onset latency was defined as the amount of time

between the participant laying down to sleep and the onset of

sleep; wakefulness after sleep onset was defined as the amount

of time spent awake in bed following the attainment of sleep;

sleep efficiency was defined as the amount of time spent asleep

as a percentage of the total time spent in bed; and total sleep

time was defined as the total time spent asleep while in bed.

Sleep onset latency and wakefulness after sleep onset were

given the highest priority in deriving conclusions from the

review, since they were considered the best indices of sleep

initiation and sleep maintenance, respectively. However,

subgroup analyses were conducted only on data relevant to

sleep onset latency, since this outcome was the most highly

reported outcome across studies.

If the majority of participants met one of the following

criteria, the study population was considered to suffer from

chronic insomnia:

• Participants suffered from a sleep disturbance of four

weeks or more.

• Participants were described as having a chronic/longstanding/persistent sleep disturbance.

• Participants were selected from a sleep disorders clinic.

In the case of combination therapy, the combined treatment

could be compared to either placebo or single treatment.

We acknowledged the fact that double-blinding is often not

feasible in studies of psychological treatments by not requiring

double-blinding in these studies for inclusion in the review.

The placebo treatment for relaxation therapy and cognitive/

behavioral therapy was minimal treatment, such as sleep

hygiene recommendations or minimal instruction. We

required that the placebo resemble the intervention of the

study except that it was known to produce either no effect or

only a minimal effect. 

Study Selection

In the first stage of study selection, two reviewers screened

the titles and abstracts of all potentially relevant articles,

independently. Each reviewer noted the titles and abstracts

that were potentially relevant to the review, and these articles

were retrieved. In the second stage of study selection, two

reviewers appraised the potentially relevant articles,

independently, using pre-determined, question-specific,

inclusion criteria. Disagreements between reviewers were

resolved by discussion and consensus. The rate of

disagreement between reviewers and the primary reason for

exclusion of potentially relevant articles were noted.

Data Extraction

Data relevant to study design, population, interventions,

and outcomes were extracted from studies, as appropriate,

using standardized data extraction forms. A trained reviewer

extracted relevant data, and a second reviewer verified the data

extracted for accuracy and completeness.

Assessment of Study Quality 

The quality of studies relevant to the questions on

manifestations of chronic insomnia was assessed using one of

three instruments; studies on prevalence and incidence were

assessed using a scale designed specifically for this purpose.20

All other studies relevant to manifestations of chronic

insomnia were assessed using one of two Newcastle-Ottawa

scales (unpublished), each scale specific to either cohort or

case-control studies.

The quality of studies relevant to management of chronic

insomnia was assessed using the Jadad scale.21 The

concealment of allocation of participants to treatment groups

was also assessed.22

Data Analysis

Data relevant to manifestations of chronic insomnia were

analyzed qualitatively, while data relevant to management of

chronic insomnia were analyzed quantitatively.

Manifestations of Chronic Insomnia

For the questions on prevalence, natural history, incidence,

risk factors, and consequences of chronic insomnia, data

relevant to each variable were analyzed separately, except for

data relevant to potential risk factors and potential

consequences of chronic insomnia, which were analyzed

together as associated factors of chronic insomnia. The data

were synthesized to provide a description of the methods and

results of the studies relevant to a given variable. 

Management of Chronic Insomnia

For continuous outcomes (e.g., sleep onset latency and sleep

efficiency), studies were combined using a mean difference

(MD), with the exception of sleep quality and quality of life,

where studies were combined using a standardized mean

difference (SMD). Dichotomous outcomes (i.e., safety

outcomes) were combined using a risk difference (RD). A
number needed to harm (NNH) was also reported for any

safety outcomes that were found to be statistically significant.

The Inverse Variance Method23 was used to weight the studies.

An efficacy estimate, with corresponding 95% confidence

interval, was computed for each outcome. All meta-analyses

were performed using a Random Effects Model.24

For some outcomes (sleep onset latency and number of

adverse events), treatment categories were compared indirectly,

via their relationship to placebo. Differences of differences

with 95% confidence intervals (CI) were computed. 

All estimates of efficacy were assessed for heterogeneity

using the I-squared statistic.25 For our primary outcome (sleep

onset latency), heterogeneity was explored in subgroup and

sensitivity analyses using a number of variables (treatment,

presence/absence of psychiatric illness, length of treatment,

age, gender and study quality). Deeks’ chi-square statistic26

was used to test for significant heterogeneity reduction in

partitioned subgroups.

We tested for publication bias visually using the Funnel

Plot27 and quantitatively using the Rank Correlation Test,28 the

Graphical Test,29 and the Trim and Fill Method.30

Main Results

Prevalence of Chronic Insomnia

In general populations: Interquartile Range (IQR): 8.5-

24.3 percent. There was evidence of an association between

female gender and chronic insomnia.

• In clinical populations: IQR: 27.8-43.0 percent.

• In outpatients of general practice: IQR: 19.8-53.7

percent.

• The majority of studies were either of moderate or high

quality.

Natural History of Chronic Insomnia

• Only one study provided evidence on natural history of

chronic insomnia: the remission rate was 13.1 percent

after a 4-month followup period in a population suffering

from insomnia for 1 month or more.

• The study was of moderate quality.

Incidence of Chronic Insomnia

• No studies were identified that provided evidence on

incidence of chronic insomnia.

Factors Associated with Chronic

Insomnia

Potential Risk Factors

• Age. Eleven studies found evidence of an association

between age and chronic insomnia, whereas seven studies

found no evidence of an association between these

variables. Of the studies that found an association, all,

except one,31 found evidence that chronic insomnia is

associated with older age. 

• Gender. Eleven studies found evidence of an association

between gender and chronic insomnia, while seven

studies found no evidence of an association between these

variables. All of the studies that found evidence of an

association between gender and chronic insomnia, found

evidence that chronic insomnia is associated with female

gender.

• Race/ethnicity. Two studies found evidence of an

association between ethnicity and chronic insomnia,32-33

while one study found no evidence of an association

between these variables.34 Bixler et al. found evidence

that chronic insomnia is associated with being a nonCaucasian minority, and Riedel et al. found evidence that

chronic insomnia is associated with being White.

• Psychiatric illness and psychological problems. Thirtyeight studies found evidence of an association between

present or past psychiatric illness or psychological

problems and chronic insomnia. Seven studies did not

find evidence of an association between these variables. 

• Medical conditions. Twelve studies found evidence of an

association between medical conditions or poor general

health and chronic insomnia, while one study35 did not

find evidence of an association between these variables. 

• Socioeconomic status. Six studies found evidence of an

association between socioeconomic status and chronic

insomnia. Nine studies did not find evidence of an

association between these variables. 

• Shift work. Only 2 studies provided evidence regarding

the relationship between shift-work and chronic

insomnia.31,36 The study by Kageyama et al. provided

evidence that chronic insomnia is associated with three or

less night shifts per month within the preceding three

months in hospital nurses. The study by Martikainen et

al. found no evidence of an association between shift

work and chronic insomnia.

5
Potential Consequences

• Healthcare utilization. Five studies provided evidence of

an association between increased healthcare utilization

and chronic insomnia. One study did not find evidence

of an association between chronic insomnia and

undergoing medical treatment in hospital nurses.31

• Absenteeism and work performance. Only two studies

provided evidence regarding the relationship between

work performance or absenteeism and chronic

insomnia;37-38 both studies found evidence of an

association between chronic insomnia and absenteeism.

The study by Zammit et al. also found evidence of an

association between chronic insomnia and impaired work

performance.

• Quality of life and quality of social relationships. Five

studies examined the relationship between either quality

of life (from a global perspective) or quality of social

relationships and chronic insomnia. All studies found

evidence of an association between chronic insomnia and

either lower quality of life or lower quality of social

relationships; one of these studies found evidence that

both quality of life and quality of social relationships are

impaired in chronic insomniacs.39

• Memory, cognitive function, and mood. Fifteen studies

found evidence of an association between decrements in

memory, mood or cognitive function and chronic

insomnia. One study40 found evidence of increased recall

of presentations made just before sleep onset in chronic

insomniacs. Eleven studies found no evidence of an

association between mood, memory, or cognitive function

and chronic insomnia. 

We did not identify any studies that provided data relevant

to the relationship between accidents or falls in the elderly and

chronic insomnia or direct and indirect costs of the disorder.

The majority of studies were of either moderate or high

quality.

Efficacy and Safety of the Six Main

Categories of Interventions Identified in

the Literature

The efficacy estimates are provided as mean differences

(MDs) in the effect of intervention and placebo on sleep onset

latency (SOL) or wakefulness after sleep onset (WASO). The

safety estimates are provided as risk differences (RDs) between

intervention and placebo.

• Benzodiazepines. MD (SOL): -16.5, 95% CI: (-20.5, -

12.5); MD (WASO): -23.1, 95% CI: (-35.7, -10.5); RD:

0.15, 95% CI: (0.10, 0.20); number needed to harm was

eight.

• Non-benzodiazepines. MD (SOL): -18.1, 95% CI: (-

22.5, -13.7); MD (WASO): -12.6, 95% CI: (-23.0, -2.3);

RD: 0.05, 95% CI: (0.01, 0.09); number needed to

harm was 20.

• Antidepressants. MD (SOL): -7.4, 95% CI (-10.5, -4.4);

MD (WASO): -11.4, 95% CI: (-16.2, -6.6); RD: 0.09,

95% CI (0.01, 0.18); number needed to harm was 12.

• L-Tryptophan. MD (SOL): -11.0, 95% CI: (-33.0,

11.1)

• Melatonin. MD (SOL): -8.3, 95% CI: (-14.5, -2.0);

MD (WASO): -9.7, 95% CI: (-33.6, 14.3); RD: 0.09,

95% CI: (-0.11, 0.29)

• Valerian. MD (SOL): -1.3, 95% CI: (-21.4, 18.9); MD

(WASO): -8.4, 95% CI: (-15.9, -1.0); RD: -0.06, 95%

CI: (-0.48, 0.35) 

• Relaxation therapy. MD (SOL): -14.6, 95% CI: (-29.3,

0.2); MD (WASO): -1.6, 95% CI: (-14.1, 10.8). No

adverse event data was provided.

• Cognitive/behavioral therapy. MD (SOL): -4.6, 95%

CI: (-9.8, 0.6); MD (WASO): -18.2, 95% CI: (-30.4, -

6.0). No adverse event data was provided.

Most studies were of moderate or high quality.

Discussion

Prevalence, Natural History, Incidence, and

Factors Associated with Chronic Insomnia

The interquartile range of prevalence varied from 8.5-24.3

percent across high-quality studies of general populations, to

19.8-53.7 percent across moderate-quality studies of

outpatient populations, to 27.8-43.0 percent across moderatequality studies of clinical populations. Therefore, the

prevalence estimates for chronic insomnia in outpatient and

clinical populations appear to be significantly higher than

those for the general population, a finding that is consistent

with evidence of an association between chronic insomnia and

6
medical conditions, poor general health, and increased

healthcare utilization. 

Only one study provided data on the natural history of

chronic insomnia; the remission rate was 13.1 percent after a

4-month followup. More research is necessary to determine

the course of chronic insomnia in various populations. We did

not identify any studies that provided evidence regarding the

incidence of chronic insomnia; more research is needed in this

area as well.

We found evidence to suggest that chronic insomnia is

associated with older age, female gender, present or past

psychiatric illness and psychological problems, medical

conditions and poor general health, increased healthcare

utilization, lower quality of life and social relationships,

socioeconomic status (marital separation, unemployment,

poorer working conditions, and lower social status), and

decrements in memory, mood, and cognitive function. Some

of the factors that are thought to contribute to insomnia in the

elderly include multiple medical problems, polypharmacy, and

environmental factors such as absence of zeitgebers

(time/schedule cues).11,41 Similarly, factors such as stress,

pregnancy, menopause, medical conditions, and complex

home life may explain the higher prevalence of insomnia in

females. 

Efficacy and Safety of Treatments for

Chronic Insomnia

The interventions for chronic insomnia that were

investigated in included studies may be categorized as either

benzodiazepines, non-benzodiazepines, antidepressants,

complementary and alternative care (L-tryptophan, melatonin

and valerian), relaxation therapy, cognitive/behavioral therapy,

barbiturates, hormone therapy, alcohol, low energy emission

therapy, and combination therapy. The majority of studies

were classified under the first six categories of the preceding

list. 

The review provides evidence that benzodiazepines and

non-benzodiazepines are effective treatments for chronic

insomnia. There is some evidence that antidepressants are

effective treatments for chronic insomnia, although more

research is required in this area. The review provides some

evidence that melatonin is effective in subsets of the chronic

insomnia population; however, more research is required in

this area. There is also evidence that relaxation therapy and

cognitive/behavioral therapy are effective treatments in subsets

of the chronic insomnia population. There were too few

studies of L-tryptophan and valerian to draw conclusions

regarding the efficacy of these treatments in the management

of chronic insomnia: additional large-scale, randomized trials

are needed. Additional large-scale, randomized trials are also

needed in the area of relaxation therapy and cognitive/

behavioral therapy in the management of chronic insomnia to

determine the efficacy of these interventions across subsets of

the chronic insomnia population. The reduction in sleep

onset latency by benzodiazepines and non-benzodiazepines was

significantly greater than that for antidepressants and

melatonin, based on indirect comparisons. However, it should

be noted that there were significantly fewer studies of

antidepressants and melatonin compared to benzodiazepines

and non-benzodiazepines, and additional large-scale,

randomized trials of the former interventions are needed

before firm conclusions can be drawn regarding the relative

efficacy of these interventions. 

The benzodiazepines, non-benzodiazepines, and

antidepressants had a significantly greater risk of harm than

placebo, while melatonin did not. There were too few studies

of L-tryptophan to draw conclusions regarding the safety of

this intervention. Although there was no evidence that

valerian poses a risk of harm, this result was based on only

three studies of relatively small sample size. Therefore, more

studies are needed before firm conclusions can be drawn

regarding the safety of valerian. The risk for benzodiazepines

was significantly greater than for non-benzodiazepines, based

on indirect comparisons. Indeed, benzodiazepine use has been

shown to increase the risk of injury in the elderly,42 and there is

pharmacologic evidence that the non-benzodiazepines have a

better side-effect profile than the benzodiazepines.43-44 Studies

of relaxation therapy and cognitive/behavioral therapy did not

provide adverse event data. 

There was substantial heterogeneity in the pooled estimate

for SOL for benzodiazepines, non-benzodiazepines, Ltryptophan, valerian, and relaxation therapy. Similarly, there

was substantial heterogeneity in the pooled estimate for

WASO for benzodiazepines, non-benzodiazepines, melatonin,

and cognitive/behavioral therapy. The heterogeneity was often

due to differences in the magnitude of the point estimate and

confidence interval across studies, rather than differences in the

directionality of the effect. The exceptions are for estimates of

the efficacy of relaxation therapy with respect to SOL and the

efficacy of melatonin with respect to WASO. The

heterogeneity in the pooled estimates for SOL was explored in

7
8

sensitivity and sub-group analyses. The results indicate that

heterogeneity in the pooled estimate for SOL for relaxation

therapy is at least partially due to type of relaxation therapy,

length of treatment, age and gender distribution of the study

population, and study quality. 

There was strong evidence of publication bias in the pooled

estimates for SOL for the benzodiazepine and nonbenzodiazepine categories of intervention. This finding

suggests that the true estimate of efficacy is lower than the

estimate calculated in the current analysis.

We identified a small sample of studies examining the

efficacy of combination treatments in the management of

chronic insomnia; some of these studies compared a

combination of treatments with placebo, while others

compared them with single treatment. Many comparisons did

not have data for our primary outcome, sleep onset latency,

and the majority of results were non-significant. The latter

finding may reflect the low power of these analyses. None of

the studies provided data on adverse events. We identified

only one study that compared the efficacy of a combined

pharmacological and psychological treatment with these

treatments administered sequentially. The research agenda for

the management of chronic insomnia should include an

evaluation of the efficacy and safety of combination treatments

and sequential treatments.

Our results relating to relaxation therapy and

cognitive/behavioral therapy are somewhat at odds with three

meta-analyses reviewing the efficacy of psychological

treatments in the management of chronic insomnia.45-47 The

difference in the findings may relate to key differences in the

conduct of the reviews. First, we restricted our meta-analysis

to a review of placebo-controlled, randomized trials and

accounted for placebo effects in our estimations of efficacy.

Other meta-analyses have included non-controlled studies, and

for these studies, have not accounted for placebo/control

effects in their estimation of efficacy. Second, we used clearly

defined criteria for chronic insomnia; however, for some

studies the criteria for insomnia was not clear. Third, we

separated predominantly cognitive/behavioral approaches from

predominantly relaxation approaches in management of

insomnia, resulting in distinct meta-analyses for each category

of intervention. These interventions have been grouped under

the broader heading of psychological/non-pharmacological

treatments in other reviews. 

Conclusions

• There is evidence that the prevalence of chronic insomnia

in outpatient and clinical populations is larger than in the

general population.

• There is evidence that chronic insomnia is associated with

older age, female gender, present or past psychiatric illness

and psychological problems, medical conditions and poor

general health, increased healthcare utilization, lower

quality of life and social relationships, socioeconomic

status (marital separation, unemployment, poorer

working conditions and lower social status), and

decrements in memory, mood, and cognitive function.

• Additional studies are needed to determine the incidence

and natural history of chronic insomnia in adults.

Similarly, additional studies are needed to explore the

relationship between chronic insomnia and race/ethnicity,

shift work, absenteeism, work performance, accidents,

falls in the elderly, and the direct and indirect costs of the

disorder. It is necessary that longitudinal studies be

undertaken to explore the risk factors and consequences

of chronic insomnia.

• There is evidence that benzodiazepines and nonbenzodiazepines are effective in the management of

chronic insomnia. There is some evidence that

antidepressants are effective in the management of

chronic insomnia: more research is required in this area.

There is evidence that benzodiazepines, nonbenzodiazepines, and antidepressants pose a risk of harm.

• There is some evidence that melatonin is effective in the

management of chronic insomnia in subsets of the

chronic insomnia population, and there is no evidence

that melatonin poses a risk of harm. However, more

research is required in this area given that the results are

based on a small number of studies. Similarly, additional

large-scale, randomized trials are needed to determine the

efficacy of melatonin across subsets of the chronic

insomnia population. There is insufficient evidence to

conclude on the efficacy and safety of L-tryptophan and

valerian in the management of chronic insomnia.

Additional large-scale, randomized trials are needed in

these areas.

• There is evidence that relaxation therapy and

cognitive/behavioral therapy are effective in the

management of chronic insomnia in subsets of the
chronic insomnia population. Additional large-scale,

randomized trials are needed to determine their efficacy

across subsets of the chronic insomnia population.

• There is evidence that benzodiazepines have a greater risk

of harm than non-benzodiazepines.

• There is insufficient evidence to conclude whether there

are differences between the short- and long-term efficacy

and safety of the various categories of interventions in the

management of chronic insomnia; additional long-term

studies are needed.

• There is insufficient evidence regarding the efficacy and

safety of combined treatments of pharmacological and

psychological interventions, and sequential treatments, in

the management of chronic insomnia; additional studies

are needed in these areas.

Availability of the Full Report

The full evidence report from which this summary was

taken was prepared for the Agency for Healthcare Research

and Quality (AHRQ) by the University of Alberta Evidencebased Practice Center, under Contract No. C400000021. It is

expected to be available in June 2005. At that time, printed

copies may be obtained free of charge from the AHRQ

Publications Clearinghouse by calling 800-358-9295.

Requesters should ask for Evidence Report/Technology

Assessment No. 125, Manifestations and Management of

Chronic Insomnia in Adults. In addition, Internet users will be

able to access the report and this summary online through

AHRQ’s Web site at www.ahrq.gov.

Suggested Citation

Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M,

Ospina M, Klassen TP, Witmans M. Manifestations and

Management of Chronic Insomnia in Adults. Summary,

Evidence Report/Technology Assessment No. 125. (Prepared

by the University of Alberta Evidence-based Practice Center,

under Contract No. C400000021.) AHRQ Publication No.

05-E021-1. Rockville, MD: Agency for Healthcare Research

and Quality. June 2005.

References

1. Sateia MJ, Doghramji K, Hauri P, et al. Evaluation of chronic

insomnia. An American Academy of Sleep Medicine Review. Sleep

2000; 23(2):243-308.

2. Trans-NIH Sleep Research Coordinating Committee. 2003 National

Sleep Disorders Research Plan. US Department of Health and

Human Services. National Institute of Health.

http://www.nhlbisupport.com/sleep/research/research-a.htm.

3. National Sleep Foundation. Sleep in America Poll. Data from 1997

and 2001, 2002 sleep poll. http://www.sleepfoundation.org/img/

2002SleepInAmericaPoll.pdf.

4. Zorick FJ, Walsh JK. In Kryger MH, Roth T, Dement WC.

Principles and Practice of Sleep Medicine. 3rd Ed. Philadelphia, PA:

W.B. Saunders Co; 2000. Chapter 53, Evaluation and management

of insomnia. 

5. Sateia MJ, Nowell P. Insomnia. Lancet 2004; 364:1959-73.

6. Breslau N, Roth T, Rosenthal L, et al. Sleep disturbances and

psychiatric disorders: a longitudinal epidemiological study of young

adults. Biol Psychiatry 1996; 39:411-18.

7. Simon GE, VonKorff M. Prevalence, burden, and treatment of

insomnia in primary care. Am J Psychiatry 1997; 154(10):1417-23.

8. Leger D, Guilleminault C, Bader G, et al. Medical and socioprofessional impact of insomnia. Sleep 2002; 25(6):625-9.

9. Ohayon M. Epidemiological study on insomnia in the general

population. Sleep 1996; 19(3 Suppl):S7-15.

10. Roberts RE, Shema SJ, Kaplan GA. Prospective data on sleep

complaints and associated risk factors in an older cohort. Psychosom

Med 1999; 61(2):188-96.

11. Foley DJ, Monjan A, Simonsick EM, et al. Incidence and remission

of insomnia among elderly adults: an epidemiologic study of 6,800

persons over three years. Sleep 1999; 22(Suppl 2):S366-72.

12. Janson C, Lindberg E, Gislason T, et al. Insomnia in men - A 10-year

prospective population based study. Sleep 2001; 24(4):425-30.

13. Gislason T, Reynisdottir H, Kristbjarnarson H, et al. Sleep habits and

sleep disturbances among the elderly—an epidemiological survey. J

Int Med 1993; 234(1):31-9.

14. Riemann D, Voderholzer U. Primary insomnia: a risk factor to

develop depression? J Affect Disord 2003; 76:255-9.

15. Kryger MH, Roth T, Dement WC. Principles and Practice of Sleep

Medicine. 3rd Ed. Philadelphia, PA: W.B. Saunders Co; 2000.

16. Walsh JK, Engelhardt CL. The direct economic costs of insomnia in

the United States for 1995. Sleep 1999; 22(Suppl 2):S386-93.

17. Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin

Psychiatry 2004; 65 Suppl 8:13-9.

18. Walsh J. Pharmacologic management of insomnia. J Clin Psychiatry

2004; 65(Supp 16):41-5.

19. Morin CM, Colecchi C, Stone J, et al. Behavioral and

pharmacological therapies for late-life insomnia: a randomized

controlled trial. J Am Med Assoc 1999; 281(11):991-9.

20. Loney PL, Chambers LW, Bennett KJ, et al. Critical appraisal of the

health research literature: prevalence or incidence of a health problem

(Review). Chronic Dis Can 1988; 19(4):170-6.

9
21. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of

reports of randomized clinical trials: is blinding necessary? Control

Clin Trials 1996; 17:1-12.

22. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias.

Dimensions of methodological quality associated with estimates of

treatment effects in controlled trials. J Am Med Assoc 1995;

273:408-12.

23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control

Clin Trials 1986; 7:177-88.

24. Bailey KR. Inter-study differences: How should they influence the

interpretation and analysis of results? Stat Med 1987; 6:351-8.

25. Higgins JPT, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002; 21(11):1539-58.

26. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for

examining heterogeneity and combining results from several studies

in meta-analysis. In: Egger M, Davey Smith G, and Altman DG.

Systematic reviews in health care. 2nd ed. London, UK: BMJ Books;

2001.

27. Light RJ, Pillemer DB. Summing up. The science of reviewing

research. Cambridge, MA: Harvard University Press; 1984.

28. Begg CB, Mazumdar M. Operating characteristics of a rank

correlation test for publication bias. Biometrics 1994; 50:1088-101.

29. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis

detected by a simple, graphical test. Br Med J 1997; 315(7109):629-

34.

30. Duval S, Tweedie R. A nonparametric “trim and fill” method of

accounting for publication bias in meta-analysis. J Am Med Assoc

2000; 95(449):89-98.

31. Kageyama T, Nishikido N, Kobayashi T, et al. Cross-sectional survey

on risk factors for insomnia in Japanese female hospital nurses

working rapidly rotating shift systems. J Hum Ergol 2001; 30(1-

2):149-54.

32. Bixler EO, Vgontzas AN, Lin HM, et al. Insomnia in Central

Pennsylvania. J Psychosom Res 2002; 53(1):589-92.

33. Riedel BW, Durrence H, Lichstein KL, et al. The Relation Between

Smoking and Sleep: The Influence of Smoking Level, Health, and

Psychological Variables. Behav Sleep Med 2004; 2(1):63-78.

34. Lopes Rocha F, Guerra HL, Lima-Costa MFF. Prevalence of

insomnia and associated socio-demographic factors in a Brazilian

community: The Bambui study. Sleep Med 2002; 3(2):121-6.

35. Kageyama T, Kabuto M, Nitta H, et al. A population study on risk

factors for insomnia among adult Japanese women: a possible effect

of road traffic volume. Sleep 1997; 20(11):963-71.

36. Martikainen K, Partinen M, Hasan J, et al. The impact of somatic

health problems on insomnia in middle age. Sleep Med 2003;

4(3):201-6.

37. Terzano MG, Parrino L, Cirignotta F, et al. Studio Morfeo: insomnia

in primary care, a survey conducted on the Italian population. Sleep

Med 2004; 5(1):67-75.

38. Zammit GK, Weiner J, Damato N, et al. Quality of life in people

with insomnia. Sleep 1999; 22(Suppl 2):S379-85.

39 Shochat T, Umphress J, Israel AG, et al. Insomnia in primary care

patients. Sleep 1999; 22(Suppl 2):S359-65.

40. Perlis ML, Smith MT, Orff HJ, et al. The mesograde amnesia of

sleep may be attenuated in subjects with primary insomnia. Physiol

Behav 2001; 74(1-2):71-6.

41. Benca RM, Ancoli-Israel S, Moldofsky H. Special considerations in

insomnia diagnosis and management: depressed, elderly, and chronic

pain populations. J Clin Psychiatry 2004; 65(Suppl 8):26-35.

42. Panneman MJ, Goettsch WG, Kramarz P, et al. The costs of

benzodiazepine-associated hospital-treated fall Injuries in the EU: a

Pharmo study. Drugs Aging 2003; 20(11):833-9.

43. Drover DR. Comparative pharmacokinetics and pharmacodynamics

of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.

Clin Pharmacokinet 2004; 43(4):227-38.

44. Roehrs T, Roth T. Hypnotics: an update. Curr Neurol Neurosci Rep

2003; 3(2):181-4.

45. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological

interventions for insomnia: A meta-analysis of treatment efficacy. Am

J Psychiatry 1994; 151(8):1172-80.

46. Murtagh DRR, Greenwood KM. Identifying effective psychological

treatments for insomnia: a meta-analysis. J Consult Clin Psychol

1995; 63(1 ):79-89.

47. Smith MT, Perlis ML, Park A, et al. Comparative meta-analysis of

pharmacotherapy and behavior therapy for persistent insomnia. Am J

Psychiatry 2002; 159:5-11.

10
11
www.ahrq.gov

AHRQ Pub. No. 05-E021-1

June 2005

ISSN 1530-440X
Evidence Report 

3 

Chapter 1. Introduction 

Prevalence of Insomnia 

Insomnia, or inability to sleep, is the most commonly reported sleep problem in the 

industrialized world.1

 Estimates suggest that between 40-70 million Americans are affected by 

either intermittent or chronic sleep problems, representing approximately 20 percent of the 

population.2

 The Sleep in America Poll, conducted by the National Sleep Foundation, revealed 

that almost 50 percent of people surveyed had complaints of frequent insomnia, but only 6 

percent were formally diagnosed.3

 Moreover, approximately, 30-35 percent of respondents 

complained of nightly insomnia.3

 The most prevalent symptoms of insomnia, experienced at 

least a few nights a week by people with insomnia, include waking up feeling un-refreshed (34 

percent) and being awake often during the night (32 percent).3

 The symptoms of difficulty 

falling asleep and waking up too early are less common, but still experienced at least a few 

nights a week by about one-fourth of adults with insomnia (23-24 percent).3

 The reported 

prevalence rates of insomnia vary in epidemiological studies based on the definitions and 

methods used to define insomnia. Earlier studies report prevalences of 5-35 percent.1

 The 

prevalence rate decreases to 10-15 percent for severe insomnia, when more stringent criteria are 

used.1

 The duration of insomnia is often classified as being transient, short-term or chronic. 

Chronic insomnia implies that insomnia is either persistent or recurrent. Definitions of chronic 

insomnia vary, ranging from greater than one month to greater than 6 months. Unfortunately, 

there is no standard definition of chronic insomnia used in studies. 

There is emerging evidence that short-term sleep deprivation, under strict experimental 

conditions, is associated with a variety of adverse physiological and cognitive effects. 

Decrements in memory, concentration and executive function have been reported. There is also 

an increased risk of injury and accidents. Physiological effects resulting from sleep deprivation 

include hypertension, activation of the sympathetic nervous system, altered glucose metabolism 

and increased inflammatory markers. Sleep deprivation is associated with excessive sleepiness. 

Acute insomnia, however, may not equate to sleep deprivation. There is no evidence to suggest 

that patients with insomnia experience similar changes. Furthermore, it is not yet clear from the 

evidence what the physiological consequences of chronic insomnia are or if there is a process of 

adaptation that occurs in individuals with chronic insomnia. Thus, further research is needed in 

the area of chronic insomnia to determine what impact chronic insomnia has on health. 

 

Risk Factors for Insomnia 

Although some risk factors and etiologies of insomnia have been identified, the nature of the 

relationships has not been fully elucidated. Some risk factors for insomnia that have emerged 

from data related to insomnia include female gender 3

 and old age.4 Additional risks factors 

include less education, unemployment, separation or divorce and medical illness.1

 Insomnia may 

be primary or secondary to other sleep problems, and may be associated with a number of comorbidities. An association has been found between insomnia and psychiatric (depression and 

anxiety) and psychological disorders.4

 There is increasing evidence that chronic insomnia may 

predispose individuals to the development of psychiatric disorders.5-6 Persistent insomnia 

increases the risk of depression, substance abuse and anxiety disorders. Environmental factors 
4 

such as irregular sleep schedules, use of caffeine or other stimulants, co-morbid medical 

conditions and/or shift-work may also predispose vulnerable individuals to insomnia. We 

speculate that genetic predisposition to insomnia and environmental factors are likely involved in 

the development and maintenance of insomnia, and differences in the relative exposure to these 

influences may explain differences in the manifestation of this disorder among affected 

individuals.

Consequences of Insomnia 

Insomnia has significant direct and indirect effects on the health and wellness of affected 

individuals. Insomnia has been correlated with frequent use of medical services,7-8 chronic 

health problems,9-10 increased drug use,7-8 perceived poor health,11 and associated with medical 

problems including heart disease,12 hypertension13 and musculoskeletal problems.12 One study 

reported associations between insomnia and medical problems, and found that individuals with 

insomnia were more likely to have hypertension (59 percent), night time heartburn (62 percent) 

and depression (74 percent).3

 The daytime consequences of chronic insomnia often include 

increased healthcare utilization, increased risk of depression,14 poor memory, reduced 

concentration, poor work performance and perceived or real risk of failure at work.15 The 

economic implications of insomnia and associated morbidity have been described.3;7 The direct 

costs of insomnia (insomnia treatments, healthcare services, hospital and nursing home care) are 

estimated to be nearly $14 billion.16-17 The indirect costs of insomnia, such as time lost from 

work and loss of productivity, are estimated to be nearly $28 billion. A National Sleep 

Foundation survey found that lost productivity from insomnia, alone, was over $18 billion. 

Another estimate of total costs of insomnia has reported amounts totaling almost $100 billion.18 

This estimate is based on a high prevalence of insomnia, in the range of 33 percent, and the costs 

are related to sleepiness rather than insomnia. The data related to costs of chronic insomnia 

cannot be fully understood because of the impact insomnia has on many aspects of life. 

Nevertheless, insomnia, in its various forms, does result in substantial burden for affected 

individuals. 

Management of Insomnia 

Management of acute insomnia has traditionally involved pharmacotherapy. The use of such 

agents is common practice for both acute and chronic insomnia, despite the fact that the Food 

and Drug Administration (FDA) has approved none of them for chronic insomnia. Another 

medication, eszopiclone (Lunesta), was recently approved by the FDA for treatment of insomnia, 

but the duration of use is not explicitly stated. An estimated 0.5 percent of the population takes 

sedative medications for insomnia for more than one year.3

 More than one in ten people (11 

percent) report using prescription (6 percent) and/or over-the-counter (OTC) medications (6 

percent), at least a few nights a month, to help them sleep, according to a Sleep in America Poll.3

 

Individuals reporting symptoms of medical conditions are more likely to take sleep aids, both 

prescription and OTC medications. For example, 14 percent of people with symptoms of 

depression report using prescription medication, and 12 percent of people with symptoms of 

depression report using OTC sleep aids.3

 Medications commonly used to treat insomnia include 

sedating antidepressants,19 antihistamines, anticholinergics, benzodiazepines and non-
5 

benzodiazepine hypnotics. A side effect of all hypnotics is to reduce slow wave sleep. Other 

side effects of concern are possible daytime residual effects related to sedation, rebound 

insomnia and tolerance, along with minor side effects specific to each drug class. Many 

questions and challenges related to pharmacological therapy for chronic insomnia remains, such 

as the appropriate treatment for different types of primary and secondary insomnia, and the longterm side effects and daytime consequences of pharmacotherapy. The evidence for management 

of chronic insomnia with pharmacotherapy has not been systematically evaluated. 

Cognitive/behavioral therapy has been recognised as a valid and successful treatment 

approach for insomnia. Cognitive/behavioral therapy can include any combination of sleep 

restriction, sleep hygiene, stimulus control, paradoxical intention and cognitive restructuring. 

Brief descriptions of these techniques are provided here. 

Sleep restriction therapy involves limiting the amount of time in bed. The affected individual 

spends only the amount of time in bed that he/she sleeps, thus sleep may be restricted to 6 hours 

for an insomniac that spends 8 hours in bed. The purpose of the exercise is to improve the sleep 

efficiency progressively until the desired sleep duration is achieved, without prolonged sleep 

latency or maintenance insomnia. 

Sleep hygiene instructions or education involves addressing environmental factors and health 

practices that may be counterproductive to sleep. It involves education about sleep patterns and 

the impact of health habits related to sleep. For example, alcohol consumed in the evening may 

help sleep onset, but promotes sleep maintenance insomnia during the night as the alcohol level 

declines. 

Stimulus control therapy involves instructions aimed at curtailing sleep maladaptive 

behaviors and altering sleep-wake schedules. The instructions include: 1) going to bed when 

sleepy; 2) no other activities, besides sleep and sex, should be undertaken in the bed and 

bedroom; 3) get out of bed when unable to sleep for 15-20 minutes and return only if sleepy; 4) 

the daily wake-up time should be the same irrespective of how much sleep was obtained the 

previous night; 5) no naps allowed during the day. 

Paradoxical intention is a technique that involves having the patient with insomnia stay 

awake, which is the most feared activity. The premise is that performance anxiety related to 

sleep would be alleviated if the patient stops trying to sleep and instead genuinely attempts to 

stay awake. 

Cognitive restructuring can involve cognitive behavioral therapy targeted at an individual’s 

unique perpetuating factors for insomnia. 

Sleep non-suppression involves allowing oneself to think about whatever comes to mind, 

without any restrictions, as one gets to bed. The mind is allowed to go free, without the 

individual attempting to control his/her thoughts. This approach is thought to counteract the 

negative effects of thought suppression that often accompanies insomnia. 

Relaxation therapy may or may not be a part of cognitive behavioral therapy. Different 

forms of relaxation therapy are designed to reduce somatic tension or cognitive arousals. 

Relaxation therapy may focus on somatic tension such as autogenic training, progressive muscle 

relaxation, or biofeedback, or may focus on the cognitive component such as intrusive thoughts 

that prevent sleep. 

Many of these commonly used clinical tools have not undergone rigorous testing to 

determine their efficacy and long-term safety. The efficacy of these treatments has been 

evaluated in some studies,4;20 but differences in the definition of insomnia and outcome measures 

make it difficult to compare study results. 
6 

In summary, insomnia is a common complaint with significant consequences. Significant 

advancements have been made in sleep research over the past three decades, yet many questions 

related to the treatment of chronic insomnia remain. Our goal was to review the evidence and 

state of research in the area of chronic insomnia. 

Objectives 

To conduct a systematic review of (1) the prevalence, natural history, incidence, risk factors 

and consequences of chronic insomnia in adults and (2) the efficacy and safety of treatments 

used in the management of chronic insomnia in adults. A population was considered to suffer 

from chronic insomnia if the sleep disturbance persisted for at least 4 weeks, regardless of 

severity of symptoms. 

Analytic Approach 

The analytic framework outlining the approach to the review is depicted in Flow Diagram 1. 

The specific questions addressed in the review appear below. 

Etiology and Population at Risk 

The following questions pertain to the clinical definition and etiology of chronic insomnia in 

adults, as well as the population at risk of the disorder. 

1. How is chronic insomnia defined, diagnosed and classified, and what is known about its 

etiology? 

2. What are the prevalence, natural history, incidence, and risk factors for chronic 

insomnia? Specific risk factors of interest include: 

• Age 

• Gender 

• Race/ethnicity 

• Psychiatric illness and psychological problems 

• Medical disease 

• Socioeconomic status 

• Shift-work 

Consequences, Morbidities, Co-morbidities, and Public Health Burden 

The following question pertains to the clinical, social and economic consequences of chronic 

insomnia in adults. 

3. What are the consequences, morbidities, co-morbidities, and public health burden 

associated with chronic insomnia? Specific outcomes of interest include: 

• Healthcare utilization 

• Risk of developing psychiatric disease 
7 

• Absenteeism, work performance 

• Accidents 

• Falls in the elderly 

• Quality of life, social relationships 

• Memory, cognitive function, mood 

• Direct and indirect costs 

Treatment 

The following question pertains to the benefits and harms of treatments used in the 

management of chronic insomnia in adults. 

4. What treatments are used in the management of chronic insomnia and what is the 

evidence regarding their safety, efficacy, and effectiveness? Specific treatments of 

interest include: 

• Prescription medication 

• Over the counter medication 

• Alcohol 

• Behavioral therapy 

• Combination of therapies 

• Complementary and alternative care 

Future Direction 

The answer to the following question is based on the evidence for the preceding questions. 

5. What are important future directions for insomnia-related research? 
8 

Flow Diagram 1. Analytic framework 

Aetiology and 

Population at Risk 

Screening for 

Treatment Treatment

Morbidity of 

Treatment

Intermediate and 

Surrogate Outcomes Medical 

Benefits

4 1

4

Consequences 

Morbidities 

Co-morbidities 

and Public Health Burden 

3

 2

Future Direction

5

5 5

5

4
9 

Chapter 2. Methods 

Overview 

The systematic review involved a number of steps: 

• Literature Search 

• Development of Inclusion Criteria 

• Study Selection 

• Data Extraction 

• Assessment of Study Quality 

• Data Analysis 

Literature Search 

The research librarian, in collaboration with the TEP (Technical Expert Panel), developed 

and implemented search strategies designed to identify relevant evidence for key questions of the 

review. A systematic search of 21 electronic databases was conducted. Table 1 outlines the 

electronic databases that were searched. Table 2 outlines the subject headings and keywords that 

were used in the search. Appendix A♦ contains details of the search strategy. Most of the 

searches were limited to humans, and no age restrictions were applied to any of the searches. 

For Question 1, which relates to the definition, classification, diagnosis, and etiology of 

chronic insomnia in adults, we searched for narrative and systematic reviews, book chapters, 

diagnostic manuals and standards of practice parameters, and applied English-language 

restrictions. For Question 2, which relates to the prevalence, natural history, incidence, and risk 

factors for chronic insomnia in adults, and Question 3, which relates to the consequences, 

morbidities, co-morbidities and public health burden associated with chronic insomnia in adults, 

we searched for observational studies, encompassing a range of designs including crosssectional, case-control, and cohort studies, and applied English-language restrictions. For 

Question 4, which relates to the treatments for chronic insomnia in adults, and the evidence 

regarding their safety, efficacy, and effectiveness, we searched for randomized controlled trials, 

and no language restrictions were applied. We did not apply language restrictions to searches for 

Question 4, since a portion of this question involves a review of complementary and alternative 

medicine (CAM), and there is evidence to suggest that studies of some CAM topics are often 

initially published in non-English languages, and many of these are not published in English.21

We searched electronic resources that specialize in CAM, including AMED (Allied and 

Complementary Medicine), Alt HealthWatch, and Cochrane Complementary Medicine Field 

Registry. In order to systematically search for the different types of studies required for each 

question, it was useful to refer to: the highly sensitive search strategy for identifying reports of 

randomized controlled trials in MEDLINE® from the Cochrane Reviewer’s Handbook 

(Appendix 5b)22; search strategies for diagnosis, etiology, natural history and morbidities from 

PDQ Evidence-based Principles and Practice23; and the search strategy for systematic reviews in 

MEDLINE® from the Alberta Research Centre for Child Health Evidence.24 Searches were also 

 

♦ The Appendices and Evidence Tables cited in this report are provided electronically at 

http://www.ahrq.gov/clinic/tp/insomntp.htm. 
10 

conducted in databases that index grey literature, including SIGLE (System for Information on 

Grey Literature in Europe), OCLC Proceedings First, Dissertation Abstracts and the NLM 

Gateway (searched specifically for meeting abstracts). 

No hand searching was conducted for this review, given that the key journals pertaining to 

chronic insomnia, such as Sleep and Sleep Medicine Reviews, are indexed in MEDLINE. 

Development of Inclusion Criteria 

We did not develop formal inclusion criteria for the question pertaining to the definition, 

classification, diagnosis and etiology of chronic insomnia, nor for the question pertaining to the 

future direction of insomnia-related research. The former question was answered by providing 

an overview of the literature, and the latter question was answered by assessing the limitations in 

the evidence for the other questions of the review. 

Inclusion criteria were developed for three questions of the review. Question-specific 

inclusion criteria appear below. The questions have been numbered according the numbering 

system outlined in the Introduction of this report. In the interest of clarity, questions 2 and 3 will 

be referred to as the questions on manifestations of chronic insomnia, while question 4 will be 

referred to as the question on management of chronic insomnia. 

 

2. What are the prevalence, natural history, incidence and risk factors for chronic 

insomnia? Specific risk factors of interest include age, gender, race/ethnicity, psychiatric 

illness and psychological problems, medical disease, socioeconomic status and shift-work. 

A study was considered to be relevant to the portion of Question 2 pertaining to the 

prevalence, natural history and incidence of chronic insomnia, if it met the following criteria: 

• the report was written in English 

• participants were at least 15 years old 

• it examined chronic insomnia 

• it had a cross-sectional or cohort design 

• it assessed the prevalence, natural history or incidence of chronic insomnia 

A study was considered to be relevant to the portion of Question 2 pertaining to risk factors 

for chronic insomnia, if it met the following criteria: 

• the report was written in English 

• participants were at least 15 years old 

• it examined chronic insomnia 

• it had a cohort, case-control, or cross-sectional design 

• it assessed one of the risk factors of interest 

3. What are the consequences, morbidities, co-morbidities, and public health burden 

associated with chronic insomnia? Specific outcomes of interest include healthcare 

utilization, psychiatric illness, absenteeism, work performance, accidents, falls in the elderly, 

quality of life and social relationships, memory, cognitive function, mood, direct and indirect 

costs.
11 

A study was considered to be relevant to this question of the review, if it met the following 

criteria: 

• the report was written in English 

• participants were at least 15 years old 

• it examined chronic insomnia 

• it had a cohort or cross-sectional design 

• it assessed one of the consequences of interest 

For Questions 2 and 3, a study was considered to examine chronic insomnia if this condition 

was defined as a sleep disturbance of four weeks or more, or the report explicitly mentioned that 

chronic sleep disturbance was examined. 

4. What treatments are used for the management of chronic insomnia and what is the 

evidence regarding their safety, efficacy, and effectiveness? Specific treatments of 

interest include prescription medication, over the counter medication, alcohol, behavioral 

therapy, combination therapy and complementary and alternative care. 

A study was considered to be relevant to this question of the review, if it met the following 

criteria. 

 

• the report was written in English 

• participants were at least 15 years old, and the majority were at least 18 years old 

• participants suffered from chronic insomnia 

• participants were randomized to intervention or placebo 

• participants and assessors were blind to treatment received 

• it assessed at least one of the following outcomes, listed in order of importance in 

deriving conclusions of the review: 

• sleep onset latency 

• wakefulness after sleep onset 

• sleep efficiency 

• total sleep time 

• sleep quality 

• quality of life 

Sleep onset latency was defined as the amount of time between the participant laying down 

to sleep and the onset of sleep; wakefulness after sleep onset was defined as the amount of time 

spent awake in bed following the attainment of sleep; sleep efficiency was defined as the amount 

of time spent asleep as a percentage of the total time spent in bed; and total sleep time was 

defined as the total time spent asleep while in bed. We used broad definitions of sleep outcomes 

in this review. For example, sleep onset latency could be defined as time to sleep, time to stage 1 

sleep, time to stage 2 sleep or latency to persistent sleep. We believe that it was acceptable to 

combine studies with differing definitions of sleep onset latency in the analysis, since differences 

in the magnitude of estimations across definitions would be accounted for by subtraction of 
12 

placebo effects from treatment effects. Although it could be argued that these definitions are 

significantly different, the optimal definition of sleep onset latency has not yet been determined. 

Nonetheless, differences between polysomnography, sleep diary and actigraphy definitions of 

sleep onset latency were explored indirectly through sub-group analyses. 

Sleep onset latency and wakefulness after sleep onset were given the highest priority in 

deriving conclusions of the review, since they were considered the best indices of sleep initiation 

and sleep maintenance, respectively. However, sub-group analyses were conducted only on data 

relevant to sleep onset latency, since this outcome was the most highly reported outcome across 

studies. 

If the majority of participants met one of the following criteria, the study population was 

considered to suffer from chronic insomnia: 

• participants suffered from a sleep disturbance of 4 weeks or more 

• participants were described as having a chronic/long-standing/persistent sleep disturbance 

• participants were selected from a sleep disorders clinic 

The 4-week cut-point for chronic insomnia was considered long enough to eliminate studies 

involving transient insomnia, and short enough to include studies involving persistent insomnia. 

In the case of combination therapy, the combined treatment could be compared to either 

placebo or single treatment. 

We acknowledged the fact that double-blinding is often not feasible in studies of 

psychological treatments by not requiring double-blinding in these studies for inclusion in the 

review. The placebo treatment for relaxation therapy and cognitive/behavioral therapy was 

minimal treatment, such as sleep hygiene recommendations or minimal instruction. We required 

a placebo control and randomization of participants to intervention groups in order to account for 

potential confounders in the analysis. That is, we wanted to control for potential improvements 

in insomnia symptoms that may occur during the natural course of observation, irrespective of 

treatment effects, and for systematic differences in the experimental and control groups. 

Given that placebo for psychological treatment is variable and not standardized across 

studies, we restricted our analysis to a particular type of placebo such that our results could be 

put in some context i.e. the efficacy of psychological treatment could be judged against a 

particular type of comparator. We required that the placebo resemble the intervention of the 

study except that it was known to produce either no effect or only a minimal effect. Thus, 

component controls or attention-placebo were considered appropriate if they were thought to 

have at most a minimal effect. A waiting-list or measurement control was considered inadequate 

because no intervention was provided. A pill-placebo was considered inadequate because it did 

not resemble the experimental intervention, which did not involve administration of a pill. 

Study Selection 

The research librarian provided three databases containing the titles and abstracts of 

potentially relevant articles of the review; one database was relevant to the question on the 

definition and etiology of chronic insomnia, another database was relevant to the questions on 

manifestations of chronic insomnia, and another database was relevant to the question on 

management of chronic insomnia. In the first stage of study selection, two reviewers screened 

the titles and abstracts of all potentially relevant articles, independently. Each reviewer noted the 
13 

titles and abstracts that were potentially relevant to the review, and these articles were retrieved. 

In the second stage of study selection, two reviewers appraised the potentially relevant articles, 

independently, using pre-determined, question-specific, inclusion criteria. Disagreements 

between reviewers were resolved by discussion and consensus. The rate of disagreement 

between reviewers and the primary reason for exclusion of potentially relevant articles were 

noted. 

Assessment of Study Quality 

 

The quality of studies relevant to the questions on manifestations of chronic insomnia was 

assessed using one of three instruments; studies on prevalence and incidence were assessed using 

a scale designed specifically for this purpose.25 This scale assesses bias in sample selection, 

sampling frame, sample size, outcomes and their assessment, response rate, confidence intervals 

and sub-group analysis, and sample description. The maximum score is eight. A priori, it was 

established that a score of zero to two would be considered low quality, a score of three to five 

would be considered moderate quality and a score of six to eight would be considered high 

quality. All other studies relevant to manifestations of chronic insomnia were assessed using one 

of two Newcastle-Ottawa scales (unpublished), each scale specific to either cohort or casecontrol studies. The scale specific to cohort studies assesses bias in the selection of exposed and 

non-exposed cohorts, ascertainment of exposure, presence of outcomes at the start of the study, 

comparability of cohorts based on design or analysis, outcome assessment, and length and 

adequacy of follow-up. The scale specific to case-control studies assesses bias in the definition, 

selection, comparability, ascertainment of exposure, and non-response rate for both cases and 

controls, and how these groups compare on these items. The maximum score for the NewcastleOttawa scales is nine. A priori, it was established that a score of zero to two would be 

considered low quality, a score of three to five would be considered moderate quality and a score 

of six to nine would be considered high quality. 

The quality of studies relevant to management of chronic insomnia was assessed using the 

Jadad scale.26 This scale assesses bias in sample selection, outcome assessment, data analysis, 

and appropriateness of randomization and blinding methods. The maximum score is five. A 

priori, it was established that a score of zero to one would be considered low quality, a score of 

two to three would be considered moderate quality and a score of four to five would be 

considered high quality. The concealment of allocation of participants to treatment groups was 

also assessed.27 Allocation was considered adequate, inadequate or unclear. 

Appendix B contains the quality assessment tools used in this review. 

Data Extraction 

The following data were extracted for studies relevant to manifestations of chronic insomnia, 

as applicable: first author and year of publication, site, objectives, design, time-frame, intended 

sample size, response and follow-up rates, type of participants, definition of comparison groups, 

participants’ gender, age, and ethnicity, and participants’ co-morbid conditions at entry. For the 

question on prevalence, incidence, natural history and risk factors for chronic insomnia, 

additional data extracted included setting, sampling frame and method of sampling, data 

collection method, prevalence, incidence and natural history parameters. We did not identify 

studies with designs that would support the categorization of outcomes as either risk factors or 
14 

consequences of chronic insomnia; therefore, data relevant to potential risk factors and potential 

consequences of chronic insomnia were extracted, and these outcomes were referred to as 

associated factors of chronic insomnia. 

The following data were extracted for studies relevant to management of chronic insomnia: 

first author and year of publication, funding source and role of funding organization, design, 

whether an intent-to-treat analysis was conducted, number of participants enrolled and their 

distribution by gender, participants’ age, number of withdrawals and reasons for withdrawal, 

duration of insomnia, participants’ co-morbid conditions at entry, methods used to assess 

outcomes, details of the intervention, such as frequency and duration of treatment and timing and 

route of delivery, number of participants allocated to treatment groups and number analyzed in 

each group, length of follow-up, patient preference, and data relevant to sleep onset latency, 

wakefulness after sleep onset, sleep efficiency, total sleep time, sleep quality, quality of life and 

adverse events. A trained reviewer extracted relevant data, and a second reviewer verified the 

data extracted for accuracy and completeness. 

Appendix B contains data extraction forms for the questions on manifestations and 

management of chronic insomnia. 

The information gathered by data extraction was used to generate Evidence Tables. 

Appendix C contains these tables. 

Data Analysis

Data relevant to manifestations of chronic insomnia were analyzed qualitatively, while data 

relevant to management of chronic insomnia were analyzed quantitatively. 

Manifestations of chronic insomnia. For the questions on prevalence, natural history, 

incidence, risk factors and consequences of chronic insomnia, data relevant to each variable were 

analyzed separately, except for data relevant to potential risk factors and potential consequences 

of chronic insomnia, which were analyzed together as associated factors of chronic insomnia. 

The key features of all studies providing information on prevalence, natural history, incidence or 

associated factors of chronic insomnia were summarized in tables, such that data relevant to each 

variable appeared in a separate table. The information on prevalence was divided into three 

tables, one for prevalence in the general population, one for prevalence in outpatients of general 

practice and one for prevalence in clinical populations.

The following information was included in the tables on prevalence: first author and year of 

publication, study quality, study design, sampling frame, sampling method, response/follow-up 

rate, method of data collection, type of participants, duration of sleep complaints and definition 

of cases and comparison groups, gender distribution of sample, age distribution of sample, and 

prevalence estimates. The following information was included in the table on natural history: 

first author and year of publication, study quality, study design, time frame for the study, 

response/follow-up rate, type of participants, duration of sleep complaints, gender distribution of 

sample, age distribution of sample, and natural history estimates. The following information was 

included in the table on associated factors for chronic insomnia: author and year of publication, 

study quality, study design, type of participants, duration of sleep complaints, gender distribution 

of sample, age distribution of sample, response/follow-up rate, and a qualitative summary of the 

findings of the study. The qualitative summary of results was derived by consolidating 
15 

information available in the results and conclusions of relevant studies. We did not identify 

information relevant to the incidence of chronic insomnia. 

The data provided in the tables were synthesized to provide a description of the methods and 

results of the studies relevant to a given variable. In the analysis of prevalence of chronic 

insomnia, a range, median and interquartile range were provided for each population (general, 

outpatient and clinical), separately for high and moderate quality studies, where appropriate. In 

the analysis of associated factors of chronic insomnia, the qualitative summary of findings were 

summarized in terms of the studies that did or did not find an association between chronic 

insomnia and the various factors of interest. 

Management of chronic insomnia. A priori, the drug interventions were categorized according 

to drug class i.e. benzodiazepines, non-benzodiazepines and antidepressants. It was considered 

acceptable to combine different drugs of the same category in a meta-analysis, based on similar 

mechanisms of action. For psychological interventions, it was considered acceptable to combine 

predominantly cognitive approaches in a meta-analysis, and also to combine predominantly 

relaxation approaches in a meta-analysis; however, it was considered unacceptable to combine 

these two types of psychological approaches in a meta-analysis, since they were considered too 

different in their modes of action. Relaxation techniques address somatized tension, and 

different forms of this type of therapy (progressive relaxation and group relaxation) were 

considered similar enough to be pooled. However, cognitive therapy addressing the cognitive 

aspects of insomnia was not thought to be equivalent to relaxation therapy because it targets 

different aspects of insomnia, and was considered separately. A few interventions (e.g. Ltryptophan, melatonin and valerian) were categorized under the heading of “complementary and 

alternative care”; however, separate meta-analyses were presented for these interventions. We 

did not combine these interventions in a meta-analysis, given their distinct modes of action. 

For continuous outcomes (i.e. sleep onset latency, sleep efficiency), studies were combined 

using a Mean Difference (MD), with the exception of sleep quality and quality of life, where 

studies were combined using a Standardized Mean Difference (SMD). Dichotomous outcomes 

(i.e. safety outcomes) were combined using a Risk Difference. A number needed to harm (NNH) 

was also reported for any safety outcomes that were found to be statistically significant. The 

Inverse Variance Method28 was used to weight the studies. An efficacy estimate, with 

corresponding 95% Confidence Interval (CI), was computed for each outcome. For interpreting 

estimates calculated using the SMD, we used the generalization of 0.2 as small, 0.5 as moderate, 

and 0.8 as large.29

We were usually able to calculate the efficacy estimates for each study exactly (i.e. mean 

difference, standardized mean difference, risk difference), but occasionally, estimates had to be 

made by extracting from graphs or using medians. Standard errors of the differences were 

calculated exactly from available data (i.e. individual patient data or exact P-values), whenever 

possible. For studies with a parallel design, this calculation was usually accomplished with the 

standard formula for variance of difference of independent variables: var(A-B) = var(A) + 

var(B). For studies with a crossover design, the standard error was estimated using the formula 

for variance of difference of dependant variables: var(A-B) = var(A) + var(B) -

2ρ(var(A)var(B))1⁄2 and using a correlation estimate of 0.5. In cases where exact values could not 

be obtained, standard errors were estimated using conservative P-values (i.e. p < 0.05), ranges, 

inter-quartile ranges, and extracting from graphs. As a last resort, an average of standard 

deviations of other studies was used to impute standard deviations of a study. 
16 

For studies with a parallel design, change from baseline data were used if available, 

otherwise final data were used. For studies with a crossover design, final data were always used. 

When continuous data were presented for multiple conditions, which we wished to combine, a 

new mean and standard deviation were computed. 

All meta-analyses were performed using a Random Effects Model. Bailey30 suggests that the 

Random Effects Model is more appropriate when making recommendations for management and 

treatment of the next given patient. 

For some outcomes (sleep onset latency and number of adverse events), treatment categories 

were compared indirectly, via their relationship to placebo. Differences of differences with 95% 

CI were computed. Indirect comparisons were not made between pharmacological and 

psychological treatments for the following reasons (1) although our inclusion criteria required 

blinding for drug and complementary and alternative care, this criteria was omitted for 

psychological treatments (2) the placebo intervention was considered to have no effect for drug 

and complementary and alternative treatments, while it may have had minimal effect for 

psychological treatments (3) the pool of participants for psychological interventions was much 

smaller than for either the benzodiazepines, non-benzodiazepines or antidepressants. Thus, only 

indirect comparisons between non-psychological intervention categories and between 

psychological intervention categories were made. 

 All estimates of efficacy were assessed for heterogeneity using the I-squared statistic.31 

Based on this statistic, heterogeneity for each outcome was classified as negligible (I2 = 0 

percent), minimal (I2 < 20 percent), moderate (20 percent < I2 < 50 percent), or substantial (I2 > 

50 percent). This measure of heterogeneity describes the degree of variation in the efficacy 

estimates among studies. For our primary outcome (sleep onset latency), heterogeneity was 

explored in sub-group analyses using a number of variables. The following variables were 

targeted a priori and explored in sub-group analyses: treatment sub-group (i.e. type of drug or 

therapy), presence or absence of psychiatric illness (as defined in the study inclusion criteria), 

length of treatment (short-term and long-term, defined as less than or equal to 4 weeks and 

greater than 4 weeks, respectively), age (adult and elderly defined as the majority of patients 15-

65 years or greater than 65 years, respectively) and gender (male and female). Method of 

measurement of sleep outcomes (polysomnography, sleep diary actigraphy) was analyzed posthoc in a sub-group analysis based on comments from peer reviewers. Study quality (low, 

moderate and high quality defined as Jadad scores of 0-1, 2-3 and 4-5, respectively) was also 

explored in a sensitivity analysis. Deeks’ chi-square statistic 32 was used to test for significant 

heterogeneity reduction in partitioned sub-groups. 

Publication bias is the publication of studies based on the nature and direction of results. We 

tested for publication bias visually using the Funnel Plot33 and quantitatively using the Rank 

Correlation Test,34 the Graphical Test,35 and the Trim and Fill Method.36 
17 

Table 1. Databases searched 

Database Platform Dates of Search 

MEDLINE® Ovid Version: rel9.1.0 1966 to September Week 1 2004 

EMBASE Ovid Version: rel9.1.0 1988 to 2004 Week 37 

CINAHL Ovid Version: rel9.1.0 1982 to September Week 2 2004 

Ovid MEDLINE In-Process & 

Other Non-Indexed Citations Ovid Version: rel9.1.0 September 14, 2004 

Ovid OLDMEDLINE(R) ® Ovid Version: rel9.1.0 1951 to 1965 – Searched 

September 15, 2004 

PsycINFO® Ovid Version: rel9.1.0 1872 to September Week 1 2004 

EBM Reviews - Cochrane Central 

Register of Controlled Trials Ovid Version: rel9.1.0 2nd Quarter 2004, Searched 

September 15, 2004 

International Pharmaceutical 

Abstracts Ovid Version: rel9.1.0 1970 to August 2004 

AMED (Allied and 

Complementary Medicine)

Ovid Version: rel9.1.0 1985 to September 2004 

HealthSTAR/Ovid Healthstar Ovid Version: rel9.1.0 1975 to August 2004 

EBM Reviews – Cochrane 

Database of Systematic Reviews 

(CDSR) ; ACP Journal Club 

(ACPJC) ; Database of Abstracts 

of Reviews of Effects (DARE) 

Ovid Version: rel9.1.0 

2nd Quarter 2004 (CDSR); 1991 

to March/April 2004 (ACPJC); 2nd

Quarter 2004 (DARE); Searched 

September 15, 2004 

Science Citation Index 

Expanded® ISI Web of Knowledge 1945-September 2004, Searched 

September 17, 2004 

Biological Abstracts WebSPIRS from SilverPlatter, Version 4.3 1969-September 17, 2004 

Cochrane Complementary 

Medicine Field Registry 

Reference Web Poster 2001, ISI 

ResearchSoft 1950-September 20, 2004 

CAB Abstracts WebSPIRS from SilverPlatter, Version 4.3 1973-September 18, 2004 

SIGLE FIZ Karlsruhe – Version Interhost 3000 1980-September 18, 2004 

OCLC Proceedings First OCLC FirstSearch 1993-September 18, 2004 

Dissertation Abstracts ProQuest 1980-September 18, 2004 

Alt HealthWatch EBSCOhost 1990-September 18, 2004 

NLM Gateway U.S. National Library of Medicine - 

http://gateway.nlm.nih.gov/gw/Cmd 1950-September 18, 2004 

PubMed U.S. National Library of Medicine 1950-September 20, 2004 
18 

Table 2. Subject headings and keywords used in searches 

Terms used for Questions 1-4 Additional Terms used for Question 4 

Insomnia Time zone change 

Sleep Initiation and Maintenance Disorders Jet lag 

Sleep onset delay ------- 

Sleep onset latency ------- 

DIMS ------- 

Disorder of initiating and maintaining sleep ------- 

Early awakening ------- 

Sleeplessness ------- 

Agrypnia ------- 

Hyposomnia ------- 
19 

Chapter 3. Results 

Literature Review 

The database searches resulted in 16,991 references of potentially relevant articles. One 

thousand two hundred studies were evaluated for inclusion in the review; 528 studies were 

potentially relevant to prevalence, natural history, incidence, risk factors and consequences of 

chronic insomnia, and 672 studies were potentially relevant to efficacy and safety of treatments 

used in the management of chronic insomnia. The application of inclusion criteria resulted in 79 

studies included and 449 studies excluded for the questions on manifestations of chronic 

insomnia, and 116 studies included and 556 studies excluded for the question on management of 

chronic insomnia. 

The primary reasons for exclusion of studies potentially relevant to manifestations of chronic 

insomnia were as follows: (1) the study was reported in a language other than English (n=9), (2) 

the report was a review (n=38), (3) the study was not relevant to the review topic (n=71), (4) the 

study was a case report (n=9), (5) the study did not have a control group (n=47), (6) the study did 

not examine an adult population (n=8), (7) the study population did not have chronic insomnia as 

defined in this report (n=208), (8) the study did not report on any of the outcomes of this review 

(n=58), and (9) data relevant to the study outcomes were not adequately reported (n=1). The 

primary reasons for exclusion of studies potentially relevant to the management of chronic 

insomnia were as follows: (1) the study was reported in a language other than English (n=27), 

(2) the report was a review/commentary/practice parameter (n=32), (3) the study report was a 

duplicate publication (n=3), (4) the study did not examine an adult population (n=17), (5) the 

study population did not suffer from chronic insomnia as defined in this report (n=221), (6) the 

study was not a randomized controlled trial (n=160), (7) the study did not have a placebo arm 

(n=48), (8) the study was not double-blind (n=15), (9) the study did not report on any of the 

outcomes of this review (n=16), and (10) data relevant to the study outcomes were not 

adequately reported (n=15). 

The rate of disagreement between reviewers for inclusion/exclusion of studies was 61/528 

(11.6 percent) for the questions on manifestations of chronic insomnia and 53/672 (7.9 percent) 

for the question on management of chronic insomnia. The primary reason for disagreement 

between reviewers was oversight of study details, such that reviewers erred on the side of overinclusion. Therefore, consensus often resulted in exclusion of studies: for the questions on 

manifestations of chronic insomnia, 18 disagreements resulted in inclusion and 43 disagreements 

resulted in exclusion, and for the question on management of chronic insomnia, eight 

disagreements resulted in inclusion and 45 disagreements resulted in exclusion. 

Flow Diagram 2 outlines study retrieval and selection for the review. 

Data Synthesis 

How is chronic insomnia defined, diagnosed and classified, and what 

is known about its etiology? 

There is lack of consensus regarding the “ideal” definition of insomnia and what constitutes 

chronic insomnia. The threshold of clinically significant sleep disturbance is not established, nor 
20 

has the morbidity resulting from insomnia been well studied. It is a matter of debate as to which 

definition of insomnia encompasses the problem as it would appear in a clinical and/or research 

setting, and whether the definition of chronic insomnia should be distinct. As a result, many 

variations in the definition of insomnia exist, especially for research purposes. We reviewed 

multiple sources to define, diagnose and classify chronic insomnia, including the Principles and 

Practice of Sleep Medicine textbook,15 diagnostic manuals (International Classification of Sleep 

Disorders-Revised (ICSD-R) and Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. 

(DSM-IV)),37-38 and standards of practice published by the American Academy of Sleep 

Medicine.1;39

Definition of chronic insomnia

The International Classification of Sleep Disorders Manual. The International Classification of 

Sleep Disorders Manual is a comprehensive diagnostic manual, which is used as a reference 

among sleep researchers and physicians for sleep disorders in adults. The manual outlines a 

highly specific system for diagnosis and classification of insomnia, and includes over 40 

diagnoses that may involve a complaint of insomnia. The International Classification of Sleep 

Disorders defines insomnia as difficulty in initiating and/or maintaining sleep or non-restorative 

sleep after a habitual sleep episode.37 The ICSD-R further differentiates insomnia based on 

severity of symptoms that impact daytime functioning. Mild insomnia is often associated with a 

feeling of restlessness, irritability, mild anxiety, daytime fatigue and tiredness, without evidence 

of social or occupational impairment. In contrast, moderate insomnia is accompanied by either 

mild or moderate impairment of social and occupational functioning. Moderate insomnia is 

always associated with feelings of restlessness, irritability, anxiety, daytime fatigue and 

tiredness. Severe insomnia is associated with symptoms similar to moderate insomnia, with 

severe impairment of social and/or occupational functioning. The duration of the insomnia is 

usually classified as acute (< 4 weeks), sub-acute (> 4 weeks but < 6 months) or chronic (> 6 

months). Investigators have not consistently adhered to this classification scheme to determine 

severity and duration of insomnia in study populations, thus the definition of insomnia across 

studies varies. This classification scheme has coding for insomnia secondary to psychiatric 

conditions, substance abuse as well as medical and sleep disorders. The ICSD-R has been 

revised, and another edition of the ICSD (ICSD2) is in press for publication. This revised coding 

manual will replace the current ICSD-R. 

International Statistical Classification of Diseases and Related Health Problems 10th Revision 

(ICD-10). The World Health Organization-supported definition for nonorganic insomnia is a 

condition of unsatisfactory quantity and/or quality of sleep, which persists for a considerable 

period of time, including difficulty falling asleep, difficulty staying asleep, or early final 

wakening. It also states that insomnia is a common symptom of many mental and physical 

disorders, and should be classified here in addition to the basic disorder only if it dominates the 

clinical picture. The duration of insomnia is not specified.

Diagnostic and Statistical Manual of Mental Disorders. In contrast to the definition of insomnia 

in the ICSD-R, in the DSM-IV, insomnia is not subcategorized, but rather referred to as primary 

insomnia,38 implying that insomnia is not caused or significantly influenced by a psychiatric 

disorder. Insomnia caused or associated with psychiatric illness is classified separately. The 
21 

duration of insomnia is listed as being longer than one month. Chronic insomnia is not defined 

in the DSM nosology. 

American Academy of Sleep Medicine: Standards of Practice. The standards of practice 

published by the American Academy of Sleep Medicine defines insomnia as a complaint of 

unsatisfactory sleep, which may involve difficulty initiating sleep, frequent or lengthy 

awakenings, early awakening, inadequate total sleep time or poor quality of sleep, impacting 

daytime functioning.1

 The daytime dysfunction may include any of the following: change in 

alertness, energy, cognitive function, behavior or emotional state. This definition of insomnia 

allows for subjective diagnosis in a clinical setting based on the patients’ history, without the aid 

of polysomnography. Although short-term insomnia is generally considered to last less than 

three months, the time frame for chronic insomnia is not explicitly stated in the standards of 

practice statement. 

Classification of insomnia 

The International Classification of Sleep Disorders Manual. A clinically relevant classification 

of insomnia is outlined in the ICSD-R, 2001.37 According to the ICSD-R, the different 

categories of insomnia include: psychophysiological insomnia, sleep state misperception, 

idiopathic insomnia, as well as insomnia secondary to other medical conditions or sleep 

disorders. Acute and chronic insomnia are not classified separately; however, insomnia is 

considered to be chronic if the symptoms last for more than six months. A brief overview of the 

ICSD-R categories follows: 

 

A. Psychophysiological insomnia, also known as conditioned or learned insomnia, is a 

disorder of somatized tension and learned sleep preventing associations that result in a 

complaint of insomnia and associated decreased functioning during wakefulness.37 

Continued problems in somatized tension and maladaptive learned sleep-preventing 

associations can worsen insomnia, creating a vicious cycle by perpetuating the initial 

problem. One must search for precipitating, predisposing and perpetuating factors for 

insomnia. A hallmark of this diagnosis is the individual’s fixation with his/her sleep 

problem. This diagnosis cannot be made in the context of other medical or psychiatric 

disorders. Associated features include perceived decrement in daytime mood and 

functioning, without overt sleepiness. The true prevalence of psychophysiological 

insomnia in the general population is not known, although approximately 15 percent of 

patients referred to a sleep disorders clinic suffer from this type of insomnia.37 

Diagnostic criteria for psychophysiological insomnia include: 

a) A combination of a complaint of insomnia and a complaint of decreased 

functioning during wakefulness. 

b) Indications of learned sleep-preventing associations such as trying too hard to 

sleep, or increased arousal in the bedroom (concern and worry about sleep). 

c) Evidence of somatized tension. 

d) Polysomnography may show increased sleep latency, reduced sleep efficiency and 

increased number and/or duration of awakenings during the sleep period. 

e) No other medical condition accounts for the sleep disturbance. 
22 

The diagnosis of psychophysiological insomnia requires that criteria a) and b) are satisfied. 

B. Sleep state misperception, or pseudo insomnia, is a subjective complaint of problems 

initiating or maintaining sleep without objective findings to support the complaint. There 

is no psychopathology per se associated with this disorder. The afflicted individual 

honestly has complaints of insomnia and decreased daytime functioning, without 

objective data to support the claim. Although the exact prevalence of this disorder is not 

known, this group accounts for approximately 5 percent of individuals with complaints of 

insomnia. Diagnostic criteria for sleep state misperception include: 

a) complaint of insomnia. 

b) sleep quality and quantity are normal. 

c) polysomnography shows normal sleep latency, sleep duration and awakenings 

during the sleep period. 

The diagnosis of sleep state misperception requires that criteria a) and b) are satisfied. 

C. Idiopathic Insomnia is defined as a life-long inability to obtain adequate sleep and may be 

related to abnormalities in the neurological systems affecting the sleep-wake cycle. The 

exact prevalence of this disorder is not known, but it is thought to be rare. Diagnostic 

criteria for idiopathic insomnia include: 

a) Complaint of insomnia with decreased functioning. 

b) Insomnia is life-long and may begin in early childhood. 

c) Insomnia is relentless and does not vary. 

d) Polysomnography shows increased sleep latency, decreased sleep efficiency and 

multiple awakenings during the night. 

e) No other medical illness or disease explains the early onset of insomnia. 

The diagnosis of idiopathic insomnia requires that criteria a), b), and d) are satisfied. 

Proposed classification for insomnia. A more recent article considers a novel method for 

classifying insomnia for research purposes.40 The authors propose research diagnostic criteria 

for Insomnia Disorder, Primary Insomnia, Insomnia due to a Mental Disorder, Paradoxical 

Insomnia and Psychophysiological Insomnia. The main differences between this classification 

scheme and that of ICDS-R, 2001, is that the criteria are more precise and the duration of 

symptoms must be more than one month for all categories. This classification scheme does not 

define a subcategory of chronic insomnia. This classification scheme was developed to allow for 

clear categorization of insomniacs within a study population, and thus avoid the study of a 

heterogeneous population. Based on a review of the literature, acute, situational or transient 

insomnia is considered to be different from chronic insomnia. It is not clear whether there are 

distinct differences in the nature of insomnia that lasts for more than 1 month, but less than 6 

months versus insomnia lasting for more than 6 months. 
23 

Diagnosis and assessment of insomnia. Different evaluation methods have evolved to identify 

individuals with insomnia. Diagnosis of insomnia is made in the context of a clinical history 

based on any of the aforementioned criteria or definitions. There are semi-structured or 

structured interviews available for diagnosing insomnia [i.e., Insomnia Interview Schedule and 

Duke Structured Sleep Inventory (the latter is currently being evaluated in a large-scale study)]. 

Sleep diaries/logs, sleep histories, actigraphy, ambulatory monitoring, and in-home 

polysomnography are often used to assess sleep parameters. The most commonly used measure 

for evaluation of insomnia is self-reported questionnaires. The use of objective tools, such as 

polysomnography or multiple sleep latency tests for the diagnosis of insomnia are not 

recommended.41-43 Sleep diaries are essential for identifying sleep onset and sleep maintenance 

difficulties; however, the reporting of sleep onset latency by diary is subjective. Scientists have 

tried to evaluate more objective measures for measuring sleep disturbances in patients with 

insomnia, but currently available tools have limitations (polysomnography and unattended home 

studies), and are most commonly used to diagnose sleep disorders other than insomnia. 

Moreover, these methods are cumbersome and costly. Actigraph monitors are small watch-like 

devices that are worn on the wrist and are used to record movement; they can be useful adjuncts 

for gathering data from individuals with sleep complaints; however, these devices are not 

indicated for the routine diagnosis of any sleep disorder.39 There is currently no biomarker of 

insomnia, which makes objective diagnosis of insomnia more difficult. Research in the area of 

insomnia has recently been directed towards identifying specific hormones or neurotransmitters 

that may be involved in this disorder.15 Various research groups are studying the link between 

specific electroencephalogram findings and insomnia. A less commonly used diagnostic tool for 

insomnia, position emission tomography imaging, has been used to evaluate brain metabolism 

and its role in insomnia.44 Insomnia is a clinical diagnosis and the lack of a research model for 

insomnia makes it difficult to target appropriate therapy for this disorder and evaluate treatment 

outcomes. 

Etiology of insomnia. Despite significant advances in sleep medicine over the past 50 years, 

much less is known about the cause of insomnia, its natural history, and its consequences than 

the treatments available for insomnia. Recent studies have demonstrated an increased metabolic 

rate in patients with insomnia,45 suggesting that sleep difficulties may at least partially have a 

physiological basis. It is also speculated that patients with insomnia are more aroused than 

people without insomnia;46 however, this theory is difficult to prove, given that the 

neurotransmitters involved in arousal are unknown. Advances in molecular genetics have shed 

light on the potential role of genetics in sleep disorders. Indeed, a familial etiology of this 

disorder has been postulated. A recent study concluded that more than 33 percent of patients 

with insomnia had a family history of insomnia.47 A similar study estimated a family history of 

insomnia among first-degree relatives of people suffering from insomnia to be 48.8 percent, 

compared to 23.5 percent among first-degree relatives of people who did not suffer from 

insomnia.48 The familial aggregates of insomnia have led researchers to investigate the genetic 

basis of insomnia, but no specific gene has been implicated. 

Certain populations, including the elderly, psychiatric patients, and those suffering from 

chronic pain are known to have more chronic sleep maintenance problems.1;49 A strong link has 

been found between insomnia and depression.50 The directionality of the association has not 

been fully elucidated, but the association appears to be strong.1
24 

Environmental factors, such as irregular sleep schedules, use of caffeine or other stimulants, 

co-morbid medical conditions, and/or shift-work may also predispose vulnerable individuals to 

insomnia.1

 Genetic predisposition, in addition to environmental factors, are likely involved in 

the development and maintenance of insomnia, and differences in the relative exposure to these 

influences may explain differences in the manifestation of this disorder across affected 

individuals. 

What are the prevalence, natural history, incidence and risk factors 

for chronic insomnia? 

What are the consequences, morbidities, co-morbidities and public 

health burden associated with chronic insomnia? 

Prevalence. A description of key features of studies relevant to prevalence of chronic insomnia 

is provided in Tables 3a (prevalence in general population), 3b (prevalence in outpatients of 

general practice) and 3c (prevalence in clinical populations), and additional information on each 

study is provided in Evidence Table C-1♦. The evidence provided in Tables 3a, b and c is 

summarized here. 

Forty-one studies provided evidence regarding the prevalence of chronic insomnia in adults; 

38/41 studies were cross-sectional studies, one study was a cross-sectional case-control study 

and compared the prevalence of chronic insomnia in bipolar subjects and healthy controls,51 one 

study had both cross-sectional and case-control components,52 and one study had both crosssectional and cohort components.53 Seventeen studies were considered of high quality, 19 

studies were considered of moderate quality and five studies were considered of low quality. 

Twenty-four studies described the sampling frame; most studies used census data, phone lists 

or patients presenting to a health clinic. Thirty-four studies described the sampling method; 21 

studies used a random method, while the majority of the remaining studies used a non-random 

method, and a minority of studies investigated entire populations. Twenty-seven studies 

provided a response or follow-up rate. The rate ranged from 25-100 percent; slightly more than 

half of the studies had a rate greater than 80 percent. All studies except one 54 clearly described 

the method of data collection; 19 studies used self-reported questionnaires, 12 studies used faceto-face interviews and 10 studies used phone interviews. One of these studies 55 used both selfreported questionnaires and phone interviews. Of the studies that described the method of data 

collection, slightly more than half used a validated method. The criteria used to establish the 

duration of chronic insomnia ranged from one month to one year; most of the studies required 

that participants suffer from insomnia symptoms for at least one month. Most studies reported 

the gender distribution of the population; the majority of studies used mixed gender populations 

and a minority of studies used all-female populations. All studies provided an estimate of the 

age of the population; the age of the populations ranged from 18 to 98 years, based on studies 

that provided a range. 

Twenty-six studies investigated general populations (Table 3a), eight studies investigated 

populations of outpatients from general practice (Table 3b), and eight studies investigated 

clinical populations (Table 3c). For high quality studies investigating general populations, the 

 

♦ The Appendices and Evidence Tables cited in this report are provided electronically at 

http://www.ahrq.gov/clinic/tp/insomntp.htm. 
25 

prevalence of chronic insomnia ranged from 5-45 percent, and the median was 17.6 percent. The 

interquartile range was 8.5-24.3 percent. For moderate quality studies investigating general 

populations, the prevalence of chronic insomnia ranged from 7.5-42.5 percent, and the median 

was 15.3. The interquartile range was 11.2-29.2 percent. 

We did not identify any high quality studies investigating the prevalence of chronic insomnia 

in outpatients of general practice. For moderate quality studies investigating this population, the 

prevalence of chronic insomnia ranged from 11.7-63.7 percent, and the median was 38.4 percent. 

The interquartile range was 19.8-53.7 percent. 

We identified only one high quality study investigating clinical populations, and it compared 

the prevalence of chronic insomnia in patients with Bipolar I disorder and a non-psychiatric 

population.56 One hundred percent of participants in the psychiatric group reported a longstanding sleep disturbance, while 21 percent of participants in the non-psychiatric group reported 

such a disorder. For moderate quality studies investigating clinical populations, the prevalence 

of chronic insomnia ranged from 26-51.3 percent, with a median of 33.5 percent. The 

interquartile range was 27.8-43 percent. The disorders of the clinical populations investigated 

were Parkinson’s Disease, brain injury, diabetes, stroke, Bipolar I disorder, migraines, blood 

disorders and metastatic breast cancer. 

Natural history. A description of key features of the study relevant to natural history is 

provided in Table 4, and additional information on this study is provided in Evidence Table C-1. 

The evidence provided in Table 4 is summarized here. 

Only one study was identified that provided evidence regarding the natural history of chronic 

insomnia,53 and it was of moderate quality. In this prospective cohort study, the participants 

consisted of outpatients from general hospitals with sleep complaints lasting for at least one 

month. The population was of mixed gender and had an age range of 18-65 years. At a fourmonth follow-up, the prevalence of chronic insomnia was reduced from 100 percent to 86.9 

percent, providing a remission rate of 13.1 percent. The follow-up rate was 42.2 percent. 

Incidence. We did not identify any studies that provided evidence on the incidence of chronic 

insomnia in adults. 

Associated factors. The majority of studies identified did not have designs that would support 

the categorization of an associated factor of chronic insomnia as either a risk factor or 

consequence of the disorder, such as longitudinal cohort studies. Most studies that examined the 

risk factors and consequences of interest were either of a cross-sectional or cross-sectional casecontrol design. Thus, we do not report on risk factors and consequences of chronic insomnia per 

se, rather we report on associated factors. For simplicity, we separate the results relevant to the 

various factors according to their categorization in the relevant question of the review, such that 

potential risk factors are reported separately from potential consequences. 

A description of key features of the studies relevant to associated factors is provided in Table 

5, and additional information for each study is provided in Evidence Table C-1. The evidence 

provided in Table 5 is summarized here. 

Sixty-seven studies provided evidence regarding the association between various factors and 

chronic insomnia in adults; 30/67 studies were cross-sectional studies and 37/67 studies were 

cross-sectional case-control studies. The cross-sectional case-control studies compared chronic 

insomniacs (cases) and normal sleepers (control) on various factors to determine whether these 
26 

factors are associated with chronic insomnia. Similarly, the cross-sectional studies examined the 

relationship of various factors and chronic insomnia by comparing chronic insomniacs and 

normal sleepers within a given population. Twenty-three studies were considered of high 

quality, 30 studies were considered of moderate quality and 14 studies were considered of low 

quality. 

The criteria for chronic insomnia varied widely across studies and it was explicitly reported 

for most studies. The duration of sleep disturbance required to meet the criteria for chronic 

insomnia ranged from one month to 5 years, although the majority of studies required symptoms 

to be present for one or 6 months. Most studies reported the gender distribution of the 

population; the majority of populations were of mixed gender, and a minority of populations 

were all-female. The age of participants was reported for most studies, and ranged from 18 to 98 

years, based on studies that provided a range. A number of studies (37/67) did not report the 

response/follow-up rate for the study. Of those that reported the response/follow-up rate, it 

ranged from 37.6-100 percent. The majority of studies had a rate of 80 percent or more. 

Potential risk factors 

Age. Eleven studies found evidence of an association between age and chronic insomnia, while 

seven studies found no evidence of an association between these variables. Of the studies that 

found an association, all, except one,57 found evidence that chronic insomnia is associated with 

older age. Kageyama et al. found evidence that chronic insomnia is associated with age 24 years 

or less. 

Gender. Eleven studies found evidence of an association between gender and chronic insomnia, 

while seven studies found no evidence of an association between these variables. All of the 

studies that found evidence of an association between gender and chronic insomnia, found 

evidence that chronic insomnia is associated with female gender. 

Race/ethnicity. Two studies found evidence of an association between ethnicity and chronic 

insomnia,58-59 while one study found no evidence of an association between these variables.60

Bixler et al. found evidence that chronic insomnia is associated with being a non-Caucasian 

minority, and Riedel et al. found evidence that chronic insomnia is associated with being White. 

Psychiatric illness and psychological problems. Thirty-eight studies found evidence of an 

association between present or past psychiatric illness or psychological problems and chronic 

insomnia. Cumulatively, chronic insomnia was found to be associated with anxiety, depression, 

tension, loneliness, neuroticism, worry, rumination, psychological distress, nervousness, 

obsessive compulsiveness, maladaptive perfectionism, impulsivity, phobia, paranoid ideation, 

psychoticism and hypochondrial concerns. Seven studies did not find evidence of an association 

between one or more of the following conditions and chronic insomnia: neurological problems, 

anxiety, depression, tension and confusion. 

Medical conditions. Twelve studies found evidence of an association between medical 

conditions or poor general health and chronic insomnia, while one study57 did not find evidence 

of an association between these variables. 
27 

Socioeconomic status. Six studies found evidence of an association between socioeconomic 

status and chronic insomnia. Cumulatively, chronic insomnia was found to be associated with 

marital separation, divorce or death of a spouse, unemployment, exposure to poorer working 

conditions and lower social status. Moreover, chronic insomnia was found to be associated with 

both lower and higher education. Nine studies did not find evidence of an association between 

one or more of the following factors and chronic insomnia: education, employment and marital 

status. 

Shift-work. Only two studies provided evidence regarding the relationship between shift-work 

and chronic insomnia.57-61 The study by Kageyama et al. provided evidence that chronic 

insomnia is associated with three or less night shifts per month within the preceding three 

months in hospital nurses. The study by Martikainen et al. found no evidence of an association 

between shift-work and chronic insomnia. 

Potential consequences 

Healthcare utilization. Five studies provided evidence of an association between increased 

healthcare utilization and chronic insomnia. Cumulatively, chronic insomnia was found to be 

associated with hospitalization, visits to neurology and psychiatric departments and undergoing 

medical treatment. One study did not find evidence of an association between chronic insomnia 

and undergoing medical treatment in hospital nurses.57 

Absenteeism and work performance. Only two studies provided evidence regarding the 

relationship between work performance or absenteeism and chronic insomnia;62-63 both studies 

found evidence of an association between chronic insomnia and absenteeism. The study by 

Zammit et al. also found evidence of an association between chronic insomnia and impaired 

work performance. 

Quality of life and quality of social relationships. Five studies examined the relationship 

between either quality of life or quality of social relationships and chronic insomnia. All studies 

found evidence of an association between chronic insomnia and either lower quality of life or 

lower quality of social relationships; one of these studies found evidence that both quality of life 

and quality of social relationships are impaired in chronic insomniacs.64 Lower quality of social 

relationships was reported as receiving less support from colleagues and conflicts with relatives. 

Memory, cognitive function and mood. Fifteen studies found evidence of an association between 

decrements in memory, mood or cognitive function and chronic insomnia. Cumulatively, the 

measures of cognitive function were cognitive fatigue, sensory acuity, perceptual/motor skills, 

reaction time, psychosocial function, concentration, psychomotor function, attention, alertness, 

mental acuity, reasoning, problem-solving ability and mental reactivity. One study65 found 

evidence of increased recall of presentations made just before sleep onset in chronic insomniacs. 

Eleven studies found no evidence of an association between mood, memory or cognitive function 

and chronic insomnia. Cumulatively, the measures of cognitive function were vigilance, proofreading, reaction time, motor performance, concentration, divided attention, recent memory, 

audio/verbal patterns, psychomotor function, words heard and repeated, free recall, alertness and 

concentration. 
28 

We did not identify any studies that provided data relevant to the relationship between 

accidents or falls in the elderly and chronic insomnia, nor did we find evidence on the direct and 

indirect costs associated with the disorder. 

What treatments are used for the management of chronic insomnia in 

adults and what is the evidence regarding their safety, efficacy and 

effectiveness? 

One hundred and sixteen studies were relevant to the management of chronic insomnia; 34 

studies were considered of high quality, 68 studies were considered of moderate quality and 14 

studies were considered of low quality. All studies were described as randomized, while only 91 

studies were described as double-blind. Seventy-eight studies provided a description of 

withdrawals and dropouts. Only nine studies described an appropriate method to generate the 

sequence of randomization, and 41 studies described an appropriate method of double-blinding. 

All other studies did not describe the method to generate the sequence of randomization, or the 

method of double-blinding. Only nine studies had adequate concealment of treatment allocation; 

for the remaining 107 studies, the adequacy of concealment was unclear. One hundred and four 

studies reported on sleep onset latency and only 33 studies reported on wakefulness after sleep 

onset, the outcomes of highest priority in this review. Regarding the other outcomes of interest 

in this review, 33 studies reported on sleep efficiency, 71 studies reported on total sleep time, 66 

studies reported on sleep quality and only one study reported on quality of life. 

Only 51 studies provided information on source of funding; 38 studies received private 

funding, 10 studies received government funding, two studies received academic funding, and 

one study received foundation funding. The majority of studies did not provide information on 

the role of the funding organization; however, only two out of 38 studies that reported receiving 

private funding explicitly stated that the funding organization was involved in data analysis 

and/or research design and selection of investigators. 

The majority of studies had a parallel design. For studies in which there was a discrepancy 

between the number of participants enrolled and analyzed, it was often unclear whether an 

intent-to-treat analysis had been conducted. The majority of studies used sleep diary to assess 

sleep outcomes, and a number used both sleep diary and polysomnography to assess outcomes. 

Of the 111 studies that reported a treatment length, it ranged from one day to six months, with a 

median of three weeks. Of the 25 studies that reported a follow-up period, it ranged from one 

week to three years, with a median of 6 months. 

The duration of chronic insomnia suffered by participants ranged from two months to 51 

years, based on the 54 studies that provided a range. The age range of the population was 15-95 

years, based on the 84 studies that provided a range; only two studies included participants under 

the age of 18 years old. Of the 111 studies that reported on the gender distribution of the 

population, 102 studies had a mixed gender population, while five studies had an all-female 

population and four studies had an all-male population. The inclusion criteria of nine studies 

were designed to select individuals with a psychiatric illness, including individuals with 

depression, dysthymic disorder, dementia, schizophrenia, personality disorder, myocolonus, 

anxiety disorders, Pick's disease, alcoholic psychoses, Huntington chorea, and cerebral laceration 

and contusion. 

The studies were categorized according to intervention: benzodiazepines (n=51), nonbenzodiazepines (n=36), antidepressants (n=7), complementary and alternative care (n=14), 
29 

relaxation therapy (n=15), cognitive/behavioral therapy (n=18), alcohol (n=1), barbiturates 

(n=2), hormones (n=1) and LEET therapy (n=1). Complementary and alternative care had two 

studies on L-tryptophan, 8 studies on melatonin and 4 studies on valerian. A number of studies 

fell under the general category of combination treatment (n=8). A given study could be relevant 

to more than one category. The number of participants analyzed in the efficacy analysis (sleep 

onset latency only) was as follows: benzodiazepines (n=1858), non-benzodiazepines (n=4169), 

antidepressants (n=298), L-tryptophan (n=47), melatonin (n=103), valerian (n=51), relaxation 

therapy (n=384), cognitive/behavioral therapy (n=276), alcohol (n=11), barbiturates (n=93), 

hormones (n=49) and LEET therapy (n=97). The number of participants analyzed in the safety 

analysis was as follows: benzodiazepines (n=3800), non-benzodiazepines (n=5485), 

antidepressants (n=288), complementary and alternative care (n=87), relaxation therapy (n=0), 

cognitive/behavioral therapy (n=0), alcohol (n=0), barbiturates (n=48), hormones (n=0) and 

LEET therapy (n=0). 

Benzodiazepines 

Sleep onset latency. Meta-analysis of the 32 studies that compared the effects of 

benzodiazepines and placebo on sleep onset latency (SOL) showed a statistically significant, 

albeit modest, difference of 16.5 minutes in favour of benzodiazepines (Figure 1). While there 

was substantial heterogeneity among the studies, all but two studies had a point estimate that 

favoured benzodiazepines. The heterogeneity was due more to different estimates of how 

effective the drugs were than as to whether or not they were superior to placebo. The study 

estimates ranged from about 65 minutes improvement in SOL to no difference.

Table 6 lists all of the sub-group analyses conducted for sleep onset latency. Nine different 

types of benzodiazepines were examined by the studies. With the exception of nitrazolam 

(which had a significantly higher estimate than all other drugs except flunitrazepam, flurazepam, 

and triazolam, but was examined by only one study) all drug types had SOL estimates between 

24 and 10 minutes. The four studies that examined patients with a psychiatric illness showed a 

mean SOL difference of about 26 minutes, 10 minutes more than the remainder of the studies 

that had patients without a psychiatric illness (not statistically significant). The two studies that 

had results for long-term treatment showed a nearly identical estimate to those with results for 

short-term treatment. Similarly, age had little impact on SOL, with a 19-minute difference for 

elderly patients compared to a 15-minute difference for adult patients. There were only three 

studies that examined solely male patients and only one study that examined solely female 

patients. These studies were not very different from each other or the remaining studies. 

Finally, subdividing the studies by method of measurement of outcomes showed that those 

studies that used a sleep diary to measure SOL had a significantly greater efficacy estimate than 

those that used polysomnography (about 18 minutes compared to 7 minutes). The sub-groups of 

drug type, psychiatric illness, age and method of measurement had a Deeks’ chi-square P-value 

less than 0.05, indicating that heterogeneity was significantly reduced by the sub-group. 

Analysis of the studies by quality revealed that the high quality studies showed a slightly 

stronger estimate of SOL difference (19 minutes) than the moderate quality studies (14 minutes) 

(there were no low quality studies). Although the difference is not statistically significant, 

Deeks’ chi-square shows that this sub-grouping significantly reduced heterogeneity. 

Although both Begg’s (P-value = 0.81) and Duval’s (no studies added) tests indicated no 

publication bias non-parametrically, Egger’s test (p-value < 0.001) showed significant 
30 

asymmetry in the funnel plot. This finding is also confirmed by a visual inspection of the funnel 

plot (Figure 2). The finding may indicate that the efficacy estimate given by the meta-analysis 

may in fact overestimate true efficacy, due to possible unpublished studies with non-significant 

results. 

Wakefulness after sleep onset. Only eight benzodiazepine studies reported data on wakefulness 

after sleep onset (WASO). They revealed an average 23-minute improvement in WASO in the 

benzodiazepine patients as compared to the placebo patients (Figure 3). This result was 

statistically significant. Although there was substantial heterogeneity in this estimate, seven of 

the eight studies showed a point estimate that favoured treatment. 

Other efficacy outcomes. Three other estimates of efficacy were measured, and the results can 

be viewed in Table 7. All outcomes showed statistically significant results that favoured 

benzodiazepines over placebo. Benzodiazepines increased sleep efficiency over placebo by an 

average of 6.3 percent and increased total sleep time by an average of 39 minutes. Sleep quality 

also showed a large difference between the groups with the benzodiazepines group having a 

standard mean difference (SMD) that was 0.8 standard deviations larger than placebo. 

Heterogeneity was negligible for sleep efficiency, substantial for total sleep time, and moderate 

for sleep quality. 

Safety. The benzodiazepines showed a significantly greater proportion of adverse events than 

did placebo, although the meta-analysis showed substantial heterogeneity (Table 7). The risk 

difference estimates had a range of (0.01, 0.30) and an interquartile range of (0.08, 0.22) across 

interventions. The pooled risk-difference of 0.15 translates into a number needed to harm of 

seven patients (95% CI: 5, 10). 

The most commonly reported adverse events of benzodiazepine use were somnolence (n=27 

studies), headache (n=18), dizziness (n=16), nausea (n=11) and fatigue (n=11). There were no 

reports of falls, injury or death. 

Non-benzodiazepines 

Sleep onset latency. Twenty-nine studies on non-benzodiazepines showed a statistically 

significant difference of about 18 minutes in sleep onset latency compared to placebo (Figure 4). 

This difference is similar to the one reported for benzodiazepines. Again, similar to 

benzodiazepines, there was substantial heterogeneity among the studies, but all studies had a 

point estimate that favoured non-benzodiazepines. The study estimates ranged from about 67 

minutes improvement to 4 minutes improvement in SOL. 

The results for the sub-group analyses for sleep onset latency can be viewed in Table 8. Four 

different types of non-benzodiazepines were examined by the studies. The four different drugs 

examined ranged in their efficacy from a 31-minute improvement (zopiclone) to a 13-minute 

improvement (zolpidem). Deeks’ chi-square test showed that this sub-grouping resulted in a 

significant reduction in heterogeneity. All of the other sub-groups examined did not show 

significant reductions in heterogeneity. For psychiatric illness, only one study had patients with 

such an illness, and that study showed a significantly shorter improvement in SOL. For length of 

treatment, the short-term and long-term studies had nearly identical improvements, as did the 

studies for adult and elderly patients. For gender, there was one study that examined an all-male 
31 

population and one study that examined an all-female population. Although the results differed 

from the overall average (less effective for males and much more effective for females), there 

was not enough data to draw any firm conclusions (no statistically significant differences). 

Finally, the studies that used polysomnography to estimate sleep onset latency were not different 

from those that used a sleep diary. 

The high quality studies had an SOL estimate (30 minutes) that was significantly greater than 

the estimate for moderate quality studies (14 minutes) (there were no low quality studies), as was 

the case with the benzodiazepines. However, this sub-grouping did not significantly reduce 

heterogeneity. 

Only Duval’s test (no studies added in the trim and fill) showed no evidence of publication 

bias. Begg’s (P-value = 0.01) and Egger’s (P-value = 0.01) tests both showed evidence of funnel 

plot asymmetry, as did a visual examination of the plot (Figure 5). This finding suggests a 

possible overestimation of the efficacy in terms of SOL of non-benzodiazepines in our metaanalysis. 

Wakefulness after sleep onset. Nine studies reported on WASO comparing non-benzodiazepines 

to placebo. The studies found that non-benzodiazepines decreased WASO by an average of 

about 13 minutes, which was statistically significant. Heterogeneity was substantial, caused 

mostly by one study, whose estimate was very different from the others (Figure 6). 

Other efficacy outcomes. Four other estimates of efficacy were measured, and their results can 

be viewed in Table 9. All outcomes showed statistically significant results that favoured nonbenzodiazepines over placebo. Sleep efficiency was increased in non-benzodiazepines by about 

6 percent, while total sleep time was increased by about 28 minutes. Both sleep quality and 

quality of life showed moderate improvements in non-benzodiazepines compared to placebo 

with SMDs of 0.48 and 0.45, respectively. Heterogeneity was negligible for sleep efficiency, 

moderate for total sleep time, and substantial for sleep quality. 

Safety. The non-benzodiazepines showed a significantly greater proportion of adverse events 

than did placebo, although the meta-analysis showed substantial heterogeneity (Table 9). The 

risk-difference had a range of (0.00, 0.15) and an interquartile range of (0.05, 0.08) across 

interventions. The pooled risk-difference of 0.05 translates into a number needed to harm of 20 

patients (95% CI: 11, 100). 

The most commonly reported adverse events of non-benzodiazepine use were headache 

(n=16 studies), dizziness (n=14), nausea (n=13) and somnolence (n=13). Accidental injury was 

reported in only one study, although there was no difference in the frequency of this event 

between experimental and control groups. 

Antidepressants 

Sleep onset latency. There were six studies that examined the effect of antidepressants (doxepin, 

pivagabine, trazodone and trimipramine) on sleep onset latency. They showed a small but 

statistically significant difference of about 7 minutes in sleep onset latency compared to placebo 

(Figure 7). The heterogeneity in this estimate was minimal and all six studies had an estimate 

that favoured the drug. The study estimates ranged from about 17 minutes improvement in SOL 

to no difference. 
32 

The results of sub-group analyses for sleep onset latency can be viewed in Table 10. All six 

studies were of mixed gender and featured only adults, so no sub-group analysis on gender or 

age was performed. Of the comparisons that were made, none significantly reduced 

heterogeneity, despite some marked differences in point estimates. This finding was mainly due 

to the low number of studies: most categories had a sub-group of only one study and method of 

measurement had a sub-group of only two studies. None of the differences in point estimates 

were statistically significant. 

The one high quality study had an SOL estimate (17 minutes) that was higher than the 

estimate for the moderate quality studies (7 minutes) (there were no low quality studies). This 

sub-grouping did not significantly reduce heterogeneity, and the difference between estimates 

was not significant. 

Since only six studies were included in this analysis, there were too few studies to perform 

any meaningful tests of publication bias. 

Wakefulness after sleep onset. Three studies reported on WASO comparing antidepressants 

(doxepin and trazodone) to placebo. The studies found that antidepressants decreased WASO by 

an average of about 11 minutes, which was statistically significant. Heterogeneity was 

negligible (Figure 8). 

Other efficacy outcomes. Three other estimates of efficacy were measured (no studies included 

an analysis of quality of life), and their results can be viewed in Table 11. All outcomes showed 

statistically significant results that favoured antidepressants over placebo. Sleep efficiency was 

increased in the antidepressant group by about 13.8 percent, while total sleep time was increased 

by about 53.1 minutes. Sleep quality showed a moderate increase for antidepressants of about 

0.63 on the SMD scale. Heterogeneity was negligible for sleep efficiency and substantial for 

both total sleep time and sleep quality.

Safety. The antidepressants showed a significantly greater proportion of adverse events than 

placebo, and the meta-analysis showed negligible heterogeneity (Table 11). The risk-difference 

had a range of (-0.07, 0.13) and an interquartile range of (0.01, 0.11). The pooled risk-difference 

of 0.09 translates into a number needed to harm of 11 patients (95% CI: 6, 100). 

The most commonly reported adverse events with antidepressant use were somnolence (n=4), 

headache (n=3), dizziness (n=3), and nausea (n=3). There were no reports of falls, injury or 

death. 

Complementary and alternative care 

There were three different types of complementary and alternative therapies observed in our 

included studies: L-tryptophan, melatonin, and valerian. These three substances were considered 

too different clinically to combine, and thus their results will be considered separately. 

L-tryptophan

Sleep onset latency. Only two studies reported data for l-trytophan versus placebo and the results 

for sleep onset latency can be seen in Figure 9. The two studies showed an average reduction in 

SOL of 11 minutes, but the result was not significant, and the heterogeneity between the two 
33 

studies was substantial. There were too few studies to do any meaningful tests for publication 

bias. No other outcomes of interest were reported for L-tryptophan (Table 12). The two studies 

used different methods to measure sleep onset latency. The study that used polysomnography 

showed a significant effect of L-tryptophan (-20.1 minutes; 95% CI: -33.6, -6.6), while the study 

that used sleep diary did not (2.9 minutes; 95% CI: -21.6, 27.4). However, the difference 

between the two studies was not statistically significant. 

Melatonin

Sleep onset latency. There were 8 studies on melatonin that examined sleep onset latency. 

Similar to the antidepressants, this category of intervention showed a small but statistically 

significant difference of about 8 minutes in sleep onset latency compared to placebo (Figure 9). 

The heterogeneity in this estimate was moderate, and all but two of the studies had an estimate 

that favoured the drug. The study estimates ranged from about 20 minutes improvement in SOL 

to 10 minutes detriment. When the eight studies were grouped by method of measurement, some 

differences in efficacy estimates were observed among the groups. The estimate for 

polysomnography (-3.6 minutes; 95% CI: -8.8, 1.6) was significantly different from the estimate 

for actigraphy (-16.7 minutes; 95% CI: -25.0, -8.3). Neither estimate was significantly different 

from the estimate for sleep diary (5.1 minutes; 95% CI: -20.0, 30.2). 

No publication bias was immediately apparent from the funnel plot (Figure 10), and both 

Begg’s test (P-value = 0.90) and Egger’s test (P-value = 0.21) did not show significant 

asymmetry. However, Duval’s trim and fill test did add one study to the meta-analysis and 

slightly increased the efficacy estimate (-8.7 minutes; 95% CI: -14.9, -2.5). 

Wakefulness after sleep onset. Five studies reported on WASO comparing melatonin to placebo. 

The studies found that melatonin decreased WASO by an average of about 10 minutes, but this 

difference was not statistically significant. Heterogeneity was substantial, with two studies 

indicating a significant effect in favour of melatonin, while the other three studies all had 

estimates on the side of the null favouring placebo (Figure 11). 

Other efficacy outcomes. Three other estimates of efficacy were measured for melatonin versus 

placebo (no studies included an analysis of quality of life), and their results can be viewed in 

Table 13. None of the three outcomes showed statistically significant results. The point 

estimates for sleep efficiency and total sleep time were 3 percent and 6 minutes, respectively. 

Sleep quality had a small efficacy difference of 0.3 standard deviations. Heterogeneity was 

substantial for both sleep efficiency and total sleep time, while it was negligible for sleep quality. 

Safety. The melatonin studies did not show any significant difference in number of adverse 

events versus placebo (Table 13), with an estimated risk difference of 0.09. Heterogeneity 

among studies was moderate. 

Valerian

Sleep onset latency. There were three studies on valerian that examined sleep onset latency. The 

studies showed a small average difference between valerian and placebo (1 minute), which was 

not statistically significant (Figure 9). The heterogeneity in this estimate was substantial with 
34 

two studies favouring valerian and the third being well on the side of placebo. The study 

estimates ranged from about 17 minutes improvement in SOL to 23 minutes detriment. There 

were too few studies to do any meaningful tests for publication bias. When the studies were 

grouped by method of measurement, differences among groups were observed. The estimate for 

polysomnography (9.5 minutes; -11.3, 30.3) was significantly different from the estimate for 

sleep diary (-16.0 minutes; 95% CI: -29.5, -2.5). 

Wakefulness after sleep onset. Only one study reported on WASO comparing melatonin to 

placebo, but it did find a difference of 8 minutes between the groups, which favoured valerian 

and was statistically significant (Figure 11). 

Other efficacy outcomes. Three other estimates of efficacy were measured for valerian versus 

placebo (no studies included an analysis of quality of life), and their results can be viewed in 

Table 14. None of the three outcomes showed statistically significant results. The point 

estimates for sleep efficiency and sleep onset latency were very small at 0.1 percent and 1 

minute, respectively. Sleep quality had a large efficacy difference of 1.38 standard deviations, 

but, as mentioned, it was not statistically significant. Heterogeneity was negligible for sleep 

efficiency and substantial for sleep quality. 

Safety. The valerian studies did not show any significant difference in number of adverse events 

versus placebo (Table 14), with an estimated risk difference of -0.06, which actually favoured 

valerian. Heterogeneity among studies was substantial. 

Relaxation therapy 

Sleep onset latency. There were 13 studies on relaxation therapy that examined sleep onset 

latency. Meta-analysis showed a pooled difference of 15 minutes favouring therapy over 

placebo (Figure 12). This result was not statistically significant. The heterogeneity in this 

estimate was extremely high (I2

: 96 percent), although all but three of the studies had an estimate 

that favoured the drug. The study estimates ranged from about 60 minutes improvement in SOL 

to 14 minutes detriment. 

The results for sub-group analyses for sleep onset latency in relaxation therapy can be viewed 

in Table 15. All 13 studies analysed patients without psychiatric illnesses and used sleep diary to 

measure SOL, so no sub-group analyses on these variables were performed. The other four subgroups examined yielded highly significant reductions in heterogeneity. Despite this finding, 

many of the individual sub-groups had very high heterogeneity. Subdividing by type of 

relaxation therapy, efficacy estimates ranged from 60 minutes improvement to 5 minutes 

improvement. Only breathing training, group relaxation, and hypnotic relaxation showed 

statistically significant efficacy despite each sub-group containing only one trial. The short-term 

effects of relaxation therapy on SOL proved significantly greater than the long-term effects (22 

minutes improvement versus 2 minutes detriment). There was only one study of elderly patients, 

and it showed no improvement in sleep onset latency compared to the studies on adults, which 

showed an improvement of 16 minutes. This difference was not significant. Finally, one study 

had only female participants (there were no studies of all-male populations), and it had a lower 

efficacy than the remainder of the studies (6 minutes compared to 16 minutes). This difference 

was non-significant. 
35 

The moderate quality studies had a slightly higher (but not significantly higher) efficacy 

estimate than the low quality studies (18 minutes compared to 9 minutes) (there were no high 

quality studies). This sub-grouping significantly reduced heterogeneity. 

No publication bias was immediately apparent from the funnel plot (Figure 13). Both 

Egger’s test (P-value = 0.49) and Duval’s trim and fill (no studies added) did not show 

significant asymmetry. However, Begg’s test did show some evidence of asymmetry (P-value = 

0.004). This finding is somewhat surprising considering that Begg’s test is usually the most 

conservative test (i.e. it is unusual to have a significant Begg P-value and a non-significant Egger 

P-value). 

Wakefulness after sleep onset. Only three studies reported on WASO comparing relaxation 

therapy to placebo. Their combined efficacy estimate was very small (-2 minutes) and favoured 

relaxation therapy (Figure 14). The result was not statistically significant. Heterogeneity was 

minimal. 

Other efficacy outcomes. Three other estimates of efficacy were measured for relaxation therapy 

versus placebo (no studies included an analysis of quality of life), and their results can be viewed 

in Table 16. Only total sleep time showed a statistically significant result, with an average 

improvement in the relaxation group of 23 minutes. Sleep efficiency had an estimate of 0.4 

percent, while sleep quality showed a small estimate of 0.4 standard deviations. Neither estimate 

was statistically significant. Heterogeneity was negligible for sleep efficiency and total sleep 

time, but was substantial for sleep quality. 

Safety. None of the trials of this category reported on adverse events. 

Cognitive/behavioral therapy

Sleep onset latency. There were nine studies on cognitive/behavioral therapy (CBT) that 

examined sleep onset latency. Meta-analysis showed a pooled difference of 5 minutes favouring 

therapy over placebo (Figure 15). This result was not statistically significant. The heterogeneity 

in this estimate was minimal, although three of the nine studies had an estimate that favoured 

placebo. The study estimates ranged from about 30 minutes improvement in SOL to 19 minutes 

detriment. 

The results of sub-group analyses for sleep onset latency in CBT can be viewed in Table 17. 

All nine studies were of mixed gender, analysed patients without psychiatric illnesses and used 

sleep diary to measure SOL, so no sub-group analyses on gender, psychiatric illness or method 

of measurement were performed. Of the three sub-groups examined, none showed significant 

reduction in heterogeneity. Subdividing by type of intervention, stimulus control and thought 

non-suppression had slightly higher estimates than multi-component CBT, paradoxical intention, 

and sleep compression, but the differences were not significant. Similarly, the short-term and 

long- term differences were comparable. There was only one study that examined elderly 

participants, and its efficacy estimate was not very different from the adult studies. 

The low quality studies had a slightly higher efficacy estimate than the moderate quality 

studies (8 minutes compared to 1 minute), but the difference was not statistically significant 

(there were no high quality studies). This sub-grouping did not significantly reduce 

heterogeneity. 
36 

There was no evidence of publication bias. The funnel plot did not appear to be asymmetric 

(Figure 16), and Begg’s (P-value = 0.53), Egger’s (P-value = 0.37) and Duval’s (no studies 

added) tests all confirmed this finding. 

Wakefulness after sleep onset. Eight studies reported on WASO comparing CBT to placebo. 

Their combined efficacy estimate showed that CBT improved WASO by an average of 18 

minutes (Figure 17). The result was statistically significant, although heterogeneity was 

substantial. Despite the high heterogeneity, all but one study showed a result that favoured CBT. 

Other efficacy outcomes. Three other estimates of efficacy were measured for CBT versus 

placebo (no studies included an analysis of quality of life), and their results can be viewed in 

Table 18. Both sleep efficiency and sleep quality showed statistically significant improvements 

for CBT over placebo. Sleep efficiency improved by an average of 6 percent, while sleep quality 

showed an improvement of 0.38 standard deviations. Total sleep time showed no difference. 

Heterogeneity was negligible for sleep quality, but substantial for both the sleep efficiency and 

total sleep time estimates. 

Safety. None of the CBT trials reported on adverse events. 

Indirect comparisons 

Efficacy. Table 19 shows the results of the pair-wise indirect comparisons of sleep onset latency 

for each of the four pharmacological treatment categories: benzodiazepines, nonbenzodiazepines, antidepressants, and complementary and alternative care, the latter divided into 

L-tryptophan, melatonin, and valerian. Both benzodiazepines and non-benzodiazepines proved 

significantly more efficacious than antidepressants and melatonin. None of the other 

comparisons showed significant differences. Comparing the two non-pharmacological treatment 

categories (relaxation therapy and cognitive/behavioral therapy) also showed no significant 

difference (-10 min.; 95% CI: -25.7, 5.7). 

Safety. Table 20 shows the results of indirect comparisons of adverse events for the four main 

pharmacological treatment categories that provided relevant data: benzodiazepines, nonbenzodiazepines, antidepressants and complementary and alternative care, the latter divided into 

melatonin and valerian (there was no safety data for L-tryptophan). The only significant 

comparison is that of benzodiazepines and non-benzodiazepines, where the latter treatment 

category was found to be significantly safer than the former in terms of number of adverse 

events. Note that despite the fact that valerian had the lowest point estimate, the larger 

confidence interval prevented a meaningful comparison of its safety relative to the other 

treatment categories. 

Other treatments

There were some studies that examined treatments that did not fall under any of the 

preceding six treatment categories. They are outlined here.
37 

Barbiturates. There were two trials that examined barbiturates versus placebo. Four different 

types of barbiturates were examined in the trials: glutethimide, methyprylon, phenobarbitol and 

secobarbitol. 

Only two outcomes (sleep onset latency and adverse events) were analysed in the two trials. 

The results can be viewed in Table 21. Neither SOL nor number of adverse events differed 

significantly from placebo in the meta-analyses. 

Hormones. One trial examined the efficacy of two different hormones (climodein and estradiol) 

in women with a diagnosis of insomnia related to post-menopausal syndrome. Four outcomes 

(sleep onset latency, sleep efficiency, total sleep time, and sleep quality) were examined (Table 

22). Sleep efficiency and sleep quality showed a statistically significant improvement (5 percent 

and 22 minutes respectively) with the hormones, while sleep onset latency and total sleep time 

showed an improvement that was not significant. 

Alcohol. One trial examined the efficacy of ethanol versus placebo. The three outcomes 

examined (sleep onset latency, WASO, and sleep efficiency) had non-significant differences 

between treatment and placebo (Table 23). All three efficacy estimates favoured placebo, 

although the differences were not significant. 

Low energy emission therapy. One study compared the effect of low energy emission therapy 

(LEET) with placebo for insomniacs. The results for the four efficacy (sleep onset latency, 

WASO, sleep efficiency, and total sleep time) and one safety outcome can be viewed in Table 

24. Statistically significant improvements in both sleep efficiency and total sleep time (11 

percent and 56 minutes, respectively) were found. The estimates for sleep onset latency and 

WASO were not significant, but did favour the LEET intervention. There was also no evidence 

that adverse events were higher for LEET than for placebo. 

Combination treatments 

This section will outline the results of eight trials that employed various combinations of the 

above treatments. Unlike all other sections of this review, we did not limit ourselves to 

comparing these treatments to placebo. All comparisons within the trials were examined. Ten 

different comparisons resulted and are outline below. The combination therapy in each case is 

always considered to be the “treatment arm.” 

Relaxation therapy and cognitive behavioral therapy versus placebo. There were four studies 

included in a meta-analysis of a combined relaxation therapy and CBT treatment versus placebo. 

The results for four outcomes (SOL, WASO, total sleep time, and sleep quality) can be viewed in 

Table 25. Although all estimates favoured treatment, only the result for sleep onset latency 

proved statistically significant, with an estimated improvement of about 22 minutes. 

Interestingly, this is nearly identical to the sum of the calculated effect from the meta-analyses of 

each of these interventions alone. 

Relaxation therapy and cognitive behavioral therapy versus relaxation therapy. Two studies 

compared relaxation therapy and CBT treatment with relaxation therapy alone. Table 26 

contains the results for the four reported outcomes (SOL, WASO, total sleep time, and sleep 
38 

quality). None of the results were statistically significant with only sleep onset latency favouring 

the combined treatment. The other three outcomes showed an efficacy estimate that favoured 

relaxation alone, although as mentioned, none were significant. 

Relaxation therapy and cognitive behavioral therapy versus cognitive behavioral therapy. Two 

studies compared relaxation therapy and CBT treatment with CBT alone. None of the results for 

the four outcomes (SOL, WASO, total sleep time, and sleep quality) were statistically significant 

(Table 27). Two of the outcomes (SOL and sleep quality) favoured the combined treatment, 

while the other two outcomes (WASO and total sleep time) favoured CBT alone. 

Relaxation therapy and cognitive behavioral therapy versus benzodiazepine. One study 

compared relaxation therapy and CBT versus a benzodiazepine. The results for SOL, WASO, 

and sleep quality can be viewed in Table 28. All three outcomes favoured the benzodiazepine 

over the combined treatment. The difference was not significant for SOL or WASO, but it was 

significant for sleep quality (a large difference of about 1.5 SDs). 

Benzodiazepine and cognitive behavioral therapy versus placebo. Table 29 lists the results for 

the four outcomes (SOL, WASO, sleep efficiency, and total sleep time) that were reported in 

comparisons of benzodiazepine and CBT versus placebo. Two studies were meta-analysed. All 

four outcomes favoured the combined treatment, and the difference was significant for sleep 

efficiency (13 percent improvement). 

Benzodiazepine and cognitive behavioral therapy versus benzodiazepine. One study compared 

the combined treatment of a benzodiazepine and CBT versus the benzodiazepine alone. The 

results for three outcomes (WASO, sleep efficiency and total sleep time) can be viewed in Table 

30. The result for sleep efficiency was statistically significant in favour of the combined 

treatment (7 percent improvement). WASO favoured the combined treatment but not 

significantly. Total sleep time favoured the benzodiazepine alone, but the difference was not 

significant. 

Benzodiazepine and cognitive behavioral therapy versus cognitive behavioral therapy. The 

comparison of a benzodiazepine and CBT versus CBT alone was available through one study. 

The results of the three outcomes (WASO, sleep efficiency, and total sleep time) can be viewed 

in Table 31. None of the results were significant and all had relatively small efficacy estimates. 

Non-benzodiazepine and cognitive behavioral therapy taken in combination versus the same two 

treatments taken sequentially. One study examined the difference between the effects of a nonbenzodiazepine taken simultaneously with CBT versus the same two treatments taken 

sequentially. The results for the two outcomes examined (sleep efficiency and total sleep time) 

can be viewed in Table 32. Neither result was significant. 

Cognitive behavioral therapy and modafinil versus cognitive behavioral therapy. One study 

compared CBT combined with the stimulant modafinil versus CBT alone. Results for the three 

reported outcomes (SOL, WASO, and total sleep time) can be viewed in Table 33. None of the 

results are significant, and all three efficacy estimates favour CBT alone over the combined 

treatment. 
39 

Cognitive behavioral therapy and modafinil versus modafinil. CBT and modafinil was 

compared to modafinil alone in one study. The results of the three outcomes examined (SOL, 

WASO, and total sleep time) can be viewed in Table 34. All outcomes favoured the combined 

treatment, but none of them were significant. 

What are the important future directions for insomnia-related 

research? 

The response to this question appears under “Limitations and Future Research” in the 

Discussion section of the Evidence Report. 
40 

Flow Diagram 2. Study retrieval and selection 

References identified from 

database searches 

n=16,991

Studies potentially relevant to 

questions on manifestations of 

chronic insomnia 

n= 528

Studies potentially relevant to 

question on management of 

chronic insomnia 

n= 672

Included in review 

n=79 

Excluded from 

review 

n=449 

Included in review

n=116 

Excluded from 

review 

n=556 

Studies assessed for potential 

inclusion in the review 

n=1200
41 

Table 3a. Prevalence of chronic insomnia in adults: general population Author / Year Quality (score) 

Study Design 

Sampling Frame / Method 

Method Of Data Collection 

Participants Duration of Sleep 

Complaints, Definition of Cases and Comparison Groups 

Gender Age 

(years) 

ResRatFolRat

Ancoli-Israel, S / 1999 Moderate (3/8) 

Crosssectional Phone list/ random Phone interview 

(nonvalidated) 

General population 

Sleep complaints on a frequent basis; population referred to as “chronic” insomniacs. 

Not specified 

Range: 18-65 

51.

Bixler, EO / 1979 Moderate (3/8) 

Crosssectional Census data/ 

random

Face-to face interview (nonvalidated) 

General population 

Current or past sleep disorders; prevalence reported for “long-term” insomniacs. 

Male: 44% Female:56% 

Over 18 Not 

spe

Bixler, EO / 2002 Moderate (3/8) 

Crosssectional Phone list/ random Self- reported Qu 

(nonvalidated) 

General population 

Sleep complaint for at least one year. 

Male: 42.6% Female:57.4%

Over 20 66.

Broman, JE / 1996 High (6/8) 

Crosssectional Population register/ 

random 

Selfreported Qu (validated) 

General population 

Sleep complaints during the last three months. 

Male: 46.9% Female:53.1%

Range: 20-64 

68% 

Hajak, G / 2001 High (6/8) - cross sectional  High (7/9)  - case control 

Crosssectional and CaseControl (matched) 

Census data/ random 

Face-to face interview (nonvalidated) 

Crosssectional: 

General population Casecontrol:: Cases: severe insomnia Controls: normal sleepers 

Cross-sectional: Insomnia disorders during the previous month (DSM-III-R and 

DSM-IV criteria). Severe insomniacs had sleep complaints during the previous month. Case-control: Cases: 

Severe insomniacs as defined above. Controls: No sleep complaints. 

Crosssectional: 

Male:46.8% Female:53.1% 

Over 18 Not 

spe
42 

Table 3a. Prevalence of chronic insomnia in adults: general population (continued) Author / Year Quality (score) 

Study Design 

Sampling Frame / Method 

Method Of Data Collection 

Participants Duration of Sleep 

Complaints, Definition of Cases and Comparison Groups 

Gender Age 

(years) 

ResRatFolRat

Hetta, J / 1999 Low (0/8) 

Crosssectional Not specified/ 

non-random (quota method) 

Not clearly specified 

General population 

Sleep complaints over the past month (DSMIII-R criteria modified). 

Not specified 

Over 18 25% 

Hidalgo, MP / 2002 Moderate (5/8) 

Crosssectional Not specified Self- reported Qu 

(validated) 

Medical students 

Sleep complaints for at least one month during the past year. 

Male: 58.2% Female:41.8%

Range: 18-35 

Not spe

Kageyama, T / 1997 Moderate (6/8) 

Crosssectional Residential registration 

information/ random sample of some districts, recruitment at block meetings in others

Self-admin Qu (nonvalidated) 

Adult women living in urban areas 

Sleep complaints for at least one month (ICD10 and DSM-IV criteria). 

All women Range: 

20-80 

Varbetdist51-

Kageyama, T / 2001 Moderate (5/8) 

Crosssectional Not specified Self-admin Qu (nonvalidated) Hospital nurses Sleep complaints for at least one month. Not specified Range: 24-59 Not spe

Kawada, T / 2003 High (6/8) 

Crosssectional Map/ Not specified Self- reported Qu 

(nonvalidated) 

Women from the general population 

Sleep complaint for at least one month (ICD10 and DSM-IV criteria). 

All female Range: 

20-80 

50.
43 

Table 3a. Prevalence of chronic insomnia in adults: general population (continued) Author / Year Quality (score) 

Study Design 

Sampling Frame / Method 

Method Of Data Collection 

Participants Duration of Sleep 

Complaints, Definition of Cases and Comparison Groups 

Gender Age 

(years) 

ResRatFolRat

Leger, D / 2000 High (6/8) 

Crosssectional Census data/ 

random

Face-to face interview (nonvalidated) 

General population 

Sleep complaint for at least a month (DSM-IV criteria). "Severe insomnia" considered as "chronic insomnia" if sleep complaints were over a four-month period. 

Male: 47% Female:53%

Over 18 85.

Martikainen, K / 2003 Moderate (5/8) 

Crosssectional Not specified / 

random 

Selfreported Qu (nonvalidated) 

General population 

Sleep complaints during the previous three months. 

Male:42.2% Female:57.8%

Range: 41-55 

52.

Millar, A / 2004 High (6/9) 

Cross sectional case-control 

Not applicable 

Selfreported Qu (validated), sleep laboratory investigations 

Cases: remitted Bipolar I disorder subjects Controls: healthy subjects

Cases: DSM-IV criteria for Bipolar I disorder. Controls: No psychiatric disorders.

Cases:

Male: 8 Female: 11 Controls:

Male: 8 Female: 11

Cases: range:26-68 Controls: range: 27-67 

Cas59.(folConNot spe

Ohayon, MM / 2002 High (8/8) 

Crosssectional Phone list/ random Phone interview 

(validated) 

General population 

Insomnia complaints during the last year (DSM-IV criteria). 

Male: 48.2% Female:51.8%

Over 15 89.
44 

Table 3a. Prevalence of chronic insomnia in adults: general population (continued) Author / Year Quality (score) 

Study Design 

Sampling Frame / Method 

Method Of Data Collection 

Participants Duration of Sleep 

Complaints, Definition of Cases and Comparison Groups 

Gender Age 

(years) 

ResRatFolRat

Ohayon, MM / 2002 High (8/8) 

Crosssectional Census data/ 

random

Phone interview (validated) 

General population 

Chronic insomnia diagnosed according to DSM-IV criteria. 

Male: 48.2% Female:51.8% 

Over 18 78.

Ohayon, MM / 1997 High (8/8) 

Crosssectional Census data/ 

random

Phone interview (validated) 

General population 

Insomnia complaints for at least one month. 

Male: 47.9% Female:52.1% 

Over 15 80.

Ohayon, MM / 2003 High (7/8) 

Crosssectional Census data/ 

random

Phone interview (validated) 

General population 

Insomnia complaints for more than six months. 

Male: 47.9% Female:52.1%

Over 15 78.

Ohayon, MM / 2000 High (7/8) 

Crosssectional Census data/ 

random 

Computerized phone interview (validated) 

General population 

Diagnoses of chronic sleep disorders according to DSM-IV criteria. 

Male: 49.2% Female: 50.8%

Range: 19 -24 

Not spe

Ohayon, MM / 2001 High (7/8) 

Crosssectional Census data/ 

random 

Phone interview (validated) 

General population 

Chronic insomnia defined by both DSM-IV and ICSD criteria. 

Male:49.5% Female:50.5%

Range: 19-24 

Not spe
45 

Table 3a. Prevalence of chronic insomnia in adults: general population (continued) Author / Year Quality (score) 

Study Design 

Sampling Frame / Method 

Method Of Data Collection 

Participants Duration of Sleep 

Complaints, Definition of Cases and Comparison Groups 

Gender Age 

(years) 

ResRatFolRat

Ohayon, MM / 2001 High (8/8) 

Crosssectional Census data/ 

random

Telephone interview (validated) 

General population 

Sleep complaints for at least a month (DSM-IV criteria). 

Male: 49% Female: 51% 

Over 15 All 

couexcGe(68parrate or hOve81.

Ohayon, MM / 2002 High (8/8) 

Crosssectional Phone lists/ random Telephone interview 

(validated) 

General population 

Chronic insomnia diagnosed according to ICSD and DSM-IV criteria. 

Male:49.5% Female:50.5%

Range: 15-90 

91.

Riedel, BW / 2004 High (6/8) 

Crosssectional Not specified/ 

random 

Selfreported Qu (validated) 

General population 

Sleep complaints for at least six months (ICSD criteria). 

Male: 49.3% Female:50.7% - 390/769

Range: 20-98 

43.

Rocha, FL / 2002 High (7/8) 

Crosssectional Census data/ whole 

population studied 

Face-toface interview (validated) 

Elderly from the general population 

Sleep complaints during the last month. 

Male: 38.9% Female:61.1%

Over 60 87% 

Rocha, FL / 2002 High (7/8) 

Crosssectional Census data/ 

random

Face-toface interview (validated) 

General population 

Sleep complaints in the last month. 

Male: 44.3% Female:55.7%

Over 18 87.

Taylor, DJ / 2003 High (6/8) 

Crosssectional Three-digit telephone 

prefixes/ random digit dialling 

Sleep diaries and self-admin Qu 

General population 

Sleep complaints for at least six months. 

Male: 49.4% Female: 50.6% 

Range: 20-98 

49% 
46 

Table 3a. Prevalence of chronic insomnia in adults: general population (continued) Author / Year Quality (score) 

Study Design 

Sampling Frame / Method 

Method Of Data Collection 

Participants Duration of Sleep 

Complaints, Definition of Cases and Comparison Groups 

Gender Age 

(years) 

ResRatFolRat

Yeo, BKL / 1996 Moderate (3/8) 

Crosssectional House registers/ 

random 

Face-to face interview (nonvalidated) 

General population 

Sleep complaint for the past year. 

Male:50% Female:50%

Range: 15-55 

Not spe

Abbreviations: CI = confidence interval; DSM-III-R = Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised; DSM-I

Statistical Manual of Mental Disorders, Fourth Edition; ICSD = International Classification of Sleep Disorders; MSK = musculoskeletal injury

rehab = rehabilitation; SCI = spinal cord injury; TBI = traumatic brain injury 
47 

Table 3b. Prevalence of chronic insomnia in adults: outpatients of general practice Author / Year Quality (score) 

Study Design 

Sampling Frame / Method 

Method Of Data Collection 

Participants Duration of Sleep 

Complaints, Definition of Cases and Comparison Groups 

Gender Age 

(years) 

ResRatFolRat

Hohagen, F / 1993 Moderate (4/8) 

Crosssectional Not specified/ 

non-random (consecutive) 

Selfreported Qu (nonvalidated) 

Outpatients from general practices 

Insomnia disorders during the last month (DSM-III-R criteria). 

Male:44.7% Female:55.3%

Range: 18-65 

97.

Hohagen, F / 1994 Moderate (4/8) 

Crosssectional Not specified / 

non-random (consecutive) 

Selfreported Qu (nonvalidated) 

Elderly outpatients from general practices 

Sleep complaints (mild, moderate, and severe) for at least one month (DSM-III-R criteria). 

Male: 28% Female:72% 

Over 65 97.

Hohagen, F / 1994 Moderate (4/8) 

Crosssectional and prospective cohort 

Not specified/ non-random (consecutive) 

Selfreported Qu (nonvalidated) 

Outpatients from general practices 

Sleep complaints for at least one month. 

Crosssectional: 

Male:44.7% Female:55.3% Cohort:

Male: 60.4%. Female: 39.6% 

Range: 18-65 

Cro

sec97.Coh

42.(fol

Ishigooka, J / 1999 Moderate (5/8) 

Crosssectional Not specified Self- reported Qu 

(nonvalidated) 

Outpatients from general hospitals 

Long-term insomnia defined as sleep complaints for more than one month. 

Male: 41.9% Female:58.1%

Range: 15-65 

88.
48 

Table 3b. Prevalence of chronic insomnia in adults: outpatients of general practice (continued) Author / Year Quality (score) 

Study Design 

Sampling Frame / Method 

Method Of Data Collection 

Participants Duration of Sleep 

Complaints, Definition of Cases and Comparison Groups 

Gender Age 

(years) 

ResRatFolRat

Kappler, C / 2003 Low (2/8) 

Crosssectional Not specified Self- reported Qu 

(nonvalidated) 

Outpatients from general practices 

Diagnosis of chronic insomnia (moderate and severe) according to DSM-III-R criteria. 

Male:49.9% Female:50.1% 

Range: 18-65 

37.

Ohayon, MM / 1999 Moderate (5/8) 

Crosssectional Not specified/ 

non-random

Face-toface clinical interview (validated) 

Outpatients from general practices 

Chronic sleep disorders diagnosed according to DSM-IV criteria. 

Male: 44.5% Female:55.5%

Over 15 Not 

spe

Scochat, T / 1999 Low (1/8) 

Crosssectional All patients presenting 

to participating family medicine clinics/ all asked to participate

Selfadministration Qu (nonvalidated) 

Patients consulting their primary care physician 

Normal sleepers: no sleep complaints; Occasional insomniacs: sleep complaints on an occasional basis. Chronic insomniacs: 

sleep complaints on a frequent basis; chronic insomniacs defined as such. 

Male:42% Female:58%

Range: 18-87 

Not spe

Terzano, MG / 2004 Moderate (4/8) 

Crosssectional List of general 

practitioner patients/ non-random 

Face-toface clinical interview (nonvalidated) 

Patients presenting to their general practitioner for medical problems other than sleep disorders 

Sleep complaints for at least one month. 

Male:39.1% Female:60.9%

Over 18 Not 

spe

Abbreviations: CI = confidence interval; DSM-III-R = Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised; DSM-I

Statistical Manual of Mental Disorders, Fourth Edition; ICSD = International Classification of Sleep Disorders; MSK = musculoskeletal injury

rehab = rehabilitation; SCI = spinal cord injury; TBI = traumatic brain injury 
49 

Table 3c. Prevalence of chronic insomnia in adults: clinical population Author / Year Quality (score) 

Study Design 

Sampling Frame / Method 

Method Of Data Collection 

Participants Duration of Sleep 

Complaints, Definition of Cases and Comparison Groups 

Gender Age 

(years) 

ResRatFolRat

Braga-Neto, P / 2004 Low (2/8) 

Crosssectional Not specified/ 

non-random (consecutive) 

Face-toface clinical interview (nonvalidated) 

Patients with Parkinson's Disease 

Sleep complaints over the last month. 

Male:64% Female:36%

Range: 34-86 

Not spe

Fichtenberg, NL / 2002 Moderate (4/8) 

Crosssectional Patients enrolled in 

outpatient rehab. clinics/ nonrandom (consecutive)

Selfreported Qu (validated), sleep diaries, clinical interview 

Rehabilitation patients (TBI, SCI, MSK) 

DSM-IV criteria TBI: Male: 

56% Female: 44%. SCI:

Male: 76% Female: 24%. MSK:

Male: 20% Female: 80% 

TBI:mean±SD:36.5±14.5 SCI:mean±SD:38.2±13.5 MSK:mean±SD:47.3±12.2

100

Han, SY / 2002 Low (2/8) 

Crosssectional Not specified Self- reported Qu 

(nonvalidated) 

Diabetic haemodialysis patients 

Sleep complaints for at least two months (DSMIV criteria modified). 

Male:61% Female:39%

Range: 27-78 

Not spe

Leppavuori, A / 2002 Moderate (4/8) 

Crosssectional Not specified / 

non-random (consecutive) 

Face-toface clinical interview (validated) 

Stroke patients 

Insomnia complaints for at least one month (DSM-IV criteria). 

Male: 50.9% Female:49.1% 

Range: 55-85 

Not spe
50 

Table 3c. Prevalence of chronic insomnia in adults: clinical population (continued) Author / Year Quality (score) 

Study Design 

Sampling Frame / Method 

Method Of Data Collection 

Participants Duration of Sleep 

Complaints, Definition of Cases and Comparison Groups 

Gender Age 

(years) 

ResRatFolRat

Millar, A / 2004 High (6/9) 

Cross sectional case-control 

Not applicable 

Selfreported Qu (validated), sleep laboratory investigations 

Cases: remitted Bipolar I disorder subjects Controls: healthy subjects

Cases: DSM-IV criteria for Bipolar I disorder. Controls: No psychiatric disorders.

Cases:

Male: 8 Female: 11 Controls:

Male: 8 Female: 11

Cases: range:26-68 Controls: range: 27-67 

Cas59.(folConNot spe

Robbins, L / 1995 Moderate (4/8) 

Retrospective crosssectional Long-term patients of headache 

clinic/ random 

Face-toface interview 

Patients with migraines 

Chronic insomnia assessed by qualitative judgement of the neurologist and patient. 

Male:20.4% Female:79.6%

Range: 18-60 

100

Sabbatini, M / 2002 Moderate (3/8) 

Crosssectional Not specified Face-to- face 

interview (nonvalidated) 

Haemodialysis patients Sleep complaints for at least one month. Male: 55.5% 

Female:44.5%

Mean±SD: 61.0±14.4 

Not spe

Savard, J / 2001 Moderate (4/8) 

Crosssectional Not specified/ 

nonrandom (consecutive)

Selfreported Qu (nonvalidated) and phone interview (validated) 

Women with metastatic breast cancer 

Insomnia symptoms, insomnia syndrome and chronic insomnia syndrome defined by sleep complaints for at least six months (DSMIV criteria). 

All female Range: 

28-90 

88% 

Abbreviations: CI = confidence interval; DSM-III-R = Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised; DSM-I

Statistical Manual of Mental Disorders, Fourth Edition; ICSD = International Classification of Sleep Disorders; MSK = musculoskeletal injury

rehab = rehabilitation; SCI = spinal cord injury; TBI = traumatic brain injury 
51 

Table 4. Natural history of chronic insomnia in adults 

Author/Year Quality (Score) 

Study Design 

Time Frame 

Response Rate / Follow-up Rate 

Participants Duration Of Sleep 

Complaints 

Gender Age (years

Hohagen, F / 1994 Moderate (4/8) 

Crosssectional and prospective cohort 

Four months 

Response rate (cross-sectional): 97.9% Follow-up rate (cohort): 42.2% 

Outpatients from general practices 

Sleep complaints for at least one month 

Cross-sectional: Male: 44.7% 

Female: 55.3% 

Cohort: Male: 60.4% 

Female: 39.6%. 

Range:18-65 

Abbreviations: CI = confidence interval 
52 

Table 5. Factors associated with chronic insomnia in adults 

Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Bastien, CH / 2003 Moderate (5/9) 

Crosssectional case-control (unmatched) 

Cases: chronic insomniacs Controls: normal sleepers

Cases: insomnia complaint for at least six months (ICSD-10 and DSM-IV criteria combined) Controls: no sleep complaints

Cases: chronic insomniacs using benzodiazepines: Male: 10, Female: 10. 

Drug-free insomniacs: Male: 9, Female: 11 

Controls: Male: 11, 

Female: 9.

Cases and controls: Over 55

Not specified 

Bixler, EO / 2002 Moderate (3/8) 

Crosssectional General population Insomnia complaint for at least one year Male: 42.6% Female: 57.4% Over 20 66.6% 

Bixler, EO / 1979 Moderate (3/8) 

Crosssectional General population Current or past sleep disorders; results 

provided for chronic insomniacs 

Male: 44% 

Female: 56%

Over 18 Not specified 

Bliwise, NG / 1992 Low (1/9) 

Crosssectional case-control (unmatched) 

Cases: poor sleepers Controls: good sleepers

Cases: sleep

complaint for at least five years Controls: no sleep complaints

All women Cases: 

mean ± SD: 68.4 ± 8.7, range: 49-82 Controls: mean ± SD: 67.5 ± 9.9, range: 52-95

Not specified 

Bonnet, MH / 1995 High (7/9) 

Crosssectional case-control (matched) 

Cases: chronic insomniacs Controls: normal sleepers

Cases: sleep complaints for at least one year Controls: no sleep complaints

Not specified Cases: 

range: 18-50 Controls:range: 18-50 

Cases: 50% Controls: 50% 

Braga-Neto, P / 2004 Low (2/8) 

Crosssectional Parkinson's Disease 

patients 

Sleep complaints over the last month 

Male: 64% 

Female: 36%

Range: 34-86 

Not specified 
53 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Broman, JE / 1996 High (6/8) 

Crosssectional General population Sleep complaints during the last three months Male: 46.9% Female: 53.1% Range: 20- 64 68% 

Broman, JE / 1992 Moderate (5/9) 

Crosssectional case-control (matched) 

Cases: persistent primary insomniacs Controls: normal sleepers

Cases: persistent sleep complaints Controls: no sleep complaints

Cases: Male: 5, 

Female: 15 

Controls: Male: 5, 

Female: 15

Cases: mean ± SD: 45.8 ± 11.5 Controls: mean ± SD: 45.0 ± 10.2

Not specified 

Chambers, MJ / 1993 Low (1/9) 

Crosssectional case-control (unmatched) 

Cases: chronic insomniacs referred to a sleep clinic Controls: good sleepers

Cases: sleep complaints for at least six months (ASDA criteria) Controls: no sleep complaints

Cases: Male: 35.5%, 

Female: 64.5% 

Controls: Male: 40%, 

Female: 60%

Cases: mean ± SD: 47.5 ± 10.9 Controls: mean ± SD: 45.9 ± 16.0

Not specified 

Coursey, RD / 1975 High (7/9) 

Crosssectional case-control (matched) 

Cases:chronic insomniacsControls:normal sleepers

Cases: sleep complaints for at least two years Controls: no sleep complaints 

Cases: Male: 13, 

Female: 5 

Controls: Male: 13, 

Female: 5

Cases and controls: mean ± SD: 44.7 ± 16.8

Not specified 

Crenshaw, MC / 1999 Moderate (3/9) 

Crosssectional case-control (agematched) 

Cases:insomniacs Controls: normal sleepers

Cases: history of insomnia complaints for ≥ 6 months Controls: no sleep complaints

Cases: Male: 50% 

Female: 50% 

Controls: Male: 50%, 

Female: 50%

Cases:mean ± SD: 67.7 ± 4.8 Controls:mean ± SD: 67.5 ± 5.7

Not specified 
54 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Dorsey, CM / 1997 Low (2/9) 

Crosssectional case-control (unmatched) 

Cases: chronic insomniacs (subjective and objective) Controls: normal sleepers

Cases: sleep complaints > 6 months Controls: no sleep complaints

Male: 17 

Female: 14

Cases and controls: range: 18-25

Not specified 

Edinger, JD / 2000 High (8/9) 

Crosssectional case-control (matched) 

Cases: persistent primary insomniacs Controls: normal sleepers

Cases: sleep complaints > 6 months (DSM-IV criteria) Controls: no sleep complaints

Cases: Male: 32, 

Female: 32 

Controls: Male: 30, 

Female: 31

Cases and controls:range: 40-79

Cases: 100% (64/64); Controls: 95.3% (61/64) 

Edinger, JD / 2000 Moderate (4/9) 

Crosssectional case-control (age and gendermatched) 

Cases:insomniacs Controls: normal sleepers

Cases: history of insomnia complaints for ≥ 6 months Controls: no sleep complaints 

Cases: Male: 44.4%, 

Female: 55.6% 

Controls: Male: 48.4% 

Female: 51.6%

Cases and controls:range: 40-79

Cases: 84.4%

Controls: 96.9%

Hajak, G / 2001 High (6/8)  - cross-sectional High (7/9)  - case control 

Crosssectional and casecontrol (matched) 

Crosssectional: General population Casecontrol:

Cases:severe insomniacs Controls:normal sleepers 

Cross-sectional: 

Insomnia disorders during the previous month (DSM-III-R and DSM-IV criteria). Severe insomnia: Sleep complaints during the previous month. Case-control: Cases: 

severe insomnia as defined above Controls: no sleep complaints 

Cross-sectional:Male: 46.8% 

Female: 53.1% 

Over 18 Not specified 
55 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Han, SY / 2002 Low (2/8) 

Crosssectional Diabetic haemodialysis 

patients 

Sleep complaints for at least two months (DSMIV criteria modified) 

Male: 61% 

Female: 39%

Range: 27-78 

Not specified 

Harvey, AG / 2003 Moderate (3/9) 

Crosssectional case-control (unmatched) 

Cases: insomniacs Controls: normal sleepers

Cases: sleep complaints for at least one month (DSM-IV criteria) Controls: no sleep complaints

Cases: Male: 40% 

Female: 60% 

Controls: Male: 36.7% 

Female: 63.3%

Cases: mean ± SD: 20.4 ± 4.7 Controls: mean ± SD: 22.3 ± 8.9

Not specified 

Hauri, PJ / 1997 High (7/9) 

Crosssectional case-control (matched) 

Cases: chronic insomniacs Controls: normal sleepers

Cases: sleep complaints for at leastsix months Controls: no sleep complaints

Cases: Male: 7, 

Female: 19 

Controls: Male: 7, 

Female: 19

Cases and controls: mean ± SD: 47.7 ± 11.8

Not specified 

Healey, ES / 1981 High (8/9) 

Crosssectional case-control (matched) 

Cases: chronic insomniacs Controls: normal sleepers

Cases: sleep complaints within the previous eight years; defined as “chronic” insomniacs Controls: no sleep complaints

Cases: Male: 9, 

Female: 22 

Controls: Male: 9, 

Female: 22

Cases:range: 19-63 Controls: range: 18-63

Not specified 

Hidalgo, MP / 2002 Moderate (5/8) 

Crosssectional Medical students Sleep complaints for at least one month during 

the past year 

Male: 58.2% 

Female: 41.8%

Range: 18-35 

Not specified 
56 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Hohagen, F / 1994 Moderate (4/8) 

Crosssectional Elderly outpatients 

from general practices 

Sleep complaints for at least one month (DSMIII-R criteria) 

Male: 28% 

Female: 72%

Over 65 97.5% 

Hohagen, F / 1993 Moderate (4/8) 

Crosssectional Outpatients from general 

practices 

Sleep complaints during the past month (DSMIII-R criteria) 

Male: 44.7% 

Female: 55.3%

Range: 18-65 

97.9%. 

Ishigooka, J / 1999 Moderate (5/8) 

Crosssectional Outpatients from general 

hospitals 

Sleep complaints for more than 1 month 

Male: 41.9% 

Female: 58.1%

Range: 15-65 

88.3% 

Kageyama, T / 2001 Moderate (5/8) 

Crosssectional Hospital nurses Sleep complaints for at least one month Not specified Range: 24- 59 Not specified 
57 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Kageyama, T / 1997 High (6/8) 

Crosssectional Adult women living in 

urban areas 

Sleep complaints for at least one month (ICD10 and DSM-IV criteria) 

All women Range: 20-

80 

Varied between district 51-59% 

Kales, JD / 1984 Low (1/9) 

Crosssectional case-control (unmatched) 

Cases: 100 

patients with sleep complaints for at least one year, + 114 insomniacs (appropriate data was available) Controls: normal sleepers

Cases: sleep 

complaints for at least one year Controls: no sleepcomplaints

Cases: Male: 41.1% 

Female: 58.9% 

Controls: Male: 41% 

Female: 59%

Cases: mean: 43.1 Controls: mean ± SD: 48.2 ± 1.5 range: 24-80

Cases: not 

specified Controls: 94%

Kales, AK / 1983 Moderate (4/9) 

Crosssectional case-control 

Cases: chronic insomniacs Controls: normal sleepers

Cases: defined as

“chronic” insomniacs Controls: no sleep complaints

Cases: Male: 41% 

Female: 59% 

Controls: Male: 41%. 

Female: 59%

Cases: mean ± SD: 43.1 ± 0.9 range: 18-84 Controls: mean ± SD: 40.9 ± 1.5 range: 19-74

Cases: 93% 

Controls: 97%
58 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Kales, A / 1982 Low (2/9) 

Crosssectional case-control (unmatched) 

Cases: chronic insomniacs Controls: normal sleepers

Cases: sleep complaints > 6 months Controls: no sleep complaints

Cases: Male: 82, 

Female: 118 

Controls: Male: 41, 

Female: 59

Cases:range: 18-78 Controls:range: 18-74

Not specified 

Kappler, C / 2003 Low (2/8) 

Crosssectional Outpatients from general 

practices 

Insomnia disorders diagnosed according to DSM-III-R criteria 

Male: 49.9% 

Female: 50.1% 

Range: 18-65 

37.6% 

Kawada, T / 2003 High (6/8) 

Crosssectional Women from the general 

population 

Sleep complaints for at least one month (ICD10 and DSM-IV criteria) 

All female Range: 20-

80 

50.4% 

Leger, D / 2000 High (6/8) 

Crosssectional General population Sleep complaints for at least one month (DSMIV criteria). 

Sleep complaints over a four-month period was considered "severe insomnia". 

Male: 47% 

Female: 53%

Over 18 85.2% 
59 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Leppavuori, A / 2002 Moderate (4/8) 

Crosssectional Stroke patients Insomnia complaints for at least one month 

(DSM-IV criteria) 

Male: 50.9% 

Female: 49.1%

Range: 55-85 

Not specified 

Levitt, H / 2004 Low (2/9)  - case control  Low (0/9)  - cross sectional 

Crosssectional and casecontrol (agematched) 

Cases: insomniacsControls: normal sleepers

Cases: primary insomnia diagnosed according to DSM-IV criteria Controls: no sleep complaints

Cases: Male: 14.3% 

Female: 85.7% 

Controls: Male: 12.5% 

Female: 87.5% 

Cases: mean ± SD: 24.1 ± 3.4 range: 20-30 Controls: mean ± SD: 23.3 ± 1.9 range: 20-30

100% 

Lichstein, KL / 2001 Moderate (5/9) 

Crosssectional case-control (unmatched) 

Cases: primary or secondary insomniacs Controls: normal sleepers 

Cases: sleep complaints of at least six months (ASDA criteria) Controls: no 

sleep complaints

Cases: Primary insomnia: Male: 24, 

Female: 58 

Secondary insomnia: Male: 23, Female: 23 

Controls: Male: 26, 

Female: 35

Cases and controls: Over 58 

Not specified 

Linzmayer, L / 2002 Low (1/9) 

Crosssectional case-control (unmatched) 

Cases: nonorganic insomniacs associated with different mental disorders Controls:normal sleepers

Cases: Group A: nonorganic insomnia: ICSD classification of psychophysiological insomnia, DSM-IV classification of primary insomnia. All other cases had insomnia plus a concomitant mental disorder. Controls: no sleep complaints

Cases: Female: 51.1% 

Male: 48.9% 

Range: 22-63 

Not specified 
60 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Lundh, LG / 1997 Moderate (5/9) 

Crosssectional case-control (matched) 

Cases: persistent insomnia Controls: normal sleepers

Cases: long-standing problems with insomnia Controls: no sleep complaints

Cases: Male: 4, 

Female: 16 

Controls: Male: 4, 

Female: 16

Cases and controls: range: 20-65 

Cases mean ± SD: 46.5 ± 11.3 Controls mean ± SD: 45.5 ± 11.1

Not specified 

Martikainen, K / 2003 Moderate (5/8) 

Crosssectional General population Sleep complaints during the previous three 

months 

Male: 42.2% 

Female: 57.8%

Range: 41-55 

52.6% 

Mendelson, WB / 1984 Moderate (4/9) 

Crosssectional case-control (matched) 

Cases: insomniacs Controls: normal sleepers

Cases: sleep complaints for at least one year Controls: no sleep complaints

Cases: Male: 1, 

Female: 9 

Controls: Male: 1, 

Female: 9

Cases and controls: range: 22-44 

Not specified 

Niemcewicz, S / 2001 Low (2/9) 

Case-control (matched for gender, age, and education) 

Cases: primary insomniacs recruited from sleep disorder clinic. Controls: normal sleepers

Cases: primary insomnia diagnosed according to DSM-IV criteria Controls: no sleep complaints

Cases: Male: 44%, 

Female: 56% 

Controls: Male: 44%, 

Female: 56% 

Mean ± SD: 40.8 ± 11.3 Range: 21-55 

100% 

Ohayon, MM / 2003 High (7/8) 

Crosssectional General population Sleep complaints > 6 months Male: 47.9% Female: 52.1% Over 15 78.6% 
61 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Ohayon, MM / 2002 High (8/8) 

Crosssectional General population Chronic insomnia diagnosed according to 

ICSD and DSM-IV criteria 

Male: 49.5% 

Female: 50.5%

Range: 15-90 

91.4% 

Ohayon, MM / 2002 High (8/8) 

Crosssectional General population Sleep complaints during the past year (DSM-IV 

criteria) 

Male: 48.2% 

Female: 51.8%

Over 15 89.4% 

Ohayon, MM / 2001 High (8/8) 

Crosssectional General population Chronic Insomnia diagnosed according to 

DSM-IV criteria 

Male: 47.9% 

Female: 52.1%

Over 15 78% 

Pallesen, S / 2002 High (7/9) 

Crosssectional case-control (matched) 

Cases: chronic primary insomniacs Controls: 1) normal sleepers, 2) community sample

Cases: chronic primary insomnia diagnosed according to DSM-IV criteria Controls: 1) no sleep complaints, 2) community sample

Cases: Male: 11, 

Female: 49. 

Controls: Good sleepers: Male: 9, 

Female: 32 

Community: Male: 19, 

Female: 41

Cases:range: 60-84 Controls: Good sleepers: 63-83; Community: 60-86 

Cases: not specified Controls: Good sleepers: not specified Community: 82.6%. 

Pavlova, M / 2001 Moderate (4/9) 

Crosssectional case-control (unmatched) 

Cases: primary insomniacs Controls: normal sleepers

Cases: primary Insomnia diagnosed according to DSM-IV criteria Controls: no sleep complaints

Not specified Cases: 

mean ± SD: 45.9 ± 14 Controls: mean ± SD: 44.6 ± 15

Not specified 
62 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Perlis, ML / 2001 Moderate (5/9) 

Crosssectional case-control (matched for age, sex, and body mass) 

Cases:insomniacs Controls:good sleepers

Cases:psychophysiologic insomnia for ≥ 6 months 

(ICSD criteria) Controls: no sleep complaints

Cases: Male: 50%, 

Female: 50% 

Controls: Male: 40%, 

Female: 60%

Cases:mean ± SD: 30.6 ± 8.9 Controls:mean ± SD: 32.3 ± 11.5

Not specified 

Riedel, BW / 2004 High (6/8) 

Crosssectional General population Sleep complaints for at least six months (ICSD 

criteria) 

Male: 49.3% 

Female: 50.7%

Range: 20-98 

43.4% 

Rocha, FL / 2002 High (7/8) 

Crosssectional Elderly from the general 

population 

Sleep complaint during the last 30 days 

Male: 38.9%

Female: 61.1%

Over 60 87% 

Rocha, FL / 2002 High (7/8) 

Crosssectional General population Sleep complaints in the last month Male: 44.3% Female: 55.7% Over 18 87.3% 
63 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Roth, T / 1999 Moderate (3/8) 

Crosssectional General population Sleep complaints on a frequent basis; defined 

as “chronic” insomniacs 

Not specified Range: 18-

65 

51.2% 

Sabbatini, M / 2002 Moderate (3/8) 

Crosssectional Haemo- dialysis 

patients 

Sleep complaints for at least one month 

Male: 55.5% 

Female: 44.5%

Mean ± SD: 61.0 ± 14.4 

Not specified 

Saletu-Zyhlarz, G / 1997 Low (1/9) 

Crosssectional case-control (unmatched) 

Cases: nonorganic 

insomniacs with concomitant generalized anxiety disorder (ICD-10) Controls: normal sleepers

Cases: sleep complaint 

for at least one month Controls: no sleep complaints

Cases: Male: 43.2%, 

Female: 56.8% 

Controls: Male: 45.5%, 

Female: 54.5%

Cases: mean ± SD: 43.2 ±11.7 range: 24-65 Controls: mean ± SD: 43.0 ±11.7 range: 24-65

Cases: 100% Controls: 77.3%

Savard, J / 2001 Moderate (4/8) 

Crosssectional Women with metastatic 

breast cancer 

Insomnia symptoms, insomnia syndrome and chronic insomnia syndrome with sleep complaints for at least six months (DSM-IV criteria) 

All female Range: 28-

90 

88% 
64 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

SchneiderHelmert, D / 1987 High (7/9) 

Crosssectional case-control (matched) 

Cases:chronic insomniacs referred to a sleep clinicControls:normal sleepers

Cases: persistent psychophysiological insomnia diagnosed by ASDC criteria Controls: no sleep complaints 

Cases: Male: 7, 

Female: 9 

Controls: Male: 7, 

Female: 9

Cases: range: 32-61 Controls: range: 28-61 

Not specified 

Shochat, T / 1999 Low (1/8) 

Crosssectional Patients consulting 

their primary care physician 

Occasionalinsomniacs: sleep complaints on an occasional basis Chronic insomniacs: 

sleep complaints on a frequent basis; defined as “chronic” insomniacs Normal Sleepers: no sleep complaints 

Male: 42% 

Female: 58% 

Range: 18-87 

Not specified 

Seidel, WF / 1984 High (6/9) 

Crosssectional case-control (matched) 

Cases: chronic insomniacs Controls: normal sleepers

Cases: sleep complaints for at least three months (ASDC criteria) Controls: no 

sleep complaints

Cases: Male: 15, 

Female: 23 

Controls: Male: 15, 

Female: 23

Cases and controls: mean ± SD: 29 ± 5 

Not specified 

Sharpley, AL / 1997 Moderate (5/9) 

Crosssectional case-control (gender matched) 

Cases: insomniacs Controls:normal sleepers

Cases: primary insomnia diagnosed according to DSM-II-R diagnosis Controls: no sleep complaint

Cases: Male: 50% 

Female: 50% 

Controls: Male: 50% 

Female: 50%

Cases: mean ± SD: 54.7 ± 40-69 Controls: mean ± SD: 53.9 ± 40-68

100% both groups 
65 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Shaver, JLF / 2002 High (6/9) 

Crosssectional case-control (unmatched) 

Cases:Psycho physiologictype insomniacs and subjectiveonly type insomniacs Controls:normal sleepers

Cases: sleep complaints for at least three months Controls: no sleep complaints

All women Cases: PPtype 

insomnia: mean ± SD: 46.7 ± 3.3, SO-type insomnia: mean ± SD: 46.1 ± 4.4 Controls:mean ± SD: 44.4 ± 3.5

Not specified 

Sugerman, JL / 1985 High (6/9) 

Crosssectional case-control (matched) 

Cases: insomniacs Controls: normal sleepers

Cases: sleep complaints for at least six months Controls: no sleep complaints

Cases: 1) Objective insomnia: Male: 2, 

Female: 6 

2) Subjective insomnia: Male: 2, 

Female: 6 

Controls: Male: 2, 

Female: 6

Cases and controls: range: 21-55

Not specified 

Taylor, DJ / 2003 High (6/8) 

Crosssectional Community volunteers Sleep complaints for at least six months Male: 49.4% Female: 50.6% Range: 20- 98 49% 

Terzano, MG / 2004 Moderate (4/8) 

Crosssectional Patients presenting to 

their GP for medical problems other than sleep disorders 

Sleep complaints for at least one month 

Male: 39.1% 

Female: 60.9%

Over 18 Not specified 
66 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Vgontzas, AN / 1995 Low (2/9) 

Crosssectional case-control (unmatched) 

Cases: insomniacs from the community and a sleep clinic Controls:normal sleepers from the community

Cases: sleep complaints for more than six months Controls: no sleep complaints

Cases: Male: 49.9% 

Female: 50.1% 

Controls:Male: 41.3% 

Female: 58.7%

Cases:range: 18-86 Controls: range: 16-80 

Not specified 

Vignola, A / 2000 Moderate (5/9) 

Crosssectional case-control (unmatched) 

Cases: chronic insomniacs (using or not benzodiazepines) Controls: normal sleepers

Cases: sleep complaints > 6 months Controls: no sleep complaints

Cases: Chronic insomnia using benzodiazepines: Male: 10, Female: 10. 

Drug-free insomnia: Male: 9, Female: 11 

Controls: Male: 11, Female: 9

Cases and Controls: Over 55

Not specified 

Vincent, NK / 2000 Moderate (4/9) 

Crosssectional case-control (unmatched) 

Cases: chronic insomniacs from the community Controls: normal sleepers

Cases: sleep complaints for at least the previous six months (DSM-IV criteria) Controls: no sleep complaints

Cases: Male: 28%, 

Female: 72% 

Controls: Not specified

Cases: mean ± SD: 46.91±10.04 Controls: mean ± SD: 39.64±11.49

Not specified 

Wang, W / 2001 Moderate (4/9) 

Crosssectional case-control (unmatched) 

Cases: chronic primary insomniacs. Controls: Normal sleepers

Cases: diagnosis of chronic primary insomnia according to DSM-IV criteria Controls: no sleep complaints

Cases: Male: 11, 

Female: 12 

Controls: Male: 9, 

Female: 19

Cases: mean ± SD: 30.2 ± 7.0 Controls: mean ± SD: 27.2 ± 5.0

Cases: 100% Controls: 89.2% 
67 

Table 5. Factors associated with chronic insomnia in adults (continued) Author / Year Quality (Score) 

Study Design 

Participants Duration of Sleep 

Complaints 

Gender Age (years) Response / 

Follow-up Rate 

Yeo, BKL / 1996 Moderate (3/8) 

Crosssectional General population Sleep complaints for the past year Male: 50% Female: 50% Range: 15- 55 Not specified 

Zammit, GK / 1999 Moderate (4/9) 

Crosssectional case-control (unmatched) 

Cases: primary insomniacs Controls: normal sleepers

Cases: sleep complaints for at least one month Controls: no sleep complaints

Cases: Male: 104, 

Female: 157 

Controls: Male: 38, 

Female: 63

Cases: mean ± SD: 44.1 ± 14.04 Controls: mean ± SD: 37.1 ± 12.7

Not specified 

Abbreviations: ASDA = American Sleep Disorders Association; ASDC = Association of Sleep Disorders Centers; DSM-III-R = Diagnosti

Mental Disorders, Third Edition, Revised; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; GP = general p

International Classification for Disease Version 10; PP = psychophysiologic; SD = standard deviation; SO = subjective only 
68 

Table 6. Sleep onset latency: benzodiazepines versus placebo 

No. of Participants 

Categorization Sub-group No. of studies 

Tr. Pl. 

Point 

Estimate 

(min.) 

95% Confidence 

Interval (min.) Hete

 All Studies 32 1345 961 -16.5 (-20.5, -12.5) Substant

Brotizolam 5 101 92 -10.5 (-16.2, -4.8) NegligEstazolam 3 235 125 -10.2 (-14.5, -5.9) NegligFlunitrazepam 2 49 30 -23.6 (-62.8, 15.6) SubstantFlurazepam 10 317 215 -23.2 (-34.3, -12.2) SubstantLormetazepam 4 137 112 -14.8 (-21.8, -7.7) MinimaNitrazepam 1 37 19 -47.4 (-76.6, -18.2) Quazepam 3 51 41 -14.2 (-23.7, -4.6) NegligTemazepam 4 128 78 -11.6 (-23.6, 0.4) Substant

Drug Type (*) 

Triazolam 8 290 249 -19.7 (-28.4, -11.0) Substant

Absent 28 1147 803 -15.4 (-19.5, -11.2) Substant

Psychiatric Illness 

Present 4 198 158 -25.8 (-41.7, -9.8) Substant

Short Term 30 1275 898 -16.5 (-20.5, -12.4) Substant

Length of Treatment 

Long Term 2 70 63 -18.5 (-51.3, 14.4) Neglig

Adult 26 999 775 -15.4 (-19.9, -10.9) Substant

Age 

Elderly 6 346 186 -19.2 (-26.6, -11.7) Moderat

Male 3 43 43 -17.0 (-29.5, -4.5) NegligFemale 1 6 6 -10.0 (-19.4, -0.6) 

Gender 

Mixed 28 1296 912 -16.9 (-21.2, -12.6) Substant

PSG 9 181 170 -7.1 (-12.5, -1.7) Substant

Method of Measurement (*) 

Sleep Diary 25 1216 842 -18.3 (-22.0, -12.4) Moderat
69 

Table 6. Sleep onset latency: benzodiazepines versus placebo (continued) 

Categorization Sub-group No. of studies No. of Participants 

Point 

Estimate 

(min.) 

95% Confidence 

Interval (min.) Hete

Moderate 18 648 400 -13.5 (-18.7, -8.3) Substant

Study Quality 

High 14 697 561 -19.2 (-24.7, -13.7) Substant

Abbreviations: min. = minutes; NA = not applicable; No. = number; Pl. = placebo group; PSG = polysomnography; Tr. = treatment gro

*Sum of studies in each group is greater than total studies because some studies are included in multiple groups. 
70 

Table 7. Other outcomes: benzodiazepines versus placebo 

No. of Participants 

Outcome (units) Comparison No. of studies 

Tr. Pl. 

Point Estimate 

(min.) 

95% Confidence 

Interval 

Efficacy Outcomes 

Wakefulness After Sleep Onset (min.) Mean Difference 8 153 137 -23.1 (-35.7, -10.5) Sleep Efficiency (%) Mean Difference 10 187 168 6.3 (4.7, 8.0) Total Sleep Time (min.) Mean Difference 17 416 404 39.1 (27.2, 51.0) Sleep Quality (SD) Standardized Mean Difference 24 1243 857 0.80 (0.66, 0.94) 

Safety Outcomes 

Adverse Events Risk Difference 34 2566 1595 0.15 (0.10, 0.20) Abbreviations: min. = minutes; No. = number; Pl. = placebo group; SD = standard deviation; Tr. = treatment group 
71 

Table 8. Sleep onset latency: non-benzodiazepines versus placebo 

No. of Participants 

Categorization Sub-group No. of studies 

Tr. Pl. 

Point 

Estimate 

(min.) 

95% Confidence 

Interval (min.) Hetero

 All Studies 29 2913 1614 -18.1 (-22.5, -13.7) Substantia

Eszopiclone 1 593 195 -16.7 (-29.4, -4.0) NZaleplon 8 1145 433 -20.1 (-29.8, -10.5) SubstantiaZolpidem 17 997 808 -12.8 (-16.4, -9.1) Minimal 

Drug Type (*) 

Zopiclone 5 178 178 -30.9 (-49.4, -12.4) Substantia

Absent 28 2837 1534 -18.7 (-23.2, -14.2) Substantia

Psychiatric Illness 

Present 1 76 80 -3.7 (-16.1, 8.7) N

Short Term 24 2591 1338 -18.4 (-23.4, -13.4) Substantia

Length of Treatment (*) 

Long Term 6 915 471 -16.8 (-25.1, -8.6) Moderate 

Adult 26 2520 1355 -18.7 (-23.9, -13.5) Substantia

Age 

Elderly 3 393 259 -16.1 (-21.2, -10.9) Negligib

Male 1 12 12 -10.3 (-36.6, 16.0) NFemale 1 6 6 -34.8 (-84.6, 15.0) N

Gender 

Mixed 27 2895 1596 -18.2 (-22.7, -13.6) Substantia

PSG 9 278 185 -16.7 (-24.3, -9.0) Moderate 

Method of Measurement (*) 

Sleep Diary 24 2809 1543 -18.5 (-23.4, -13.6) Substantia

Moderate 20 2462 1219 -14.1 (-16.9, -11.3) Negligib

Study Quality 

High 9 451 395 -29.7 (-43.7, -15.6) Substantia

Abbreviations: min. = minutes; NA = not applicable; No. = number; Pl. = placebo group; PSG = polysomnography; Tr. = treatment gro

*Sum of studies in each group is greater than total studies because some studies are included in multiple groups. 
72 

Table 9. Other outcomes: non-benzodiazepines versus placebo 

No. of Participants 

Outcome (units) Comparison No. of studies 

Tr. Pl. 

Point Estimate 95% Confidence Interval 

Efficacy Outcomes 

Wakefulness After Sleep Onset (min.) Mean Difference 9 950 552 -12.6 (-23.0, -2.3) Sleep Efficiency (%) Mean Difference 7 172 115 5.9 (3.7, 8.0) Total Sleep Time (min.) Mean Difference 23 2505 1247 28.0 (21.3, 34.6) Sleep Quality (SD) Standardized Mean Difference 20 2818 1554 0.48 (0.37, 0.59) Quality of Life (SD) Standardized Mean Difference 1 231 227 0.45 (0.27, 0.64) 

Safety Outcomes 

Adverse Events Risk Difference 21 3718 1951 0.05 (0.01, 0.09) Abbreviations: min. = minutes; NA = not applicable; No. = number; Pl. = placebo group; SD = standard deviation; Tr. = treatment grou
73 

Table 10. Sleep onset latency: antidepressants versus placebo 

No. of Participants 

Categorization Sub-group No. of studies 

Tr. Pl. 

Point 

Estimate 

(min.) 

95% Confidence 

Interval (min.) Hetero

All Studies 6 159 166 -7.4 (-10.5, -4.4) Minimal 

Doxepin 3 40 40 -6.7 (-10.7, -2.6) Moderate Trazodone 2 100 108 -12.2 (-22.3, -2.2) Negligib

Drug Type 

Trimipramine 1 19 18 -15.4 (-36.8, 6.0) N

Absent 5 152 159 -7.2 (-10.3, -4.1) Minimal 

Psychiatric Illness 

Present 1 7 7 -17.4 (-36.8, 2.0) N

Short Term 6 159 166 -7.8 (-10.2, -5.4) Negligib

Length of Treatment (*) 

Long Term 1 10 10 -4.4 (-7.7, -1.1) N

PSG 4 59 59 -7.0 (-10.7, -3.3) Moderate 

Method of Measurement 

Sleep Diary 2 100 108 -12.2 (-22.3, -2.2) Negligib

Moderate 5 152 159 -7.2 (-10.3, -4.1) Minimal 

Study Quality 

High 1 7 7 -17.4 (-36.8, 2.0) N

Abbreviations: min. = minutes; NA = not applicable; No. = number; Pl. = placebo group; PSG = polysomnography; Tr. = treatment gro

*Sum of studies in each group is greater than total studies because some studies are included in multiple groups. 
74 

Table 11. Other outcomes: antidepressants versus placebo 

No. of Participants 

Outcome (units) Comparison No. of studies 

Tr. Pl. 

Point 

Estimate 

95% Confidence 

Interval 

Efficacy Outcomes 

Wakefulness After Sleep Onset (min.) Mean Difference 3 123 131 -11.4 (-16.2, -6.6) NSleep Efficiency (%) Mean Difference 4 59 58 13.8 (9.6, 18.0) NTotal Sleep Time (min.) Mean Difference 5 66 65 53.1 (2.8, 103.5) SubSleep Quality (SD) Standardized Mean Difference 3 162 169 0.63 (0.27, 0.99) Sub

Safety Outcomes 

Adverse Events Risk Difference 3 143 145 0.09 (0.01, 0.18) NAbbreviations: min. = minutes; No. = number; Pl. = placebo group; SD = standard deviations; Tr. = treatment group 
75 

Table 12. All outcomes: L-trytophan versus placebo 

No. of Participants 

Outcome (units) Comparison No. of studies 

Tr. Pl. 

Point 

Estimate 

95% Confidence 

Interval 

Efficacy Outcomes 

Sleep Onset Latency (min.) Mean Difference 2 47 41 -11.0 (-33.0, 11.1) Abbreviations: min. = minutes; No. = number; Pl. = placebo group; Tr. = treatment group 
76 

Table 13. All outcomes: melatonin versus placebo 

No. of Participants 

Outcome (units) Comparison No. of studies 

Tr. Pl. 

Point 

Estimate 

95% Confidence 

Interval 

Efficacy Outcomes 

Sleep Onset Latency (min.) Mean Difference 8 103 103 -8.3 (-14.5, -2.0) Wakefulness After Sleep Onset (min.) Mean Difference 5 68 68 -9.7 (-33.6, 14.3) Sleep Efficiency (%) Mean Difference 8 121 121 3.3 (-0.4, 6.9) Total Sleep Time (min.) Mean Difference 7 95 95 5.8 (-13.2, 24.8) Sleep Quality (SD) Standardized Mean Difference 3 35 35 0.25 (-0.22, 0.73) 

Safety Outcomes 

Adverse Events Risk Difference 2 27 27 0.09 (-0.11, 0.29) Abbreviations: min. = minutes; No. = number; Pl. = placebo group; SD = standard deviation; Tr. = treatment group 
77 

Table 14. All outcomes: valerian versus placebo 

No. of Participants 

Outcome (units) Comparison No. of studies 

Tr. Pl. 

Point 

Estimate 

95% Confidence 

Interval 

Efficacy Outcomes 

Sleep Onset Latency (min.) Mean Difference 3 51 50 -1.3 (-21.4, 18.9) Wakefulness After Sleep Onset (min.) Mean Difference 1 10 9 -8.4 (-15.9, -1.0) Sleep Efficiency (%) Mean Difference 2 26 25 -0.1 (-3.4, 3.2) Total Sleep Time (min.) Mean Difference 1 10 9 0.8 (-50.6, 52.2) Sleep Quality (SD) Standardized Mean Difference 3 50 49 1.38 (-0.49, 3.25) 

Safety Outcomes 

Adverse Events Risk Difference 3 51 50 -0.06 (-0.48, 0.35) Abbreviations: min. = minutes; NA = not applicable; No. = number; Pl. = placebo group; SD = standard deviation; Tr. = treatment grou
78 

Table 15. Sleep onset latency: relaxation therapy versus placebo 

No. of Participants 

Categorization Sub-group No. of studies 

Tr. Pl. 

Point 

Estimate 

(min.) 

95% Confidence 

Interval (min.) Heteroge

All Studies 13 199 185 -14.6 (-29.3, 0.2) Substantial (

Autogenic Training 1 8 4 -27.0 (-126.2, 72.2) NA Breathing Training 1 23 23 -60.0 (-64.5, -55.5) NA EMG Feedback Training 3 27 27 -5.3 (-28.4, 17.8) Substantial (Group 1 14 14 -5.5 (-10.8, -0.2) NA Hypnotic 1 15 15 -16.3 (-24.3, -8.3) NA Progressive 5 61 55 -15.7 (-39.2, 7.8) Moderate (I

Relaxation Description(*) 

Relaxation 4 51 47 -5.3 (-17.3, 6.8) Substantial (

Short Term 9 124 114 -22.0 (-41.0, -2.9) Substantial (

Length of Treatment 

Long Term 4 75 71 1.9 (-6.7, 10.6) Minimal (I2

Adult 12 172 162 -15.9 (-31.5, -0.3) Substantial (

Age 

Elderly 1 27 23 -0.2 (-10.4, 10.0) NA 

Female 1 14 14 -5.5 (-10.8, -0.2) NA Gender 

Mixed 12 185 171 -15.5 (-32.0, 0.9) Substantial (

Low 8 101 94 -9.1 (-16.0, -2.2) Substantial (

Study Quality 

Moderate 5 98 91 -17.6 (-54.2, 19.0) Substantial (

Abbreviations: EMG = electromyographic; min. = minutes; NA = not applicable; No. = number; Pl. = placebo group; Tr. = treatment gr

*Sum of studies in each group is greater than total studies because some studies are included in multiple groups. 
79 

Table 16. Other outcomes: relaxation therapy versus placebo 

No. of Participants 

Outcome (units) Comparison No. of studies 

Tr. Pl. 

Point 

Estimate 

95% Confidence 

Interval 

Efficacy Outcomes 

Wakefulness After Sleep Onset (min.) Mean Difference 3 60 57 -1.6 (-14.1, 10.8) Sleep Efficiency (%) Mean Difference 2 50 47 0.4 (-3.7, 4.6) Total Sleep Time (min.) Mean Difference 3 60 57 23.0 (2.7, 43.4) Sleep Quality (SD) Standardized Mean Difference 3 50 47 0.37 (-0.49, 1.24) SAbbreviations: min. = minutes; No. = number; Pl. = placebo group; SD = standard deviation; Tr. = treatment group 
80 

Table 17. Sleep onset latency: cognitive/behavioral therapy versus placebo 

No. of Participants 

Categorization Sub-group No. of studies 

Tr. Pl. 

Point 

Estimate 

(min.) 

95% Confidence 

Interval (min.) Heteroge

All Studies 9 152 124 -4.6 (-9.8, 0.6) Minimal (I2: 

Multicomponent CBT 

2 20 19 -2.6 (-15.4, 10.2) Moderate (I2: 

Paradoxical Intention 3 37 23 -3.7 (-28.7, 21.3) Moderate (I2: Sleep Compression 1 24 23 -0.8 (-13.7, 12.1) NA Stimulus Control 4 58 46 -7.3 (-18.3, 3.7) Moderate (I2: 

Cognitive Behavioral Therapy Type (*) 

NonSuppression 1 13 13 -9.7 (-24.2, 4.8) NA 

Short Term 7 99 87 -4.3 (-10.4, 1.8) Minimal (I2: 

Length of Treatment 

Long Term 2 53 37 -8.5 (-24.7, 7.8) Moderate (I2: 

Adult 8 128 101 -5.3 (-11.4, 0.7) Minimal (I2: 

Age 

Elderly 1 24 23 -0.8 (-13.7, 12.1) NA 

Low 5 60 62 -8.1 (-14.6, -1.6) Negligible (

Study Quality 

Moderate 4 92 62 -1.2 (-7.8, 5.5) Minimal (I2: 

Abbreviations: min. = minutes; NA = not applicable; No. = number; Pl. = placebo group; Tr. = treatment group 

*Sum of studies in each group is greater than total studies because some studies are included in multiple groups. 
81 

Table 18. Other outcomes: cognitive/behavioral therapy versus placebo 

No. of Participants 

Outcome (units) Comparison No. of studies 

Tr. Pl. 

Point 

Estimate 

95% Confidence 

Interval 

Efficacy Outcomes 

Wakefulness After Sleep Onset (min.) Mean Difference 8 128 120 -18.2 (-30.4, -6.0) SSleep Efficiency (%) Mean Difference 4 75 74 5.5 (1.2, 9.9) STotal Sleep Time (min.) Mean Difference 5 85 84 0.7 (-28.1, 29.5) SSleep Quality (SD) Standardized Mean Difference 6 94 95 0.38 (0.09, 0.67) Abbreviations: min. = minutes; No. = number; Pl. = placebo group; SD = standard deviation; Tr. = treatment group 
82 

Table 19. Sleep onset latency: indirect comparisons of main pharmacological treatment categories 

Comparison Difference in SOL (min.) 95% Confidence Interval (min.) Difference Favours: Sig

BNZ versus NBNZ 1.6 (-4.3, 7.5) NBNZ BNZ versus ADP -9.1 (-14.1, -4.1) BNZ BNZ versus LT -5.5 (-28.0, 17.0) BNZ BNZ versus MLT -8.2 (-15.7, -0.7) BNZ BNZ versus VAL -15.2 (-35.8, 5.4) BNZ NBNZ versus ADP -10.7 (-16.0, -5.4) NBNZ NBNZ versus LT -7.1 (-29.6, 15.4) NBNZ NBNZ versus MLT -9.8 (-17.5, -2.1) NBNZ NBNZ versus VAL -16.8 (-37.5, 3.9) NBNZ ADP versus LT 3.6 (-18.7, 25.9) LT ADP versus MLT 0.9 (-6.1, 7.9) MLT ADP versus VAL -6.1 (-26.5, 14.3) ADP LT versus MLT -2.7 (-25.7, 20.3) LT LT versus VAL -9.7 (-39.6, 20.2) LT MLT versus VAL -7.0 (-28.2, 14.2) MLT Abbreviations: ADP = antidepressants; BNZ = benzodiazepines; LT = L-tryptophan; min. = minutes; MLT = melatonin; NBNZ = non-b

sleep onset latency; VAL = valerian 
83 

Table 20. Adverse events: indirect comparisons of main pharmacological treatment categories 

Comparison Difference in risk difference 95% Confidence Interval Difference Favors: 

S

BNZ versus NBNZ 0.10 (0.04, 0.16) NBNZ BNZ versus ADP 0.06 (-0.04, 0.16) ADP BNZ versus MLT 0.06 (-0.15, 0.27) MLT BNZ versus VAL 0.21 (-0.20, 0.62) VAL NBNZ versus ADP -0.04 (-0.14, 0.06) NBNZ NBNZ versus MLT -0.04 (-0.24, 0.16) NBNZ NBNZ versus VAL 0.11 (-0.30, 0.52) VAL ADP versus MLT 0.00 (-0.22, 0.22) neither ADP versus VAL 0.15 (-0.27, 0.57) VAL  MLT versus VAL 0.15 (-0.31, 0.61) VAL Abbreviations: ADP = antidepressants; BNZ = benzodiazepines; MLT = melatonin; NBNZ = non-benzodiazepines; VAL = valerian
84 

Table 21. All outcomes: barbiturates versus placebo 

No. of Participants 

Outcome (units) Comparison No. of studies 

Tr. Pl. 

Point Estimate 95% Confidence Interv

Efficacy Outcomes 

Sleep Onset Latency (min.) Mean Difference 2 166 71 -4.5 (-14.2, 5.2) 

Safety Outcomes 

Adverse Events Risk Difference 1 144 48 0.02 (-0.10, 0.15) Abbreviations: min. = minutes; NA = not applicable; No. = number; Pl. = placebo group; Tr. = treatment group 
85 

Table 22. All outcomes: hormones versus placebo 

No. of Participants 

Outcome (units) Comparison No. of studies 

Tr. Pl. 

Point Estimate 95% Confidence Interval 

Efficacy Outcomes 

Sleep Onset Latency (min.) Mean Difference 1 33 16 -6.9 (-17.3, 3.6) Sleep Efficiency (%) Mean Difference 1 33 16 5.0 (0.3, 9.7) Total Sleep Time (min.) Mean Difference 1 33 16 21.9 (-0.2, 44.1) Sleep Quality (SD) Standardized Mean Difference 1 33 16 0.83 (0.21, 1.45) Abbreviations: min. = minutes; NA = not applicable; No. = number; Pl. = placebo group; SD = standard deviations; Tr. = treatment gro
86 

Table 23. All outcomes: alcohol versus placebo 

No. of Participants 

Outcome (units) Comparison No. of studies 

Tr. Pl. 

Point Estimate 95% Confidence Interval 

Efficacy Outcomes 

Sleep Onset Latency (min.) Mean Difference 1 11 11 4.7 (-7.5, 16.9) Wakefulness After Sleep Onset (min.) Mean Difference 1 11 11 11.3 (-9.1, 31.7) Sleep Efficiency (%) Standardized Mean Difference 1 11 11 -3.4 (-8.7, 1.9) Abbreviations: min. = minutes; NA = not applicable; No. = number; Pl. = placebo group; Tr. = treatment group 
87 

Table 24. All outcomes: low energy emission therapy versus placebo 

No. of Participants 

Outcome (units) Comparison No. of studies 

Tr. Pl. 

Point Estimate 95% Confidence Interval 

Efficacy Outcomes 

Sleep Onset Latency (min.) Mean Difference 1 49 48 -15.6 (-32.1, 0.9) Wakefulness After Sleep Onset (min.) Mean Difference 1 49 48 -23.5 (-50.0, 3.0) Sleep Efficiency (%) Mean Difference 1 49 48 10.5 (4.2, 16.8) Total Sleep Time (min.) Mean Difference 1 49 48 56.0 (21.7, 90.3) 

Safety Outcomes 

Adverse Events Risk Difference 1 49 48 0.04 (-0.11, 0.18) Abbreviations: min. = minutes; NA = not applicable; No. = number; Pl. = placebo group; SD = standard deviation; Tr. = treatment grou
88 

Table 25. All outcomes: relaxation therapy and cognitive/behavioral therapy versus placebo 

No. of Participants 

Outcome (units) Comparison No. of studies 

Com. Pl. 

Point Estimate 95% Confidence Interval 

Sleep Onset Latency (min.) Mean Difference 4 45 46 -21.5 (-42.2, -0.8) Wakefulness After Sleep Onset (min.) Mean Difference 2 23 26 -7.6 (-26.3, 11.1) Total Sleep Time (min.) Mean Difference 1 10 10 24.0 (-15.8, 63.8) Sleep Quality (SD) Standardized Mean Difference 2 23 26 0.69 (-0.34, 1.73) Abbreviations: Com. = combined treatment group; min. = minutes; NA = not applicable; No. = number; Pl. = placebo group; SD = stan
89 

Table 26. All outcomes: relaxation therapy and cognitive/behavioral therapy versus relaxation therapy 

No. of Participants 

Outcome (units) Comparison No. of studies 

Com. Rel. 

Point Estimate 95% Confidence Interval 

Sleep Onset Latency (min.) Mean Difference 2 18 16 -9.2 (-37.9, 19.5) Wakefulness After Sleep Onset (min.) Mean Difference 1 10 10 8.3 (-24.8, 41.4) Total Sleep Time (min.) Mean Difference 1 10 10 -12.0 (-44.9, 20.9) Sleep Quality (SD) Standardized Mean Difference 1 10 10 -0.08 (-0.95, 0.80) Abbreviations: Com. = combined treatment group; min. = minutes; NA = not applicable; No. = number; Rel. = relaxation group; SD = s
90 

Table 27. All outcomes: relaxation therapy and cognitive/behavioral therapy versus cognitive/behavioral therapy 

No. of Participants 

Outcome (units) Comparison No. of studies 

Com. CBT 

Point Estimate 95% Confidence Interval 

Sleep Onset Latency (min.) Mean Difference 2 23 24 -4.6 (-20.7, 11.5) Wakefulness After Sleep Onset (min.) Mean Difference 2 23 24 5.1 (-12.0, 22.2) Total Sleep Time (min.) Mean Difference 1 10 10 -24 (-84.8, 36.8) Sleep Quality (SD) Standardized Mean Difference 2 23 24 0.20 (-0.38, 0.77) Abbreviations: CBT = cognitive behavioral therapy group; Com. = combined treatment group; min. = minutes; NA = not applicable; No

standard deviation 
91 

Table 28. All outcomes: relaxation therapy and cognitive/behavioral therapy versus benzodiazepines 

No. of Participants 

Outcome (units) Comparison No. of studies 

Com. Ben. 

Point Estimate 95% Confidence Interval 

Sleep Onset Latency (min.) Mean Difference 1 13 10 8.3 (-16.4, 33.0) Wakefulness After Sleep Onset (min.) Mean Difference 1 13 10 7.3 (-12.5, 27.1) Sleep Quality (SD) Standardized Mean Difference 1 13 10 -1.51 (-2.46, -0.55) Abbreviations: Ben. = benzodiazepine group; Com. = combined treatment group; min. = minutes; NA = not applicable; No. = number; 
92 

Table 29. All outcomes: benzodiazepine and cognitive/behavioral therapy versus placebo 

No. of Participants 

Outcome (units) Comparison No. of studies 

Com. Pl. 

Point Estimate 95% Confidence Interval 

Sleep Onset Latency (min.) Mean Difference 1 8 7 -5.5 (-18.0, 7.0) Wakefulness After Sleep Onset (min.) Mean Difference 1 19 18 -32.1 (-54.1, -10.2) Sleep Efficiency (%) Mean Difference 1 19 18 12.8 (6.3, 19.3) Total Sleep Time (min.) Mean Difference 2 27 25 23.2 (-2.3, 48.8) Abbreviations: Com. = combined treatment group; min. = minutes; NA = not applicable; No. = number; Pl. = placebo group
93 

Table 30. All outcomes: benzodiazepine and cognitive/behavioral therapy versus benzodiazepine 

No. of Participants 

Outcome (units) Comparison No. of studies 

Com. CBT 

Point 

Estimate 

95% Confidence 

Interval 

Wakefulness After Sleep Onset (min.) Mean Difference 1 19 17 -15.5 (-37.1, 6.1) Sleep Efficiency (%) Mean Difference 1 19 17 6.8 (0.3, 13.3) Total Sleep Time (min.) Mean Difference 1 19 17 -13.3 (-45.3, 18.7) Abbreviations: CBT = cognitive behavioral therapy group; Com. = combined treatment group; min. = minutes; NA = not applicable; No
94 

Table 31. All outcomes: benzodiazepine and cognitive/behavioral therapy versus cognitive/behavioral therapy 

No. of Participants 

Outcome (units) Comparison No. of studies 

Com. Ben. 

Point Estimate 95% Confidence Interval 

Wakefulness After Sleep Onset (min.) Mean Difference 1 19 18 -10.1 (-34.6, 14.4) Sleep Efficiency (%) Mean Difference 1 19 18 3.1 (-3.4, 9.6) Total Sleep Time (min.) Mean Difference 1 19 18 7.0 (-23.8, 37.8) Abbreviations: Ben. = benzodiazepine group; Com. = combined treatment group; min. = minutes; NA = not applicable; No. = number 
95 

Table 32. All outcomes: non-benzodiazepine and cognitive/behavioral therapy (in combination) versus non-benzodiazepine antherapy (sequential) 

No. of Participants 

Outcome (units) Comparison No. of studies 

Com. Seq. 

Point Estimate 95% Confidence Interval 

Sleep Efficiency (%) Mean Difference 1 2 2 4.0 (-23.4, 31.4) Total Sleep Time (min.) Mean Difference 1 2 2 -25.8 (-169.9, 118.3) Abbreviations: Com. = combined treatment group; min. = minutes; NA = not applicable; No. = number; Seq. = sequential treatment gr
96 

Table 33. All outcomes: cognitive/behavioral therapy and modafinil versus cognitive/behavioral therapy 

No. of Participants 

Outcome (units) Comparison No. of studies 

Com. CBT 

Point Estimate 95% Confidence Interval 

Sleep Onset Latency (min.) Mean Difference 1 10 9 3.6 (-13.5, 20.7) Wakefulness After Sleep Onset (min.) Mean Difference 1 10 9 2.0 (-28.4, 32.4) Total Sleep Time (min.) Mean Difference 1 10 9 -7.0 (-69.3, 55.3) Abbreviations: CBT = cognitive behavioral therapy group; Com. = combined treatment group; min. = minutes; NA = not applicable; No
97 

Table 34. All outcomes: cognitive/behavioral therapy and modafinil versus modafinil 

No. of Participants 

Outcome (units) Comparison No. of studies 

Com. Mod. 

Point Estimate 95% Confidence Interval 

Sleep Onset Latency (min.) Mean Difference 1 10 8 -2.0 (-29.2, 25.2) Wakefulness After Sleep Onset (min.) Mean Difference 1 10 8 -25.4 (-61.1, 10.3) Total Sleep Time (min.) Mean Difference 1 10 8 15.8 (-29.5, 61.1) Abbreviations: Com. = combined treatment group; min. = minutes; Mod. = modafinil group; NA = not applicable; No. = number 
98 

Figure 1. Meta graph: Sleep onset latency: benzodiazepines versus placebo 

 
99 

Figure 2. Funnel Plot: Sleep onset latency: benzodiazepines versus placebo 

 

SE 
100 

Figure 3. Meta graph: Wakefulness After Sleep Onset: benzodiazepines versus placebo 

 
101 

Figure 4. Meta graph: Sleep Onset Latency: non-benzodiazepines versus placebo 
102 

Figure 5. Funnel Plot: Sleep Onset Latency: non-benzodiazepines versus placebo 

 

SE 
103 

Figure 6. Meta graph: Wakefulness After Sleep Onset: non-benzodiazepines versus placebo 

 
104 

Figure 7. Meta graph: Sleep Onset Latency: antidepressants versus placebo 
105 

Figure 8. Meta graph: Wakefulness After Sleep Onset: antidepressants versus placebo 
106 

Figure 9. Meta graph: Sleep Onset Latency: complementary and alternative care versus placebo 
107 

Figure 10. Funnel Plot: Sleep Onset Latency: melatonin versus placebo 

 

SE 
108 

Figure 11. Meta graph: Wakefulness After Sleep Onset: complementary and alternative care versus placebo 
109 

Figure 12. Meta graph: Sleep Onset Latency: relaxation therapy versus placebo 
110 

Figure 13. Funnel Plot: Sleep Onset Latency: relaxation therapy versus placebo 

 

 

SE 
111 

Figure 14. Meta graph: Wakefulness After Sleep Onset: relaxation therapy versus placebo 
112 

Figure 15. Meta graph: Sleep Onset Latency: cognitive/behavioral therapy versus placebo 
113 

Figure 16. Funnel Plot: Sleep Onset Latency: cognitive/behavioral therapy versus placebo 

SE 
114 

Figure 17. Meta graph: Wakefulness After Sleep Onset: cognitive/behavioral therapy versus placebo 
115 

Chapter 4. Discussion 

Our inclusion criteria for age allowed for the inclusion of studies in the review for which 

participants between the ages of 15 and 18 years were eligible. This decision was in agreement 

with our aim to conduct a comprehensive review of the literature, since we would have otherwise 

excluded predominantly adult studies based on the possibility that their populations included a 

sub-population of adolescents. Only 10 out of 79 studies relevant to the manifestations of 

chronic insomnia explicitly stated that individuals under the age of 18 years were eligible for the 

study, and only two out of 116 studies relevant to the management of chronic insomnia explicitly 

stated that individuals under the age of 18 years were eligible for the study. Given the low 

number of included studies for which adolescents were eligible for inclusion, it is reasonable to 

assume that the findings of the review apply to adults. 

We reviewed only English-language reports. The inclusion of non-English language reports 

in systematic reviews has been shown to increase treatment estimates in reviews of 

complementary and alternative medicine (CAM).66 This effect is thought to occur due to the 

presence of publication bias in CAM literature, such that studies with negative CAM findings are 

more likely to be published in English-language journals, and studies with positive CAM 

findings are more likely to be published in non-English language journals.66 However, we found 

no evidence of publication bias by three out of four tests conducted for studies on melatonin. 

There were not enough studies on L-tryptophan and valerian to conduct meaningful tests of 

publication bias for these interventions. Only seven non-English language reports were 

identified that were potentially relevant to this category of intervention, and given that the 

inclusion rate for the question on management of chronic insomnia was approximately 15 

percent, only one study would likely have been relevant to the review. Given the relatively small 

sample sizes of the studies identified for this category of intervention, it is unlikely that the 

addition of one study to this category would have considerably affected treatment estimates. 

Prevalence, Natural History, Incidence and Factors 

Associated with Chronic Insomnia 

The range of prevalence of chronic insomnia in the three categories of populations analyzed 

was wide. This variability may be due to the cumulative effect of variation in a number of 

factors across studies such as the sampling frame and method of sampling, the response rate, 

whether the method of data collection was validated, the criteria for chronic insomnia, the age 

distribution of the population, and the presence of psychological or psychiatric problems in the 

population. Indeed, the criteria for the duration of insomnia varied across studies from one 

month to one year and the severity of chronic insomnia varied across these populations as well. 

The interquartile range of prevalence varied from 8.5-24.3 percent across high quality studies of 

general populations, to 19.8-53.7 percent across moderate quality studies of outpatient 

populations, to 27.8-43.0 percent across moderate quality studies of clinical populations. 

Therefore, the prevalence estimates for chronic insomnia in outpatient and clinical populations 

appear to be significantly higher than for the general population, a finding that is consistent with 

evidence of an association between chronic insomnia and medical conditions, poor general 

health and increased healthcare utilization. Although we identified a number of high quality 

studies examining a general population, we did not identify any high quality studies examining 
116 

outpatients of general practice and only one examining clinical populations, suggesting that high 

quality studies investigating the prevalence of chronic insomnia in outpatients of general practice 

and clinical populations are needed. 

Only one study provided data on the natural history of chronic insomnia; the remission rate 

was 13.1 percent after a four-month follow-up. More research is necessary to determine the 

course of chronic insomnia in various populations. We did not identify any studies that provided 

evidence regarding the incidence of chronic insomnia; more research is needed in this area as 

well. 

The majority of studies identified did not have designs that would support the categorization 

of associated factors of chronic insomnia as risk factors or consequences of the disorder. That is, 

most identified studies had designs in which both chronic insomnia and a factor of interest were 

assessed in a population at the same point in time. It is necessary that longitudinal cohort studies 

be conducted to elucidate the relationship between chronic insomnia and its associated factors. 

We found evidence to suggest that chronic insomnia is associated with older age, female gender, 

present or past psychiatric illness and psychological problems, medical conditions and poor 

general health, increased healthcare utilization, lower quality of life and social relationships, 

socioeconomic status (marital separation, unemployment, poorer working conditions and lower 

social status), and decrements in memory, mood and cognitive function. Some of the factors that 

are thought to contribute to insomnia in the elderly include multiple medical problems, 

polypharmacy and environmental factors, such as absence of zeitgebers (time/schedule cues).50;67

Similarly, factors such as stress, pregnancy, menopause, medical conditions and complex home 

life may explain the higher prevalence of insomnia in females.68 It is noteworthy that there were 

studies that did not find evidence of an association between these factors and chronic insomnia. 

One of the reasons for this finding may be the different methods of data analysis employed in 

these studies; some studies performed multivariate analyses, while others performed univariate 

analyses. Other factors that may explain this finding are the age and gender distribution of the 

population, the response rate, and the duration of insomnia. Similarly, studies showing a lack of 

association between variables may have been underpowered. The relationship between chronic 

insomnia and race/ethnicity, shift-work, and absenteeism and work performance is not clear; 

there were too few studies examining these relationships to arrive at any conclusions. We did 

not identify any studies that examined the relationship between chronic insomnia and accidents 

or falls in the elderly. There was also no evidence regarding the direct and indirect costs of the 

disorder. Research in these areas is required. 

Efficacy and Safety of Treatments for Chronic Insomnia 

The interventions for chronic insomnia that were investigated in included studies may be 

categorized as either benzodiazepines, non-benzodiazepines, antidepressants, complementary 

and alternative care (L-tryptophan, melatonin and valerian), relaxation therapy, 

cognitive/behavioral therapy, barbiturates, hormone therapy, alcohol, low energy emission 

therapy and combination therapy. The majority of studies were classified under the first six 

categories of the preceding list. The discussion of results relevant to the management of chronic 

insomnia is focused on the results as they pertain to the primary and secondary outcomes of this 

review, sleep onset latency (SOL) and wakefulness after sleep onset (WASO); however, any 

major discrepancies between the estimates for these outcomes and other outcomes will be 

discussed. 
117 

The benzodiazepines, non-benzodiazepines, antidepressants and melatonin significantly 

decreased SOL. L-tryptophan, valerian, relaxation therapy and cognitive/behavioral therapy 

reduced SOL, but the results were not statistically significant. Although the overall SOL 

estimate for relaxation therapy was not significantly different from placebo, when only shortterm studies were analyzed, the effect became statistically significant in favour of relaxation 

therapy. The benzodiazepines, non-benzodiazepines and antidepressants significantly reduced 

WASO. Melatonin decreased WASO, but the result was not statistically significant. Melatonin 

had a non-significant effect on sleep efficiency, total sleep time and sleep quality. The studies on 

L-tryptophan did not report on any other outcomes besides SOL, and only one study on valerian 

provided data on WASO; valerian significantly reduced WASO in this study. Valerian did not 

have a significant effect on sleep efficiency, total sleep time or sleep quality. Relaxation therapy 

reduced WASO, but the result was not significant; however, this intervention significantly 

increased total sleep time (no significant effect on sleep efficiency or sleep quality). 

Cognitive/behavioral therapy significantly reduced WASO, and significantly increased sleep 

efficiency and sleep quality (no significant effect on total sleep time). The review provides 

evidence that benzodiazepines and non-benzodiazepines are effective treatments for chronic 

insomnia. The review provides some evidence that antidepressants are effective treatments for 

chronic insomnia, although more research is required in this area. There is some evidence that 

melatonin is an effective treatment for subsets of the chronic insomnia population, although more 

research is required in this area as well. The review provides evidence that relaxation therapy 

and cognitive/behavioral therapy are effective treatments in subsets of the chronic insomnia 

population. There were too few studies of L-tryptophan and valerian to draw conclusions 

regarding the efficacy of these treatments in the management of chronic insomnia: additional 

large-scale, randomized trials are needed. Additional large-scale, randomized trials are also 

needed in the area of relaxation therapy and cognitive/behavioral therapy in the management of 

chronic insomnia, in order to determine the efficacy of these interventions across subsets of the 

chronic insomnia population. The reduction in sleep onset latency by benzodiazepines and nonbenzodiazepines was significantly greater than for antidepressants and melatonin, based on 

indirect comparisons. However, it should be noted that there were significantly fewer studies of 

antidepressants and melatonin compared to benzodiazepines and non-benzodiazepines, and 

additional large-scale, randomized trials of the former interventions are needed before firm 

conclusions can be drawn regarding the relative efficacy of these interventions. 

The benzodiazepines, non-benzodiazepines and antidepressants had a significantly greater 

risk of harm than placebo, while melatonin did not. There were too few studies of L-tryptophan 

to draw conclusions regarding the safety of this intervention. Although there was no evidence 

that valerian poses a risk of harm, this result was based on only three studies of relatively small 

sample size. Therefore, more studies are needed before firm conclusions can be drawn regarding 

the safety of valerian. The risk for benzodiazepines was significantly greater than for nonbenzodiazepines, based on indirect comparisons. Indeed, benzodiazepine use has been shown to 

increase the risk of injury in the elderly,69 and there is pharmacologic evidence that the nonbenzodiazepines have a better side-effect profile than the benzodiazepines.70-71 Studies of 

relaxation therapy and cognitive/behavioral therapy did not provide adverse event data. 

We did not aim to conduct a head-to-head comparison between pharmacological and nonpharmacological treatments for chronic insomnia, in which case we would have required 

randomized, controlled trials, which directly compare these interventions, in order to control for 

systematic differences between control and experimental groups. An indirect comparison 
118 

between these categories of interventions is not presented here for the following reasons: (1) 

although our inclusion criteria required blinding for drug and CAM treatments, this criteria was 

omitted for psychological treatments; (2) the placebo intervention was considered to have no 

effect for drug and CAM treatments, while it may have had minimal effect for psychological 

treatments; (3) the pool of participants for psychological interventions was much smaller than for 

either the benzodiazepines, non-benzodiazepines or antidepressants. Thus, only indirect 

comparisons between non-psychological intervention categories and between psychological 

interventions were made. 

There was substantial heterogeneity in the pooled estimate for SOL for benzodiazepines, 

non-benzodiazepines, L-tryptophan, valerian and relaxation therapy. Similarly, there was 

substantial heterogeneity in the pooled estimate for WASO for benzodiazepines, nonbenzodiazepines, melatonin and cognitive/behavioral therapy. The heterogeneity was often due 

to differences in the magnitude of the point estimate and confidence interval across studies, 

rather than differences in the directionality of the effect. The exceptions are for estimates of the 

efficacy of relaxation therapy with respect to SOL and the efficacy of melatonin with respect to 

WASO. The heterogeneity in the pooled estimates for SOL was explored in sensitivity and subgroup analyses. The results indicate that heterogeneity in the pooled estimate for SOL for 

relaxation therapy is at least partially due to type of relaxation therapy, length of treatment, age 

and gender distribution of the study population, and study quality. 

There was strong evidence of publication bias in the pooled estimates for SOL for the 

benzodiazepine and non-benzodiazepine categories of intervention. This finding suggests that 

the true estimate of efficacy is lower than the estimate calculated in the current analysis. 

The results of sub-group analyses of SOL were varied. The efficacy of non-benzodiazepines 

was greater in participants without a psychiatric illness relative to those with such a disorder. 

This finding may reflect the strong, poorly understood, complex relationship between 

psychological or psychiatric disorders and insomnia,4

 which necessitates individualized 

treatment of insomnia for people suffering from these psychological or psychiatric disorders. 

The efficacy of relaxation therapy was greater with short-term treatment compared to long-term 

treatment. There were no salient differences in the design, population, intervention or method of 

measurement of sleep outcomes between short- and long-term studies that could explain the 

differences in effect of relaxation therapy with length of treatment. The possibility exists that the 

subgroup for long-term treatment did not have sufficient power to detect a statistically significant 

difference between relaxation therapy and placebo. There were too few long-term studies of 

cognitive/behavioral therapy to arrive at a conclusion regarding the difference in efficacy of this 

intervention with short- and long-term treatment. There was no evidence to suggest that 

treatment efficacy is affected by age or gender distribution of the population. It is noteworthy 

that many of the sub-group analyses were conducted with very few studies in sub-groupings, and 

some analyses could not be performed at all due to lack of data. Thus, the results of these 

analyses should be interpreted with caution. It is important that future research examine the role 

of factors such as psychiatric illness, length of treatment, age and gender in treatment efficacy in 

chronic insomnia. 

We made an a priori decision to combine summary estimates of outcomes even if they were 

measured by different methods i.e. (polysomnography, actigraphy and sleep diary). We assumed 

that any differences between methods would be cancelled out when absolute differences in the 

effect of treatment and placebo were obtained. This assumption is correct as long as the 

differences in measurement between methods were not correlated with the value of the 
119 

measurement, which is a reasonable assumption in our view. The sub-group analyses based on 

method of measurement produced variable results. Of the six comparisons made between 

polysomnography and sleep diary data, the methods most commonly used in the studies included 

in this review, only two analyses revealed a significant difference between pooled estimates 

(benzodiazepines and valerian); in both cases sleep diary overestimated effects relative to 

polysomnography. However, while four comparisons showed sleep diary to overestimate effects 

relative to polysomnography (benzodiazepines, non-benzodiazepines, antidepressants, and 

valerian), two other comparisons showed polysomnography to overestimate effects relative to 

sleep diary (L-tryptophan and melatonin). These results appear to be inconsistent in terms of the 

direction of a potential bias and cause us to doubt whether any true relationship between 

measurement method and effect estimates exists. It is noteworthy that the direction and 

significance of the estimates were not different between overall and sub-group estimates for the 

benzodiazepine, non-benzodiazepine and antidepressant categories of interventions. Although 

some differences were observed in the directionality and significance of overall and sub-group 

estimates for L-tryptophan, melatonin and valerian, the results may simply reflect the lower 

power of these sub-group analyses: sub-groups contained only one to three studies of small 

sample size. 

There was no evidence of an effect of barbiturates, hormone therapy, alcohol and low energy 

emission therapy on sleep onset latency of chronic insomniacs. The lack of evidence may reflect 

the low number of studies and/or participants encompassed by these categories. It would be 

worthwhile to explore these interventions in future research on chronic insomnia. 

We identified a small sample of studies examining the efficacy of combination treatments in 

the management of chronic insomnia; some of these studies compared a combination of 

treatments with placebo, while others compared them with single treatment. Many comparisons 

did not have data for our primary outcome, sleep onset latency, and the majority of results were 

non-significant. The latter finding may reflect the low power of these analyses. None of the 

studies provided data on adverse events. We identified only one study that compared the 

efficacy of a combined pharmacological and psychological treatment with these treatments 

administered sequentially. The research agenda for the management of chronic insomnia should 

include an evaluation of the efficacy and safety of combination treatments and sequential 

treatments. 

Our results regarding the efficacy of benzodiazepines and non-benzodiazepines in the 

management of chronic insomnia are consistent with those of other meta-analyses.72-74 Our 

results regarding the efficacy of melatonin in subsets of the chronic insomnia population are 

similar to another review.75 Our results regarding the efficacy of relaxation therapy and 

cognitive/behavioral therapy in subsets of the chronic insomnia population are similar to a recent 

meta-analysis reviewing the efficacy of cognitive/behavioral therapy in the management of sleep 

problems in older adults.76 Similar to our meta-analysis, the authors restricted the review to 

randomized, controlled trials. Our results relating to relaxation therapy and cognitive/behavioral 

therapy are somewhat at odds with three meta-analyses reviewing the efficacy of psychological 

treatments in the management of chronic insomnia.74;77-78 The difference in the findings may 

relate to key differences in the conduct of the reviews. First, we restricted our meta-analysis to a 

review of placebo-controlled, randomized trials and accounted for placebo effects in our 

estimations of efficacy. Other meta-analyses have included non-controlled studies, and for these 

studies, have not accounted for placebo/control effects in their estimation of efficacy. Second, 

we used clearly defined criteria for chronic insomnia; however, for some studies the criteria for 
120 

insomnia was not clear. Third, we separated predominantly cognitive/behavioral approaches 

from predominantly relaxation approaches in management of insomnia, resulting in distinct 

meta-analyses for each category of intervention. These interventions have been grouped under 

the broader heading of psychological/non-pharmacological treatments in other reviews. 

Limitations of the Review and Future Research 

Additional high quality studies investigating the prevalence of chronic insomnia in 

outpatients of general practice and clinical populations are needed. Similarly, we found a 

paucity of data on the natural history and incidence of chronic insomnia, which necessitates 

further research in these areas. We did not identify any cohort studies that examined the causal 

relationship between various factors and chronic insomnia; future research should be directed at 

conducting such studies in order to determine the nature of the relationship between chronic 

insomnia and its associated factors. Additional studies are needed to examine the relationship 

between chronic insomnia and race/ethnicity, shift-work, and absenteeism and work 

performance, since few studies in this area exist. Future research should also examine the 

relationship between chronic insomnia and accidents and falls in the elderly, and the direct and 

indirect costs of this disorder, since we did not identify any studies that addressed these issues. 

The pooled estimates of efficacy for antidepressants, CAM therapies, relaxation therapy and 

cognitive/behavioral therapy were based on a small sample size relative to benzodiazepines and 

non-benzodiazepines. It is necessary that additional large-scale, randomized trials be conducted 

before firm conclusions can be drawn regarding their efficacy and safety and how they compare 

to other treatments for chronic insomnia. We found a relatively small number of studies 

examining the long-term efficacy and safety of various interventions for chronic insomnia: more 

long-term studies are needed in order to differentiate the short and long-term efficacy and safety 

of these interventions. It is necessary that an agreed upon criteria be developed to determine 

what constitutes short- and long- term treatment of chronic insomnia. In addition, research 

should be conducted to establish a threshold for a clinically significant treatment effect in the 

management of chronic insomnia, such that statistically significant findings can be put into some 

clinical context. Future research should report on outcomes in addition to SOL, such as WASO, 

in order to determine the efficacy of treatments across subsets of the chronic insomnia 

population; our analysis revealed that studies tend to report SOL much more often than WASO. 

Quality of life outcomes should also be given more attention. It is necessary that future research 

be directed at establishing an agreed upon placebo treatment for psychological treatment that is 

standardized across studies, such that meaningful comparisons can be made across studies of this 

type. Finally, additional studies are necessary to determine the efficacy and safety of combined 

pharmacological and psychological treatments, as well as sequential treatments in the 

management of chronic insomnia. 

Many of the sub-group analyses conducted in this review were based on a small number of 

studies within sub-groupings, and some analyses could not be conducted at all due to lack of 

data. The paucity of data may reflect a need for future research to determine the efficacy and 

safety of treatments for chronic insomnia within specific sub-populations stratified by age, 

gender, and presence or absence of psychiatric illness. There was no evidence of an effect of 

barbiturates, hormone therapy, alcohol and low energy emission therapy on sleep onset latency 

of chronic insomniacs, however, there was a small amount of data in these areas, which prevents 

one from drawing firm conclusions before additional research is conducted. 
121 

A number of the six major categories of interventions for chronic insomnia had substantial 

heterogeneity, suggesting that the studies within these categories were significantly different. In 

some cases, sub-categorization by type of intervention significantly reduced heterogeneity within 

some of these categories. The categorization of interventions into classes is reasonable when the 

goal is to determine the efficacy and safety of a given class of intervention; however, it should be 

noted that although the interventions of a given class may be similar in some respects, they are in 

fact unique. For many interventions within these categories, there were few studies that 

addressed their safety and efficacy, and additional research is required into the efficacy and 

safety of these various interventions of chronic insomnia. 

There was strong evidence of publication bias for the benzodiazepine and nonbenzodiazepine categories, which suggests that the pooled estimates of treatment efficacy may 

be overestimates. 

It is noteworthy that research in the area of bright light therapy and physical exercise in the 

management of insomnia is ongoing; however, we did not identify any studies of these 

interventions that fulfilled our inclusion criteria. 

We restricted our analysis of efficacy and safety to evidence derived from randomizedcontrolled trials in order to provide the least biased estimate of these parameters. However, it 

should be noted that the short follow-up period that generally characterizes these types of studies 

is a limitation when assessing the long-term safety of pharmacological treatments. 

Conclusions 

• There is evidence that the prevalence of chronic insomnia in outpatient and clinical 

populations is larger than in the general population. 

• There is evidence that chronic insomnia is associated with older age, female gender, 

present or past psychiatric illness and psychological problems, medical conditions and 

poor general health, increased healthcare utilization, lower quality of life and social 

relationships, socioeconomic status (marital separation, unemployment, poorer working 

conditions and lower social status), and decrements in memory, mood and cognitive 

function. 

• Additional studies are needed to determine the incidence and natural history of chronic 

insomnia in adults. Similarly, additional studies are needed to explore the relationship 

between chronic insomnia and race/ethnicity, shift-work, absenteeism and work 

performance, accidents, falls in the elderly, and the direct and indirect costs of the 

disorder. It is necessary that longitudinal studies be undertaken to explore the risk factors 

and consequences of chronic insomnia. 

• There is evidence that benzodiazepines and non-benzodiazepines are effective in the 

management of chronic insomnia. There is some evidence that antidepressants are 

effective in the management of chronic insomnia: more research is required in this area. 

There is evidence that benzodiazepines, non-benzodiazepines and antidepressants pose a 

risk of harm. 
122 

• There is some evidence that melatonin is effective in the management of chronic 

insomnia in subsets of the chronic insomnia population, and there is no evidence that 

melatonin poses a risk of harm. However, more research is required in this area, given 

that the results are based on a small number of studies. Similarly, additional large-scale, 

randomized trials are needed to determine the efficacy of melatonin across subsets of the 

chronic insomnia population. There is insufficient evidence to conclude on the efficacy 

and safety of L-tryptophan and valerian in the management of chronic insomnia. 

Additional large-scale, randomized trials are needed in these areas. 

• There is evidence that relaxation therapy and cognitive/behavioral therapy are effective in 

the management of chronic insomnia in subsets of the chronic insomnia population. 

Additional large-scale, randomized trials are needed in order to determine their efficacy 

across subsets of the chronic insomnia population. 

• There is evidence that benzodiazepines have a greater risk of harm than nonbenzodiazepines. 

• There is insufficient evidence to conclude if there are differences between the short-term 

and long-term efficacy and safety of the various categories of interventions in the 

management of chronic insomnia; additional long-term studies are needed. 

• There is insufficient evidence regarding the efficacy and safety of combined treatments of 

pharmacological and psychological interventions, and sequential treatments, in the 

management of chronic insomnia; additional studies are needed in these areas. 
123 

References and Included Studies 

References 

 1. Sateia MJ, Doghramji K, Hauri P,, et al. Evaluation 

of chronic insomnia. An American Academy of 

Sleep Medicine Review. Sleep 2000; 23(2):243-

308. 

 2. Trans-NIH Sleep Research Coordinating 

Committee. 2003 National Sleep Disorders 

Research Plan. U.S. Department of Health and 

Human Services. National Institutes of Health. 

http://www.nhlbisupport.com/sleep/research/researc

h-a.htm. 

 3. National Sleep Foundation. Sleep in America Poll. 

Data from 1997 and 2001, 2002 sleep poll. 

http://www.sleepfoundation.org/img/2002SleepInA

mericaPoll.pdf. 

 4. Zorick FJ, Walsh JK. In Kryger MH, Roth T, 

Dement WC. Principles and Practice of Sleep 

Medicine. 3rd Ed. Philadelphia, PA: W.B. 

Saunders Co; 2000. Chapter 53, Evaluation and 

management of insomnia. 

 5. Sateia MJ, Nowell P. Insomnia. Lancet 2004; 

364:1959-73. 

 6. Breslau N, Roth T, Rosenthal L, et al. Sleep 

disturbances and psychiatric disorders: a 

longitudinal epidemiological study of young adults . 

Biol Psychiatry 1996; 39:411-18. 

 7. Simon GE, VonKorff M. Prevalence, burden, and 

treatment of insomnia in primary care. Am J 

Psychiatry 1997; 154(10):1417-23. 

 8. Leger D, Guilleminault C, Bader G, et al. Medical 

and socio-professional impact of insomnia. Sleep 

2002; 25(6):625-9. 

 9. Ohayon M. Epidemiological study on insomnia in 

the general population. Sleep 1996; 19(3 Suppl):S7-

15. 

 10. Roberts RE, Shema SJ, Kaplan GA. Prospective 

data on sleep complaints and associated risk factors 

in an older cohort. Psychosom Med 1999; 

61(2):188-96. 

 11. Foley DJ, Monjan A, Simonsick EM, et al. 

Incidence and remission of insomnia among elderly 

adults: an epidemiologic study of 6,800 persons 

over three years. Sleep 1999; 22(Suppl 2):S366-72. 

 12. Janson C, Lindberg E, Gislason T, et al. Insomnia in 

men - A 10-year prospective population based 

study. Sleep 2001; 24(4):425-30. 

 13. Gislason T, Reynisdottir H, Kristbjarnarson H, et al. 

Sleep habits and sleep disturbances among the 

elderly--an epidemiological survey. J Int Med 1993; 

234(1):31-9. 

 14. Riemann D, Voderholzer U. Primary insomnia: a 

risk factor to develop depression? J Affect Disord 

2003; 76:255-9. 

 15. Kryger MH, Roth T, Dement WC. Principles and 

Practice of Sleep Medicine. 3rd Ed. Philadelphia, 

PA: W.B. Saunders Co; 2000. 

 16. Walsh JK, Engelhardt CL. The direct economic 

costs of insomnia in the United States for 1995. 

Sleep 1999; 22(Suppl 2):S386-93. 

 17. Walsh JK. Clinical and socioeconomic correlates of 

insomnia. J Clin Psychiatry 2004; 65 Suppl 8:13-9. 

 18. Stoller MK. Economic effects of insomnia. 

[Review] [66 refs]. Clin Ther 1994; 16(5):873-97; 

854. 

 19. Walsh J. Pharmacologic management of insomnia. J 

Clin Psychiatry 2004; 65(Supp 16):41-5. 

 20. Morin CM, Colecchi C, Stone J, et al. Behavioral 

and pharmacological therapies for late-life 

insomnia: a randomized controlled trial. J Am Med 

Assoc 1999; 281(11):991-9. 

 21. Linde K, Ramirez G, Mulrow CD, et al. St John's 

wort for depression--an overview and meta-analysis 

of randomised clinical trials. Br Med J 1996; 

313(7052):253-8. 

 22. Alderson P, Green S, Higgins JPT . MEDLINE 

highly sensitive search strategies for identifying 

reports of randomized controlled trials. Cochrane 

Reviewer's Handbook: 4.2.2 [March 2004]. 

Appendix 5b 

http://www.cochrane.org/resources/handbook/hboo

k.htm . 

 23. McKibbon A, Eady A, Marks S. PDQ Evidencebased Principles and Practice. Hamilton: B.C. 

Decker Inc., 1999. 
124 

 24. Tjosvold L. Systematic Reviews Filter. ARCHE 

(Alberta Research Centre for Child Health 

Evidence) website. 

http://www.ualberta.ca/ARCHE/filters.html#srmedl

ine. 

 25. Loney PL, Chambers LW, Bennett KJ, et al. Critical 

appraisal of the health research literature: 

prevalence or incidence of a health problem. 

Chronic Dis Can 1988; 19(4):170-6. 

 26. Jadad AR, Moore RA, Carroll D, et al. Assessing 

the quality of reports of randomized clinical trials: 

is blinding necessary? Control Clin Trials 1996; 

17:1-12. 

 27. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical 

evidence of bias. Dimensions of methodological 

quality associated with estimates of treatment 

effects in controlled trials. J Am Med Assoc 1995; 

273:408-12. 

 28. DerSimonian R, Laird N. Meta-analysis in clinical 

trials. Control Clin Trials 1986; 7:177-88. 

 29. Cohen J. Statistical power analysis for the 

behavioural sciences. Academic Press, New York. 

1969. 

 30. Bailey KR. Inter-study differences: How should 

they influence the interpretation and analysis of 

results? Stat Med 1987; 6:351-8. 

 31. Higgins JPT, Thompson SG. Quantifying 

heterogeneity in a meta-analysis. Stat Med 2002; 

21(11):1539-58. 

 32. Deeks JJ, Altman DG, Bradburn MJ. Statistical 

methods for examining heterogeneity and 

combining results from several studies in metaanalysis. In: Egger M; Davey Smith G, and Altman 

DG. Systematic reviews in health care. 2nd ed. 

London, UK: BMJ Books; 2001. 

 33. Light RJ, Pillemer DB. Summing up. The science 

of reviewing research. Cambridge, MA: Harvard 

University Press; 1984. 

 34. Begg CB, Mazumdar M. Operating characteristics 

of a rank correlation test for publication bias. 

Biometrics 1994; 50:1088-101. 

 35. Egger M, Smith GD, Schneider M, et al. Bias in 

meta-analysis detected by a simple, graphical test. 

Br Med J 1997; 315(7109):629-34. 

 36. Duval S, Tweedie R. A nonparametric "trim and 

fill" method of accounting for publication bias in 

meta-analysis. J Am Med Assoc 2000; 95(449):89-

98. 

 37. American Academy of Sleep Medicine. The 

International Classification of Sleep Disorders, 

Revised. Diagnostic and Coding Manual. 

Rochester, MN: American Academy of Sleep 

Medicine; 2001. 

 38. American Psychiatric Association. Diagnostic and 

Statistical Manual of Mental Disorders. 4th ed. 

Washington, DC: American Psychiatric 

Association Press; 1994. 

 39. Chesson A, Hartse K, McDowell Anderson W, et al. 

Practice Parameters for the Evaluation of Chronic 

Insomnia. An American Academy of Sleep 

Medicine Report. Sleep 1999; 23(2):1-5. 

 40. Edinger J, Bonnet M, Bootzin R, et al. Derivation of 

research diagnostic criteria for insomnia: report of 

an American Academy of Sleep Medicine work 

group. Sleep 2004; 27(8):1567-96. 

 41. American Sleep Disorders Standards of Practice 

Committee. Practice parameters for the use of 

polysomnography in the evaluation of insomnia. 

Sleep 1995; 18:55-7. 

 42. American Sleep Disorders Standards of Practice 

Committee. Practice parameters for the indications 

for polysomnography and related procedures. Sleep 

1997; 20:506-22. 

 43. Sadeh A, Hauri PJ, Kripke DF, et al. The role of 

actigraphy in the evaluation of sleep disorders. 

Sleep 1995; 18:55-7. 

 44. Drummond SA, Smith MT, Orff HJ, et al. 

Functional imaging of the sleeping brain: review of 

findings and implications for the study of insomnia. 

Sleep Med Rev 2004; 8:227-42. 

 45. Bonnett MH, Arand D. 24 hour metabolic rate in 

insomniacs and matched normal sleepers. Sleep 

1995; 18(7):581-8. 

 46. Vgontzas AN, Tsigos C, Bixler EO, et al. Chronic 

insomnia and activity of the stress system: a 

preliminary study. J Psychosom Res 1998; 45(1 

Spec No):21-31. 

 47. Bastien CH, Morin CM. Familial incidence of 

insomnia. J Sleep Res 2000; 9(1):49-54. 

 48. Yves D, Morin C, Cervena K, et al. Family studies 

in insomnia (abstract). Sleep 2003; 

26(suppl):A:304, A0764 2003; 26(Suppl A):304. 

 49. Krystal A, Roth T. Definitions, measurements, and 

management in insomnia. J Clin Psychiatry 2004; 

65(Suppl 8):5-7. 
125 

 50. Foley DJ, Monjan AA, Izmirlian G, et al. Incidence 

and remission of insomnia among elderly adults in a 

biracial cohort. Sleep 1999; 22 Suppl 2:S373-8. 

 51. Millar A, Espie CA, Scott J. The sleep of remitted 

bipolar outpatients: A controlled naturalistic study 

using actigraphy. J Affect Disord 2004; 80(2-

3):145-53. 

 52. Hajak G, SINE Study Group, Study of Insomnia in 

Europe. Epidemiology of severe insomnia and its 

consequences in Germany. Eur Arch Psychiatry 

Clin Neurosci 2001; 251(2):49-56. 

 53. Hohagen F, Kappler C, Schramm E, et al. Sleep 

onset insomnia, sleep maintaining insomnia and 

insomnia with early morning awakening--temporal 

stability of subtypes in a longitudinal study on 

general practice attenders. Sleep 1994; 17(6):551-4. 

 54. Hetta J, Broman JE, Mallon L. Evaluation of severe 

insomnia in the general population--implications for 

the management of insomnia: insomnia, quality of 

life and healthcare consumption in Sweden. J 

Psychopharmacol 1999; 13(4 Suppl 1):S35-6. 

 55. Savard J, Simard S, Blanchet J, et al. Prevalence, 

clinical characteristics, and risk factors for insomnia 

in the context of breast cancer . Sleep 2001; 

24(5):583-90. 

 56. Millar A, Espie CA, Scott J. The sleep of remitted 

bipolar outpatients: A controlled naturalistic study 

using actigraphy. J Affect Disord 2004; 80(2-

3):145-53. 

 57. Kageyama T, Nishikido N, Kobayashi T, et al. 

Cross-sectional survey on risk factors for insomnia 

in Japanese female hospital nurses working rapidly 

rotating shift systems. J Hum Ergol 2001; 30(1-

2):149-54. 

 58. Bixler EO, Vgontzas AN, Lin HM, et al. Insomnia 

in Central Pennsylvania. J Psychosom Res 2002; 

53(1):589-92. 

 59. Riedel BW, Durrence H, Lichstein KL, et al. The 

Relation Between Smoking and Sleep: The 

Influence of Smoking Level, Health, and 

Psychological Variables. Behav Sleep Med 2004; 

2(1):63-78. 

 60. Lopes Rocha F, Guerra HL, Lima-Costa MFF. 

Prevalence of insomnia and associated sociodemographic factors in a Brazilian community: The 

Bambui study. Sleep Med 2002; 3(2):121-6. 

 61. Martikainen K, Partinen M, Hasan J, et al. The 

impact of somatic health problems on insomnia in 

middle age. Sleep Med 2003; 4(3):201-6. 

 62. Terzano MG, Parrino L, Cirignotta F, et al. Studio 

Morfeo: insomnia in primary care, a survey 

conducted on the Italian population. Sleep Med 

2004; 5(1):67-75. 

 63. Zammit GK, Weiner J, Damato N, et al. Quality of 

life in people with insomnia. Sleep 1999; 22(Suppl 

2):S379-85. 

 64. Shochat T, Umphress J, Israel AG, et al. Insomnia 

in primary care patients. Sleep 1999; 22(Suppl 

2):S359-65. 

 65. Perlis ML, Smith MT, Orff HJ, et al. The 

mesograde amnesia of sleep may be attenuated in 

subjects with primary insomnia. Physiol Behav 

2001; 74(1-2):71-6. 

 66. Moher D, Pham B, Lawson M, et al. The inclusion 

of reports of randomized trials published in 

languages other than English in systematic reviews 

National Health Service (NHS) Research and 

Development Program (Health Technology 

Assessment Report). Health Technol Assess 2003; 

7:1-90. 

 67. Benca RM, Ancoli-Israel S, Moldofsky H. Special 

considerations in insomnia diagnosis and 

management: depressed, elderly, and chronic pain 

populations. J Clin Psychiatry 2004; 65(Suppl 

8):26-35. 

 68. Miller EH. Women and insomnia. Clin Cornerstone 

2004; 6(Suppl 1B):S8-18. 

 69. Panneman MJ, Goettsch WG, Kramarz P, et al. The 

costs of benzodiazepine-associated hospital-treated 

fall Injuries in the EU: a Pharmo study. Drugs 

Aging 2003; 20(11):833-9. 

 70. Drover DR. Comparative pharmacokinetics and 

pharmacodynamics of short-acting hypnosedatives: 

zaleplon, zolpidem and zopiclone. Clin 

Pharmacokinet 2004; 43(4):227-38. 

 71. Roehrs T, Roth T. Hypnotics: an update. Curr 

Neurol Neurosci Rep 2003; 3(2):181-4. 

 72. Nowell PD, Mazumdar S, Buysse DJ, et al. 

Benzodiazepines and zolpidem for chronic 

insomnia: meta-analysis of treatment efficacy. J Am 

Med Assoc 1997; 278:2170-7. 

 73. Holbrook AM, Crowther R, Lotter A, et al. Metaanalysis of benzodiazepine use in the treatment of 

insomnia. Can Med Assoc J 2000; 162(2):225-33. 
126 

 74. Smith MT, Perlis ML, Park A, et al. Comparative 

meta-analysis of pharmacotherapy and behavior 

therapy for persistent insomnia. Am J Psychiatry 

2002; 159:5-11. 

 75. Buscemi N, Vandermeer B, Pandya R, et al. 

Melatonin for treatment of sleep disorders. Evid 

Rep Technol Assess 2004;(108):1-7. 

 76. Montgomery P, Dennis J. Cognitive behavioural 

interventions for sleep problems in adults aged 60+ 

[review]. Cochrane Database Syst Rev 2003; 1(Art. 

No.: CD003161. DOI: 10.1002/14651858. 

CD003161). 

 77. Morin CM, Culbert JP, Schwartz SM. 

Nonpharmacological interventions for insomnia: A 

meta-analysis of treatment efficacy. Am J 

Psychiatry 1994; 151(8):1172-80. 

 78. Murtagh DRR, Greenwood KM. Identifying 

effective psychological treatments for insomnia: a 

meta-analysis. J Consult Clin Psychol 1995; 

63(1):79-89. 
127 

Included Studies 

 1. Aden GC, Thatcher C. Quazepam in the short-term 

treatment of insomnia in outpatients. J Clin 

Psychiatry 1983; 44(12):454-6. 

 2. Allain H, Arbus L, Schuck S. Efficacy and safety of 

zolpidem administered as needed in primary 

insomnia: results of a double-blind, placebocontrolled study. Clin Drug Invest 2001; 21(6):391-

400. 

 3. Allain H, Le Coz F, Borderies P, et al. Use of 

zolpidem 10 mg as a benzodiazepine substitute in 

84 patients with insomnia. Hum Psychopharmacol 

1998; 13(8):551-9. 

 4. Ancoli-Israel S, Roth T. Characteristics of insomnia 

in the United States: results of the 1991 National 

Sleep Foundation Survey. Sleep 1999; 22(Suppl 

2):S347-53. 

 5. Ascher LM, Turner RM. Paradoxical intention and 

insomnia: An experimental investigation. Behav 

Res Ther 1979; 17(4):408-11. 

 6. Asnis GM, Chakraburtty A, DuBoff EA, et al. 

Zolpidem for persistent insomnia in SSRI-treated 

depressed patients. J Clin Psychiatry 1999; 

60(10):668-76. 

 7. Bastien CH, Fortier-Brochu E, Rioux I, et al. 

Cognitive performance and sleep quality in the 

elderly suffering from chronic insomnia. 

Relationship between objective and subjective 

measures.[erratum appears in J Psychosom Res. 

2003 Nov;55(5):475]. J Psychosom Res 2003; 

54(1):39-49. 

 8. Beary MD, Lacey JH, Crutchfield MB, et al. 

Psycho-social stress, insomnia and temazepam: a 

sleep laboratory evaluation in a "general practice" 

sample. Psychopharmacol 1984; 83(1):17-9. 

 9. Bixler EO, Kales A, Soldatos CR, et al. Prevalence 

of sleep disorders in the Los Angeles metropolitan 

area. Am J Psychiatry 1979; 136(10):1257-62. 

 10. Bixler EO, Vgontzas AN, Lin HM, et al. Insomnia 

in Central Pennsylvania. J Psychosom Res 2002; 

53(1):589-92. 

 11. Bliwise NG. Factors related to sleep quality in 

healthy elderly women. Psychol Aging 1992; 

7(1):83-8. 

 12. Bonnet MH, Arand DL. 24-Hour metabolic rate in 

insomniacs and matched normal sleepers. Sleep 

1995; 18(7):581-8. 

 13. Botter PA. Comparative double blind study of 

loprazolam, 1 mg and 2 mg, versus placebo in 

anxiety induced insomnia. Curr Med Res Opin 

1983; 8(9):626-30. 

 14. Bowen AJ. Comparative efficacy of triazolam, 

flurazepam and placebo in out-patient insomniacs. 

J Int Med Res 1978; 6(4):337-42. 

 15. Braga-Neto P, Da Silva FP, Monte FS, et al. 

Snoring and excessive daytime sleepiness in 

Parkinson's Disease. J Neurol Sci 2004; 217(1):41-

5. 

 16. Broman JE, Lundh LG, Aleman K, et al. Subjective 

and objective performance in patients with 

persistent insomnia. Scand J Behav Ther 1992; 

21(3):115-26. 

 17. Broman JE, Lundh LG, Hetta J. Insufficient sleep in 

the general population. Neurophysiol Clin 1996; 

26(1):30-9. 

 18. Brown CC, Horrom NJ, Wagman AM. Effects of Ltryptophan on sleep onset insomniacs. Waking 

Sleeping 1979; 3(2):101-8. 

 19. Campbell RD, Grace MGA, Bourgouin J, et al. 

Efficacy and safety of zopiclone in the treatment of 

insomnia. Curr Ther Res 1987; 42(4):665-70. 

 20. Carr-Kaffashan L, Woolfolk RL. Active and 

placebo effects in treatment of moderate and severe 

insomnia. J Consult Clin Psychol 1979; 47(6):1072-

80. 

 21. Chambers MJ, Kim JY. The role of state-trait 

anxiety in insomnia and daytime restedness. Behav 

Med 1993; 19(1):42-6. 

 22. Chaudoir PJ, Jarvie NC, Wilcox GJ. The 

acceptability of a non-benzodiazepine hypnotic 

(Zopiclone) in general practice. J Int Med Res 1983; 

11(6):333-7. 

 23. Choliz M. A breathing-retraining procedure in 

treatment of sleep-onset insomnia: theoretical basis 

and experimental findings. Percept Mot Skills 1995; 

80(2):507-13. 

 
128 

 24. Cohn JB, Wilcox CS, Bremner J, et al. Hypnotic 

efficacy of estazolam compared with flurazepam in 

outpatients with insomnia. J Clin Pharmacol 1991; 

31:747-50. 

 25. Cohn JB. Double-blind crossover comparison of 

triazolam and lorazepam in the posthypnotic state. J 

Clin Psychiatry 1984; 45(3):104-7. 

 26. Cohn JB. Triazolam treatment of insomnia in 

depressed patients taking tricyclics. J Clin 

Psychiatry 1983; 44(11):401-6. 

 27. Coursey RD, Buchsbaum M, Frankel BL. 

Personality measures and evoked responses in 

chronic insomniacs. J Abnorm Psychol 1975; 

84(3):239-49. 

 28. Coxeter PD, Schluter PJ, Eastwood HL, et al. 

Valerian does not appear to reduce symptoms for 

patients with chronic insomnia in general practice 

using a series of randomised N-of-I trials. 

Complement Ther Med 2003; 11(4):215-22. 

 29. Crenshaw MC, Edinger JD. Slow-wave sleep and 

waking cognitive performance among older adults 

with and without insomnia complaints. Physiol 

Behav 1999; 66(3):485-92. 

 30. Davies R, Lacks P, Storandt M, et al. 

Countercontrol treatment of sleep-maintenance 

insomnia in relation to age. Psychol Aging 1986; 

1(3):233-8. 

 31. Dawson D, Rogers NL, van den Heuvel CJ, et al. 

Effect of sustained nocturnal transbuccal melatonin 

administration on sleep and temperature in elderly 

insomniacs. J Biol Rhythms 1998; 13(6):532-8. 

 32. Declerck A, Smits M. Zolpidem, a valuable 

alternative to benzodiazepine hypnotics for chronic 

insomnia? J Int Med Res 1999; 27(6):253-63. 

 33. Dominguez RA, Goldstein BJ, Jacobson AF, et al. 

Brotizolam in the treatment of insomnia. 

Psychopharmacol Bull 1985; 21(1):97-100. 

 34. Dominguez RA, Goldstein BJ, Jacobson AF, et al. 

Comparative efficacy of estazolam, flurazepam, and 

placebo in outpatients with insomnia. J Clin 

Psychiatry 1986; 47(7):362-5. 

 35. Donath F, Quispe S, Diefenbach K, et al. Critical 

evaluation of the effect of valerian extract on sleep 

structure and sleep quality. Pharmacopsychiatry 

2000; 33(2):47-53. 

 

 36. Dorsey CM, Bootzin RR. Subjective and 

psychophysiologic insomnia: An exmaination of 

sleep tendency and personality. Biol Psychiatry 

1997; 41(2):209-16. 

 37. Drake CL, Roehrs TA, Mangano RM, et al. Doseresponse effects of zaleplon as compared with 

triazolam (0.25 mg) and placebo in chronic primary 

insomnia. Hum Psychopharmacol 2000; 15(8):595-

604. 

 38. Dujardin K, Guieu JD, Leconte-Lambert C, et al. 

Comparison of the effects of zolpidem and 

flunitrazepam on sleep structure and daytime 

cognitive functions. A study of untreated 

unsomniacs. Pharmacopsychiatry 1998; 31(1):14-8. 

 39. Edinger JD, Glenn DM, Bastian LA, et al. Slowwave sleep and waking cognitive performance II: 

Findings among middle-aged adults with and 

without insomnia complaints. Physiol Behav 2000; 

70(1-2):127-34. 

 40. Edinger JD, Sampson WS. A Primary Care 

"Friendly" Cognitive Behavioral Insomnia Therapy. 

Sleep 2003; 26(2):177-182. 

 41. Edinger JD, Wohlgemuth W, Radtke R, et al. 

Cognitive behavioral therapy for treatment of 

chronic primary insomnia: A randomized controlled 

trial. [References]. J Am Med Assoc 2001; 

285(14):1856-64. 

 42. Edinger JD, Fins AI, Glenn DM, et al. Insomnia and 

the eye of the beholder: are there clinical markers of 

objective sleep disturbances among adults with and 

without insomnia complaints? J Consult Clin 

Psychol 2000; 68(4):586-93. 

 43. Elie R, Frenay M, Le Morvan P, et al. Efficacy and 

safety of zopiclone and triazolam in the treatment of 

geriatric insomniacs. Int Clin Psychopharmacol 

1990; 5(Suppl 2):39-46. 

 44. Elie R, Ruther E, Farr I, et al. Sleep latency is 

shortened during 4 weeks of treatment with 

zaleplon, a novel nonbenzodiazepine hypnotic. J 

Clin Psychiatry 1999; 60(8):536-44. 

 45. Ellis CM, Lemmens G, Parkes JD. Melatonin and 

insomnia. J Sleep Res 1996; 5(1):61-5. 

 46. Espie CA, Lindsay WR, Brooks DN, et al. A 

controlled comparative investigation of 

psychological treatments for chronic sleep-onset 

insomnia. Behav Res Ther 1989; 27(1):79-88. 

 
129 

 47. Farag NH, Mills PJ. A randomised-controlled trial 

of the effects of a traditional herbal supplement on 

sleep onset insomnia. Complement Thera Med 

2003; 11(4):223-5. 

 48. Ferguson JM, Bielski RJ, Houston J, et al. 

Comparison of estazolam and placebo in the 

outpatient treatment of insomnia associated with 

major depression. Curr Ther Res 1991; 49(5):898-

907. 

 49. Fichtenberg NL, Zafonte RD, Putnam S, et al. 

Insomnia in a post-acute brain injury sample. Brain 

Inj 2002; 16(3):197-206. 

 50. Fillingim JM . Double blind evaluation of 

temazepam, flurazepam, and placebo in geriatric 

insomniacs. Clin Ther 1982; 4(5):369-80. 

 51. Fleming J, Moldofsky H, Walsh JK, et al. 

Comparison of the residual effects and efficacy of 

short term zolpidem, flurazepam and placebo in 

patients with chronic insomnia. Clin Drug Invest 

1995; 9:303-13. 

 52. Fry J, Scharf M, Mangano R, et al. Zaleplon 

improves sleep without producing rebound effects 

in outpatients with insomnia. Zaleplon Clinical 

Study Group. Int Clin Psychopharmacol 2000; 

15(3):141-52. 

 53. Garfinkel D, Laudon M, Nof D, et al. Improvement 

of sleep quality in elderly people by controlledrelease melatonin . Lancet 1995; 346:541-4. 

 54. Garfinkel D, Laudon M, Zisapel N. Improvement of 

sleep quality by controlled-release melatonin in 

benzodiazepine-treated elderly insomniacs. Arch -

Gerontol Geriatr 1997; 24(2):223-31. 

 55. Gelinas B, Thorsteinson L, Lapierre YD, et al. 

Zopiclone in the treatment of insomniacs of family 

practice. Psychiatr J Univ Ottawa 1985; 10(3):165-

8. 

 56. Goethe JW, Kader G . Short-term clinical study of 

quazepam 15 mg in outpatient insomniacs. Curr 

Ther Res 1982; 32:150-6. 

 57. Goldenberg F, Hindmarch I, Joyce CRB, et al. 

Zopiclone, sleep and health-related quality of life. 

Hum Psychopharmacol 1994; 9(4):245-51. 

 58. Haffmans PMJ, Vos MS. The effects of trazodone 

on sleep disturbances induced by brofaromine. Eur 

Psychiatry 1999; 14(3):167-71. 

 59. Haimov I, Lavie P, Laudon M, et al. Melatonin 

replacement therapy of elderly insomniacs. Sleep 

1995; 18(7):598-603. 

 60. Hajak G, Clarenbach P, Fischer W, et al. Zopiclone 

improves sleep quality and daytime well-being in 

insomniac patients: comparison with triazolam, 

flunitrazepam and placebo. Int Clin 

Psychopharmacol 1994; 9(5):251-61. 

 61. Hajak G, Rodenbeck A, Adler L, et al. Nocturnal 

melatonin secretion and sleep after doxepin 

administration in chronic primary insomnia. 

Pharmacopsychiatry 1996; 29(5):187-92. 

 62. Hajak G, Rodenbeck A, Voderholzer U, et al. 

Doxepin in the treatment of primary insomnia - a 

placebo-controlled, double-blind, 

polysomnographic study [abstract]. In: J Eur Coll 

Neuropsychopharmacol. Proceedings of the 13th 

ECNP Congress; 2000 Sep 9-13; Munich, Germany. 

Suppl 3, S248. 

 63. Hajak G, SINE Study Group, Study of Insomnia in 

Europe. Epidemiology of severe insomnia and its 

consequences in Germany. Eur Arch Psychiatry 

Clin Neurosci 2001; 251(2):49-56. 

 64. Han SY, Yoon JW, Jo SK, et al. Insomnia in 

diabetic hemodialysis patients: Prevalence and risk 

factors by a multicenter study. Nephron 2002; 

92(1):127-32. 

 65. Hartmann E, Lindsley JG, Spinweber C. Chronic 

insomnia effects of tryptophan, flurazepam, seco 

bartibal and placebo. Psychopharmacol 1983; 

80(2):138-42. 

 66. Harvey AG, Greenall E. Catastrophic worry in 

primary insomnia. J Behav Ther Exp Psychiatry 

2003; 34(1):11-23. 

 67. Harvey AG . The attempted suppression of presleep 

cognitive activity in insomnia. Cognit Ther Res 

2003; 27(6):593-602. 

 68. Hauri PJ. Cognitive deficits in insomnia patients. 

Acta Neurol Belg 1997; 97(2):113-7. 

 69. Haynes SN, Sides H, Lockwood G. Relaxation 

instructions and frontalis electromyographic 

feedback intervention with sleep-onset insomnia. 

Behav Ther 1977; 8(4):644-52. 

 70. Haynes SN, Woodward S, Moran R, et al. 

Relaxation treatment of insomnia. Behav Ther 

1974; 5(4):555-8. 

 71. Healey ES, Kales A, Monroe LJ, et al. Onset of 

insomnia: role of life-stress events. Psychosom Med 

1981; 43(5):439-51. 

 
130 

 72. Hedner J, Yaeche R, Emilien G, et al. Zaleplon 

shortens subjective sleep latency and improves 

subjective sleep quality in elderly patients with 

insomnia. The Zaleplon Clinical Investigator Study 

Group. Int J Geriatr Psychiatry 2000; 15(8):704-12. 

 73. Heidrich H, Ott H, Beach RC. Lormetazepam A 

benzodiazepine derivative without hangover effect. 

A double-blind study with chronic insomniacs in a 

general practice setting. Int J Clin Pharmacol Ther 

Toxicol 1981; 19(1):11-17. 

 74. Hernandez LR, Del Rosal PL, Ponce MC. Shortterm study of quazepam 15 milligrams in the 

treatment of insomnia. J Inte Med Res 1983; 

11(3):162-6. 

 75. Herrmann WM, Kubicki ST, Boden S, et al. Pilot 

controlled double-blind study of the hypnotic 

effects of zolpidem in patients with chronic 'learned' 

insomnia: Psychometric and polysomnographic 

evaluation. J Int Med Res 1993; 21(6):306-22. 

 76. Hetta J, Broman JE, Mallon L. Evaluation of severe 

insomnia in the general population--implications for 

the management of insomnia: insomnia, quality of 

life and healthcare consumption in Sweden. J 

Psychopharmacol 1999; 13(4 Suppl 1):S35-6. 

 77. Hidalgo MP, Caumo W . Sleep distrubances 

associated with minor psychiatric disorders in 

medical students. Neurol Sci 2002; 23(1):35-9. 

 78. Hohagen F, Kappler C, Schramm E, et al. Sleep 

onset insomnia, sleep maintaining insomnia and 

insomnia with early morning awakening--temporal 

stability of subtypes in a longitudinal study on 

general practice attenders. Sleep 1994; 17(6):551-4. 

 79. Hohagen F, Kappler C, Schramm E, et al. 

Prevalence of insomnia in elderly general practice 

attenders and the current treatment modalities. Acta 

Psychiatr Scand 1994; 90(2):102-8. 

 80. Hohagen F, Rink K, Kaeppler C, et al. Prevalence 

and treatment of insomnia in general practice: A 

longitudinal study. Eur Arch Psychiatry Clin 

Neurosci 1993; 242(6):329-36. 

 81. Hughes RC, Hughes HH. Insomnia: Effects of 

EMG biofeedback, relaxation training, and stimulus 

control. Behav Eng 1978; 5(2):67-72. 

 82. Ishigooka J, Suzuki M, Isawa S, et al. 

Epidemiological study on sleep habits and insomnia 

of new outpatients visiting general hospitals in 

Japan. Psychiatry Clin Neurosci 1999; 53(4):515-

22. 

 

 83. Jacobson AF, Dominguez RA, Goldstein BJ, et al. 

Efficacy of brotizolam in geriatric patients with 

insomnia. Curr Ther Res 1986; 39:528-36. 

 84. James S, Sack D, Rosenthal N, et al. Melatonin 

administration in insomnia. Neuropsychopharmacol 

1990; 3(1):19-24. 

 85. Kageyama T, Kabuto M, Nitta H, et al. A 

population study on risk factors for insomnia among 

adult Japanese women: a possible effect of road 

traffic volume. Sleep 1997; 20(11):963-71. 

 86. Kageyama T, Nishikido N, Kobayashi T, et al. 

Cross-sectional survey on risk factors for insomnia 

in Japanese female hospital nurses working rapidly 

rotating shift systems. J Hum Ergol 2001; 30(1-

2):149-54. 

 87. Kales A, Caldwell AB, Soldatos CR, et al. 

Biopsychobehavioral correlates of insomnia. II. 

Pattern specificity and consistency with the 

Minnesota Multiphasic Personality Inventory. 

Psychosom Med 1983; 45(4):341-56. 

 88. Kales A, Bixler EO, Soldatos CR, et al. 

Biopsychobehavioral correlates of insomnia: I. Role 

of sleep apnea and nocturnal myoclonus. 

Psychosomat J Consult Liais Psychiatry 1982; 

23(6):589-600. 

 89. Kales JD, Kales A, Bixler EO, et al. 

Biopsychobehavioral correlates of insomnia, V: 

Clinical characteristics and behavioral correlates. 

Am J Psychiatry 1984; 141(11):1371-6. 

 90. Kappler C, Hohagen F. Psychosocial aspects of 

insomnia: Results of a study in general practice. Eur 

Arch Psychiatry Clin Neurosci 2003; 253(1):49-52. 

 91. Kawada T, Yosiaki S, Yasuo K, et al. Population 

study on the prevalence of insomnia and insomniarelated factors among Japanese women. Sleep Med 

2003; 4(6):563-7. 

 92. Krystal AD, Walsh JK, Laska E, et al. Sustained 

efficacy of eszopiclone over 6 months of nightly 

treatment: results of a randomized, double-blind, 

placebo-controlled study in adults with chronic 

Iisomnia. Sleep 2003; 26(7):793-9. 

 93. Lacks P, Bertelson AD, Sugerman J, et al. 

Treatment of sleep maintenance insomnia with 

stimulus control techniques. Behav Res Ther 1983; 

21(3):291-6. 

 94. Lacks P, Bertelson AD, Gans L, et al. The 

effectiveness of three behavioral treatments for 

different degrees of sleep onset insomnia. Behav 

Ther 1983; 14(5):593-605. 
131 

 95. Lahmeyer H, Wilcox CS, Kann J, et al. Subjective 

efficacy of zolpidem in outpatients with chronic 

insomnia: double blind comparison with placebo. 

Clin Drug Invest 1997; 13:134-44. 

 96. Lamphere JK, Roehrs TA, Zorick FJ, et al. The 

dose effects of zopiclone. Hum Psychopharmacol 

1989; 4(1):41-6. 

 97. Leger D, Guilleminault C, Dreyfus JP, et al. 

Prevalence of insomnia in a survey of 12,778 adults 

in France. J Sleep Res 2000; 9(1):35-42. 

 98. Leppavuori A, Pohjasvaara T, Vataja R, et al. 

Insomnia in ischemic stroke patients. Cerebrovasc 

Dis 2002; 14(2):90-7. 

 99. Leppik IE, Roth-Schechter GB, Gray GW, et al. 

Double blind, placebo controlled comparison of 

zolpidem, triazolam, and temazepam in elderly 

patients with insomnia. Drug Dev Res 1997; 

40:230-8. 

 100. Levitt H, Wood A, Moul DE, et al. A pilot study of 

subjective daytime alertness and mood in primary 

insomnia participants using ecological momentary 

assessment. Behav Sleep Med 2004; 2(2):113-31. 

 101. Lichstein KL, Durrence HH, Bayen UJ, et al. 

Primary versus secondary insomnia in older adults: 

subjective sleep and daytime functioning. Psychol 

Aging 2001; 16(2):264-71. 

 102. Lichstein KL, Riedel BW, Wilson NM, et al. 

Relaxation and sleep compression for late-life 

insomnia: a placebo-controlled trial. J Consult Clin 

Psychol 2001; 69(2):227-39. 

 103. Linzmayer L, Arnold O, Saletu-Zyhlarz GM, et al. 

Daytime noopsychic and thymopsychic 

dysfunctions in nonorganic insomnia related to 

different mental disorders. Somnologie 2002; 

6(4):141-8. 

 104. Lopes Rocha F, Guerra HL, Lima-Costa MFF . 

Prevalence of insomnia and associated sociodemographic factors in a Brazilian community: The 

Bambui study. Sleep Med 2002; 3(2):121-6. 

 105. Lundh L-G, Froeding A, Gyllenhammar L, et al. 

Cognitive bias and memory performance in patients 

with persistent insomnia. Scand J Behav Ther 1997; 

26(1):27-35. 

 106. Mamelak M, Buck L, Csima A, et al. Effects of 

flurazepam and zopiclone on the performance of 

chronic insomniac patients: a study of ethanol-drug 

interaction. Sleep 1987; 10(Suppl 1):79-87. 

 107. Mamelak M, Csima A, Buck L, et al. A 

comparative study on the effects of brotizolam and 

flurazepam on sleep and performance in the elderly. 

J Clin Psychopharmacol 1989; 9(4):260-7. 

 108. Martikainen K, Partinen M, Hasan J, et al. The 

impact of somatic health problems on insomnia in 

middle age. Sleep Med 2003; 4(3):201-6. 

 109. McAlpine CJ, Ankier SI, Elliott CS. A multicentre 

hospital study to compare the hypnotic efficacy of 

loprazolam and nitrazepam. J Int Med Res 1984; 

12(4):229-37. 

 110. Melo de Paula AJ. Comparative study of 

lormetazepam and flurazepam in the treatment of 

insomnia. Clin Ther 1984; 6(4):500-8. 

 111. Mendels J, Stern S. Evaluation of the short-term 

treatment of insomnia in out patients with 15 

milligrams of quazepam. J Int Med Res 1983; 

11(3):155-61. 

 112. Mendelson WB, Garnett D, Gillin JC, et al. The 

experience of insomnia and daytime and nighttime 

functioning. Psychiatry Res 1984; 12(3):235-50. 

 113. Milby JB, Williams V, Hall JN, et al. Effectiveness 

of combined triazolam-behavioral therapy for 

primary insomnia. Am J Psychiatry 1993; 

150:1259-60. 

 114. Millar A, Espie CA, Scott J. The sleep of remitted 

bipolar outpatients: A controlled naturalistic study 

using actigraphy. J Affect Disord 2004; 80(2-

3):145-53. 

 115. Minnekeer R, Marchal J, Van de Velde L, et al. A 

double-blind study comparing the efficacy and 

safety of quazepam with flunitrazepam and placebo 

in patients with chronic insomnia. Acta Ther 1988; 

14(2):159-70. 

 116. Mitchell KR. Behavioral treatment of presleep 

tension and intrusive cognitions in patients with 

severe predormital insomnia. J Behav Med 1979; 

2(1):57-69. 

 117. Mitler MM, Seidel WF, van den Hoed J, et al. 

Comparative hypnotic effects of flurazepam, 

triazolam, and placebo: a long-term simultaneous 

nighttime and daytime study. J Clin 

Psychopharmacol 1984; 4(1):2-13. 

 118. Monchesky TC, Billings BJ, Phillips R. Zopiclone: 

a new nonbenzodiazepine hypnotic used in general 

practice. Clin Ther 1986; 8(3):283-91. 
132 

 119. Montes LG, Uribe MP, Sotres JC, et al. Treatment 

of primary insomnia with melatonin: A doubleblind, placebo-controlled, crossover study. J 

Psychiatry Neurosci 2003; 28(3):191-6. 

 120. Monti JM, Monti D, Estevez F, et al. Sleep in 

patients with chronic primary insomnia during longterm zolpidem administration and after its 

withdrawal. Int Clin Psychopharmacol 1996; 

114(255-63). 

 121. Monti JM, Alvarino F, Monti D. Conventional and 

power spectrum analysis of the effects of zolpidem 

on sleep EEG in patients with chronic primary 

insomnia. Sleep 2000; 23(8):1075-84. 

 122. Morin CM, Colecchi C, Stone J, et al. Behavioral 

and pharmacological therapies for late-life 

insomnia: a randomized controlled trial.[comment]. 

J Am Med Assoc 1999; 281(11):991-9. 

 123. Nair NP, Schwartz G, Dimitri R, et al. A dose-range 

finding study of zopiclone in insomniac patients. Int 

Clin Psychopharmacol 1990; 5(Suppl 2):1-10. 

 124. Negri L. Evaluation of the efficacy of pivagabine on 

insomnia associated with mood disorders. 

Arzneimittel Forschung 1997; 47(11 Suppl a):1322-

5. 

 125. Nicassio P, Bootzin R. A comparison of progressive 

relaxation and autogenic training as treatments for 

insomnia. J Abnorm Psychol 1974; 83(3):253-60. 

 126. Niemcewicz S, Szelenberger W. 

Psychophysiological correlates of primary 

insomnia. Arch Hellenic Med 2001; 18(1):64-8. 

 127. Ohayon MM. Prevalence of DSM-IV diagnostic 

criteria of insomnia: distinguishing insomnia related 

to mental disorders from sleep disorders. J Psychiatr 

Res 1997; 31(3):333-46. 

 128. Ohayon MM, Hong SC. Prevalence of insomnia and 

associated factors in South Korea. J Psychosom Res 

2002; 53(1):593-600. 

 129. Ohayon MM, Partinen M. Insomnia and global 

sleep dissatisfaction in Finland. J Sleep Res 2002; 

11(4):339-36. 

 130. Ohayon MM, Roberts RE. Comparability of sleep 

disorders diagnoses using DSM-IV and ICSD 

classifications with adolescents. Sleep 2001; 

24(8):920-5. 

 131. Ohayon MM, Roberts RE, Zulley J, et al. 

Prevalence and patterns of problematic sleep among 

older adolescents. J Am Acad Child Adolesc 

Psychiatry 2000; 39(12):1549-56. 

 132. Ohayon MM, Roth T. Place of chronic insomnia in 

the course of depressive and anxiety disorders. J 

Psychiatric Res 2003; 37(1):9-15. 

 133. Ohayon MM, Roth T. What are the contributing 

factors for insomnia in the general population? J 

Psychosom Res 2001; 51(6):745-55. 

 134. Ohayon MM, Smirne S. Prevalence and 

consequences of insomnia disorders in the general 

population of Italy. Sleep Med 2002; 3(2):115-20. 

 135. Ohayon MM, Zulley J, Guilleminault C, et al. How 

age and daytime activities are related to insomnia in 

the general population: consequences for older 

people.[see comment]. J Am Geriatr Soc 2001; 

49(4):360-6. 

 136. Ohayon MM, Caulet M, Arbus L, et al. Are 

prescribed medications effective in the treatment of 

insomnia complaints? [References]. J Psychosom 

Res 1999; 47(4):359-68. 

 137. Pallesen S, Nordhus IH, Kvale G, et al. 

Psychological characteristics of elderly insomniacs. 

Scand J Psychol 2002; 43(5):425-32. 

 138. Pasche B, Erman M, Hayduk R, et al. Effects of low 

energy emission therapy in chronic 

psychophysiological insomnia. Sleep 1996; 

19(4):327-36. 

 139. Pavlova M, Berg O, Gleason R, et al. Self-reported 

hyperarousal traits among insomnia patients. J 

Psychosom Res 2001; 51(2):435-41. 

 140. Perlis ML, Smith MT, Orff H, et al. The effects of 

modafinil and cognitive behavior therapy on sleep 

continuity in patients with primary insomnia. Sleep 

2004; 27(4):715-25. 

 141. Perlis ML, Smith MT, Orff HJ, et al. The 

mesograde amnesia of sleep may be attenuated in 

subjects with primary insomnia. Physiol Behav 

2001; 74(1-2):71-6. 

 142. Poyares DR, Guilleminault C, Ohayon MM, et al. 

Can valerian improve the sleep of insomniacs after 

benzodiazepine withdrawal? Prog 

NeuroPsychopharmacol Biol Psychiatry 2002; 

26(3):539-45. 

 143. Reeves RL. Comparison of triazolam, flurazepam 

and placebo as hypnotics in geriatric patients with 

insomnia. J Clin Pharmacol 1977; 17:319-23. 

 144. Rickels K, Morris RJ, Mauriello R, et al. 

Brotizolam, a triazolothienodiazepine, in insomnia. 

Clin Pharmacol Ther 1986; 40:293-9. 
133 

 145. Riedel BW, Durrence H, Lichstein KL, et al. The 

Relation Between Smoking and Sleep: The 

Influence of Smoking Level, Health, and 

Psychological Variables. Behav Sleep Med 2004; 

2(1):63-78. 

 146. Riemann D, Voderholzer U, Cohrs S, et al. 

Trimipramine in Primary Insomnia: Results of a 

Polysomnographic Double-Blind Controlled Study. 

Pharmacopsychiatry 2002; 35(5):165-74. 

 147. Robbins L. Anxiety, depression, and insomnia in 

migraine: A retrospective review of 494 patients. 

Headache Q 1995; 6(4):303-5. 

 148. Rocha FL, Uchoa E, Guerra HL, et al. Prevalence of 

sleep complaints and associated factors in 

community-dwelling order people in Brazil: The 

Bambui health and ageing study (BHAS). Sleep 

Med 2002; 3(3):231-8. 

 149. Rodenbeck A, Cohrs S, Jordan W, et al. The SleepImproving Effects of Doxepin Are Paralleled by a 

Normalized Plasma Cortisol Secretion in Primary 

Insomnia - a Placebo-Controlled, Double-Blind, 

Randomized, Cross-Over Study Followed by an 

Open Treatment Over 3 Weeks. Psychopharmacol 

2003; 170(4):423-8. 

 150. Roehrs T, Papineau K, Rosenthal L, et al. Ethanol 

as a hypnotic in insomniacs: self administration and 

effects on sleep and mood. Neuropsychopharmacol 

1999; 20(3):279-86. 

 151. Roehrs T, Zorick F, Koshorek GL, et al. Effects of 

acute administration of brotizolam in subjects with 

disturbed sleep. Br J Clin Pharmacol 1983; 

16(Suppl 2):S371-6. 

 152. Roth T, Tietz EI, Kramer M, et al. The effect of a 

single dose of quazepam (Sch-16134) on the sleep 

of chronic insomniacs. J Int Med Res 1979; 

7(6):583-7. 

 153. Roth TG, Roehrs TA, Koshorek GL, et al. Hypnotic 

effects of low doses of quazepam in older 

insomniacs. J Clin Psychopharmacol 17(5):401-6 

1997; 17(5):401-6. 

 154. Roth T, Ancoli-Israel S. Daytime consequences and 

correlates of insomnia in the United States: Results 

of the 1991 National Sleep Foundation Survey. II. 

Sleep 1999; 22(Suppl 2):S354-8. 

 155. Sabbatini M, Minale B, Crispo A, et al. Insomnia in 

maintenance haemodialysis patients. Nephrol Dial 

Transplant 2002; 17(5):852-6. 

 156. Saletu-Zhylarz G, Saletu B, Anderer P, et al. 

Nonorganic insomnia in generalized anxiety 

disorder. Neuropsychobiol 1997; 36(3):117-29. 

 157. Saletu-Zyhlarz G, Anderer P, Gruber G, et al. 

Insomnia Related to Postmenopausal Syndrome and 

Hormone Replacement Therapy: Sleep Laboratory 

Studies on Baseline Differences Between Patients 

and Controls and Double-Blind, Placebo-Controlled 

Investigations on the Effects of a Novel EstrogenProgestogen Combination (Climodien (R), 

Lafamme (R)) Versus Estrogen Alone. J Sleep Res 

2003; 12(3):239-54. 

 158. Sanavio E, Vidotto G, Bettinardi O, et al. Behaviour 

therapy for DIMS: Comparison of three treatment 

procedures with follow-up. Behav Psychother 1990; 

18(3):151-67. 

 159. Sastre-y-Hernandez M, Visser P, Schutt B, et al. 

Sublingual lormetazepam in the treatment of sleep 

disorders in general practice patients. Hum 

Psychopharmacol 1988; 3(2):139-44. 

 160. Savard J, Simard S, Blanchet J, et al. Prevalence, 

clinical characteristics, and risk factors for insomnia 

in the context of breast cancer. Sleep 2001; 

24(5):583-90. 

 161. Scharf MB, Roth PB, Dominguez RA, et al. 

Estazolam and flurazepam: multicenter, placebocontrolled comparative study in outpatients with 

insomnia. J Clin Pharmacol 1990; 30:461-7. 

 162. Scharf MB, Roth T, Vogel GW, et al. A 

multicenter, placebo-controlled study evaluating 

zolpidem in the treatment of chronic insomnia. J 

Clin Psychiatry 1994; 55(5):192-9. 

 163. Schneider-Helmert D. Twenty-four-hour sleepwake function and personality patterns in chronic 

insomniacs and healthy controls. Sleep 1987; 

10(5):452-62. 

 164. Seidel WF, Ball S, Cohen S, et al. Daytime 

alertness in relation to mood, performance, and 

nocturnal sleep in chronic insomniacs and 

noncomplaining sleepers. Sleep 1984; 7(3):230-8. 

 165. Sharpley AL, Attenburrow ME, Cowen PJ. 

Assessment and treatment of insomnia (including a 

case control study of patients with Primary 

Insomnia). Int J Psychiatry Clin Pract 1997; 

1(2):107-17. 

 166. Shaver JL, Johnston SK, Lentz MJ, et al. Stress 

exposure, psychological distress, and physiological 

stress activation in midlife women with insomnia. 

Psychosom Med 2002; 64(5):793-802. 
134 

 167. Shaw SH, Curson H, Coquelin JP. A double-blind, 

comparative study of zolpidem and placebo in the 

treatment of insomnia in elderly psychiatric inpatients.[erratum appears in J Int Med Res 1992 

Nov;20(6):following 494]. J Int Med Res 1992; 

20(2):150-61. 

 168. Shealy R. The effectiveness of various treatment 

techniques on different degrees and durations of 

sleep onset insomnia. Behav Res Ther 1979; 

17(6):541-6. 

 169. Shochat T, Umphress J, Israel AG, et al. Insomnia 

in primary care patients. Sleep 1999; 22(Suppl 

2):S359-65. 

 170. Stanton HE. Hypnotic relaxation and the reduction 

of sleep onset insomnia. Int J Psychosom 1989; 

36(1-4):64-8. 

 171. Steens RD, Pouliot Z, Millar TW, et al. Effects of 

zolpidem and triazolam on sleep and respiration in 

mild to moderate chronic obstructive pulmonary 

disease. Sleep 1993; 16(4):318-26. 

 172. Stip E, Furlan M, Lussier I, et al. Double-blind, 

placebo-controlled study comparing effects of 

zopiclone and temazepam on cognitive functioning 

of insomniacs. Hum Psychopharmacol 1999; 

14(4):253-61. 

 173. Sugerman JL, Stern JA, Walsh JK. Daytime 

alertness in subjective and objective insomnia: some 

preliminary findings . Biol Psychiatry 1985; 

20(7):741-50. 

 174. Taylor DJ. A cross-sectional analysis of depression, 

anxiety, and insomnia [dissertation]. Memphis 

(TN): University of Memphis; 2003. 

 175. Terzano MG, Parrino L, Cirignotta F, et al. Studio 

Morfeo: insomnia in primary care, a survey 

conducted on the Italian population. Sleep Med 

2004; 5(1):67-75. 

 176. Tietz EI, Roth T, Zorick FJ, et al. The acute effect 

of quazepam on the sleep of chronic insomniacs. A 

dose-response study. Arzneimittel- orschung 1981; 

31(11):1963-6. 

 177. Tuk B, Oberye JJ, Pieters MS, et al. 

Pharmacodynamics of temazepam in primary 

insomnia: assessment of the value of quantitative 

electroencephalography and saccadic eye 

movements in predicting improvement of sleep. 

Clin Pharmacol Ther 1997; 62:444-52. 

 178. Vallieres A, Morin CM, Guay B, et al. Sequential 

treatment for chronic insomnia: A pilot study. 

[References]. Behav Sleep Med 2004; 2(2):94-112. 

 179. Vgontzas AN, Kales A, Bixler EO, et al. Usefulness 

of polysomnographic studies in the differential 

diagnosis of insomnia. Int J Neurosci 1995; 82(1-

2):47-60. 

 180. Vignola A, Lamoureux C, Bastien CH, et al. Effects 

of chronic insomnia and use of benzodiazepines on 

daytime performance in older adults. J Gerontol 

Series B Psychol Sci Soc Sci 2000; 55(1):P54-62. 

 181. Vincent NK, Walker JR. Perfectionism and chronic 

insomnia. J Psychosom Res 2000; 49(5):349-54. 

 182. Viukari M, Jaatinen P, Kylmamaa T. Flunitrazepam 

and nitrazepam as hypnotics in psychogeriatric 

inpatients. Clin Ther 1983; 5(6):662-70. 

 183. Walsh JK. Zolpidem "as Needed" for the Treatment 

of Primary Insomnia: a Double-Blind, PlaceboControlled Study. Sleep Med Rev 2002; 6:S7-11. 

 184. Walsh JK, Fry J, Erwin CW, et al. Efficacy and 

tolerability of 14-day administration of zaleplon 5 

mg and 10 mg for the treatment of primary 

insomnia. Clin Drug Invest 1998; 16:347-54. 

 185. Walsh JK, Fry J, Richardson GS, et al. Short term 

efficacy of zaleplon in older patients with chronic 

insomnia. Clin Drug Invest 2000; 20:143-9. 

 186. Walsh JK, Targum SD, Pegram V, et al. Multicenter 

clinical investigation of estazolam: short term 

efficacy. Curr Ther Res 1984; 36:866-74. 

 187. Walsh JK, Erman M, Erwin CW, et al. Subjective 

hypnotic efficacy of trazodone and zolpidem in 

DSMIII-R primary insomnia. Hum 

Psychopharmacol 1998; 13(3):191-8. 

 188. Walsh JK, Roth T, Randazzo A, et al. Eight weeks 

of non-nightly use of zolpidem for primary 

insomnia. Sleep 2000; 23(8):1087-96. 

 189. Wang RIH, Stockdale SL. Subjective and objective 

method assessing the efficacy of hypnotic 

medications in insomniacs. J Clin Pharmacol 1977; 

17:728-33. 

 190. Wang W, Zhu SZ, Pan LC, et al. Mismatch 

negativity and personality traits in chronic primary 

insomniacs. Funct Neurol 2001; 16(1):3-10. 

 191. Waters WF, Hurry MJ, Binks PG, et al. Behavioral 

and hypnotic treatments for insomnia subtypes. 

Behav Sleep Med 2003; 1(2):81-101. 

 192. Winsauer HJ, O'Hair DE, Valero R. Quazepam: 

short term treatment of insomnia in geriatric 

outpatients. Curr Ther Res 1984; 35:228-34. 
135 

 193. Yeo BK, Perera IS, Kok LP, et al. Insomnia in the 

community. Singapore Med J 1996; 37(3):282-4. 

 194. Zammit GK, Weiner J, Damato N, et al. Quality of 

life in people with insomnia. Sleep 1999; 22(Suppl 

2):S379-85. 

 195. Zhdanova IV, Wurtman RJa, Regan MM, et al. 

Melatonin treatment for age-related insomnia. J 

Clin Endocrinol Metab 2001; 86(10):4727-30
136 
A-1

Appendix A: Exact Search Strings 

Table A-1. MEDLINE® - Ovid Version: rel9.1.0 

Table A-2. EMBASE - Ovid Version: rel9.1.0 

Table A-3. CINAHL® (Cumulative Index to Nursing & Allied Health Literature) - Ovid 

Version: rel9.1.0 

Table A-4. Ovid MEDLINE® In-Process & Other Non-Indexed Citations - Ovid Version: 

rel9.1.0 

Table A-5. Ovid OLDMEDLINE® - Ovid Version: rel9.1.0 

Table A-6. PsycINFO® - Ovid Version: rel9.1.0 

Table A-7. EBM Reviews - Cochrane Central Register of Controlled Trials - Ovid Version: 

rel9.1.0 

Table A-8. International Pharmaceutical Abstracts - Ovid Version: rel9.1.0 

Table A-9. AMED (Allied and Complementary Medicine) - Ovid Version: rel9.1.0 

Table A-10. HealthSTAR/Ovid Healthstar - Ovid Version: rel9.1.0 

Table A-11. EBM Reviews - Cochrane Database of Systematic Reviews (2nd Quarter 2004); 

ACP Journal Club (1991 to March/April 2004); Database of Abstracts of Reviews 

of Effects (2nd Quarter 2004) - Ovid Version: rel9.1.0 

Table A-12. Science Citation Index ExpandedTM -1945-September 2004 - ISI Web of Knowledge 

Table A-13. Biological Abstracts - WebSPIRS from SilverPlatter, Version 4.3 

Table A-14. Cochrane Complementary Medicine Field Registry - Reference Web Poster 2001; 

ISI ResearchSoft 

Table A-15. CAB Abstracts - WebSPIRS from SilverPlatter, Version 4.3 

Table A-16. SIGLE - FIZ Karlsruhe - Version Interhost 3000 

Table A-17. OCLC Proceedings First - OCLC FirstSearch 

Table A-18. Dissertation Abstracts - ProQuest 

Table A-19. Alt HealthWatch - EBSCOhost 

Table A-20. NLM Gateway 

Table A-21. PubMed®
A-2

Table A-1. MEDLINE® - Ovid Version: rel9.1.0 

1966 to September Week 1 2004 

Searched Sept. 15, 2004

1. insomni$.mp. 

2. exp "Sleep Initiation and Maintenance Disorders"/ 

3. (sleep adj initiation adj2 maintenance adj disorder$).mp. 

4. (sleep adj onset adj3 (delay$ or latenc$)).mp. 

5. dims.mp. 

5. (disorder$ adj initiating adj2 maintaining adj sleep).mp. 

6. (early adj2 awaken$).mp. 

7. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

8. or/1-8 

9. "analytic stud$".mp. 

10. exp case-control studies/ or exp retrospective studies/ 

11. exp cohort studies/ or exp longitudinal studies/ or exp follow-up studies/ or exp prospective studies/ or 

comparative study/ or exp Evaluation Studies/ 

12. exp Cross-Sectional Studies/ 

13. exp RISK FACTORS/ or exp RISK/ or exp RISK ASSESSMENT/ 

14. exp Odds Ratio/ 

15. exp CAUSALITY/ 

16. exp Logistic Models/ 

17. exp epidemiologic factors/ or exp age factors/ or exp "bias (epidemiology)"/ or exp comorbidity/ or exp 

"confounding factors (epidemiology)"/ or exp "effect modifiers (epidemiology)"/ or exp observer 

variation/ or exp reproductive history/ or exp sex factors/ 

18. exp morbidity/ or exp incidence/ or exp prevalence/ 

19. (cohort or observational or correlational or non-experimental or "non experimental" or 

nonexperimental or control$ or prospectiv$ or volunteer$ or "case series" or "case-series" or "case 

comparison" or "case-comparison" or "case referent" or "case-referent" or "cross sectional" or "crosssectional" or risk or "relative risk" or causation or causal$ or "odds ratio$" or etiol$ or aetiol$ or 

incidence).mp. 

20. exp prognosis/ or exp medical futility/ or exp treatment outcome/ 

21. exp mortality/ or exp "cause of death"/ or exp fatal outcome/ or exp survival rate/ 

22. exp survival analysis/ or exp disease-free survival/ 

23. exp disease susceptibility/ or exp genetic predisposition to disease/ 

24. exp disease progression/ or exp "Severity of Illness Index"/ 

25. exp Time Factors/ 

26. exp RECURRENCE/ 

27. ("natural history" or "inception cohort" or predict$ or prognos$ or outcome$ or course).mp. 

28. exp "costs and cost analysis"/ or exp "cost allocation"/ or exp cost-benefit analysis/ or exp "cost 

control"/ or exp "cost savings"/ or exp "cost of illness"/ or exp "cost sharing"/ or exp "deductibles and 

coinsurance"/ or exp health care costs/ or exp direct service costs/ or exp drug costs/ or exp employer 

health costs/ or exp hospital costs/ or exp health expenditures/ or exp capital expenditures/ 

29. exp "Quality of Life"/ or exp "Activities of Daily Living"/ 

30. exp "OUTCOME ASSESSMENT (HEALTH CARE)"/ or exp "OUTCOME AND PROCESS 

ASSESSMENT (HEALTH CARE)"/ or exp Health Status Indicators/ or exp Health Status/ or exp 

Questionnaires/ 

31. (cost$ or economic or social or "quality of life" or "life quality" or hrql or well-being or wellbeing or "well 

being" or "outcome adj assessment$" or "health status").mp. 

32. (et or pc or ae or ep or to or ge or ec or in or ut or mo).fs. 

33. or/10-33 

34. animal/ not human/ 

35. 34 not 35 

36. 9 and 36 

37. eng.la. 

38. 37 and 38 

39. insomni$.mp. 

40. exp "Sleep Initiation and Maintenance Disorders"/ 

41. (sleep adj initiation adj2 maintenance adj disorder$).mp. 
A-3

Table A-1. MEDLINE® - Ovid Version: rel9.1.0 (continued)

1966 to September Week 1 2004 

Searched Sept. 15, 2004

42. (sleep adj onset adj3 (delay$ or latenc$)).mp. 

43. dims.mp. 

44. "disorder$ of initiating and maintaining sleep".mp. 

45. (early adj2 awaken$).mp. 

46. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

47. (((time-zone or "time zone") adj2 change$) or "jet lag").mp. 

48. or/40-48 

49. randomized controlled trial.pt. 

50. controlled clinical trial.pt. 

51. randomized controlled trials/ 

52. random allocation/ 

53. double blind method/ 

54. single blind method/ 

55. clinical trial.pt. 

56. exp Clinical Trials/ 

57. (clin$ adj25 trial$).ti,ab. 

58. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab. 

59. placebos/ 

60. placebo$.ti,ab. 

61. random$.ti,ab. 

62. research design/ 

63. or/50-63 

64. 64 not 35 

65. 49 and 65 

66. 66 not 39 

67. meta-analysis.pt,sh. 

68. (meta-anal$ or metaanal$).mp. 

69. ((systematic$ adj3 review$) or (systematic$ adj3 overview$)).mp. 

70. ((quantitativ$ adj3 review$) or (quantitativ$ adj3 overview)).mp. 

71. ((methodol$ adj3 review$) or (methodol$ adj3 overview$)).mp. 

72. (integrative research review$ or research integration$).mp. 

73. (quantitativ$ adj (synthes$ or analys$)).mp. 

74. (("evidence based" or evidence-based) adj3 (medicine or guideline$ or recommendation$)).mp. 

75. guideline.pt. 

76. "cochrane database of systematic reviews".mp. 

77. cdsr.mp. 

78. acp journal club.mp. 

79. "health tech$ assess$".mp. 

80. hta.mp. 

81. "evidence based nursing".mp. 

82. "evidence based mental health".mp. 

83. "clinical evidence".mp. 

84. technolog$ assess$.mp. 

85. "evidence report$".mp. 

86. or/68-86 

87. review.pt. or (review or overview$ or reviews or handsearch or "hand search" or hand-search or 

"manual search").mp. 

88. (medline or medlars or pubmed or embase or "index medicus" or cochrane or scisearch or "Web of 

Science" or psychinfo or psycinfo or psychlit or psyclit or cinahl or cinhal or "experta medica" or 

"excerpta medica" or "science citation index" or "sciences citation index" or "biological abstracts" or 

"current contents").mp. 

89. (((electronic or bibliographic) adj3 database$) or "periodical index$").mp. 

90. ((pool$ or combined or combining) adj (data or trials or studies or results)).mp. 

91. (peto or "der simonian" or dersimonian or "fixed effect$" or "treatment outcome$" or "mantel 

haenszel").mp. 
A-4

Table A-1. MEDLINE® - Ovid Version: rel9.1.0 (continued)

1966 to September Week 1 2004

Searched Sept. 15, 2004

92. or/89-92 

93. 88 and 93 

94. 87 or 94 

95. case report.ti,sh. 

96. editorial.ti,pt. 

97. letter.pt. 

98. newspaper article.pt. 

99. comment.pt. 

100. or/96-100 

101. 95 not 101 

102. animal/ not human/ 

103. 102 not 103 

104. eng.la. 

105. 104 and 105 

106. 9 and 106 

107. 107 not (39 or 67) 
A-5

Table A-2. EMBASE - Ovid Version: rel9.1.0

1988 to 2004 Week 37 

Searched September 15, 2004 

1. insomni$.mp. or exp insomnia/ 

2. (sleep adj initiation adj2 maintenance adj disorder$).mp. 

3. (sleep adj onset adj3 (delay$ or latenc$)).mp. 

4. dims.mp. 

5. (disorder$ adj initiating adj2 maintaining adj sleep).mp. 

6. (early adj2 awaken$).mp. 

7. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

8. or/1-7 

9. "analytic stud$".mp. 

10. exp case-control study/ or exp retrospective study/ 

11. exp cohort analysis/ or exp longitudinal study/ or exp prospective study/ or exp Comparative Study/ or 

exp Evaluation/ 

12. (("follow up" or follow-up) adj stud$).mp. 

13. exp GENETIC RISK/ or exp POPULATION RISK/ or exp CORONARY RISK/ or exp HIGH RISK 

PATIENT/ or exp HIGH RISK PREGNANCY/ or exp RISK FACTOR/ or exp CARDIOVASCULAR 

RISK/ or exp RISK ASSESSMENT/ or exp RISK/ or exp HIGH RISK POPULATION/ or exp CANCER 

RISK/ or exp RISK MANAGEMENT/ or exp RISK REDUCTION/ or exp RISK BENEFIT ANALYSIS/ or 

exp INFECTION RISK/ or exp RECURRENCE RISK/ 

14. causality.mp. 

15. (Logistic adj Model$).mp. or exp Statistical Model/ 

16. exp COMORBIDITY/ or exp Onset Age/ or exp Observer Variation/ or exp Sex Difference/ 

17. exp epidemiology/ or exp incidence/ or exp morbidity/ or exp mortality/ or prevalence/ 

18. (cohort or control$ or correlational or non-experimental or "non experimental" or nonexperimental or 

prospectiv$ or volunteer$ or "case series" or "case-series" or "case comparison" or "casecomparison" or "case referent" or "case-referent" or "cross sectional" or "cross-sectional" or risk or 

"relative risk" or causation or causal$ or "odds ratio$" or etiol$ or aetiol$ or incidence).mp. 

19. exp prognosis/ or medical futility.mp. or exp treatment outcome/ 

20. exp "cause of death"/ or exp fatality/ or exp survival rate/ 

21. exp SURVIVAL RATE/ or exp SURVIVAL/ or exp SURVIVAL TIME/ 

22. exp Disease Predisposition/ or exp Genetic Predisposition/ 

23. exp Disease Course/ or "Severity of illness index".mp. 

24. exp Recurrent Disease/ or exp Disease Severity/ or exp Chronic Disease/ 

25. ("natural history" or "inception cohort" or predict$ or prognos$ or outcome$ or course).mp. 

26. exp "HOSPITAL COST"/ or exp "COST EFFECTIVENESS ANALYSIS"/ or exp "COST UTILITY 

ANALYSIS"/ or exp "ENERGY COST"/ or exp "COST CONTROL"/ or exp "DRUG COST"/ or exp 

"COST BENEFIT ANALYSIS"/ or exp "COST MINIMIZATION ANALYSIS"/ or exp "COST"/ or exp 

"HEALTH CARE COST"/ or exp "COST OF ILLNESS"/ 

27. exp "Quality of Life"/ or exp Daily Life Activity/ 

28. exp Health Status/ or exp Follow Up/ or exp Questionnaire/ or exp Outcomes Research/ or exp 

Health Care Quality/ 

29. (cost$ or economic or social or "quality of life" or Hrql or "life quality" or well-being or wellbeing or 

"well being" or "outcome adj assessment$" or "health status").mp. 

30. ((human or "daily living") adj2 activit$).mp. 

31. (et or pc or ae or ep or to or ge or ec or in or ut or mo).fs. 

32. or/9-31 

33. limit 32 to human/ 

34. Nonhuman/ 

35. 33 not 34 

36. 8 and 35 

37. eng.la. 

38. 36 and 37 

39. insomni$.mp. or exp insomnia/ 

40. (sleep adj initiation adj2 maintenance adj disorder$).mp. 

41. (sleep adj onset adj3 (delay$ or latenc$)).mp. 

42. dims.mp. 
A-6

Table A-2. EMBASE - Ovid Version: rel9.1.0 (continued)

1988 to 2004 Week 37 

Searched September 15, 2004 

43. (disorder$ adj initiating adj2 maintaining adj sleep).mp. 

44. (early adj2 awaken$).mp. 

45. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

46. exp Jet Lag/ 

47. (((time-zone or "time zone") adj2 change$) or "jet lag").mp. 

48. or/39-47 

49. Randomized Controlled Trial/ 

50. exp Randomization/ 

51. Double Blind Procedure/ 

52. Single Blind Procedure/ 

53. Clinical Trial/ 

54. (clin$ adj25 trial$).mp. 

55. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).mp. 

56. exp Placebo/ 

57. (placebo$ or random$).mp. 

58. exp Methodology/ 

59. or/49-58 

60. limit 59 to human/ 

61. 60 not 34 

62. 48 and 61 

63. 62 not 38 

64. meta-analysis.sh. 

65. (meta-anal$ or metaanal$).mp. 

66. ((systematic$ adj3 review$) or (systematic$ adj3 overview$)).mp. 

67. ((quantitativ$ adj3 review$) or (quantitativ$ adj3 overview)).mp. 

68. ((methodol$ adj3 review$) or (methodol$ adj3 overview$)).mp. 

69. (integrative research review$ or research integration$).mp. 

70. (quantitativ$ adj (synthes$ or analys$)).mp. 

71. (("evidence based" or evidence-based) adj3 (medicine or guideline$ or recommendation$)).mp. 

72. "cochrane database of systematic reviews".mp. 

73. cdsr.mp. 

74. acp journal club.mp. 

75. "health tech$ assess$".mp. 

76. hta.mp. 

77. "evidence based nursing".mp. 

78. "evidence based mental health".mp. 

79. "clinical evidence".mp. 

80. technolog$ assess$.mp. 

81. "evidence report$".mp. 

82. or/64-81 

83. review.pt. or (review or overview$ or reviews or handsearch or "hand search" or hand-search or 

"manual search").mp. 

84. (medline or medlars or pubmed or embase or "index medicus" or cochrane or scisearch or "Web of 

Science" or psychinfo or psycinfo or psychlit or psyclit or cinahl or cinhal or "experta medica" or 

"excerpta medica" or "science citation index" or "sciences citation index" or "biological abstracts" or 

"current contents").mp. 

85. (((electronic or bibliographic) adj3 database$) or "periodical index$").mp. 

86. ((pool$ or combined or combining) adj (data or trials or studies or results)).mp. 

87. (peto or "der simonian" or dersimonian or "fixed effect$" or "treatment outcome$" or "mantel 

haenszel").mp. 

88. or/84-87 

89. 83 and 88 

90. 82 or 89 

91. case report.ti,sh. 

91. editorial.ti,pt. 

92. letter.pt. 

93. note.pt. 

94. or/91-94 
A-7

Table A-2. EMBASE - Ovid Version: rel9.1.0 (continued)

1988 to 2004 Week 37 

Searched September 15, 2004 

95. 90 not 95 

96. Nonhuman/ not human/ 

97. 96 not 97 

98. eng.la. 

99. 98 and 99 

100. 8 and 100 

101. 101 not (38 or 63) 
A-8

Table A-3. CINAHL® (Cumulative Index to Nursing & Allied Health Literature) - Ovid Version: rel9.1.0

1982 to September Week 2 2004 

Searched September 15, 2004

1. insomni$.mp. or exp INSOMNIA/ 

2. (sleep adj initiation adj2 maintenance adj disorder$).mp. 

3. (sleep adj onset adj3 (delay$ or latenc$)).mp. 

4. dims.mp. 

5. (disorder$ adj initiating adj2 maintaining adj sleep).mp. 

6. (early adj2 awaken$).mp. 

7. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

8. or/1-7 

9. exp Analytic Research/ or (analytic adj (stud$ or research)).mp. 

10. exp Nonexperimental Studies/ or exp Case Control Studies/ or exp Hospital-Based Case Control/ or 

exp Matched Case Control/ or exp Population-Based Case Control/ or exp Correlational Studies/ 

11. exp Prospective Studies/ or exp concurrent prospective studies/ or exp nonconcurrent prospective 

studies/ or exp panel studies/ or exp retrospective panel studies/ or exp revolving panel studies/ or 

exp pseudolongitudinal studies/ 

12. exp Cross Sectional Studies/ 

13. exp RELATIVE RISK/ or exp CARDIOVASCULAR RISK FACTORS/ or exp RISK MANAGEMENT/ or 

exp RISK FACTORS/ or exp FALL RISK ASSESSMENT TOOL/ or exp RISK ASSESSMENT/ 

14. exp Odds Ratio/ or ("relative odd$" or "rate ratio").mp. 

15. exp Causal Attribution/ 

16. exp professional practice, research-based/ or exp medical practice, research-based/ or exp nursing 

practice, research-based/ 

17. exp epidemiological research/ or exp seroprevalence studies/18. exp Age Factors/ or exp "age of 

onset"/ or exp comorbidity/ or exp disease surveillance/ or exp injury pattern/ or exp Sex Factors/ 

18. exp morbidity/ or exp incidence/ or exp prevalence/ 

19. (cohort or comparative or "evaluation stud$" or observational or non-experimental or "non 

experimental" or nonexperimental or control$ or prospectiv$ or volunteer$ or "case series" or "caseseries" or "case comparison" or "case-comparison" or "case referent" or "case-referent" or "cross 

sectional" or "cross-sectional" or risk or "relative risk" or causation or causal$ or "odds ratio$" or etiol$ 

or aetiol$ or incidence).mp. 

20. exp prognosis/ or exp medical futility/ or exp treatment outcomes/ 

21. exp mortality/ or exp "cause of death"/ or exp survival/ 

22. exp survival analysis/ 

23. exp disease susceptibility/ 

24. exp disease progression/ or exp "Severity of Illness Indices"/ 

25. exp Time Factors/ 

26. exp RECURRENCE/ 

27. ("natural history" or "inception cohort" or predict$ or prognos$ or outcome$ or course).mp. 

28. exp "costs and cost analysis"/ or exp "cost benefit analysis"/ or exp "cost control"/ or exp diagnosisrelated groups/ or exp health care costs/ or exp HEALTH FACILITY COSTS/ 

29. exp "Quality of Life"/ or exp "Activities of Daily Living"/ 

30. exp "Outcomes (Health Care)"/ or exp Outcome Assessment/ or exp Health Status/ or exp Health 

Status Indicators/ or exp QUESTIONNAIRES/ 

31. (cost$ or economic or social or "quality of life" or "life quality" or hrql or well-being or wellbeing or "well 

being" or "outcome adj assessment$" or "health status").mp. 

32. (et or pc or ae or ep or to or ge or ec or in or nu or ut or mo).fs. 

33. or/9-33 

34. 8 and 34 

35. limit 35 to English 

36. insomni$.mp. or exp INSOMNIA/ 

37. (sleep adj initiation adj2 maintenance adj disorder$).mp. 

38. (sleep adj onset adj3 (delay$ or latenc$)).mp. 

39. dims.mp. 

40. "disorder$ of initiating and maintaining sleep".mp. 
A-9

Table A-3. CINAHL® (Cumulative Index to Nursing & Allied Health Literature) - Ovid Version: rel9.1.0 

(continued)

1982 to September Week 2 2004 

Searched September 15, 2004

41. (early adj2 awaken$).mp. 

42. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

43. exp Jet Lag Syndrome/ or (((time-zone or "time zone") adj2 change$) or "jet lag").mp. 

44. or/37-44 

45. Random Assignment/ 

46. random sample/ 

47. Crossover Design/ 

48. exp Clinical Trials/ 

49. Double-Blind Studies/ 

50. Single-Blind Studies/ 

51. Control Group/ or Factorial Design/ or Quasi-Experimental Studies/ or Community Trials/ or 

Experimental Studies/ or PRETEST-POSTTEST DESIGN/ or PRETEST-POSTTEST CONTROL 

GROUP DESIGN/ or SOLOMON FOUR-GROUP DESIGN/ 

52. clinical trial.pt. 

53. (clin$ adj25 trial$).ti,ab. 

54. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab. 

55. ((clin$ or intervention$ or compar$ or experiment$ or preventive or therapeutic) adj10 trial$).mp. 

56. placebos/ 

57. placebo$.ti,ab. 

58. random$.ti,ab. 

59. Study Design/ 

60. or/46-60 

61. 45 and 61 

62. 62 not 36 

63. meta-analysis.sh. 

64. (meta-anal$ or metaanal$).mp. 

65. ((systematic$ adj3 review$) or (systematic$ adj3 overview$)).mp. 

66. ((quantitativ$ adj3 review$) or (quantitativ$ adj3 overview)).mp. 

67. ((methodol$ adj3 review$) or (methodol$ adj3 overview$)).mp. 

68. (integrative research review$ or research integration$).mp. 

69. (quantitativ$ adj (synthes$ or analys$)).mp. 

70. (("evidence based" or evidence-based) adj3 (medicine or guideline$ or recommendation$)).mp. 

71. guideline$.mp. 

72. "cochrane database of systematic reviews".mp. 

73. cdsr.mp. 

74. acp journal club.mp. 

75. "health tech$ assess$".mp. 

76. hta.mp. 

77. "evidence based nursing".mp. 

78. "evidence based mental health".mp. 

79. "clinical evidence".mp. 

80. technolog$ assess$.mp. 

81. "evidence report$".mp. 

82. or/64-82 

83. review.pt. or (review or overview$ or reviews or handsearch or "hand search" or hand-search or 

"manual search").mp. 

84. (medline or medlars or pubmed or embase or "index medicus" or cochrane or scisearch or "Web of 

Science" or psychinfo or psycinfo or psychlit or psyclit or cinahl or cinhal or "experta medica" or 

"excerpta medica" or "science citation index" or "sciences citation index" or "biological abstracts" or 

"current contents").mp. 

85. (((electronic or bibliographic) adj3 database$) or "periodical index$").mp. 

86. ((pool$ or combined or combining) adj (data or trials or studies or results)).mp. 

87. (peto or "der simonian" or dersimonian or "fixed effect$" or "treatment outcome$" or "mantel 

haenszel").mp. 

88. or/85-88 

89. 84 and 89 

90. 83 or 90 
A-10

Table A-3. CINAHL® (Cumulative Index to Nursing & Allied Health Literature) - Ovid Version: rel9.1.0 

(continued) 

1982 to September Week 2 2004 

Searched September 15, 2004

91. "case report".ti. or "case study".pt. 

92. editorial.ti,pt. 

93. letter.pt. 

94. commentary.pt. 

95. or/92-95 

96. 91 not 96 

97. limit 97 to English 

98. 8 and 98 

99. 99 not (36 or 63) 
A-11

Table A-4. Ovid MEDLINE® In-Process & Other Non-Indexed Citations - Ovid Version: rel9.1.0 

Searched September 14, 2004

1. insomni$.mp. 

2. (sleep adj initiation adj2 maintenance adj disorder$).mp. 

3. (sleep adj onset adj3 (delay$ or latenc$)).mp. 

4. (disorder$ adj initiating adj2 maintaining adj sleep).mp. 

5. (early adj2 awaken$).mp. 

6. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

7. (((time-zone or "time zone") adj2 change$) or "jet lag").mp. 

8. or/1-7 

9. "randomized controlled trial$".mp. 

10. "controlled clinical trial$".mp. 

11. "random allocation".mp. 

12. ("double blind" adj3 method$).mp. 

13. ("single blind" adj3 method$).mp. 

14. (clin$ adj25 trial$).mp. 

15. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab. 

16. placebo$.ti,ab. 

17. random$.ti,ab. 

18. "research design$".mp. 

19. "clinical research".mp. 

20. or/9-19 

21. 8 and 20 
A-12

Table A-5. Ovid OLDMEDLINE® - Ovid Version: rel9.1.0 

1951 to 1965 

Searched September 15, 2004 

1. insomni$.mp 

2. (sleep adj initiation adj2 maintenance adj disorder$).mp. 

3. (sleep adj onset adj3 (delay$ or latenc$)).mp. 

4. (disorder$ adj initiating adj2 maintaining adj sleep).mp. 

5. (early adj2 awaken$).mp. 

6. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

7. (((time-zone or "time zone") adj2 change$) or "jet lag").mp. 

8. or/1-7 

9. "randomized controlled trial$".mp. 

10. "controlled clinical trial$".mp. 

11. "random allocation".mp. 

12. ("double blind" adj3 method$).mp. 

13. ("single blind" adj3 method$).mp. 

14. (clin$ adj25 trial$).mp. 

15. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab. 

16. placebo$.ti,ab. 

17. random$.ti,ab. 

18. "research design$".mp. 

19. "clinical research".mp. 

20. or/9-19 

21. 8 and 20 
A-13

Table A-6. PsycINFO® - Ovid Version: rel9.1.0 

1872 to September Week 1 2004 

Searched September 15, 2004

1. insomni$.mp. or exp INSOMNIA/ 

2. (sleep adj initiation adj2 maintenance adj disorder$).mp. 

3. (sleep adj onset adj3 (delay$ or latenc$)).mp. 

4. dims.mp. 

5. (disorder$ adj initiating adj2 maintaining adj sleep).mp. 

6. (early adj2 awaken$).mp. 

7. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

8. or/1-7 

9. "analytic stud$".mp. 

10. exp Between Groups Design/ or exp Cohort Analysis/ or exp Followup Studies/ or exp Longitudinal 

Studies/ or exp Repeated Measures/ or empirical methods/ or observation methods/ or exp Causal 

Analysis/ or exp Cohort Analysis/ or exp Content Analysis/ or exp Data Collection/ or exp Self Report/ 

or exp QUESTIONNAIRES/ 

11. prevention/ or exp accident prevention/ or exp preventive medicine/ or exp risk management/ or exp 

risk perception/ 

12. exp EPIDEMIOLOGY/ or exp COMORBIDITY/ 

13. (cohort or observational or correlational or non-experimental or "non experimental" or 

nonexperimental or control$ or prospectiv$ or volunteer$ or "case series" or "case-series" or "case 

comparison" or "case-comparison" or "case referent" or "case-referent" or "cross sectional" or "crosssectional" or risk or "relative risk" or causation or causal$ or "odds ratio$" or etiol$ or aetiol$ or 

incidence).mp. 

14. exp At Risk Populations/ or exp Coronary Prone Behavior/ or exp Age Differences/ or exp Human 

Sex Differences/ or exp PREDISPOSITION/ or exp DISORDERS/ or exp "SUSCEPTIBILITY 

(DISORDERS)"/ 

15. exp ETIOLOGY/ or exp ATTRIBUTION/ 

16. exp PROGNOSIS/ or exp "DEATH AND DYING"/ or exp Disease Course/ or exp Treatment 

Effectiveness Evaluation/ or exp Treatment Outcomes/ or exp Psychotherapeutic Outcomes/ or exp 

"RECOVERY (DISORDERS)"/ or exp "RELAPSE (DISORDERS)"/ or exp "remission (disorders)"/ 

17. (morbidity or prevalence or mortality or "cause of death" or "survival rate" or "disease progression" or 

"time factor$" or "disease free survival" or cure$).mp. 

18. recurrence.mp. 

19. ("natural history" or "inception cohort" or predict$ or prognos$ or outcome$ or course).mp. 

20. "costs and cost analysis"/ or exp health care costs/ or exp Resource Allocation/ 

21. exp "Quality of Life"/ or exp Psychosocial Factors/ or exp Sociocultural Factors/ or exp "Activities of 

Daily Living"/ 

22. (cost$ or economic or social or "quality of life" or "life quality" or hrql or well-being or wellbeing or "well 

being" or "outcome adj assessment$" or "health status").mp. 

23. ("empirical study" or "followup study" or "longitudinal study" or "prospective study").fc. 

24. or/9-23 

25. exp animals/ 

26. 24 not 25 

27. 8 and 26 

28. limit 27 to english language 

29. insomni$.mp. or exp INSOMNIA/ 

30. (sleep adj initiation adj2 maintenance adj disorder$).mp. 

31. (sleep adj onset adj3 (delay$ or latenc$)).mp. 

32. dims.mp. 

33. "disorder$ of initiating and maintaining sleep".mp. 

34. (early adj2 awaken$).mp. 

35. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

36. (((time-zone or "time zone") adj2 change$) or "jet lag").mp. 

37. or/29-36 

38. ("Quantitative Study" or "experimental replication").fc. 

39. exp experimental methods/ or exp experimental design/ or exp quantitative methods/ 
A-14

Table A-6. PsycINFO® - Ovid Version: rel9.1.0 (continued)

1872 to September Week 1 2004

Searched September 15, 2004

40. exp Experiment Controls/ 

41. treatment/ or alternative medicine/ or interdisciplinary treatment approach/ or "medical treatment 

(general)"/ or multimodal treatment approach/ or physical treatment methods/ or preventive medicine/ 

or psychotherapeutic techniques/ or psychotherapy/ or rehabilitation/ or relaxation therapy/ or 

sociotherapy/ 

42. (therapy or treat$).mp. 

43. ((clin$ or intervention$ or compar$ or experiment$ or preventive or therap$) adj25 (trial$ or study or 

studies)).mp. 

44. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).mp. 

45. exp placebo/ 

46. (cross?over or placebo$ or control$ or factorial or sham).mp. 

47. "clinical research".mp. 

48. random$.mp. 

49. or/38-48 

50. 49 not 25 

51. 37 and 50 

52. 51 not 28 
A-15

Table A-7. EBM Reviews - Cochrane Central Register of Controlled Trials - Ovid Version: rel9.1.0 

2nd Quarter 2004 

Searched September 15, 2004

1. insomni$.mp. 

2. exp "Sleep Initiation and Maintenance Disorders"/ 

3. (sleep adj initiation adj2 maintenance adj disorder$).mp. 

4. (sleep adj onset adj3 (delay$ or latenc$)).mp. 

5. dims.mp. 

6. "disorder$ of initiating and maintaining sleep".mp. 

7. (early adj2 awaken$).mp. 

8. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

9. (((time-zone or "time zone") adj2 change$) or "jet lag").mp. 

10. or/1-9 

11. randomized controlled trial.pt. 

12. controlled clinical trial.pt. 

13. randomized controlled trials/ 

14. random allocation/ 

15. double blind method/ 

16. single blind method/ 

17. clinical trial.pt. 

18. exp Clinical Trials/ 

19. (clin$ adj25 trial$).ti,ab. 

20. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab. 

21. placebos/ 

22. placebo$.ti,ab. 

23. random$.ti,ab. 

24. research design/ 

25. or/11-24 

26. animal/ 

27. 25 not 26 

28. 10 and 27 
A-16

Table A-8. International Pharmaceutical Abstracts - Ovid Version: rel9.1.0 

1970 to August 2004 

Searched September 15, 2004

1. insomni$.mp. 

2. (sleep adj initiation adj2 maintenance adj disorder$).mp. 

3. (sleep adj onset adj3 (delay$ or latenc$)).mp.4. (disorder$ adj initiating adj2 maintaining adj 

sleep).mp. 

4. (early adj2 awaken$).mp. 

5. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

6. (((time-zone or "time zone") adj2 change$) or "jet lag").mp. 

7. or/1-7 

8. "randomized controlled trial$".mp. 

9. "controlled clinical trial$".mp. 

10. "random allocation".mp. 

11. ("double blind" adj3 method$).mp. 

12. ("single blind" adj3 method$).mp. 

13. (clin$ adj25 trial$).mp. 

14. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab. 

15. placebo$.ti,ab. 

16. random$.ti,ab. 

17. "research design$".mp. 

18. "clinical research".mp. 

19. or/9-19 

20. limit 20 to human 

21. 8 and 21 
A-17

Table A-9. AMED (Allied and Complementary Medicine) - Ovid Version: rel9.1.0 

1985 to September 2004 

Searched September 15, 2004

1. insomni$.mp. 

2. exp insomnia/ 

3. (sleep adj onset adj3 (delay$ or latenc$)).mp. 

4. (disorder$ adj initiating adj2 maintaining adj sleep).mp. 

5. (early adj2 awaken$).mp. 

6. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

7. (((time-zone or "time zone") adj2 change$) or "jet lag").mp. 

8. or/1-7 

9. "randomized controlled trial$".mp. 

10. "controlled clinical trial$".mp. 

11. "random allocation".mp. 

12. ("double blind" adj3 method$).mp. 

13. ("single blind" adj3 method$).mp. 

14. (clin$ adj25 trial$).mp. 

15. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab. 

16. placebo$.ti,ab. 

17. random$.ti,ab. 

18. "research design$".mp. 

19. "clinical research".mp. 

20. or/9-19 

21. animal/ 

22. 20 not 21 

23. 8 and 22 
A-18

Table A-10. HealthSTAR/Ovid Healthstar - Ovid Version: rel9.1.0 

1975 to August 2004 

Searched September 15, 2004

1. insomni$.mp. 

2. exp "Sleep Initiation and Maintenance Disorders"/ 

3. (sleep adj initiation adj2 maintenance adj disorder$).mp. 

4. (sleep adj onset adj3 (delay$ or latenc$)).mp. 

5. dims.mp. 

6. (disorder$ adj initiating adj2 maintaining adj sleep).mp. 

7. (early adj2 awaken$).mp. 

8. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

9. or/1-8 

10. "analytic stud$".mp. 

11. exp case-control studies/ or exp retrospective studies/ 

12. exp cohort studies/ or exp longitudinal studies/ or exp follow-up studies/ or exp prospective studies/ or 

comparative study/ or exp Evaluation Studies/ 

13. exp Cross-Sectional Studies/ 

14. exp RISK FACTORS/ or exp RISK/ or exp RISK ASSESSMENT/ 

15. exp Odds Ratio/ 

16. exp CAUSALITY/ 

17. exp Logistic Models/ 

18. exp epidemiologic factors/ or exp age factors/ or exp "bias (epidemiology)"/ or exp comorbidity/ or exp 

"confounding factors (epidemiology)"/ or exp "effect modifiers (epidemiology)"/ or exp observer 

variation/ or exp reproductive history/ or exp sex factors/ 

19. exp morbidity/ or exp incidence/ or exp prevalence/ 

19. (cohort or observational or correlational or non-experimental or "non experimental" or 

nonexperimental or control$ or prospectiv$ or volunteer$ or "case series" or "case-series" or "case 

comparison" or "case-comparison" or "case referent" or "case-referent" or "cross sectional" or "crosssectional" or risk or "relative risk" or causation or causal$ or "odds ratio$" or etiol$ or aetiol$ or 

incidence).mp. 

20. exp prognosis/ or exp medical futility/ or exp treatment outcome/ 

21. exp mortality/ or exp "cause of death"/ or exp fatal outcome/ or exp survival rate/ 

22. exp survival analysis/ or exp disease-free survival/ 

23. exp disease susceptibility/ or exp genetic predisposition to disease/ 

24. exp disease progression/ or exp "Severity of Illness Index"/ 

25. exp Time Factors/ 

26. exp RECURRENCE/ 

27. ("natural history" or "inception cohort" or predict$ or prognos$ or outcome$ or course).mp. 

28. exp "costs and cost analysis"/ or exp "cost allocation"/ or exp cost-benefit analysis/ or exp "cost 

control"/ or exp "cost savings"/ or exp "cost of illness"/ or exp "cost sharing"/ or exp "deductibles and 

coinsurance"/ or exp health care costs/ or exp direct service costs/ or exp drug costs/ or exp employer 

health costs/ or exp hospital costs/ or exp health expenditures/ or exp capital expenditures/ 

29. exp "Quality of Life"/ or exp "Activities of Daily Living"/ 

30. exp "OUTCOME ASSESSMENT (HEALTH CARE)"/ or exp "OUTCOME AND PROCESS 

ASSESSMENT (HEALTH CARE)"/ or exp Health Status Indicators/ or exp Health Status/ or exp 

Questionnaires/ 

31. (cost$ or economic or social or "quality of life" or "life quality" or hrql or well-being or wellbeing or "well 

being" or "outcome adj assessment$" or "health status").mp. 

32. (et or pc or ae or ep or to or ge or ec or in or ut or mo).fs. 

33. or/10-33 

34. animal/ not human/ 

35. 34 not 35 

36. 9 and 36 

37. eng.la. 

38. 37 and 38 
A-19

Table A-11. EBM Reviews - Cochrane Database of Systematic Reviews (2nd Quarter 2004); 

ACP Journal Club (1991 to March/April 2004); Database of Abstracts of Reviews of Effects (2nd Quarter 2004) - 

Ovid Version: rel9.1.0 

Searched September 15, 2004

1. insomni$.ti,ab. 

2. (sleep adj initiation adj2 maintenance adj disorder$).mp. 

3. (sleep adj onset adj3 (delay$ or latenc$)).mp. 

4. (early adj2 awaken$).mp. 

5. (sleeplessness or agrypnia$ or hyposomnia$).mp. 

6. or/1-5 
A-20

Table A-12. Science Citation Index ExpandedTM - 1945-September 2004 - ISI Web of Knowledge 

Searched September 17, 2004 

#8 

#7 NOT #5 

DocType=All document types; Language=All languages; Database=SCI-EXPANDED; 

Timespan=1945-2004 

#7 

#6 AND #3 

DocType=All document types; Language=All languages; Database=SCI-EXPANDED; 

Timespan=1945-2004 

#6 

TS=Analytic Stud* OR TS=Case Control Stud* OR TS=Case-Control Stud* OR 

TS=Retrospective Stud* OR TS=Cohort OR TS=Longitudinal OR TS=Follow-up Stud* OR 

TS=Follow up Stud* OR TS=Prospective Stud* OR TS=Comparative Stud* OR TS=Evaluation 

Stud* OR TS=Cross Sectional Stud* OR TS=Cross-sectional Stud* OR TS=Observational 

Stud* OR TS=Questionnaire* 

DocType=All document types; Language=All languages; Database=SCI-EXPANDED; 

Timespan=1945-2004 

#5 

#4 AND #3 

DocType=All document types; Language=All languages; Database=SCI-EXPANDED; 

Timespan=1945-2004 

#4 

TS=Random* OR TS=Placebo* OR TS=Randomized Controlled Trial* OR TS=Controlled 

Clinical Trial* OR TS=Clinical Trial* OR TS=Double Blind Method* OR TS=Single Blind 

Method* 

DocType=All document types; Language=All languages; Database=SCI-EXPANDED; 

Timespan=1945-2004 

#3 

#2 OR #1 

DocType=All document types; Language=All languages; Database=SCI-EXPANDED; 

Timespan=1945-2004 

#2 

TS=Sleeplessness OR TS=Agrypnia* OR TS=Hyposomnia* 

DocType=All document types; Language=All languages; Database=SCI-EXPANDED; 

Timespan=1945-2004 

#1 

TS=Insomni* 

DocType=All document types; Language=All languages; Database=SCI-EXPANDED; 

Timespan=1945-2004 
A-21

Table A-13. Biological Abstracts - WebSPIRS from SilverPlatter, Version 4.3 

Searched September 17, 2004

1. #1 insomni* or sleeplessness or agrypnia* or hyposomnia* 

2. #2 analytic stud* or case control stud* or case-control stud* or retrospective stud* or cohort or 

longitudinal or follow up stud* or follow-up stud* or prospective stud* or comparative stud* or 

evaluation stud* or cross sectional stud* or cross-sectional stud* or observational stud* or 

questionnaire* 

3. #3 #1 and #2 

4. #4 random* or placebo* or randomized controlled trial* or controlled clinical trial* or clinical trial* or 

double blind method* or single blind method 

5. #5 #1 and #4 
A-22

Table A-14. Cochrane Complementary Medicine Field Registry - Reference Web Poster 2001; ISI 

ResearchSoft 

Searched September 20, 2004

1. Insomni or sleeplessness or agrypnia or hyposomnia 
A-23

Table A-15. CAB Abstracts - WebSPIRS from SilverPlatter, Version 4.3

Searched September 18, 2004

1. Insomni* or agrypnia* or hypsomnia* or sleeplessness 

2. Clinical trial* or randomized controlled trial* or random* or cohort or retrospective or prospective or 

volunteer* or questionnaire* 
A-24

Table A-16. SIGLE - FIZ Karlsruhe – Version Interhost 3000

Searched September 18, 2004 

1. Insomnia or sleeplessness 
A-25

Table A-17. OCLC Proceedings First - OCLC FirstSearch

Searched September 18, 2004 

1. Insomnia or insomniacs 
A-26

Table A-18. Dissertation Abstracts – ProQuest

Searched September 18, 2004

1. Insomnia 
A-27

Table A-19. Alt HealthWatch – EBSCOhost

Searched September 18, 2004 

1. Insomnia or insomnia – alternative treatment 
A-28

Table A-20. NLM Gateway

Searched September 18, 2004 

1. Searched for insomnia under Meeting Abstracts 
A-29

Table A-21. PubMed®

Searched September 20, 2004 

1. A search was conducted for the period of Jan. 01, 2004, to Sept. 20, 2004 for “Sleep Initiation and 

Maintenance Disorders” [MeSH] 
Appendix B: Data Extraction and 

Quality Assessment Forms 

Form B-1: Data extraction form for studies on manifestations of chronic insomnia in adults 

Form B-2: Data extraction form for studies on management of chronic insomnia in adults 

Form B-3: Quality assessment form for studies on prevalence or incidence of chronic insomnia 

in adults 

Form B-4: Quality assessment form for cohort studies on manifestations of chronic insomnia in 

adults 

Form B-5: Quality assessment form for case-control studies on manifestations of chronic 

Insomnia in adults 

Form B-6: Quality assessment form for studies on management of chronic insomnia in adults 
B-2

Form B-1: Data extraction form for studies on manifestations of chronic insomnia To be extracted from all studies, except where indicated. 

Record ID Indicate if 

Relevant to 

Prevalence 

Indicate if Relevant 

to Natural History 

Indicate if 

Relevant to 

Incidence 

Indicate if 

Relevant to 

Associated 

Factors 

Reviewer/Date 

Year of 

Publication 

Study Site Study Setting (if 

relevant to 

prevalence) 

Objective(s) Study Design Sampling Frame 

and Method of 

Sampling (if 

relevant to 

prevalence) 

Ti
B-3

To be extracted from all studies, except where indicated. 

Intended Sample 

Size 

Response/Follow-up 

Rate 

Method of Data 

Collection (if 

relevant to 

prevalence) 

Type of 

Participants 

Definition of 

Cases and 

Comparison 

Groups, if 

applicable 

Gender 

Distribution of 

Population 

D

Ethnicity of 

Population 

Co-morbid 

Conditions of 

Population at Entry 

Prevalence of 

Chronic Insomnia 

(if relevant to 

prevalence) 

Incidence of 

Chronic 

Insomnia (if 

relevant to 

incidence) 

Natural History 

of Chronic 

Insomnia (if 

relevant to 

natural history) 

Associated 

Factors of 

Chronic 

Insomnia (if 

relevant to 

associated 

factors) 

S
B-4

Form B-2: Data extraction form for studies on management of 

chronic insomnia in adults 

Study ID: Reviewer Initials: Verifier Initials: 

First Author: 

Title: 

Year of Publication: Language of Publication: Country of Corresponding Author: 

Funding: 

Private Industry ___ Not Specified ___

Government ___

Foundation ___

Internal ___

Other ___

Role of Funding Organization: 

Study Design: Parallel ___ Crossover ___ Unclear ___

Intent to Treat Analysis: Yes ___ No ___ Unclear ___ N/A ___ 

Quality Score: 

Number of Participants Enrolled: 

Number of Males Enrolled: Number of Females Enrolled: 

Age of Participants: 

Withdrawals/Dropouts: Yes ___ No ___ Unclear ___

Overall: 

Treatment Group(s): 

If yes, state 

number of 

withdrawals/ group 

and reasons for 

withdrawal: 

Control Group: 
B-5

Criteria for Insomnia: 

Length of Insomnia: 

Primary Chronic Insomnia: Yes ___

 

No ___

If primary chronic insomnia, list any co-morbid conditions: 

Secondary Chronic Insomnia: Yes ___ No ___

If secondary chronic insomnia, secondary to what condition (if psychiatric, see below)? 

Psychiatric Illness: Yes ___ 

If Yes, specify: 

No ___ 

Method used to Assess Outcomes: 

PSG: ___ 

Actigraphy: ___ 

Diary: ___ 

If different methods were used for different outcomes OR more than one method was used for one or more 

outcomes, please specify: 

Treatment 

Group 

Intervention Frequency 

and Duration 

of Treatment 

Timing Route of 

Delivery 

Number of 

Participants 

Allocated/ 

Analyzed 

Length of 

Follow-up 

1 

2 

3 

4 
B-6

Did participants have a treatment preference? If so, indicate which treatment was preferred and related 

information. 

Treatment 

Group 1 

Treatment 

Group 2 

Treatment 

Group 3 

Treatment 

Group 4 

Interventions 

Sleep Onset 

Latency (SOL) 

Definition of SOL: 

Wakefulness after 

Sleep Onset 

(WASO) 

 

Definition of WASO: 

Sleep Efficiency 

(SE) 

 

Definition of SE: 

Total Sleep Time 

(TST) 

 

Definition of TST: 

Sleep Quality (SQ) 

Definition of SQ: 
B-7

Quality of Life 

(QOL) 

 

Definition of QOL: 

Adverse 

Effects/Events 

 
B-8

Form B-3: Quality assessment form for studies on prevalence or 

incidence of chronic insomnia in adults 

The criteria used to rate studies relevant to the prevalence or incidence of chronic insomnia 

in adults is outlined below (Loney PL, 1998). One point was assigned for each criterion that was 

satisfied. The maximum score was eight. 

1. Random sample or whole population 

2. Unbiased sampling frame (i.e. census data) 

3. Adequate sample size 

4. Measures were the standard 

5. Outcomes measured by unbiased assessors 

6. Adequate response rate (70 percent), refusers described 

7. Confidence intervals, subgroup analysis 

8. Study subjects described
B-9

Form B-4: Quality assessment form for cohort studies on 

manifestations of chronic insomnia in adults (Newcastle-Ottawa 

scale)

Note: A study could be awarded a maximum of one star for each numbered item within the Selection and Outcome 

categories. A maximum of two stars could be awarded for Comparability. Each star was equivalent to one point. The 

maximum score was nine. 

Selection 

1) Representativeness of the exposed cohort

a) truly representative of the average _______________ (describe) in the community ∗

b) somewhat representative of the average ______________ in the community ∗

c) selected group of users e.g. nurses, volunteers 

d) no description of the derivation of the cohort 

2) Selection of the non exposed cohort

a) drawn from the same community as the exposed cohort ∗

b) drawn from a different source 

c) no description of the derivation of the non exposed cohort 

3) Ascertainment of exposure

a) secure record (e.g. surgical records) ∗

b) structured interview ∗

c) written self report 

d) no description 

4) Demonstration that outcome of interest was not present at start of study

a) yes ∗

b) no 

Comparability 

1) Comparability of cohorts on the basis of the design or analysis

a) study controls for _____________ (select the most important factor) ∗

b) study controls for any additional factor ∗ (This criteria could be modified to indicate specific 

control for a second important factor.) 

Outcome 

1) Assessment of outcome

a) independent blind assessment ∗

b) record linkage ∗

c) self report 

d) no description 

2) Was follow-up long enough for outcomes to occur

a) yes (select an adequate follow up period for outcome of interest) ∗

b) no 

3) Adequacy of follow up of cohorts

a) complete follow up - all subjects accounted for ∗

b) subjects lost to follow up unlikely to introduce bias - small number lost - > ____ % (select an 

adequate percent) follow up, or description provided of those lost) ∗

c) follow up rate < ____% (select an adequate percent) and no description of those lost 

d) no statement 
B-10

Form B-5: Quality assessment form for case-control studies on 

manifestations of chronic insomnia in adults (Newcastle-Ottawa 

scale) 

Note: A study could be awarded a maximum of one star for each numbered item within the Selection and Exposure 

categories. A maximum of two stars could be awarded for Comparability. Each star was equivalent to one point. The 

maximum score was nine. 

Selection 

1) Is the case definition adequate?

a) yes, with independent validation ∗

b) yes, e.g. record linkage or based on self reports 

c) no description 

2) Representativeness of the cases

a) consecutive or obviously representative series of cases ∗

b) potential for selection biases or not stated 

3) Selection of Controls

a) community controls ∗

b) hospital controls 

c) no description 

4) Definition of Controls

a) no history of disease (endpoint) ∗

b) no description of source 

Comparability 

1) Comparability of cases and controls on the basis of the design or analysis

a) study controls for _______________ (Select the most important factor.) ∗

b) study controls for any additional factor ∗ (This criteria could be modified to indicate specific 

control for a second important factor.) 

Exposure 

1) Ascertainment of exposure

a) secure record (e.g. surgical records) ∗

b) structured interview where blind to case/control status ∗

c) interview not blinded to case/control status 

d) written self report or medical record only 

e) no description 

2) Same method of ascertainment for cases and controls

a) yes ∗

b) no 

3) Non-Response rate

a) same rate for both groups ∗

b) non respondents described 

c) rate different and no designation 
B-11

Form B-6: Quality assessment form for studies on management of 

chronic insomnia in adults (Jadad scale and allocation concealment 

for quality assessment of RCTs) 

 

Study # _______________ Initials of Assessor: _____ 

 

Part 1 (from Jadad – Controlled Clin Trials 1996; 17:1-12) 

 

1. Was the study described as randomized (this includes the use of words such as 

randomly, random and randomization)? 

Yes = 1 No = 0 

2. Was the study described as double-blind? 

Yes = 1 No = 0 

3. Was there a description of withdrawals and drop-outs? 

Yes = 1 No = 0 

Additional points: Add 1 point if: 

Method to generate the sequence of randomization was described and was 

appropriate (e.g. table of random numbers, computer generated, coin tossing, etc.) 

Method of double-blinding described and appropriate (identical placebo, active 

placebo, dummy) 

Point deduction: Subtract 1 point if: 

Method of randomization described and it was inappropriate (allocated alternately, 

according to date of birth, hospital number, etc.) 

Method of double-blinding described but it was inappropriate (comparison of tablet 

vs. injection with no double dummy) 

OVERALL SCORE (Maximum 5)

Score 

______ 

______ 

______ 

______ 

______ 

-_____ 

-_____ 

 _____ 

Part 2 (from Schulz – JAMA 1995; 273:408-12) 

 

Concealment of treatment allocation:  Adequate 

 Inadequate 

 Unclear 

 

Adequate: e.g. central randomization; numbered/coded containers; drugs prepared by 

pharmacy; serially numbered, opaque, sealed envelopes 

 Inadequate: e.g. alternation, use of case record numbers, dates of birth or day of week; open lists 

 Unclear: Allocation concealment approach not reported or fits neither above category 
Appendix C: Evidence Tables 

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic 

insomnia in adults 

Evidence Table C-1: References

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic 

insomnia in adults 

Evidence Table C-2: References
C-1

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults Abbreviations: adj = adjusted; BAI = Beck Anxiety Inventory; BDI = Beck Depression Inventory; BMI = body mass index; BNZ = benzodiazepine; ChI = chronic insomnia; CI = 

community; CS = case; CT = control group; DSM-IV = Diagnostic and Statistical Manual of mental Disorders, 4th edition; GS = good sleepers; Hx = history; INS = drug-free inso

use insomnia; mo = months; msec = mili-seconds; MSK = musculoskeletal; MMPI = Minnesota Multiphasic Personality Inventory; NA = not applicable; NR = not reported; OR 

statistically significant; QoL = Quality of Life; TBI = traumatic brain injury; VAS = visual analogue scale; yrs = years 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Ancoli-Israel, S / 1999 Moderate (3/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 18->65 yrs NR NR White:86%(860/1000) Black:8%(80/1000) Hispanic:3%(30/1000) Other:3%(30/1000) 1950 51.2%(1000/1950) 

Prevalence: 

All: (ChI) 9% (90/1000) 95%CI: 7.23-10.77. No prevalence data by gender. >65 group: 20% (37/183) 95%CI:14.20-25.80 Associated Factors: 

Significant Socioeconomic status: (<$50,000/yr vs >$50,000/yr): 42% vs 31%; OR (no insomnia) 0.89; 9

Non-significant Age: (<65 vs >65): 37% vs 44%; OR (no insomnia) 1.33; 95%CI: 0.83-2.14, p=0.29. Race/ethn

38% vs 35%; OR (no insomnia) 1.59; 95%CI: 0.99-2.54, p=0.66; Socioeconomic status: Edu

college): 41% vs 35%; OR (no insomnia) 0.78; 95%CI: 0.54-1.13, p=0.22. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Bastien, CH / 2003 Moderate (5/9) 

Study Design: Age Group: GenderFemale: Male:Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol >55 yrs X=62.5± 5.8 

30 30 60 NR 

Associated Factors: 

3 groups: drug-free insomniacs (INS) vs benzodiazepine use insomniacs (INSBZ) vs good sleeSignificant Psychiatric illness and psychological problems: 1) Depression (BDI): INS vs GS: 9.00 ± 4.4INSBZ vs GS: 9.40 ± 7.16 vs 1.75 ± 1.68, p<0.01; 2) Anxiety (BAI): INS vs GS: 9.10 ± 8.38, p<vs 1.20 ± 1.47; (p<0.01). 3) Sleep impairment index: INS vs INSBZ vs GS: 17.9 ± 4.85, 16.85 ± 

Non-significant INS vs INSBZ vs GS: 61.7 ± 6.43, 62.3 ± 5.89, 63.35 ± 5.15, p=NS. Socioeconomic status: E

13.6 ± 5.15, 11.65 ± 2.76, 13.35 ± 3.67, p=NS. Cognitive function: 1) Folstein Mini-mental Sta

29.1 ± 1.12, 28.75 ± 1.2, 28.85 ± 1.04, p=NS. 2) Vocabulary: INS vs INSBZ vs GS: 12.65 ± 3.8p=NS. Information: INS vs INSBZ vs GS: 10.15 ± 3.51, 10.0 ± 3.01, 11.5 ± 3.40, p=NS. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Bixler, EO / 2002 Moderate (3/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional > 20 yrs 57.4%(1000/1741) 42.6%(741/1741) NR 1741 66.6%(1160/1741) 

Prevalence: 

Insomnia ≥1 year: 7.5% (131/1741), 95%CI: 6.27-8.73. 

Associated Factors: 

Significant Age: CS vs CT: 50.4 ± 1.0 vs 46.9 ± 0.7 yrs, p=0.02. Gender: M vs F: 5.9% vs 9%; OR=1.6, 95

Race/ethnicity: Non-Caucasian vs Caucasian 12.9% vs 6.6%; OR: 2.1; 95%CI: 1.3-3.2, p<0.0

psychological problems: Depression: adj OR: 5.5; 95%CI: 3.6-8.4, p<0.0001. Medical condi

95%CI: 1.0-6, p<0.02. 2) Hypertension: adj OR: 1.2; 95%CI: 1.1-1.3, p<0.0001. 3) Anemia: adj p=0.004. Non-significant None reported 
C-2

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued) 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Bixler, EO / 1979 Moderate (3/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size: 

Response Rate: 

Cross-sectional > 18 yrs 56%(563/1006) 44%(443/1006) NR 1006 NR 

Prevalence: 

Life-time prevalence: (Current or past insomnia): 42.5% (428/1006), 95%CI: 39.4-45.5. Curre

(324/1006), 95%CI: 29.3-35.0. Gender: M vs F: 39% (172/443), 95%CI: 34.5-43.5 vs 61% (343

Associated Factors: 

Significant Age: >51yr (higher prevalence) 39.8%, 95%CI: 34.6-45.3, p<0.05. Psychiatric illness and ps

Tension: 29.2%, p<0.01. 2) Depression: 19.4%, p<0.05. 3) Loneliness: 12.9%, p<0.01. Medica

persistent or recurring health problem: 50%, p<0.01. 2) Multiple health problems: 17.3%, p<0.0

past year: 15.7%, p<0.01. Non-significant Gender: reported NS difference. Other factors: Marital/family problems: 17.8%, Alcohol relate

Healthcare utilization: 9.2%, all p=NS.

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Bliwise, NG / 1992 Low (1/9) 

Study Design: Age Group (years): GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 68.4 ± 8.7, 49-82 (CS) 67.5 ± 9.9, 52-95 (CT) 38 0 NS 38 total 16 (CS) 22 (CT) NR 

Associated Factors: 

Significant Psychiatric illness and psychological problems: (SCL-90-R Revised Symptom Checklist) C0.54 vs 0.26 ± 0.30, p<0.05. 2) Obsessive-compulsive: 1.06 ± 0.48 vs 0.68 ± 0.66, p<0.10. 3) A0.26, p<0.10. 4) Phobic anxiety: 0.15 ± 0.25 vs 0.02 ± 0.05, p<0.05. 8) Paranoid ideation: 0.50 

Psychoticism: 0.31 ± 0.27 vs 0.12 ± 0.23, p<0.05. 6 Geriatric Depression Scale (total score): 8.

p<0.10. Non significant Psychiatric illness and psychological problems: 1) Interpersonal: 0.44 ± 0.33 vs 0.31 ± 0.38

0.54 ± 0.54; 3) Hostility: 0.33 ± 0.36 vs 0.16 ± 0.17. Other factors: Chronic illness, Psychosoc

Socioeconomic status, Exercise, Alcohol and Caffeine intake all reported p=NS. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Bonnet, MH / 1995 High (7/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional matched case-control 18-50 yrs NR NR NR 40 total 20 (CS) 20 (CT) 50%, 10/20 (CS) 50%, 10/20 (CT) 

Associated Factors: 

SignificantPsychiatric illness and psychological problems: (Profile of Mood States scale): 1) Confusio

2) Tension: 6.0 ± 5.8 vs 4.0 ± 3.8, p<0.05. 3) Depression: 9.0 ± 11.8 vs 4.1 ± 5.3, p<0.05. 4) Vi

p<0.001. Memory and cognitive function: 1) Low results on short-term memory (# words): 5.

Low results on MAST test (# correct): 53.2 ± 24 vs 60.5 ± 19, p<0.001. Non Significant: (cases vs controls): Memory and cognitive function: 1) Proofread lines: 246 ± 71 vs 258 ± 75; 2) Vigilance: 0.88 Psychiatric illness and psychological problems: 1) Fatigue: 5.7± 5.7 vs 3.6 ± 4.3; 2) Anger: scores: Hypochondriasis: 57 ± 13 vs 51 ± 6.6; Psychopathic deviate: 72 ± 12 vs 62 ± 14; M/F: 5± 6.5 vs 56 ± 7.4; Psychasthenia: 58 ± 10 vs 54 ± 6.4; Schizophrenia: 59 ± 12 vs 57 ± 7.1; HypSocial introversion: 52 ± 12 vs 48 ± 9.3, all p=NS. 
C-3

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Braga-Neto. P / 2004 Low (2/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 34-86 yrs 36% (31/86) 64% (55/86) NR 86 NR 

Co-Morbidity: 

Medically ill (Parkinson's disease). Prevalence: 

One-month prevalence: 53.3% (49/86) (95%CI: 42.8-63.8). No prevalence data by gender. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Broman, JE / 1996 High (6/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 20-64 yrs 53.1% (210/396) 46.9% (186/396) NR 583 68% (396/583) 

Prevalence: 

Three-month prevalence: (ChI): 12% (47/396) 95%CI: 8.8-15.2. Associated Factors: 

Groups 1) M vs F; 2) Age: 20-34 (reference group), 35-49 and 50-64 Significant(Basic Nordic Sleep Questionnaire scores) Medical conditions: 1) Personal illness (age): p<0

activities (age): p<0.0001. 2) Having too little time (age): p<0.0001, 3) Watching TV (age): p<0

Relatives' illness (gender): p<0.05, 2) Children's sleeping pattern (age): p<0.0001. Cognitive f

factor (age): p <0.05; Sleepiness (age): p<0.01; Non-Significant (Basic Nordic Sleep Questionnaire scores) Quality of life: Working conditions/hours, low capacity for sleep both p=NS. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Broman, JE / 1992 Moderate (5/9) 

Study Design: Age Groupmean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 45.8 ± 11.5 yrs (CS) 45.0 ± 10.2 yrs (CT) 15 (CS), 15 (CT) 5 (CS), 5 (CT) NR 40 total 20 (CS), 20 (CT) NR 

Associated Factors: 

Significant Psychiatric illness and psychological problems: 1) Mood, anxiety and cognitive performanc

43.4, p<0.01. 2) State anxiety (State-Trait Anxiety Inventory): 39.9 ± 9.5 vs 32.6 ± 7.6, p<0.05. Non-Significant Objective performance: Reaction time dominant hand 1) Speed (ms:) 225.9 ± 42.3 vs 230.1 ± 

vs 54.3 ± 25.4; Word recognition 1) # correct: 19.5 ± 2.6 vs 19.8 ± 2.5; 2) Latency (s): 2.66 ± 1.recognition 1) # correct: 12.9 ± 3.1 vs 12.2 ± 3.1; 2) Latency (s): 3.55 ± 1.46 vs 3.24 ± 1.07; Fin

taps 61.0 ± 7.6 vs 61.7 ± 8.9; 2) Variability 3.9 ± 2.9 vs 4. ± 2.8, all p=NS. Psychiatric illness a

VAS for Tension: 47.5 vs 38.5, Excitement 46.4 vs 41.7, Stress 40.9 vs 35.4, Concentration 53

(Jenkins Activity scale) all subscales p=NS. 
C-4

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Chambers, MJ / 1993 Low (1/9) 

Study Design: Age Groupmean ± SD:GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 47.5 ± 10.9 yrs (CS) 45.9 ± 16.0 yrs (CT) 64.5%, 20/31 (CS) 60%, 21/35 (CT) 35.5%, 11/31 (CS) 40%, 14/35 (CT) NR 66 total 31 (CS), 35 (CT) NR 

Associated Factors: 

Significant Psychiatric illness and psychological problems: Anxiety 1) State anxiety: 39.1 ± 10.3 vs 31anxiety: 44.8 ± 9.8 vs 32.3 ± 7.7, p<0.001. Non-Significant None reported 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Coursey, RD / 1975 High (7/9) 

Study Design: Age Groupmean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 44.7 ± 16.8 yrs 5 (CS), 5 (CT) 13 (CS), 13 (CT) NR 36 total 18 (CS), 18 (CT) NR 

Associated Factors: 

SignificantPsychiatric illness and psychological problems: 1) Anxious worriers (Byrne's Repression-S

vs 50.4 ± 20.9, p<0.01; Taylor Manifest Anxiety scale: 22.5 ± 9.5 vs 13.3 ± 11.6, p<0.01; Edwa25.4 ± 6.1 vs 30.1 ± 5.8, p<0.05; Eysenck's Neuroticism scale: 12.1 ± 4.5 vs 5.7 ± 4.6, p<0.001vs 19.8 ± 3.5, p<0.001; Zung's Depression scale: 53.0 ± 11.5 vs 35.7 ± 6.2, p<0.001; MMPI Psvs 25.94 ± 3.75, p<0.01. 2) Concern with internal vs external stimuli (MMPI Hysteria scale): 20

MMPI Hypochondriasis scale: 19.0 ± 5.3 vs 12.5 ± 3.1, p<0.001; Zuckerman Sensation-Seekinp<0.001. Memory and cognitive function: Wechsler Adult Intelligence Scale 1) Low scores: Block Comp<0.05, Object Assembly: 8.4 ± 3.4 vs 11.4 ± 3.4, p<0.05 and Performance IQ: 107.1 ± 13.5 vs Non-significant Psychiatric illness and psychological problems: 1) MMPI K: 14.24 ± 4.43 vs 16.33 ± 5.39; 2

29.24 ± 9.88 vs 24.39 ± 9.47; 3) Depression Adjective Checklist: 8.94 ± 6.78 vs 7.0 ± 6.32; 4) M

4.71 vs 20.83 ± 4.51; 5) Eysenck’s Extraversion: 11.82 ± 3.13 vs 11.56 ± 4.18; all p=NS. All Teneurotic scales NS differences. Memory and cognitive function: Wechsler Adult Intelligence 

for: Information, Comprehension, Arithmetic, Similarities, Digit span, Vocabulary, Digit symbol, 

Full scale IQ. 
C-5

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Crenshaw, MC / 1999 Moderate (3/9) 

Study Design: Age Groupmean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 67.7 ± 4.8 yrs (CS) 67.5 ± 5.7 yrs (CT) 16 (CS), 16 (CT) 16 (CS), 16 (CT) NR 64 total 32 (CS), 32 (CT) NR 

Co-Morbidity:

Stable medical conditions: 3.2 ± 2.4 vs 2.3 ± 1.7, p>0.10. CS vs CT: hypertension 43.8% (14/39.4% (3/32) vs 3.1% (1/32), asthma 6.3% (2/32) vs 6.3% (2/32). Associated Factors: 

Significant None detected Non-significant Cognitive function: Performance measures: 1) SRT- latency (ms): 256.9 ± 77.1 vs 265.4 ± 92

± 29.7 vs 67.9 ± 37.5; 3) CPT-mean latency (ms): 381.6 ± 60.0 vs 373.9 ± 60.0; 4) CPT-mean 

20.7; 5) SWAT - Part I: mean latency (ms): 306.9 ± 63.8 vs 293.0 ± 57.3; 6) SWAT - Part I: me± 26.0; 7) SWAT - Part II: mean latency (ms): 472.8 ± 93.3 vs 478.2 ± 77.4; 8) SWAT - Part II: 

111.8 ± 43.2. For all, p >0.10. SRT = simple reaction time; CPT = continuous performance test; SWAT = Switching attention t

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Dorsey, CM / 1997 Low (2/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 18-25 yrs 14 17 NR 31 total 18 (CS), 13 (CT) NR 

Associated Factors: 

Non-significant Psychiatric illness and psychological problems: Objective Insomnia vs Subjective Insomnia Inventory Extraversion scale: 10.2 ± 3.9 vs 12.7 ± 3.9 vs 14.4 ± 3.7, p<0.058; 2) Neuroticism: 9

4.3, p=0.062, 3) Sociability 5.0 ± 3.0 vs 6.8 ± 2.3 vs 7.7 ± 3.1 p >0.05. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Edinger, JD / 2000A Moderate (4/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 40-59 yrs (CS) 40-59 yrs (CT) 55.6%, 15/27 (CS) 51.6%, 16/31 (CT) 44.4%, 12/27 (CS) 48.4%, 15/31 (CT) NR 32 (CS), 32 (CT) 84.4%, 27/32 (CS) 96.9%, 31/32 (CT) 

Associated Factors: 

Significant Cognitive function: Performance measures - mean latencies (ms): 1) SWAT Part II: 406.7 ± 7

SWAT-Part III-B-direction: 611.9 ± 110.0 vs 689.8 ± 177.9, p=0.05. Non-significant Cognitive function: Performance measures - mean latencies (ms): 1) Simple reaction time: 22p=NS; 2) Continuous performance test: 353.8 ± 37.3 vs 362.7 ± 45.2, p=NS; 3) SWAT - Part I: p=NS; 4) SWAT - Part III-A-side: 459.7 ± 138.7 vs 543.2 ± 192.0, p=NS. SWAT = Switching attention test 
C-6

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Edinger, JD / 2000B High (8/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 40-79 yrs 32 (CS), 31 (CT) 32 (CS), 31 (CT) NR 128 total 64 (CS), 64 (CT) 100%, 64/64 (CS) 95.3%, 61/64 (CT) 

Associated Factors: 

Significant Psychiatric illness and psychological problems: Objective Insomnia CS vs Objective normadysfunctional beliefs and attitudes about sleep control: 37.7 ± 11.6 vs 18.5 ± 10.9; p<0.05. SubSubjective normal sleepers: 2) High scores on Trait portion of the State-Trait Anxiety Inventory 

6.5; p<0.05. 3) High scores on the Beck Depression Inventory: 8.6 ± 5.2 vs 3.5 ± 3.3; p<0.05. 4beliefs and attitudes about sleep effects: 44.6 ± 18.6 vs 26.9 ± 20.4; p<0.05. 5) High scores on attitudes about sleep control: 33.6 ± 11.4 vs 18.3 ± 10.8; p<0.05. 6) High scores on Dysfunctiosleep needs: 46.3 ± 24.4 vs 30.6 ± 15.9; p<0.05. Non-significant Psychiatric illness and psychological problems: Objective Insomnia CS vs Objective normadysfunctional beliefs and attitudes about sleep [a] Effects: 41.5 ± 19.9 vs 33.2 ± 15.6, [b] Cause

Needs: 38.3 ± 15.9 vs 37.2 ± 11.9, [d] Habits: 25.7 ± 13.9 vs 27.0 ± 11.1, all p>0.05. 2) High sc

State-Trait Anxiety Inventory (STAI-2): 34.9 ± 6.7 vs 30.7 ± 6.1, p>0.05. 3) High scores on the ± 4.0 vs 4.6 ± 3.7, p>0.05. Subjective Insomnia CS vs Subjective normal sleepers: 1) High scoattitudes about sleep [a] Cause: 30.6 ± 17.0 vs 23.0 ± 15.4, p>0.05; [b] Habits: 27.2 ± 13.3 vs 2

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Fichtenberg, NL / 2002 Moderate (4/8) 

Study Design: Age Groupmean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 36.5 ± 14.5 yrs (TBI) 38.2 ± 13.5 yrs (SCI) 47.3 ± 12.2 yrs (MSK) 44%, 22/50 (TBI) 24%, 6/25 (SCI) 80%, 20/25 (MSK) 56%, 28/50 (TBI) 76%, 19/25 (SCI) 20%, 5/25 (MSK) NR 100 total 50 (TBI), 25 (SCI), 25 (MSK) 100% 

Co-Morbidity:

Traumatic back injury, spinal cord injury, or muskuloskeletal injury. Prevalence: 

DSM-IV Criteria: 30% (15/50) 95%CI: 27.3-42.7% of TBI patients. PSQI Criteria: 28% (14/50) 

patients. 56% (14/25) 95%CI: 36.5-75.5 for SCI patients. 56% (14/25) 95%CI: 36.5-75.5 for MS
C-7

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Hajak, G / 2001 High (6/8)  - cross sectional High (7/9)  - case control 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol Over 18 yrs Cross-sectional: 53.1% (1016/1913) 46.8% (897/1913) NR 1913 Cross-sectional 368 Case-control: 206 (CS), 162 (CT) NR 

Prevalence: 

One-month prevalence: (Sleep disturbances) 45% (784/1913), 95%CI: 42.7-47.2%. (Severe i

3.2-4.8%. Male: 3% (26/897), 95%CI: 1.89-4.11%. Female: 5% (51/1016), 95%CI: 3.66-6.34%

Associated Factors: 

Significant Cross-sectional data: Gender: 1) Female: OR: 1.77; 95%CI: 1.09-2.86; p=0.04. Social relation

divorced: OR: 3.45; 95%CI: 1.84-6.47, p<0.01; 2) Living in cities > 20,000: OR: 12.88; 95%CI: 

Case-control: Healthcare utilization: 1) Regular medication use: OR: 1.63; 95%CI: 1.06-2.52; 

≤ 6 mo.: OR: 1.54; 95%CI: 1.02-2.34. Cross-sectional: Quality of life: 1) Bad/Very Bad QoL (S

21.97. Non-significant Age: <65 vs > 65: OR 1.06; 95%CI: 0.60-1.89. Social Relationships: # in household, # childrestatus: working status, type of employment; all p=NS. Healthcare utilization: 1) Consult phys

95%CI: 0.78-2.18; 2) Hospitalizations in <12 m: OR 1.38; 95% C!: 0.71-2.65. Quality of life: Q

vs no sleep complaints; SF-36 scores); Vitality scale: 41.17 vs 62.7; Social functioning scale: 6

scale: 55.17 vs 87.57; Mental health scale: 50.35 vs 73.61; all p=NS. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Han, SY / 2002 Low (2/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 27-78 yrs 39% (32/82) 61% (50/82) NR 82 NR 

Co-Morbidity: 

Diabetes requiring hemodyalisis.Prevalence: 

Point prevalence: (Sleep difficulties ≥2 months): 68.2% (56/82), 95%CI: 58.2-78.2; Male: 72% 

Female: 62.5% (20/32), 95%CI: 45.7-79.2. Associated Factors: 

Significant Psychiatric illness and psychological problems: 1) Depression (Center for Epidemiologic S

CES-D) score ± SD; insomnia vs non-insomnia: 25.2 ± 12.1 vs 18.9 ± 10.3; p=0.02. Medical coadj OR: 0.80; 95%CI: 0.67-0.98; p=0.028. Non-significant Age: Older vs younger: CS vs CT: 60.5 ± 9.0 vs 56.1 ± 9.6; p=0.053. Gender: M/F: OR 1.54; 9

Socioeconomic status: 1) Education (>12yr vs ≤12yrs): OR 0.81; 95%CI: 0.25-2.63; 2) Job (y

1.13, p=NS. Medical conditions: Duration of diabetes, frequency of somatic symptoms, p=NS

Alcohol, p=NS.
C-8

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Harvey, AG / 2003 Moderate (3/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 20.4 ± 4.7 yrs (CS) 22.3 ± 8.9 yrs (CT) 60%, 18/30 (CS) 63.3%, 19/30 (CT) 40%, 12/30 (CS) 36.7%, 11/30 (CT) NR 60 total 30 (CS), 30 (CT) NR 

Associated Factors: 

SignificantPsychiatric illness and psychological problems: Measures of Psychopathology 1) Sleep co

"Very much") 3.7 ± 1.8 vs 0.1 ± 0.3, p<0.001. Quality of life: Cost (scale: 0 "There is no cost, s

me at all" to 10 "Sleeping badly is extremely costly and significantly disrupts my life") 5.5 ± 1.8 

Psychiatric conditions: 1) Beck Anxiety Inventory 13.6 ± 9.6 vs 7.3 ± 7.2, p<0.01. 2) Penn St

15.1 vs 41.2 ± 14.9, p<0.001. Non-significant Age: Insomnia vs good sleeper: (mean ± SD): 20.4 ± 4.7 vs 22.3 ± 8.9, p=NS.

Psychiatric illness and psychological problems: 1) Beck Depression Inventory 10.3 ± 7.3 v

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Hauri, PJ / 1997 High (7/9) 

Study Design: Age Groupmean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 47.7 ± 11.8 yrs 19 (CS), 19 (CT) 7 (CS), 7 (CT) NR 52 total 26 (CS), 26 (CT) NR 

Associated Factors: 

Significant Memory and cognitive function: (CS vs CT) Performance: 1) Simple reaction tasks: Sway Fo

41.2, p<0.02; Initiation time (msec): 486 ± 614 vs 330 ± 115, p<0.01; Total time (msec): 662 ± 

Complex reaction tasks: Initiation time (msec): 489 ± 218 vs 401 ± 98, p<0.02; Total time (mse

p<0.03; 3) Performance on Digit Span test (Number remembered): 21.4 vs 24.5; p<0.01), 4) Sl(Stanford Sleepiness scale mean scores: 3.67 vs 2.33; p<0.0001).Non-significant Memory and cognitive function: Performance: 1) Sway sideward (sec) 43.4 vs 49.7; 2) Simp

time (msec) 188 ± 150 vs 156 ± 79; 3) Complex reaction tasks: Initiation time (msec) 259 ± 157 

on Digit Span test: Divided Attention: Sum of squares 2711 vs 1826; Reaction time (msec) 274

substitution: # attempted 58.9 vs 62.1, all p=NS. 
C-9

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Healey, ES / 1981 High (8/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 19-63 yrs (CS) 18-63 yrs (CT) 22 (CS), 22 (CT) 9 (CS), 9 (CT) NS 62 total 31 (CS), 31 (CT) NS 

Associated Factors:

Significant Psychiatric illness and psychological problems: Childhood variables 1) Nightmares (1-5 scp<0.05, 2) Sleeping problems (1-5 scale); 1 = never: 1.90 vs 1.48; p<0.05, 3) Sleep quality in cexcellent: 1.90 vs 1.45; p<0.01, 4) Reporting of eating problems: 1.77 vs 1.35; p<0.05. Self con

Affiliation: 42.3 vs 48.2; p<0.05, 2) Abasement: 54.4 vs 47.8; p<0.05, 3) Aggression: 55.9 vs 49

readiness: 55.9 vs 47.4; p<0.01, 5) Low defensiveness: 43.1 vs 52.4; p<0.01, 6) Low self-contrpersonal adjustment: 41.4 vs 50.9; p<0.01, 8) Low achievement: 46.1 vs 52.7; p<0.05, 9) Low p<0.05, 10) Low affiliation: 39.9 vs 49.7; p<0.001, 11) Poor self-perception: 59.3% vs 4.5%; p<

perception: 65.2% vs 21.7%; p<0.01, 13) Passive traits: 60% vs 20%; p<0.05, 14) Nervousnes

vs 31.8%; p<0.05, 15) Suicidal thoughts: Health Questionnaire: 35.5% vs 9.7%; p<0.05, 16) Incdisturbance (Health Questionnaire): 38.7% vs 6.5%; p<0.01. Medical conditions: 1) Total # ill

3.19% vs 1.84%; p<0.001, 2) Incidence of allergies (Health Questionnaire): 45.2% vs 12.9%; p

1) Change in financial status (Social Readjustment Rating Scale): 53.23 vs 40.48 ± 69.37; p<0

work: 56.13 vs 41.61; p<0.05. Healthcare utilization 1) More hospitalizations two years prior tevaluation time (Health Questionnaire): 1.55% vs 0.34%; p<0.01, 2) Major hospitalizations ≥ 3 Questionnaire): 1.07% vs 0.26%; p<0.05. Quality of life: 1) Satisfaction with parent relationshisubscores; 1 = satisfied): 4.07 vs 2.85; p<0.01, 2) Satisfaction with social life (Life Satisfaction 

satisfied): 3.74 vs 2.94; p<0.05, 3) Satisfaction with leisure time (Life Satisfaction scale mean s

3.16; p<0.05, 4) Satisfaction with living arrangements (Life Satisfaction scale mean subscores; p<0.01, 5) Satisfaction with oneself (Life Satisfaction scale mean subscores; 1 = satisfied): 3.9

with health prior to sleep problem (Life Satisfaction scale mean subscores; 1 = satisfied): 2.90 

with health in the present (Life Satisfaction scale mean subscores; 1 = satisfied): 3.84 vs 1.97; health complaints (Health Questionnaire): 9.55 vs 5.87; p<0.001, 9) Lack of energy (Health Qup<0.05. Social relationships: 1) Mean # losses from social field: 1.19 ± 1.01 vs 0.52 ± 1.03; p

function: 1) Trouble concentrating (Health Questionnaire): 51.6% vs 12.9%; p<0.05. Other fac

year of insomnia onset (Life Change Unit scale): 157.52 ± 65.96 vs 91.90 ± 69.37; p<0.0), 2) Rof insomnia onset (Schedule of Recent Experience interview): 345.56 ± 148.08 vs 197.78 ± 15personal events experienced: 2.71 ± 1.97 vs 1.58 ± 1.95; p<0.05, 4) Mean # undesirable eventp<0.001. Non-significant Social relationships: Area of activity: 1) mean # life events: work, financial, legal, family, desir

p=NS. 2) Mean # entrances into social field 0.32 ± 0.60 vs 0.19 ± 0.48; p=NS. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Hetta, J / 1999 Low (0/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional Over 18 yrs NS NS NS 1,996 total 25%, 499/1996 

Prevalence: 

One-month prevalence: 31% (155/499) (95%CI: 27-35). No prevalence data by gender. 
C-10

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Hidalgo, MP / 2002 Moderate (5/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 18-35 yrs 41.8%, 143/342 58.2%, 199/342 NS 342 total NS 

Prevalence: 

One-year prevalence: (Sleep difficulties ≥ 1 mo): 26% (89/342) 95%CI: 21.3-30.6. No prevalenAssociated Factors: 

Significant Psychiatric illness and psychological problems: 1) Minor psychiatric disorders and insomni4.56; p<0.05. Non-significant Gender: (F vs M) OR 0.87; 95%CI: 0.56-0.65; p=NS. Psychiatric illness and psychological 

psychopathologies: OR 0.99, 95%CI: 0.5 -1.96; p=NS. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Hohagen, F / 1993 Moderate (4/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 18-65 yrs 55.3%, 1389/2512 44.7%, 1123/2512 NS 2,512 total 97.9%, 2459/2512 

Prevalence: 

Six-month prevalence: (Severe, moderate, mild insomnia): 45.9% (1152/2512) 95%CI: 44-4895%CI: 17.1-20.2. No prevalence data by gender. Associated Factors: 

Significant Psychiatric illness and psychological problems: 1) Depression (mild chronic insomnia): n = 

ChI: n = 18, 7%; p<0.001; severe ChI: n = 85, 21.7%; p<0.001, 2) Neurosis/personality disorde= 28, 7.2%; p<0.001, 3) Acute psychological distress (moderate chronic insomnia): n = 20, 7.8%10.2%; p<0.001, 4) Alcohol drug abuse (severe ChI): n = 18, 4.6%; p<0.001, 5) Psychosomatic 5.6%; p<0.001. Non-significant Psychiatric illness and psychological problems: 1) Neurosis/personality disorders - modera

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Hohagen, F / 1994 Moderate (4/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional Over 65 yrs 72%, 237/330 8%, 93/330 NS 338 97.5%, 330/338 

Prevalence: 

Point prevalence: (All DSM-III-R insomnia): 56.3% (186/330) 95%CI: 50.9-61.6. Severe DSM-95%: 18.4-27.5. No prevalence data by gender. Associated Factors: 

Significant Gender: severe insomnia F/M 29.1 vs 7.9, p <0.001. Healthcare utilization: 1) Prescribed hyp

95%CI: 3.19-12.0; p<0.001; physician report: OR: 2.09; 95%CI: 2.09-12.6; p<0.001. Psychiatrproblems: Depression OR 2.93; 95%CI: 1.51-5.71; p <0.01. Mental disorders (Total) OR 1.71; Non-significant Medical conditions (acute/chronic): reported NS. 
C-11

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Ishigooka, J / 1999 Moderate (5/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 15-65 yrs 58.1%, 3645/6277 41.9%, 2632/6277 All Asian (Japanese) 7112 total 88.3%, 6277/7112 

Prevalence: 

Point prevalence: (Insomnia lasting ≥ 1 mo): 11.7% (735/6277), 95%CI: 10.9-12.4. Male: 11.2

Female: 12% (440/3645), 95%CI: 10.9-13. Associated Factors:

SignificantAge: 1) Older age group (45-54 yrs): OR 1.42; p<0.001; 55-64 yrs OR: 1.81; p<0.0001; 65+ OR

Female/male: OR 1.12; p<0.05. Healthcare utilization: 1) Neurology service: OR: 1.73; p<0.01), 2) Psychiatry service: OR: 3.8Living alone: OR: 1.18; p<0.05), 2) Dissatisfaction with sleep environment: OR: 1.58; p<0.0001Non-significant Other factors: Occupation, Residential area, Season, Alcohol consumption, Smoking, Caffein

p=NS. (no data) 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Kageyama, T / 2001 Moderate (5/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional study 24-59 yrs NS NS Japanese 555 total NS 

Prevalence: 

Point prevalence: 29.2% (162/555) 95%CI: 28.7, 29.7. 

Associated Factors: 

Significant Age: (40-49 yrs reference group): <24 yrs: 34% (62/184), adj OR = 2.34; 95%CI: 1.19-4.62. W

mean score ± SE): 1) Workload: 2.47 ± 0.06 vs 2.30 ± 0.004, p<0.05; 2) Mental workload: 2.41 3) Problem in personal relationships: 2.18 ± 0.06 vs 2.00 ± 0.03, p<0.05; 4) Job satisfaction: 2.p<0.05; 5) Support from colleagues and superiors: 2.66 ± 0.05 vs 2.82 ± 0.03, p<0.01; 7) Seve0.06 vs 2.57 ± 0.04, p<0.01. 8) # non-working days in ≤ 3mo: (≤ 6 days/mo): OR 2.62; 95%CI: 

3mo. (≥ 9 nights/mo is reference gr): (1-3 nights/mo) OR 3.32; 95%CI: 1.0-11.16. Socioecono

last 3 mo (<10 vs ≥10) p<0.05 

Non-significantAge: (40-49 yrs reference group): 25-29 yrs: 26% (37/143), adj OR = 1.45; 95%CI: 0.69-30.2), = 1.48; 95%CI: 0.71-3.11; 50-59 yrs: 33% (14/43), adj OR = 2.41; 95%CI: 0.96-6.05, all p=NS. 

Undergoing medical treatment (no vs yes): 27% (119/441) vs 36% (37/104), p=NS. Work perfoscore ± SE): 1) Job control: 2.36 ± 0.05 vs 2.45 ± 0.03, p=NS). 2) # non-working days in ≤ 3mo

95%CI: 0.74-1.76; 3) # night shifts in ≤ 3mo. (≥ 9 nights/mo is reference gr): (4-5 nights/mo) OR 

nights/mo): OR 1.80; 95%CI: 0.54-6.02. Relationships: 1) Marital status OR 1.31; 95%CI: 0.89

nurse relationship: 1.94 ± 0.04 vs 2.10 ± 0.06. 3) # Children < 6: OR 0.95; 95%CI: 0.51-1.76, 4

2): OR 0.74, 95%CI: 0.49-1.12. Medical conditions: Current OR 0.67, 95%CI: 0.43-1.05. 
C-12

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Kageyama, T / 1997 High (6/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 20 - 80 yrs 3600 0 Japanese 3600 total Varied between district 51-59% 

Prevalence: 

Point prevalence: 11.2% (403/3600) 95%CI: 10.2, 12.2. 

Associated Factors: 

SignificantAge: (% ± SE, reference group 30-39 yr): 70+ years: 14.2% (46/322) ± 1.9, adj OR = 2.1; 95%

1) Sleep apnea-like symptoms (absent vs present, absent is reference category): adj OR = 2.7

Disease: OR = 2.4, p<0.01. Relationships: 1) Children ≤ 6 in home: OR 1.5; 95%CI: 1.0-2.1; 2

1.4; 95%CI 1.1-1.9. Healthcare utilization: 1) Consulting a physician or other specialist (insom

SE): Current: 11.4% ± 1.6 (46/403) vs 1.3% ± 0.2 (42/3197), OR = 9.68; 95%CI: 6.28-14.92; Pa

4.9% ± 0.4 (157/3197), OR = 4.07; 95%CI: 3.00-5.51; Never: 71.2% ± 2.3 (287/403) vs 93.8% 

95%CI: 0.13-0.21; 2) Undergoing medical treatment (yes vs no, no is reference category) adj Operformance: (insomniacs vs non-insomniacs % ± SE): 1) Inefficiency in work: 17.2% ± 1.9 (6p<0.001, OR = 2.20; 95%CI: 1.65-2.93; 2) Tardiness: 10.2% ± 1.5 (41/403) vs 4.4% ± 0.4 (14195%CI: 1.71-3.53; 3) Prone to errors in work (8.9% ± 1.4 (36/403) vs 3.5% ± 0.3 (112/3197), p<3.99. Non-significant Age: (% ± SE, reference group 30-39 yr): 20-29 yrs: 13.3% (45/337) ± 1.8, adj OR = 1.5; 95%C

(90/982) ± 0.9, adj OR = 1.1; 95%CI: 0.7-1.7, 50 - 59 yrs: 12.6% (107/852) ± 1.1, adj OR = 1.1; 

13.1% (66/501) ± 1.5, adj OR = 1.6; 95%CI: 0.9-2.6; all p=NS. Socio-economic status: (% wit

10.5% (183/1739) ± 0.7, unemployed: 11.9% (195/1639) ± 0.8; p=NS. Social relationships: M

(291/2722) ± 0.2, Single 13.0% (94/721) ± 1.3, p=NS. Other factors: Exercise, Smoking, Alcohdata). 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Kales, AK / 1983 Moderate (4/9) 

Study Design: Age Groupmean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 43.1 ± 0.9 (CS) 40.9 ± 1.5 (CT) 59%, 177/300 (CS) 59%, 59/100 (CT) 41%, 123/300 (CS) 41%, 41/100 (CT) NS 400 total 300 (CS), 100 (CT) 93%, 279/300 (CS) 97%, 97/100 (CT) 

Associated Factors: 

SignificantPsychiatric illness and psychological problems: (MMPI) (mean ± SE): 1) F Scale: 7.4 ± 0.2 

13.9 ± 0.3 vs 15.8 ± 0.5, p<0.01; 3) Hypochondriasis Scale: 63.2 ± 0.8 vs 50.2 ± 0.8, p<0.01); 4

vs 52.8 ± 1.1, p<0.01; 5) Conversion Hysteria Scale: 66.8 ± 0.7 vs 54.8 ± 0.8, p<0.01; 6) Psych

0.7 vs 56.2 ± 1.1, p<0.01; 9) Paranoia Scale: 60.7 ± 0.6 vs 55.4 ± 0.9, p<0.01; 10) Psychasthe

0.9, p<0.01; 11) Schizophrenia Scale: 66.4 ± 0.9 vs 54.5 ± 1.0, p<0.01. 

Non-significant Psychiatric illness and psychological problems: (MMPI) (mean ± SE): 1) L Scale: 50.1 ± 0.

Masculine-Feminine Scale: Male 65.5 ± 0.9 vs 62.3 ± 1.7, p=NS. Female 45.2 ± 0.7 vs 45.5 ± 157.2 ± 0.7 vs 55.0 ± 1.0, p=NS. MMPI = Minnesota Multiphasic Personality Inventory Scale 
C-13

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Kales, AK / 1982 Low (2/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 18-78 yrs (CS) 18-74 yrs (CT) 118 (CS), 59 (CT) 82 (CS), 41(CT) NS 300 total 200 (CS), 100 (CT) NS 

Associated Factors: 

SignificantPsychiatric illness and psychological problems: (CSs with sleep apnea vs CTs with sleep ain MMPI Psychopathic deviate scale: 64.5 ± 2.2 vs 52.4 ± 2.7; p<0.01. 2) Elevation in MMPI Ps

vs 55.7 ± 2.1; p<0.01. 3) Elevation in MMPI Schizophrenia scale: 64.4. ± 2.9 vs 53.8 ± 1.8; p<0

MMPI scale: 68.4% vs 36.4%; p<0.01. 5) Mean # elevated MMPI scales: 1.9 ± 0.5 vs 0.4 ± 0.2myoclonic activity vs CTs with nocturnal myoclonic activity; mean ± SD): 1) Elevation in MMPI 50.5 ± 3.2; p<0.01. 2) Elevation in MMPI Conversion hysteria scale: 64.3. ± 2.8 vs 55.6 ± 2.2; pPsychopathic deviate scale: 65.8. ± 2.6 vs 54.8 ± 2.8; p<0.01. 4) Elevation in MMPI Psychasth

2.4; p<0.01. 5) Elevation in MMPI Schizophrenia scale: 64.2. ± 2.6 vs 50.6 ± 2.7; p<0.01. 6) Ele

scale: 62.2. ± 3.1 vs 51.4 ± 2.1; p<0.01. 7) Elevations in at least one MMPI scale: 83.3% vs 36elevated MMPI clinical scales: 2.1 ± 0.5 vs 0.4 ± 0.2; p<0.01. Non-significant Psychiatric illness and psychological problems: 1) CSs with sleep apnea vs CTs with sleep difference in frequency: 9.1± 1.3 vs 9.5 ± 2.2 or duration of episodes (sec): 16.2 ± 1.0 vs 13.8 ± 

myoclonic activity vs CTs with nocturnal myoclonic activity; mean ± SE: Prevalence: 5% (n=10) 

106.5 ± 16.9 vs 171.3 ± 41.2, p=NS. 3) Elevation in MMPI Hypochndriasis scale: 60.9 ± 3.8 vs 

MMPI Paranoia scale: 56.4 ± 2.3 vs 53.2 ± 2.5; p=NS. MMPI = Minnesota Multiphasic Personality Inventory Scale 
C-14

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Kales, JD / 1984 Low (1/9) 

Study Design: Age Groupmean ± SD: GenderFemale: Male:Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 43.1± NS (CS) 48.2 ± 1.5 (CT) 58.9%, 126/214 (CS) 59%, 59/100 (CT) 41.1%, 88/214 (CS) 41%, 41/100 (CT) NS 314 total 214 (CS), 100 (CT) NS (CS) 94%, 94/100 (CT) 

Associated Factors:

Significant Psychiatric illness and psychological problems: 1). Mental Health: a) More nervous than ot(11/94), p<0.01 (OR = 7.55, 95%CI: 3.81-14.95), b) Ready to go to pieces 51% (109/214) vs 12

95%CI: 3.95-15.52), c) Feeling life is a strain 46% (99/214) vs 7% (7/94), p<0.01 (OR = 10.70, 

happy than others 52% (111/214) vs 20% (19/94), p<0.01 (OR = 4.25, 95%CI: 2.40-7.53), e) L

(94/214) vs 20% (19/94), p<0.01 (OR = 3.09, 95%CI: 1.75-5.47), f) Lonely much of the time 43(OR = 9.37, 95%CI: 4.14-21.20), g) Brood a great deal 41% (88/214) vs 8% (8/94), p<0.01 (OR 

Feeling blue 35% (75/214) vs 2% (2/94), p<0.01 (OR = 24.82, 95%CI: 5.95-103.59), i) Feeling 

vs 0, p<0.01), j) "take things hard" 65% (139/214) vs 34% (32/94), p<0.01 (OR = 3.59, 95%CI: "the right kind of life" 31.8% (68/214) vs 11.7% (11/94), p<0.01 (OR = 3.51, 95%CI: 1.76-7.02)

"wrong with their mind" 21.5% (46/214) vs 2.1% (2/94), p<0.01 (OR = 12.60, 95%CI: 2.99-53.0(174/214) vs 38.3% (36/94), p<0.01 (OR = 7.01, 95%CI: 4.09-12.02), n) Feeling anxious 50.5% 

p<0.01 (OR = 12.66, 95%CI: 5.60-28.62), o) Feeling "high strung" 59.8% (128/214) vs 17.0% (

95%CI: 3.97-13.27), p) Not usually feeling calm 43.5% (93/214) vs 11.7% (11/94), p<0.01 (OR 

Medical conditions: a) Poor currently 43% (43/100) vs 3% (3/100), p<0.01 (OR = 24.39, 95%

doctor's care 55% (55/100) vs 11% (11/100), p<0.01 (OR = 9.89, 95%CI: 4.72-20.73), c) "Psyc(126/214) vs 31% (29/94), p<0.01 (OR = 3.21, 95%CI: 1.92-5.37), d) Work limited by illness 49p<0.01 (OR = 4.69, 95%CI: 2.44-9.01), e) Hospitalizations (means only) 2.7 vs 1.4, p<0.01, f) H

1.1% (1/94), p<0.01 (OR = 22.04, 95%CI: 2.98-162.81), g) Diarrhea 28.0% (60/214) vs 9.6% (9

95%CI: 1.40-6.15), h) Stomach discomfort 28.5% (61/214) vs 3.2% (3/94), p<0.01 (OR = 12.09

Palpitations 40.7% (87/214), 16.0% (15/94), p<0.01 (OR = 3.61, 95%CI: 1.95-6.68), j) Non-spe

13.8% (13/94), p<0.01 (OR = 3.29, 95%CI: 1.72-6.31), k) Tiredness 64.0% (137/214) vs 12.8% 

95%CI: 6.24-23.69), l) Weakness 26.2% (56/214) vs 3.2% (3/94), p<0.01 (OR = 10.75, 95%CI: 

Utilization: Hospitalizations (mean #) 2.7 vs 1.4 times, p<0.01). Quality of life: a) "I believe th

that of most people I know” 64.5% (138/214) vs 94.7% (89/94), p<0.01 (OR = 0.08, 95%CI: 0.0

friends about as quickly as others do" 69.2% (148/214) vs 91.5% (86/94), p<0.01 (OR = 0.21, 9

children" 79.9% (171/214) vs 95.7% (90/94), p<0.01 (OR = 0.18, 95%CI: 0.06-0.51), d) "My sex 

(113/214) vs 81.9% (77/94), p<0.01 (OR = 0.16, 95%CI: 0.09-0.29). Mood: Behavioural correla

before going to sleep: a) "Mind racing" 48% (48/100) vs 15% (15/100), p<0.01 (OR = 5.23, 95%Tense/anxious 44% (44/100) vs 2% (2/100), p<0.01 (OR = 38.50, 95%CI: 8.99, 164.89), c) Wo

(6/100), p<0.01 (OR = 8.44, 95%CI: 3.36-21.21), d) Depressed 24% (24/100) vs 2% (2/100), p

67.52), e) Desperate 10% (10/100) vs 0%, p<0.01, f) Mentally tired 56% (56/100) vs 39% (39/1

1.13-3.50), g) Sleepy 31% (31/100) vs 71% (71/100), p<0.01 (OR = 0.18, 95%CI: 0.10-0.34). 2

sleep: a) About getting enough sleep 77% (77/100) vs 12% (12/100), p<0.01 (OR = 24.55, 95%

personal problems 49% (49/100) vs 30% (30/100), p<0.05 (OR = 2.24, 95%CI: 1.25-4.00), c) A

(29/100), p<0.05 (OR = 2.17, 95%CI: 1.21-3.89), d) About health 36% (36/100) vs 16% (16/100

1.51-5.79), e) About death 14% (14/100) vs 3% (3/100), p<0.05 (OR = 5.26, 95%CI: 1.16-18.94

without thoughts or ideas bothering me" 23.8% (51/214) vs 80.9% (76/94), p<0.01 (OR = 0.07, frightened in the middle of the night 25.2% (54/214) vs 5.3% (5/94), p<0.01 (OR = 6.01, 95%C

Non-significant Medical conditions: a) Poor in childhood 19% (19/100) vs 11% (11/100), OR = 1.90; 95%CI: 0

11% vs 3%, p=NS. Smoking and Caffeine consumption reported NS. 
C-15

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Kappler, C / 2003 Low (2/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size: 

Response Rate: 

Cross-sectional 18-65 yrs 50.1%, 1257/2512 49.9%, 1253/2512 NS 2512 total 37.6%, 945/2512 

Prevalence: 

Six-month prevalence: (DSM-III severe/moderate insomnia): 27.3% (258/945) (95%CI: 24.5-3

gender. Associated Factors: SignificantAge: 1) Older (OR: 18.17; p<0.001). Psychiatric illness and psychological problems: (95%disorder (OR: 7.38; p=0.007). Socio-economic status: 1) Social status (OR: 1.64; p=0.0009). 

housekeeping (OR: 11.02; p=0.01). Social relationships: 1) Conflicts with relatives (OR: 16.44

relatives (OR: 1.7; p=0.04), 3) Overload profession (OR: 11.02; p=0.0003). Non-significant None reported 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Kawada, T / 2003 High (6/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 20-80 yrs 1286 0 All Asian (Japanese) 1286 50.4%, 648/1286 

Prevalence: 

Point prevalence: (DSM-IV criteria for at least 1 month): 8.8% (57/648) (95%CI: 6.6-10.9). No 

Associated Factors: 

SignificantPsychiatric illness and psychological problems: 1) Depressive state (adj OR: 1.2; 95%CI: 1

condition: 1) Poor self-rated health (adj OR: 3.2; 95%CI: 1.0-10.1; p<0.05). 2) Medical treatmeOther factors: 1) Experiencing a major life event (adj OR: 4.4; 95%CI: 1.7-11.4; p<0.01). 2) Ch

1.13-3.84. Non-significant Age: (<50 vs >50) adj OR: 2.7; 95%CI: 0.9-7.9. Social Relationships: (Married vs not married

Socioeconomic status: (Employed vs other) OR: 0.97; 95%CI: 0.26-1.7. Other factors: 1) Sm

2.5; 2) Alcohol (yes vs no) OR: 1.42; 95%CI: 0.76-2.66; 3) Regular exercise: OR: 0.67; 95%CI: 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Leger, D / 2000 High (6/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional Over 18 yrs 53%, 6772/12,778 47%, 6006/12,778 NS 14,998 85.2%, 12778/14,997 

Prevalence: 

One-month prevalence: (Insomnia) 19% (2376/12,778) (95%CI: 18.3-19.6). Associated Factors: 

Significant Gender: Male: 14% (841/6006), 95%CI: 13.1-14.80). Female: 23% (1542/6772), 95%CI: 22-24

(1192/12,778), 95%CI: 8.51-9.49. Male: 6.3% (377/6006), 95%CI: 5.4-6.6. Female: 12% (815/6

Age: Severe insomnia increased significantly both sexes p<10-4. 

Socio-economic status: 1) Retired: 18.3%; p <0.0001, 2) White-collar worker: 20.8%; p<0.03

less insomnia than other states 13% p<10-4. 

Non-significant Other factors: Urban vs rural p=NS
C-16

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Leppavuori, A / 2002 Moderate (4/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 55-85 yrs 49.1%, 136/277 50.9%, 141/277 NS 277 NS 

Co-Morbidity: 

Medically ill (stroke).Prevalence: 

Point prevalence: (DSM-IV criteria of insomnia): 37.6% (104/277) (95%CI: 31.9-43.3). (Insom

(157/277) (95%CI: 50.9-62.5). (Before-stroke insomnia complaints): 38.6% (107/277) (95%CI: insomnia complaints): 18.1% (50/277) (95%CI: 13.6-22.6). (Before-stroke DSM-IV insomnia): 677.9). (Post-stroke DSM-IV insomnia): 60% (30/50) (95%CI: 46.5-73.5). No prevalence data by Associated Factors:

SignificantAge: 1) Age (mean ± SD years) (71.1 ± 7.1 vs 72.6 ± 7.2 (p<0.01) vs 71.6 ± 7.8 (p<0.05) vs 69

(Prestroke insomniacs vs New insomniacs vs All insomniacs vs Non-insomniacs: 52.3% vs 60% Psychiatric illness and psychological problems: 1) History of depression (29.9% vs 16% vs anxiety disorders (32.7% (p<0.001) vs 8.0% vs 24.8% (p<0.01) vs 11.7%), 2) Any depression ((p<0.001) vs 51.6% (p<0.00001) vs 25%), 3) Major depression (34.6% (p<0.001) vs 34% (p<015.0%), 4) Organic depression (3.7% vs 18% (p<0.01) vs 8.3% vs 4.2%), 5) Any anxiety disord30.0% (p<0.001) vs 31.2% (p<0.00001) vs 9.2%), 6) Generalized anxiety (21.5% (p<0.00001) 4.2%), 7) Organic anxiety (9.3% vs 22.0% (p<0.001) vs 13.4% (p<0.01) vs 4.2%), 8) Dementia 24.2% (p<0.05) vs 13.3%), 9) High scores on Beck Depression Inventory (mean score ± SD: 1

5.2 (p<0.01) vs 11.2 ± 7.6 (p<0.00001) vs 7.1 ± 5.9) 10) High scores on Montgomery-Åsberg D(MADRS): 9.9 ± 8.0 (p<0.00001) vs 10.3 ± 8.6 (p<0.00001) vs 10.1 ± 8.2 (p<0.00001) vs 4.9 ± depression scale (40.7 ± 10.0 (p<0.00001) vs 41.7 ± 9.3 (p<0.00001) vs 41.0 ± 9.7 vs 35.0 ± 9anxiety scale (30.9 ± 7.8 (p<0.00001) vs 30.5 ± 7.1 (p<0.00001) vs 30.8 ± 7.6 (p<0.00001) vs 2Global Assessment of Functioning scale (GAF) after stroke (58.6 ± 13.1 (p<0.00001) vs 56.6 ± (p<0.00001) vs 65.3 ± 11.1), 14) Low score on Global Assessment of Functioning scale (GAF) 

(p<0.00001) vs 72.6 ± 8.8 vs 70.7 ± 9.3 (p<0.00001) vs 74.8 ± 7.3). Medical conditions: 1) Ma

(14.2% vs 26.0% (p<0.05) vs 17.9% vs 12.5%, 2) Stroke severity (Scandinavian Stroke Scale m49.9 ± 12.3 (p<0.01) vs 53.3 ± 9.0 vs 54.8 ± 8.1). 3) Migraine (17.8% vs 10.0% vs 15.3% (p<0.Being dependent (34.6% vs 56.0% (p<0.001) vs 41.4% (p<0.01) vs 25.8%), 2) Activities of dailscore ± SD: 72.4 ± 15.4 vs 61.6 ± 23.1 (p<0.00001) vs 68.9 ± 18.9 (p<0.01) vs 74.4 ± 13.7). Me

1) Cognition (Mini Mental Status Examination mean score ± SD: 25.7 ± 4.0 vs 23.8 ± 5.4 (p<0.026.6 ± 3.0). Prestroke insomniacs vs New insomniacs vs All insomniacs vs Non-insomniinsomnia): 1) Sleep-promoting drug use (86.9% (p<0.0001) vs 78% (p<0.0001) vs 84.1% (p<0(32.7% (p<0.0001) vs 22% (p<0.0001) vs 29.3% (p<0.0001) vs 1.7%), 3) Antidepressants use 32.5% (p<0.0001) vs 10.8%), 4) Antipsychotics use (8.4% (p<0.05) vs 14.0% (0.01) vs 10.2% Non-significant Non reported 
C-17

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Levitt, H / 2004 Low (2/9) 

- case control 

Low (0/9)  - cohort 

Study Design: Age Group: mean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 20-30 yrs 24.1±3.4 (CS) 23.3±1.9 (CT) 85.7%, 6/7 (CS) 87.5%, 7/8 (CT) 14.3%, 1/7 (CS) 12.5%, 1/8 (CT) NS 15 total 7 (CS), 8 (CT) 100% 

Associated Factors: 

SignificantPsychiatric illness and psychological problems (CS vs CT): 1) Hamilton Rating Scale for A

-8.74, p<0.001. 2) Inventory of depressive symptomatology: 11.6 ± 3.0 vs 1.9 ± 2.2, t = -7.01, pQuality Index: 8.9 ± 1.0 vs 1.4 ± 1.1, t = -6.33, p<0.001. 4) SF-36 Vitality Index: 52.9 ± 21.4 vs 

Cognitive function: 1) Subjective alertness morning: 46.59 ± 5.28 vs 80.86 ± 4.27, p=0.003. 2vs 84.08 ± 5.11, p=0.003; noon: 73.28 ± 5.45 vs 87.68 ± 4.10, p=0.052. 3) Concentration morn

5.23, p=0.003; night: 53.01 ± 4.78 vs 68.21 ± 4.93, p=0.045. Mood (CS vs CT, mean ± SE) mo

4.49, p=0.004. Non-significant Psychiatric illness and psychological problems (CS vs CT): 1) Perceived Stress Scale: 12.NS. 2) SF-36 General Health Perceptions Index: 84.4 ± 9.3 vs 91.0 ± 8.5, t = 1.42, p=NS. Cog

alertness noon: 75.88 ± 4.62 vs 88.34 ± 4.69, p=0.08; evening: 74.32 ± 3.96 vs 83.04 ± 4.29, p45.65 ± 3.87, p=0.74. 2) Energy evening: 72.17 ± 4.26 vs 84.08 ± 5.21; p=0.098; night: 51.40 ± Concentration noon: 69.96 ± 6.67 vs 83.17 ± 5.42, p=0.15; evening: 70.20 ± 5.53 vs 81.67 ± 5.

mean ± SE) noon: 77.43 ± 3.83 vs 86.99 ± 3.75, p=0.10; evening: 77.02 ± 4.30 vs 86.16 ± 3.43

83.25 ± 3.95, p=0.17. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Lichstein, KL / 2001 Moderate (5/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol Over 58 yrs 58 (CS) primary 23 (CS) secondary 35 (CT) 24 (CS) primary 23 (CS) secondary 23 (CT) NS 189 total 82 (CS) primary 46 (CS) secondary 61 (CT) NS 

Co-Morbidity:

Among secondary insomnia: Depression (n = 13), Anxiety (n = 8), Chronic pain (n = 10), Prostadisorders (n = 5), Respiratory disease (n = 3). Associated Factors: 

SignificantPsychiatric illness and psychological problems: (primary insomnia vs secondary insomnia 

reported anxiety (State-Trait Anxiety Inventory -Form Y Trait Scale (STAI): 33.6 ± 7.7 (p<0.00129.8 ± 7.1; 2) Depression (Geriatric Depression Scale (GDS): 5.4 ± 4.3 (p<0.001) vs 11.6 ± 7.9 

of life: 1) Mental health (SF-36 Mental health subscale: 80.7 ± 14.0 vs 56.0 ± 21.0 (p<0.001) v

functioning (SF-36 Physical functioning subscale: 78.1 ± 18.5 vs 52.4 ± 24.3 (p<0.001) vs 77.7 Non-significant Age: 68.1 ± 7.0 vs 68.4 ± 6.4 vs 71.4 ± 6. Socioeconomic status: Education years (primary in

± 2.2). Gender: 70%; 95%CI: 60-80 vs 57%; 95%CI: 36-64 vs 57%; 95%CI: 45-69; all reported 
C-18

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Linzmayer, L / 2002 Low (1/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 22-63 yrs 51.1%, 93/182 (CS) 52.2%, 131/251 (CT) 48.9%, 89/182 (CS) 47.8%, 120/251 (CT) NS 433 total 182 (CS), 251 (CT) NS 

Co-Morbidity:

Group A: nonorganic insomnia (psychophysiological insomnia in ICSD’ primary insomnia in DSGroup B: bipolar affective disorder (N = 16 CS, 32 CT). Group C: depressive episode (N = 13 depressive disorder (N = 31 CS, 31 CT). Group E: dysthymia (N = 30 CS, 30 CT). Group F: ge

41 CS, 41 CT). Group G: mixed anxiety and depressive disorder (N = 16 CS, 27 CT). Group H

CS, 32 CT). Associated Factors:

Significant Cognitive function: Intelligence (IQ): Group A: 100-112, Group B: 100-118, Group C: 100-118

100-112, Group F: 100-118, Group G: 100-107, Group H: 100-112). IQ not ascertained in contvalues found in Groups B, C and F. Memory: 1) Visual Memory: differed significantly (>2 points

dependent expected values only for Group F. 2) Numerical Memory (GVG): Group B (5.6 ± 1.7 

(4.9 ± 1.4 vs 6.4 ± 1.7, p ≤ 0.01), Group D (5.3 ± 1.5 vs 6.2 ± 1.8, p ≤ 0.05). 3) Total Verbal Me

vs 27.8 ± 6.4, p ≤ 0.05), Group D (25.3 ± 7.6 vs 28.7 ± 6.7, p ≤ 0.05). Mood: 1) Thymopsychic 

SD): Drive: Group C (70.8 ± 22.3 vs 34.7 ± 27.0, p ≤ 0.01), Group D (51.4 ± 24.9 vs 24.4 ± 19.921.5 vs 23.9 ± 20.9, p ≤ 0.01) 2) Mood (VAS): Group C (35.9 ± 18.1 vs 69.4 ± 25.1, p ≤ 0.01) G

19.1, p ≤ 0.01), Group E (47.8 ± 18.0 vs 66.7 ± 22.7, p ≤ 0.01). 3) Affectivity (VAS): Group C (4

0.01), Group D (57.9 ± 19.6 vs 83.5 ± 14.0, p ≤ 0.001), Group E (60.1 ± 14.9 vs 81.9 ± 18.8, p 77.8 ± 22.9, p ≤ 0.01). 4) Wakefulness (VAS): Group A (48.7 ± 21.0 vs 31.0 ± 21.9, p ≤ 0.05), G

26.7, p ≤ 0.01), Group D (54.3 ± 30.0 vs 22.2 ± 19.9, p ≤ 0.01), Group E (55.9 ± 28.4 vs 28.4 ± 

30.2 vs 29.0 ± 25.8, p ≤ 0.05), Group H (43.1 ± 26.9 vs 25.2 ± 25.0, p ≤ 0.05). 5) Well-being (B

8.3, p ≤ 0.01), Group C (32.5 ± 13.6 vs 12.6 ± 10.4, p ≤ 0.01), Group D (29.1 ± 11.6 vs 9.9 ± 8.

10.5 vs 13.6 ± 10.5, p ≤ 0.01), Group G (20.5 ± 12.0 vs 13.0 ± 12.1, p ≤ 0.01), Group H (19.1 ± 

State Anxiety: Group B (49.3 ± 13.9 vs 35.7 ± 7.1, p ≤ 0.01), Group C (54.3 ± 13.8 vs 37.0 ± 9.12.1 vs 33.6 ± 5.8, p ≤ 0.01), Group E (45.5 ± 9.9 vs 38.9 ± 8.7, p ≤ 0.05), Group G (45.1 ± 8.4 

Anxiety: Group B (58.5 ± 6.7 vs 34.6 ± 9.2, p ≤ 0.01), Group C (53.5 ± 11.2 vs 38.6 ± 12.3, p ≤ 

34.7 ± 8.2, p ≤ 0.01), Group E (50.4 ± 9.0 vs 39.9 ± 12.0, p ≤ 0.01), Group G (49.6 ± 8.0 vs 37.

Non-significant Cognitive function: 1) Intelligence (IQ): Daytime Nonpsychic performance (cases vs controls, 

Memory: Group A: (8.7 ± 1.9 vs 9.9 ± 2.1, p ≤ 0.10), Group B: (8.8 ± 1.5 vs 8.8 ± 2.5, p=NS), G

p=NS), Group D: (7.9 ± 2.4 vs 8.5 ± 2.6, p=NS), Group E: 8.3 ± 2.2 vs 8.4 ± 2.6, p=NS), Group p=NS), Group G: 7.6 ± 2.7 vs 8.5 2.5, p ≤0.10), Group H: (8.1 ± 1.3 vs 8.0 ± 2.6, p=NS). 3) Ass

(Gruenberger Verbal Memory): Memory Test: Group A (14.9 ± 2.7 vs 16.2 ± 3.2, p ≤ 0.10), Grop=NS), Group C (11.9 ± 3.8 vs 13.2 ± 4.3, p=NS), Group D (12.1 ± 5.1 vs 14.1 ± 4.3, p=NS), Gp=NS), Group F (15.1 ± 3.6 vs 13.5 ± 4.3, p ≤ 0.10), Group G (11.9 ± 5.2 vs 14.1 ± 4.3, p ≤ 0.1

4.3, p=NS). 4) Numerical Memory (GVG): Group A (6.1 ± 2.2 vs 6.1 ± 1.9, p=NS), Group E (6.2 

Group F (6.0 ± 2.0 vs 6.1 ± 1.9, p=NS), Group G (6.2 ± 1.7 vs 6.4 ± 1.7, p=NS), Group H (5.8 ± Total Verbal Memory (GVG): Group A (29.8 ± 5.6 vs 32.8 ± 5.1, p ≤ 0.10), Group B (27.9 ± 4.3 

(27.4 ± 6.0 vs 28.5 ± 6.5, p=NS), Group F (30.1 ± 6.2 vs 28.3 ± 7.0, p=NS), Group G (25.7 ± 8.H (26.5 ± 6.0 vs 28.4 ± 6.9, p ≤ 0.10). Mood: 1)Thymopsychic Variables (cases vs controls, meA (43.9 ± 11.9 vs 35.0 ± 24.8, p ≤ 0.10), Group B (41.1 ± 31.5 vs 26.7 ± 21.2, p=NS), Group F p=NS), Group G (36.0 ± 25.7 vs 31.6 ± 26.3, p=NS), Group H (30.4 ± 19.5 vs 25.6 ± 24.4, p=N

(66.3 ± 17.0 vs 71.3 ± 18.5. p=NS), Group B (59.3 ± 29.3 vs 73.1 ± 21.0, p=NS), Group F (69.1 Group G (73.5 ± 10.8 vs 71.6 ± 24.5, p=NS), Group H (71.3 ± 20.5 vs 67.3 ± 26.2, p=NS). 3) A

23.0 vs 76.1 ± 19.1, p ≤ 0.10), Group B (64.3 ± 27.2 vs 78.8 ± 18.4, p ≤ 0.10), Group F (77.8 ± Group H (77.7 ± 15.4 vs 77.1 ± 22.7, p=NS). 4) Wakefulness (VAS): Group B (46.4 ± 34.8 vs 2

(41.5 ± 28.5 vs 29.6 ± 25.7, p ≤ 0.10). 5) Well-being (Bf): Group A (13.7 ± 5.8 vs 11.1 ± 9.2, p ≤ 

13.4 ± 11.2, p=NS). 6) State Anxiety: Group A (33.4 ± 7.2 vs 37.2 ± 7.1, p ≤ 0.10), Group F (40

Group H (42.0 ± 13.1 vs 36.0 ± 7.9, p ≤ 0.10). 6) Trait Anxiety: Group A (32.5 ± 5.8 vs 36.9 ± 1

vs 37.9 ± 10.2, p ≤ 0.10), Group H (42.9 ± 9.4 vs 39.3 ± 12.5, p ≤ 0.10). 
C-19

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Lundh, LG / 1997 Moderate (5/9) 

Study Design: Age Groupmean ± SD:GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 20-65 yrs 46.5 ± 11.3 (CS) 45.5 ± 11.1 (CT) 16 (CS) 16 (CT) 4 (CS) 4 (CT) NS 40 total 20 (CS), 20 (CT) NS 

Associated Factors: 

Significant Psychiatric illness and psychological problems: (CS vs CT; mean scores): 1) Depression (

scores; 8.5 vs 3.7; p<0.01). Memory and cognitive function: 1) Verbal ability (WAIS-R vocab

p<0.05). 2) Cued recall (Emotional Stroop test scores: 0.37 vs 0.47; p<0.005). 

Non-significant Psychiatric illness and psychological problems: (CS vs CT; mean scores): Spielberger Travs 35.4; p=NS. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Martikainen, K / 2003 Moderate (5/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 41-55 yrs 57.8%, 362/626 42.2%, 264/626 NS 1190 52.6%, 626/1190 

Prevalence: 

Three-month prevalence: 14% (88/626) 95%CI: 11.3-16%. Male: 9.8% (26/264) 95%CI: 6.2-1

95%CI: 13.1-20.8%. Associated Factors: 

Significant (CS vs CT) Age: (> 55 yrs): p<0.01. Psychiatric illness and psychological problems: 1) Depression: ad

p=0.023. 2) Nervousness and tension: adj OR: 3.05; 95%CI: 1.66-5.63; p<0.001. Medical con

2.24; 95%CI: 1.22-4.12; p<0.001, 2) Hypertension: adj OR: 2.05; 95%CI: 1.10-3.82; p=0.026. 3heart failure): 14 vs 4%, p=<0.001. 4) Allergic rhinitis: 18.6%; p=0.006. Socio-economic statu

95%CI: 1.82-20.5; p<0.001; Unemployed: 83.9 vs 91.7%; p=0.019. Healthcare utilization: Hop=0.003 Other factors: 1) Moving house: adj OR: 0.19; 95%CI: 0.04-0.83; p=0.003. 2) Insomn

8 vs 17.1%; p=0.032; 3) Insomniacs less caffeine/day (mean cups coffee): 4.16 vs 4.76; p=0.0

Non-significant Other factors: Marital status, BMI, Exercise, Snoring, Alcohol consumption all reported p=NS. 

conditions (Angina, myocardial or brain infarction) p=NS 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Mendelson, WB / 1984 Moderate (4/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 22-44 yrs 9 (CS), 9 (CT) 1 (CS), 1 (CT) NS 20 total 10 (CS), 10 (CT) NS 

Associated Factors:

SignificantPsychiatric illness and psychological problems: (CS vs CT; mean scores ± SD): 1) Depres

62.0 ± 9.3 vs 49.0 ± 6.5; p<0.009). 2) Social introversion (MMPI Social introversion scale: 56.3 

Memory and cognitive function: (CS vs CT; number of responses ± SD): 1) Long-term sema

time of day) (11 am: 10.4 ± 3.3 vs 12.9 ± 3.6. 2 pm: 11.3 ± 3.9 vs 13.8 ± 2.7. 5 pm: 10.6 ± 3.6 v

13.9 ± 3.3). Non-significant Psychiatric illness and psychological problems: (CS vs CT; mean scores ± SD): MMPI subPT, SC, MA all p=NS. Psychomotor functioning: On 12 tasks no significant differences. CogVigilance, Learning and Memory no significant difference. 
C-20

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Millar, A / 2004 High (6/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 26-68 yrs (CS) 27-67 yrs (CT) 11 (CS), 11 (CT) 8 (CS), 8 (CT) NS 51 total 32 (CS), 19 (CT) Follow-up rate: 59.3%, 19/32 (CS) NS (CT) 

Prevalence: 

Percentage of reported longstanding sleep disturbances (Sleep History Questionnaire): Cases

(4/19) (95%CI: 2.7-39.3). No data by gender.

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Niemcewicz, S / 2001 Low (2/9) 

Study Design: Age Groupmean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Case-control 21-55 yrs 40.8 ± 11.3 56%, 9/16 (CS) 56%, 9/16 (CT) 44%, 7/16 (CS) 44%, 7/16 (CT) NS 32 total 16 (CS), 16 (CT) 100% 

Associated Factors:

SignificantPsychiatric illness and psychological problems: (MMPI scale, CS vs CT, mean ± SD): 1) H

49.00 ± 6.65, t = -2.489, df = 30, p = 0.019). 2) Depression (57.31 ± 10.44 vs 45.53 ± 7.79, t = 

Hysteria (58.62 ± 8.77 vs 50.50 ± 6.34, t = -3.001, df = 30, p = 0.005). 4) Psychasthenia (51.18 2.999, df = 30, p = 0.005). 5) Hamilton score (6.4 ± 2.4 vs 0.5 ± 1.0, U = 2.5, p<0.001). 6) Beck = 42.5, p = 0.001). 6) Hyperarousal score (65.0 ± 7.54 vs 55.12 ± 8.74, U = 49.0, p = 0.003). Memory: (CS vs CT, mean ± SD: 1) (Selective Reminding Test) # of presentations needed to m

vs 6.56 ± 2.25, U = 68.5, p=0.02). 2) Reaction time (514.60 ± 69.24 msec vs 577.44 ± 78.25 mNon-significant Memory: 1) False target detections (Continuous Attention Test) (2.81 ± 3.10 vs 2.16 ± 4.19, U

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Ohayon, MM / 2003 High (7/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional Over 15 yrs 52.1% 7771/14,915 47.9% 7144/14,915 NS 18,972 78.6%, 14,915/18,972 

Prevalence: 

Point prevalence: (ChI > 6 mo): 17.6% (2625/14,915), 95%CI: 16.9-18.21. Male: 13.5% (965/

Female: 22.3% (1733/7771), 95%CI: 21.38-23.22. (Insomnia ≥ month): 18.4% (2744/14,915), 9

Associated Factors: 

Significant Psychiatric illness and psychological problems: 1) Previous psychiatry hx: adj OR: 5.8; 95%Non-significant None reported 
C-21

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Ohayon, MM / 2002A High (8/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional Over 15 yrs 51.8%, 2055/3470 48.2%, 1916/3470 NS 4442 89.4%, 3970/4442 

Prevalence: 

One-year prevalence (Insomnia symptoms): 27.6% (1096/3970) (95%CI: 26.2-28.9). Male: 24

26.4). Female: 30.5% (627/2055) (95%CI: 28.5-32.4). (Insomnia disorder diagnoses): 7% (278

4.2% (80/1916) (95%CI: 3.3-5.1). Female: 9.2% (189/2055) (95%CI: 8.0-10.4). 

Associated Factors: 

SignificantGender (DSM-IV insomnia diagnoses): 1) Gender: OR: 9.2; 95%CI: 8.0-10.4; p<0.001. 

Non-significant Healthcare utilization: (95%CI not reported) 1) Use of sleep-enhancing medication (Having onHaving two insomnia symptoms: OR: 3.4; Having three or four insomnia symptoms: OR: 2.9. O

sleep dissatisfaction) Marital status, BMI, MSK disease, heart disease, hypertension, snoring, d

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Ohayon, MM / 2002B High (8/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional Over 18 yrs 51.8%, 509/982 48.2%, 473/982 NS 1256 78.2%, 982/1256 

Prevalence: 

Point prevalence: Insomnia disorder diagnoses: 11.7% (115/982). No prevalence data by gen

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Ohayon, MM / 2002C High (8/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 15-90 yrs 50.5%, 1877/3719 49.5%, 1842/3719 NS 4067 91.4%, 3719/4067 

Prevalence: 

Point prevalence: 5% (186/3719) (95%CI: 4.3, 5.7). 

Associated Factors: 

Significant Age: Elderly (>65yr) 8.2% (26/314) vs other age groups (4.2 to 5%), p<0.05. Non-significant Gender: Male 4.7% (87/1842) vs Female 5.1% (96/1877), OR = 0.92 (0.68, 1.24). 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FACT

Ohayon, MM / 2001A High (7/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 19-24 yrs 50.5%, 731/1447 49.5%, 716/1447 NS 1447 NS 

Co-Morbidity:

Psychiatric illness and psychological problems: 12.6% (182/1447) had ICDS dyssomnia or with a mental disorder. Prevalence: 

Point prevalence: 8.1% (117/1447) (95%CI: 7.4, 8.8). 
C-22

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Ohayon, MM / 2001B High (8/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional Over 15 yrs 51%, 12665/24600 49%, 11936/24600 NS 24,600 total (France=5622, UK=4972, Germany=4115, Italy=3970, Portugal=1856) 81.0% overall (Germany=68.1, all others over 80%) 

Prevalence: 

Point prevalence: 6.1% (1,501/24,600) (95%CI: 5.8, 6.4). 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Ohayon, MM / 2001C High (8/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size: 

Response Rate: 

Cross-sectional Over 15 yrs 52.1%, 6791/13,057 47.9%, 6266/13,057 NS 16,738 78%, 13,057/16,738 

Prevalence: 

No prevalence estimates for DSM-IV insomnia disorder overall. Data for each insomnia symsleep: 13.11% (1712/13,057) 95%CI: 12.6-13.6%, 2) Disrupted sleep: 21.3% (2792/13,057) morning awakenings: 13.1% (1712/13,057) 95%CI: 12.6-13.6%, 4) Nonrestorative sleep: 1415% (data extracted from graphs). No prevalence data by gender. Associated Factors:

SignificantFor difficulties initiating sleep: Gender: 1) Female (adj OR: 1.4; 95%CI: 1.2-1.6; p<0.001

Physical illness (adj OR: 1.9; 95%CI: 1.7-2.2; p<0.001). Psychiatric illness and psycholog

disorder (adj OR: 3.5; 95%CI: 3.1-4.1; p<0.001). Quality of life: Satisfaction with life (adj OR

For disrupted sleep: Gender: 1) Female (adj OR: 1.3; 95%CI: 1.2-1.5; p<0.001). Psychiat

factors: 1) Mental disorder (adj OR: 3.0; 95%CI: 2.6-3.4; p<0.001). Quality of life: Satisfac95%CI: 0.2-0.7; p<0.01). For early morning awakening: Gender: 1) Female (adj OR: 1.3; 95%CI: 1.1-1.4; p<0.001)

Physical illness (adj OR: 1.6; 95%CI: 1.4-1.8; p<0.001). For nonrestorative sleep: Gender: 1) Female (adj OR: 1.3; 95%CI: 1.1-1.4; p<0.001). Med

illness (adj OR: 1.9; 95%CI: 1.6-2.2; p<0.001). Psychiatric illness and psychological fact

3.6; 95%CI: 3.2-4.2; p<0.001). Quality of life: Satisfaction with life (adj OR: 0.4; 95%CI: 0.2

Non-significant None reported 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Ohayon, MM / 2000 High (7/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 19 - 24 yrs 50.8%, 1102/2169 49.2%, 1067/2169 NS 2169 NS 

Co-Morbidity:

Psychiatric disorders: 1) adjustment disorders (20, 0.9%, 95%CI: 0.5-1.3), 2) anxiety disorde2a) panic disorder (37, 1.7%, 95%CI: 1.2-2.2), 2b) generalized anxiety (24, 1.1%, 95%CI: 0.compulsive disorder (11, 0.5%, 95%CI: 0.2-0.8), 2d) posttraumatic stress disorder (30, 1.4%

phobia (20, 0.9%, 95%CI: 0.5-1.3), 2f) specific phobia (46, 2.1%, 95%CI: 1.5-2.7), 2g) agora0.7), 3) depressive disorders (52, 2.4%, 95%CI: 1.8-3.0). Prevalence: 

Point prevalence: 5.4% (117/2169), 95%CI: 4.5, 6.4. 
C-23

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Ohayon, MM / 1999 Moderate (5/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size: 

Response Rate: 

Cross-sectional Over 15 yrs 55.5%, 6555/11,810 44.5%, 5255/11,810 NS 11,810 NS 

Prevalence: 

Point prevalence: (Complaint of insomnia symptoms accompanied with sleep dissatisfactio

15.3--16.7. No prevalence data by gender. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Ohayon, MM / 1997 High (8/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional Over 15 yrs 52.1%, 2929/5622 47.9%, 2693/5622 NS 6966 80.7%, 5622/6966 

Prevalence: 

Point prevalence: (Insomnia complaints lasting for at least 1 month): 15.3% (860/5622) (95

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Pallesen, S / 2002 High (7/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size: 

Response Rate: 

Cross-sectional casecontrol 60-84 yrs (CS) 63-83 yrs (CT) - Gs 60-86 yrs (CT) - Com 49 (CS), 32 (CT) - Gs 41 (CT) - Com 11 (CS), 9 (CT) - Gs 19 (CT) - Com NS 187 total 60 (CS), 41 (CT) - Gs, 60 (CT) - Com NS (CS), NS (CT) - Gs, 82.6% (CT) - Com 

Associated Factors: 

SignificantPsychiatric illness and psychological problems: (CS vs GS vs CT; mean ± SD): 1) Sleep Index scale: 23.1 ± 4.8 vs 10.1 ± 2.7 vs 14.6 ± 6.0; F(1,96) = 237.6), 2) Somatization (Symp

vs GS: 0.78 ± 0.59 vs 0.32 ± 0.28 F(1, 97) = 20.3), 3) Obsessive-compulsive traits (Symptom 

GS: 0.95 ± 0.80 vs 0.44 ± 0.31; F(1, 95) = 14.0), 4) Interpersonal sensitivity (Symptom Chec

0.56 ± 0.58 vs 0.25 ± 0.28; F(1, 97) = 9.4), 5) Depression (Symptom Checklist 90-Revised: C0.26; F(1, 95) = 14.7), 6) Anxiety (Symptom Checklist 90-Revised: CS vs GS): 0.46 ± 0.47 v7) Hostility (Symptom Checklist 90-Revised: CS vs GS): 0.32 ± 0.33 vs 0.11 ± 0.16; F(1, 96) (Symptom Checklist 90-Revised: CS vs GS): 0.17 ± 0.27 vs 0.03 ± 0.07; F(1, 97) = 10.4). 9) (GSI CS vs GS: 0.61 ± 0.39 vs 0.23 ± 0.15; F(1, 92) = 31.0; Positive Symptom Distress IndeF(1, 92) = 39.6; Positive Symptom Total: 31.4 ± 16.8 vs 16.6 ± 9.6; F(1, 99) = 25.8; PSWQ: 92) = 18.8, TAS-20: 49.8 ± 9.4 vs 42.6 ± 8.8; F(1, 91) = 14.2) 10) Difficulties identifying feeliGS: 15.2 ± 5.8 vs 11.4 ± 4.3; F (1, 93) = 11.7). Socioeconomic status: Education: CS vs G

controls (p=0.26). Non-significant Age: CS vs GS (p=0.48) vs CT (p=0.23). Gender: CS vs GS (p=0.65) vs community contro

and psychological problems: (CS vs GS vs CT; mean ± SD): 1) Paranoid ideation: 0.35 ± 0.41; F=NS; 2) Psychoticism: 0.21 ± 0.27 vs 0.09 ± 0.14 vs 0.19 ± 0.26; p=NS; 3) Difficulty d11.8 ± 3.7 vs 12.6 ± 3.9; p=NS; 4) Externally oriented thinking: 21.2 ± 4.1 vs 19.3 ± 4.7 vs 2

3.5 ± 3.36 vs 3.1 ± 1.7 vs 4.55 ± 4.21; p=NS; 6) Subjective impact Life events: 8.52 ± 9.44 v

p=NS. 
C-24

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Pavlova, M / 2001 Moderate (4/9) 

Study Design: Age Groupmean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 45.9 ± 14 yrs (CS) 44.6 ± 15 yrs (CT) NS NS NS 532 total 256 (CS), 139 (CT) NS 

Associated Factors: 

SignificantPsychiatric illness and psychological problems: (CS vs CT; mean scores for scales/subIntrospectiveness (Introspectiveness score from the Hyperarousal scale): 40.5 ± 0.3 vs 37.1 

cognitive function: (CS vs CT) 1) Hyperarousal (Hyperarousal scale mean total score ± SD

39.9-42.3) vs 32.6 ± 7.3 (95%CI: 31.4-33.8); p<0.0001). 2) Reaction type (Median React sco± range: 4.5 (6-23) vs 2 (0-12). Non-significant None reported 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Perlis, ML / 2001 Moderate (5/9) 

Study Design: Age Groupmean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 30.6 ± 8.9 yrs (CS) 32.3 ± 11.5 yrs (CT) 3 (CS), 2 (CT) 2 (CS), 2 (CT) NS 9 total 5 (CS), 4 (CT) NS 

Associated Factors: 

SignificantMemory: (CT vs CS, mean ± SD): 1) First trial: 46.2 ± 12.6 vs 75.8 ± 12.7, p=0.01. Non-significant Memory: (CT vs CS, mean ± SD): 1) number of words encoded (43 ± 20.0 vs 49 ± 18.3, p=

positive %) (8.9 ± 7.2 vs 20 ± 19.1, p=0.27), 3) free recall (all trials, %) (4.6 ± 3.2 vs 9.8 ± 10trials (%) (45.2 ± 11.8 vs 68.6 ± 19.9, p=0.08), Second trial (42.0 ± 17.6 vs 58.0 ± 38.1, p=0

59.7 ± 25.5, p=0.38), Fourth trial (51.6 ± 8.6 vs 59.3 ± 29.9, p=0.69), 5) Recognition speed (vs 2137 ± 761, p=0.29), 6) Recognition speed (false-positive, msec) (3358 ± 510 vs 2664 ± (false/true-positive) (1.259 ± 0.20 vs 1.261 ± 0.17, p = 0.99). 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Riedel, BW / 2004 High (6/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 20-98 yrs 50.7%, 390/769 49.3%, 379/769 53.6%, 536/769 (White) 28.6%, 220/769 (Black) 0.7%, 6/769 (Asian) 10.8%, 7/769 (NS) 1769 43.4%, 769/1769 

Prevalence: 

Point prevalence: 32.1% (247/769) (95%CI: 28.8-35.3). No prevalence data by gender. Associated Factors:

Significant (3 groups: Nonsmokers, Light smokers (<15/day) Heavier smoker (≥15/day).

Race/ethnicity: (non-smoker vs <15/day vs ≥15/day) p<0.01. Psychiatric illness and psyc

Depression (Beck depression inventory OR: 2.03, 95%CI: 1.45-2.83), 2) Anxiety (Trait Anxie

3.21-22.28; p<0.05). Other factors: 1) Heavy smoking among females (OR: 2.31; p<0.05), 

95%CI: 1.17-6.49; p<0.05). Medical conditions: 1) Physical health problems (Cancer OR: 2

2) High blood pressure (OR: 1.53, 95%CI: 1.11-2.69; p<0.05), 3) Breathing problems (OR: 34) Gastrointestinal problems (OR: 2.00, 95%CI: 1.22-3.28; p<0.05). Non-significant None reported 
C-25

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Robbins, L / 1995 Moderate (4/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Retrospective crosssectional 18-60 yrs 79.6%, 393/494 20.4%, 101/494 NS 494 100% 

Co-Morbidity:

Migraines. Prevalence: 

Sleep onset insomnia: 27% (133/494), 95%CI: 23.1-30.9. Difficulty maintaining sleep insom22.1-29.9. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Rocha, FL / 2002A High (7/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size: 

Response Rate: 

Cross-sectional Over 60 yrs 61.1%, 926/1516 38.9%, 590/1516 NS 1742 87%, 1516/1742 

Prevalence: 

One-month prevalence: (Insomnia): 38.9% (590/1516), 95%CI: 34.6-41.3. Male: 28.8% (17Female: 45.3% (419/916), 95%CI: 42.0-48.5. Associated Factors: 

SignificantGender: 1) Female (adj OR: 1.78; 95%CI: 1.41-2.24). Medical condition: 1) Self-rated reas

1.50-2.72) and very bad health (adj OR: 3.12; 95%CI: 2.21-4.39), 2) History of previous medcondition (adj OR: 1.38; 95%CI: 1.10-1.73), 3) Inability to perform routine activities due to a weeks (adj OR: 1.54; 95%CI: 1.10-2.15). Other factors: 1) Staying in bed in the last 2 week

2.48), 2) Dissatisfaction with free time arrangements (adj OR: 1.88; 95%CI: 1.28-2.77). Hea

sleeping pills: OR: 1.74 (95%CI: 1.38-2.21). Social Relationships: Social support UnsatisfiNon-significant Age: 60-69yr: 60.9 vs 59.2%, OR 1; 70-79yr: 29.1 vs 30.6% OR 0.92; 95%CI: 0.73-1.16); ≥8

95%CI: 0.68-1.37. Social Relationships: 1) Married/live together vs single: OR 1.05; 95%CIndifferent OR 0.95; 95%CI: 0.62-1.43. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Rocha, FL / 2002B High (7/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional Over 18 yrs 55.7%, 594/1066 44.3%, 472/1066 53.6%, 572/1066 (White) 2.4%, 26/1066 (Black) 43.8%, 467/1066 (Other) 0.2%, 1/1066 (Unknown) 1221 87.3%, 1066/1221 

Prevalence: 

One-month prevalence: 35.4% (377/1066), 95%CI: 32.5-38.3. Male: 20.7% (98/472), 95%

(279/594), 95%CI: 42.9-50.9. Associated Factors:

SignificantSocioeconomic status: 1) Low education: (1-3 years): males adj OR: 2.2; 95%CI: 1.1-4.1; 

1.1-3.0; no years of education: females adj OR: 2.6; 95%CI: 1.3-5.1. Age: 1) Age group ove

95%CI: 1.1-3.3. Healthcare utilization: 1) Use of sleeping pills in the previous 30 days: OR

Non-significant Race/Ethnicity: white vs other: p=0.751. Relationships: Religion: p=0.35 
C-26

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Roth, T / 1999 Moderate (3/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 18-65 yrs NS NS 86%, 860/1000 (White) 8%, 80/1000 (Black) 3%, 30/1000 (Hispanic) 3%, 30/1000 (Other) 1950 51.2%, 1000/1950 

Associated Factors:

Significant Memory and cognitive function: 1) Impaired concentration (ChI vs non-insomnia); "little troDifficulties remembering things; "very often or sometimes": 53% vs 29%; p=0.0). Social relationships: 1) Ability to enjoy relationships; "good or excellent": 64% vs 89%; p=0

spouse; "good or excellent": 70% vs 81%; p=0.01. Medical condition 1) Self-perceived healt

86%; p=0.01. Psychiatric illness and psychological problems: Ability to handle minor irri

vs 81%; p = 0.0). Non-significant Accidents: (Had an automobile accident due to being tired; ChI vs non-insomnia): 5% vs 2% vs non-insomnia; "good or excellent": 70% vs 96%; p = NS). Psychiatric illness and psych

perceived mental health; "good or excellent": 67% vs 90%; p=NS). 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Sabbatini, M / 2002 Moderate (3/8) 

Study Design: Age Group mean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 61.0 ± 14.4 yrs 44.5%, 309/694 55.5%, 385/694 NS 694 NS 

Co-Morbidity: 

Medically Ill (Renal disorders). Prevalence: 

Point prevalence: 45% (311/694), 95%CI: 41.3-48.7. Male: 40.5% (156/385), 95%CI: 35.6-

95%CI: 44.5-55.6. Associated Factors:

SignificantPsychiatric illness and psychological problems: (insomnia vs non-insomnia): 1) Anxiety Medical conditions: 1) Longer time on dialysis (13-48 months adj OR: 1.7; 95%CI: 1.1-2.8; 1.8; 95%CI: 1.2-2.8; p=0.006; ≥ 85 months adj OR: 1.7; 95%CI: 1.2-2.7; p=0.01), 2) Having 

1.6; 95%CI: 1.2-2.2; p=0.003), 3) High levels of parathyroid hormone (> 149 pg/ml) (adj OR

Pruritus (% insomnia vs non-insomnia; 19.9% vs 13.1%; p<0.04). Non-significant Other factors: BMI, Blood pressure, Smoking, Alcohol, Caffeine intake all p=NS 
C-27

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Saletu-Zyhlarz, G / 1997 Low (1/9) 

Study Design: Age Group: mean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 24-65 yrs 43.2 ± 11.7 yrs (CS) 43.0 ± 11.7 yrs (CT) 56.8%, 25/44 (CS) 54.5%, 24/44 (CT) 43.2%, 19/44 (CS) 45.5%, 20/44 (CT) NS 88 total 44 (CS), 44 (CT) 100%, 44/44 (CS) 77.3%, 34/44 (CT) 

Co-Morbidity: 

Cases: all CS have generalized anxiety disorder (GAD). Controls: normal. 

Associated Factors: 

Significant Psychiatric illness and psychological problems: Mood: (CS vs CT, median, mean ± SD)

(18, 19 ± 12 vs 7, 11 ± 10, p<0.01), 2) Morning well-being score (16, 18 ± 12 vs 7, 11 ± 10, 26 vs 37, 38 ± 25, p<0.05), 4) Mood (mm) (63, 62 ± 18 vs 74, 75 ± 17, p<0.01), 5) Drowsine26, p<0.01). Cognitive function: (psychometry) (cases vs controls, median, mean ± SD): 1

37 ± 11 vs 52, 49 ± 9, p , 0.01), 2) Fine-motor activity, left (27, 28 ± 9 vs 41, 40 ± 11, p<0.01left (65, 66 ± 18 vs 91, 86 ± 17, p , 0.01), 4) Reaction time (mean score ) (534, 545 ± 108 vs Non-significant Psychiatric illness and psychological problems: Mood: Affectivity (mm) (68, 63 ± 23 vs 7

function: (psychometry) (CS vs CT, median, mean ± SD): 1) Attention score (522, 536 ± 14Concentration (% errors) (3, 4 ± 3 vs 3, 5 ± 5, p=NS), 3) Attention variability score (15, 16 ± Numerical memory (6, 6 ± 2 vs 6, 6 ± 2, p=NS 5) Reaction time, variability (mean score) (10p=NS), 6) Reaction time, errors of omission (n) (1, 2 ± 2 vs 1, 3 ± 3, p=NS), 7) Reaction time

vs 0, 0 ± 1, p=NS). 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Savard, J / 2001 Moderate (4/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 28-90 yrs 339 0 All White (Caucasian) 339 88%, 300/339 

Co-Morbidity: 

Medically ill (Metastatic breast cancer). Prevalence: 

Point prevalence: (Insomnia symptoms): 51.3% (154/300) (95%CI: 45.7-56.9); (Insomnia s(95%CI: 14.6-23.4); (Chronic Insomnia syndrome): 17.6% (53/300) (95%CI: 13.3-21.9). Associated Factors:

SignificantFor insomnia symptoms: Medical conditions: 1) Cancer stage at diagnosis (I-III) (OR: 0.4

2) Lumpectomy (OR: 5.2; 95%CI: 1.5-18.1; p<0.01), 3) Chemotherapy (OR: 4.3; 95%CI: 1.7

Relationships: 1) Widowhood (OR: 4.7; 95%CI: 1.5-15.2; p<0.01). Other factors: 1) Antec

(OR: 0.18; 95%CI: 0.06-0.52; p<0.01). For insomnia syndrome: Socioeconomic factors: Socioeconomic status: 1) University 

15.0; p<0.05). Social Relationships: Separated/divorced (OR: 4.2; 95%CI: 1.4-13.1; p<0.0

95%CI: 0.01-0.64; p<0.05). Direct and indirect costs: 1) Sick leave: (OR: 14.1; 95%CI: 1.1-173.8; p<0.05), 2) Unemplo

13.6; p<0.05). Non-significant None reported 
C-28

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Schneider-Helmert, D / 1987 High (7/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size: 

Response Rate: 

Cross-sectional casecontrol 32-61 yrs (CS) 28-61 yrs (CT) 9 (CS), 9 (CT) 7 (CS), 7 (CT) NS 32 total 16 (CS), 16 (CT) NS 

Associated Factors: 

SignificantPsychiatric illness and psychological problems: (CS vs CT; mean scores ± SD): 1) Pers

Hypochondriasis: 62.3 ± 9.5 vs 48.1 ± 7.2,; p<0.00001; Depression: 64.0 ± 12.7 vs 45.9 ± 77.6 vs 52.7 ± 9.2, 0.0001; Psychopatic deviate: 62.9 ± 9.2 vs 49.2 ± 7.4, p<0.0001; Paranoiap<0.01; Psychasthenia: 47.3 ± 8.2 vs 62.0 ± 9.6, p<0.0001; Schizophrenia: 60.6 ± 11.0 vs 4strength: 44.4 ± 12.5 vs 56.5 ± 5.1, p<0.001; Impulsivity: 52.8 ± 8.8 vs 45.6 ± 5.6, p<0.01; CAnxiety: 57.3 ± 11.6 vs 45.2 ± 9.9, 0.005; Internalization: 55.2 ± 10.1 vs 48.8 ± 7.6, p<0.05. 

function: 7.9 vs 10.5, p<=0.001; 2) Line judgment all sessions p =0.01; 3) Line tracing (3 err

Non-significant Psychiatric illness and psychological problems: (CS vs CT; mean scores ± SD): 1) Scal

Scale K: 50.8 ± 8.3 vs 54.6 ±8.1; 3) Masculinity-femininity: 45.5 ± 10.3 vs 48.3 ± 11.0; 4) Hy12.3; 5) Social introversion: 56.9 ± 12.2 vs 52.3 ± 12.3. All p=NS. Cognitive function: (3 se

correct responses: Logical reasoning, Addition, Digit symbol substitution, Word detection, V

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Seidel, WF / 1984 High (6/9) 

Study Design: Age Groupmean ± SD: GenderFemale: Male: Ethnicity: Sample Size: 

Response Rate: 

Cross-sectional casecontrol 29 ± 5 yrs 23 (CS), 23 (CT) 15 (CS), 15 (CT) NS 76 total 38 (CS), 38 (CT) NS 

Associated Factors: 

SignificantLaboratory measures (CS vs CT; mean min. ± SD): 1) Objective total sleep time: 402.8 ± 50Subjective total sleep time: 352.2 ± 94.9 vs 441.2 ± 44.7, p<0.001. Non-significant Psychiatric illness and psychological problems: 1) Profile of mood state (POMS): Fatigu

Depression: 2.3 ± 3.6 vs 1.2 ± 1.9; Anger/hostility: 3.2 ± 5.9 vs 1.2 ± 2.2; Tension/anxiety:1.

6.5 vs 11.7 ± 7.8; Total mood disturbance: 5.2 ± 19.3 vs -5.9 ± 16.9; all p=NS. 2) MMPI scal

5.7; Scale F: 56.5 ± 8.7 vs 53.8 ± 10.2; Scale K: 54.3 ± 8.1 vs 56.5 ± 8.8; Hypochondriasis: 

Depression: 56.8 ± 9.8 vs 53.0 ± 8.1; Hysteria: 59.2 ± 7.2 vs 55.5 ± 8.5; Psychopathic devia

Paranoia: 61.1 ± 6.7 vs 57.7 ± 6.8; Psychasthenia: 59.9 ± 7.7 vs 55.1 ± 6.8; Schizophrenia: 

Hypomania: 65.2 ± 10.7 vs 61.6 ± 11.1. All p=NS. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Sharpley, AL / 1997 Moderate (5/9) 

Study Design: Age Group(mean, range) GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 54.7, 40-69 yrs (CS) 53.9, 40-68 yrs (CT) 50% (CS), 50% (CT) 50% (CS), 50% (CT) NS 40 total 20 (CS), 20 (CT) 100% in both groups 

Associated Factors: 

SignificantPsychiatric illness and psychological problems: (CS vs CT): 1) Past psychiatric disordeP<0.01; OR = 7.36, 95%CI: 1.34, 40.55, 2) Major depression 35% (7/20) vs 5% (1/20), p<0.

20% (4/20) vs 0, p<0.05,. Non-significant Psychiatric illness and psychological problems: (CS vs CT): 1) Panic disorder 5% (1/205% (1/20) vs 0, p=NS; 3) Past alcohol abuse 5% (1/20) vs 5% (1/20), p=NS; 4) Past drug de
C-29

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Shaver, JLF / 2002 High (6/9) 

Study Design: Age Group: mean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol PP-type: 46.7±3.3 yrs (CS) SO-type: 46.1±4.4 yrs (CS) 44.4±3.5 yrs (CT) 131 0 Cases: PP-type: White 76.2%, African American 9.5%, unknown 14.3%. Cases: SO-Type: White 72.2%, Asian/Pacific Islander 5.6%, African American 11.1%, Native American 5.6%, unknown 5.6%. Controls: White 92.9%, Asian/Pacific Islander 7.1% 101 (CS), 30 (CT) NS 

Associated Factors: 

Significant Psychiatric illness and psychological problems: Psychological Distress Scores (PP-type mean ± SD): 1) Somatization: 0.65 ± 0.61 vs 0.54 ± 0.47 vs 0.27 ± 0.31, p = 0.03; 2) Global 0.38 vs 0.28 ± 0.28, p = 0.04, 3) Positive symptom distress: 1.6 ± 0.40 vs 1.4 ± 0.20 vs 1.1 ± Non-significantPsychiatric illness and psychological problems: Stress Exposure (PP-type vs SO-type inDaily diary: the sum of items, how stressful: (a) felt today, (b) relationship with closest friend

= not at all to 6 = very much (2.4 ± 0.6 vs 2.4 ± 0.5 vs 2.2 ± 0.76, p=NS), 2) Daily hassles, DNumber (23.9 ± 15.1 vs 19.8 ± 13.9 vs 16.7 ± 15, p=NS), Severity (29.6 ± 26.2 vs 28 ± 22.4 Severity (1.1 ± 0.32 vs 0.89 ± 0.47 vs 0.95 ± 0.32, p=NS). 3) Stressful life events, Stressful Positive (4.8 ± 3.1 vs 4.6 ± 3.4 vs 6.2 ± 3.2, p=NS), Negative: (5.3 ± 3.9 vs 5.2 ± 4.8 vs 4.8 ± 

events, Inventory of Small Life Events: Positive (27.9 ± 10 vs 27.6 ± 8.9 vs 30.2 ± 7.9, p=NS± 7.3 vs 12.1 ± 6.0, p=NS). Psychological Distress Scores 1) Obsessive compulsive (0.78 ± 0.59, p = 0.24), 2) Interpersonal sensitivity (0.67 ± 0.64 vs 0.46 ± 0.43 vs 0.42 ± 0.54, p = 0.

vs 0.69 ± 0.63 vs 0.42 ± 0.37, p = 0.26), 4) Anxiety (0.47 ± 0.76 vs 0.39 ± 0.39 vs 0.16 ± 0.20.67 vs 0.32 ± 0.43 vs 0.27 ± 0.32, p = 0.98), 6) Psychoticism (0.31 ± 0.63 vs 0.25 ± 0.29 vs Phobic anxiety (0.21 ± 0.58 vs 0.12 ± 0.20 vs 0.06 ± 0.13, p = 0.52), 8) Paranoid ideation (0± 0.32, p = 0.85), 9) Positive symptom total (31.7 ± 20.8 vs 30.1 ± 17.7 vs 19.1 ± 16.7, p = 0PP-type = psychophysiologic type insomnia; SO-type = subjective only type insomnia; 
C-30

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Shochat, T / 1999 Low (1/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size: 

Response Rate: 

Cross-sectional 18-87 yrs 58%, 166/286 42%, 120/286 White 52%, Asian 28%, African-American 2.8%, Hispanic 4.5%, Other 12.2% 286 NS 

Prevalence: 

Point prevalence: 19% (54/286) (95%CI: 14.5, 23.5). 

Associated Factors: 

SignificantFor all factors (GS vs occasional insomniac vs ChI). Psychiatric illness and psychologica

mood Excellent p<0.0010 (25.3% (22/88) vs 11.3% (16/141) vs 11.3% (6/54)) Good (62.1% 49.1% (27/54) Fair (10.3% (9/88) vs 24.8% (35/141) vs 35.8% (19/54) Poor (1.1% (1/88) vs Ability to handle minor irritations p = 0.0060 Excellent (15.9% (14/88) vs 9.3% (13/141) vs 1(51/88) vs 43.6% (61/141) vs 45.3% (24/54)) Fair (21.6% (19/88) vs 36.4% (51/141) vs 30.210.7% (15/141) vs 13.2% (7/54). Cognitive function: 1) Ability to concentrate p = 0.0010 E

(13/141) vs 13.2% (7/54) Good (68.2% (60/88) vs 57.9% (82/141) vs 52.8% (29/54) Fair (11vs 30.2% (16/54) Poor (1.1% (1/88) vs 2.1% (3/141) vs 3.8% (2/54). Memory: 1) Having tro

Very often (4.5% (4/88) vs 9.3% (13/141) vs 11.1% (6/54) Sometimes (34.1% (30/88) vs 43Not very often (45.5% (40/88) vs 37.9% (53/141) vs 20.4% (11/54) Never (13.6% (12/88) vs Social relationships: 1) Personal relationship with spouse p = 0.0030 Excellent (44.9% (40

23.8% (13/54) Good (38.5% (34/88) vs 43.2% (61/141) vs 40.5% (22/54) Fair (14.1% (12/88(15/54) Poor (2.6% (2/88) vs 11.9% (17/141) vs 7.1% (4/54). 2) Ability to enjoy family/social (26/88) vs 16.3% (23/141) vs 17.0% (9/54)) Good 48.9% (43/88) vs 48.2% (68/141) vs 35.8vs 27.7% (39/141) vs 34.0% (18/54)) Poor (4.8% (4/88) vs 7.8% (11/141) vs 13.2% (7/54). Q

of life p = 0.0060 Excellent (18.2% (16/88) vs 10.7% (15/141) vs 9.6% (5/54)) Good (67.0% 51.9% (28/54)) fair (11.4% (10/88) vs 25.7% (36/141) vs 34.6% (19/54)) Poor (2.3% (2/88) vWork performance: 1) Ability to accomplish things during the day p<0.0010 Excellent (29.511.3% (6/54)) Good (59.1% (52/88) vs 53.6% (75/141) vs 56.6% (31/54)) Fair (6.8% (6/88) v(12/54)) Poor (3.4% (3/88) vs 3.6% (5/141) vs 7.5% (4/54)). Non-significant None reported 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Sugerman, JL / 1985 High (6/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 21-55 yrs 6 (CS)-objective 6 (CS)-subjective, 6 (CT) 2 (CS)-objective 2 (CS)-subjective, 2 (CT) NS 24 total 16 (CS), 8 (CT) NS 

Associated Factors:

Significant Memory and cognitive function: (Objective vs Subjective insomnia vs CT): 1) Waking func

number of misses: 7.73 vs 29.95 vs 6.68, p<0.05). Non-significant None reported 
C-31

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Taylor, DJ / 2003 High (6/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional 20-98 yrs 50.6%, 391/772 49.4%, 381/772 Caucasians 69.8% (539/772), African Americans 28.9% (223/772), Asian 0.9% (7/772), Hispanic 0.1% (1/772) 1769 49%, 859/1,769 

Prevalence: 

Prevalence parameters: 19.6% (151/772), 95%CI: 16.8, 22.4. Associated Factors: 

SignificantAge: (no insomnia vs insomnia, mean ± SD): 50.41 ± 19.1 vs 61.49 ± 19.68, F = 35.73, p<0

insomnia, % female): 45.3 (174/384) vs 60.0 (90/150), p<0.01, OR = 0.55 (0.38, 0.81. Medic

vs % insomnia): 1) Heart 9.1 (35/384) vs 23.3 (35/150), F = 19.15, p<0.001, OR = 0.32 (0.20vs 9.3 (14/150), F = 5.43, p<0.05, OR = 0.42 (0.20, 0.89), 3) HTN 18.2 (70/384) vs 44 (66/10.28 (0.19, 0.43), 4) Neurological 1.3 (5/384), vs 7.3 (11/150), F = 13.50, p<0.001, OR = 0.1

(22/384) vs 24.7 (37/150), F = 39.36, p<0.001, OR = 0.19 (0.11, 0.33), 6) Urinary 9.6 (37/38Race/Ethnicity: (no insomnia vs insomnia, % African American): 25 (96/384) vs 28 (42/150

F== 7.154, p<0.01, OR = 0.49 (0.28, 0.83), 7) Diabetes 3.6 (14/384) vs 12.7 (19/150), F = 10.54), 8) Pain 19 (73/384) vs 48 (72/150), F = 45.83, p<0.001, OR = 0.25 (0.17, 0.38), 9) Ga32.7 (49/150), F = 43.77, p<0.001, OR = 0.21 (0.13, 0.35). Healthcare Utilization: 1) Numb

3.44 ± 2.79, F = 68.20, p<0.001.2) Psychiatric Conditions: Beck Depression Inventory 5.72 ± adjusted for ethnicity and gender: 6.63 ± 7.19 vs 12.42 ± 6.79, p<0.001, adjusted for neurolocigarette use, OR = 8.96 (3.97, 20.19, p<0.001, reference group people with insomnia). Psy9.33 vs 42.26 ± 11.70, p<0.001. Non-significant Race/Ethnicity: (no insomnia vs insomnia, % African American): 25 (96/384) vs 28 (42/150

Other factors: Alcohol (drinks/wk): 2.74 ±5.19 vs 2.0 ± 4.93, p=NS; Caffeine drinks/day: 2.3

Smoking and BMI p=NS. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Terzano, MG / 2004 Moderate (4/8) 

Study Design:

Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional > 18 yrs 60.9% 39.1% NS 3284 NS 

Co-morbidity: 

Medically ill: [1) Cardiovascular (1149; 35%), 2) MSK and connective (921; 28%), 3) Diges

nutritional, metabolic, immunity (556, 16.9%), 5) Brain, nervous system and sense organs (414%), 7) Genitourinary (362, 11%), 8) Infectious and parasitic (74, 2.3%), 9) Other (1008, 30Prevalence: 

Point prevalence (Sleep difficulties ≥ one month): 63.7% (2093/3284) (95%CI: 62-65). Mal

56.9-62.2). Female: 66.3% (1327/2000) (95%CI: 64.2-68.3). 

Associated Factors: 

Significant Age: Older (adj OR: 1.02; 95%CI: 1.02-1.03). Gender: 1) Female (adj OR: 1.19; 95%CI: 1.0

and psychological problems: 1) Depression (adj OR: 2.70; 95%CI: 2.31-3.15). Medical coorgan system (adj OR: 1.24; 95%CI: 1.06-1.48). Socioeconomic status: 1) < junior high (a

Healthcare utilization: 1) Use of prescribed drugs (OR: 2.26; 95%CI: 1.95-2.62), 2) > 1 hos

1.11-2.32), 3) > 1 GP home visit (OR: 2.31; 95%CI: 1.30-4.09), 4) > 1 GP office visit (OR: 1.

call to a GP (OR: 1.48; 95%CI: 1.27-1.73), 6) > 1 laboratory test (OR: 1.43; 95%CI: 1.23-1.61.81; 95%CI: 1.56-2.09). Quality of life: 1) SF-36 mean scores ± SD); No insomnia vs Leveextracted from graphs): Physical functioning (90.01 vs 81.11 vs 79.34), Role limitations physBodily pain (74.4 vs 69.8 vs 61.8), Health perception (69.8 vs 61.6 vs 55.9), Energy/fatigue functioning (81.4 vs 78.1 vs 64.0), Role limitations emotional (83.9 vs 78.5 vs 56.7), Mental Work Performance: Direct and indirect costs: 1) > 1 sick leave day (OR: 1.54; 95%CI: 1.17

patients). Non-significant Other factors: BMI, Smoking, and Caffeine intake p=NS.
C-32

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Vgontzas, AN / 1995 Low (2/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 18-86 yrs (CS) 16-80 yrs (CT) 50.1%, 188/375 (CS) 58.7%, 88/150 (CT) 49.9%, 187/375 (CS) 41.3%, 62/150 (CT) NS 525 total 375 (CS), 150 (CT) NS 

Co-Morbidity: 

Psychiatric illness in cases recruited from the sleep clinic: 98.3% (172/175) had at least one 

secondary disorder: 1) depression 58.3% (102/175): 1a) major depression 10.3% (18/175), 1c) other minor depression (atypical depression) 10.9% (19/175), 1d) bipolar disorder 5.7% Associated Factors:

Non-Significant Medical conditions: (CS vs CT) 1) sleep apnea 2.3% 8/375) vs 1.3% (2/150), OR = 1.61 (0activity 13.9% (52/375) vs 14.7% (22/150), OR = 0.94 (0.55, 1.61), 3) nocturnal myoclonus/n11.5% (43/375) vs 8.5% (11/150), OR = 1.63 (0.82, 3.27). 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Vignola, A / 2000 Moderate (5/9) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol Over 55 yrs 10-ChI/BNZ (CS) 11-drug-free ChI (CS) 9 (CT) 10-ChI/BNZ (CS) 9-drug-free ChI (CS) 11 (CT) NS 60 total 20 – ChI/BNZ (CS), 20 drug-free ChI (CS), 20 (CT) NS 

Associated Factors:

SignificantPsychiatric illness and psychological problems: (drug-free ChI vs insomnia using benzo

1) Depression (Beck Depression Inventory): 9.00 ± 4.48 vs 9.40 ± 7.16 vs 1.75 ± 1.6, p<0.0Inventory): 9.10 ± 8.38 vs 8.60 ± 5.4 vs 1.20 ± 1.47, p<0.01. 3) Global security (Brief sympto

± 0.42 vs 0.13 ± 0.15, p<0.01. 4) Subjective measures related to neuropsychological performVAS for Energy): 49.80 ± 19.35 vs 46.10 ± 23.23 vs 24.25 ± 12.23, p<0.01. VAS for Mood: 3vs 15.75 ± 9.94, p<0.01. VAS for Tiredness: 51.50 ± 20.77 vs 47.70 ± 17.14 vs 21.55 ± 11.1Stress/Tension: 38.50 ± 18.70 vs 39.60 ± 17.90 vs 16.85 ± 8.77, p<0.01. VAS for Motivationvs 84.80 ± 15.7, p<0.05. Memory and cognitive function: 1) Attention and concentration (33.60 ± 27.23 vs 41.80 ± 28.89 vs 63.95 ± 25.64, p< 0.01; Digit Span Backward (percentiles21.43 vs 65.45 ± 23.32, p<0.05. 2) Subjective measures related to neuropsychological perfoVAS for alertness: 44.20 ± 22.52 (p<0.01) vs 37.55 ± 22.72 (p<0.05) vs 21.55 ± 13.01, VAS 57.85 ± 17.22 (p<0.01) vs 73.55 ± 16.98 vs 83.90 ± 12.78, VAS for Performance: 61.40 ± 13(p<0.05) vs 71.07 ± 13.56).Non-significant Memory and cognitive function: 1) Mini-mental state: 29.1 ± 1.12 vs 28.75 ± 1.25 vs 28.8

3.84 vs 12.0 ± 3.09 vs 13.3 ± 2.36. 3) Information: 10.15 ± 3.51 vs 10.0 ± 3.01 vs 11.5 ± 3.4

visual and verbal memory, p>0.19; psychomotor speed, p> 0.23; and executive functions, p
C-33

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Vincent, NK / 2000 Moderate (4/9) 

Study Design: Age Groupmean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 46.91±10.04 yrs (CS) 39.6 ±11.49 yrs (CT) 72%,23/32 (CS), NS(CT) 28%, 9/32 (CS), NS (CT) 30/32 Caucasian (CS) 58 total 32 (CS), 26 (CT) NS 

Co-Morbidity: 

Cases: 39% (12/32) had at least one secondary co-morbidity: generalized anxiety disorder (

hypochondriasis (3%), obsessive-compulsive disorder (3%), and major depression (3%). Co

Associated Factors: 

SignificantPsychiatric illness and psychological problems: Perfectionism variables (CS vs CT, mea

action: 10.38 ± 3.59 vs 7.46 ± 2.47, t = 3.52, p = 0.001; 2) Parental criticism: 9.44 ± 4.49 vs 3) Concern over mistake: 20.97 ± 7.29 vs 16.11 ± 5.38, t = 2.83, p = 0.007; 4) Socially presc13.92, t = 2.35, p = 0.02. Non-significant 1) Personal standards: 21.94 ± 4.87 vs 20.42 ± 5.08, t = 1.16, p = 0.25; 2) Parental expectat3.74, t = 0.76, p = 0.45. 3) Self-oriented; 64.24 ± 18.23 vs 58.38 ± 14.51;T = 1.34, P=0.36; 4vs 54.23 ± 13.08, t = 0.17, p = 0.86. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Wang, W / 2001 Moderate (4/9) 

Study Design: Age Groupmean ± SD: GenderFemale: Male: Ethnicity: Sample Size:

Response Rate: 

Cross-sectional casecontrol 30.2 ± 7.0 yrs (CS) 27.2 ± 5.0 yrs (CT) 12 (CS), 19 (CT) 11 (CS), 9 (CT) NS 51 total 23 (CS), 28 (CT) 100%, 23/23 (CS) 89.2%, 25/28 (CT) 

Associated Factors: 

SignificantPsychiatric illness and psychological problems: (CS vs CT; mean ± SD): 1) Thrill and ad

(Zuckerman's sensation seeking scales): 4.0 ± 2.4 vs 6.4 ± 2.5; p<0.05; 2) Impulsivity (Zuck

questionnaire): 4.0 ± 1.9 vs 2.7 ± 1.6; p<0.05; 3) Neuroticism-anxiety (Zuckerman-Kuhlman'

± 4.6 vs 7.3 ± 2.8; p<0.05). Non-significant Psychiatric illness and psychological problems: Zuckerman's sensation seeking scales 

Experience seeking: 3.1 ± 1.7 vs 4.0 ± 1.9; 2) Disinhibition: 2.9 ± 2.1 vs 2.8 ± 1.8; 3) Boredo

± 1.5. 4) Impulsive sensation seeking (Zuckerman-Kuhlman's personality questionnaire): 8.8 sensation seeking: 4.8 ± 2.3 vs 5.5 ± 2.1; 6) Aggression-hostility: 7.8 ± 3.7 vs 6.3 ± 2.7; 7) A

Sociability: 7.3 ± 3.8 vs 7.3 ± 2.4. All p=NS. 

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Yeo, BKL / 1996 Moderate (3/8) 

Study Design: Age Group: GenderFemale: Male: Ethnicity: Sample Size: 

Response Rate: 

Cross-sectional 15-55 yrs 50%, 1209/2418 50%, 1209/2418 All Asian (Chinese and Malays) 2418 NR 

Prevalence: 

One-year prevalence: 15.3% (370/2418) (95%CI: 13.8-16.73). Male: 12.9% (159/1209) (95

17.5% (211/1209) (95%CI: 15.36-19.64). Associated Factors: 

SignificantGender: 1) Female (OR: 1.39; 95%CI: 1.11- 1.74; p<0.01). Race/ethnicity: 1) Malay vs Ch

1.75; p<0.05). Psychiatric illness and psychological problems: 1) Moderate to severe st

2.58; p<0.001), 2) Phobic disorder (Insomnia vs Non insomnia; 20.5% vs 13.6%; p<0.001), 7.0%; p<0.001), 4) Anxiety disorder (6.5% vs 13.5%; p<0.001). Non-significant Age: % Insomniacs (15-29 vs 30-49 vs 50+ ) 40.8 vs 46.85 vs 12.4%, p=NS. Psychiatric ill

problems: Source of stress – work and others (financial, travel etc) p=NS 
C-34

Evidence Table C-1: Prevalence, natural history, incidence and associated factors of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

STUDY DESIGN & POPULATION CHARACTERISTICS CO-MORBIDITY / PREVALENCE / NATURAL HISTORY / INCIDENCE / ASSOCIATED FA

Zammit, GK / 1999 Moderate (4/9) 

Study Design: Age Groupmean ± SD: GenderFemale: Male: Ethnicity: Sample Size: 

Response Rate: 

Cross-sectional casecontrol 44.1±14.04 yrs (CS) 37.1±12.7 yrs (CT) 157 (CS), 63 (CT) 104 (CS), 38 (CT) NR 362 total 261 (CS), 101 (CT) NR 

Associated Factors:

SignificantPsychiatric illness and psychological problems: 1) Depression (Zung Depression Scale

p<0.0001), 2) Anxiety (Zung Anxiety Scale: 1.96 ± 0.02 vs 1.4 ± 0.04; p<0.0001). Quality of 

quality of life (SF-36 overall: No scores provided. F-21.73; p<0.001). 2) Quality of life domai84.46 vs 62.80 (p<0.0001), General health: 84.00 vs 61.05 (p<0.0001), Mental health: 80.27 emotional: 85.98 vs 48.82 (p<0.0001), Role physical: 94.48 vs 56.28 (p<0.0001), Social func(p<0.0001), Vitality: 71.65 vs 41.13 (p<0.0001), Physical functioning: 93.31vs 77.82 (p<0.00watching TV (Quality of Life Inventory: 3.26 ± 0.15 vs 2.46 ± 0.24; p<0.006), 4) Hours readin0.17; p<0.03), 5) Hours of recreation per day (1.54 ± 0.11 vs 2.3 ± 0.18; p<0.0001). Memory 

vs CT; mean ± SD): 1) Cognitive functions (Medical Outcomes Study Cognitive scale sum s0.58; p<0.0001). Work variables: (CS vs CT): 1) Levels of optimism regarding career and f

Daily Activities Questionnaire: 3.17 ± 0.11 vs 3.90 ± 0.18; p<0.0001). 2) Average # days absvs 0.13 ± 0.22; p<0.001). Non-significant Memory and cognitive function: (Medical Outcomes Study Cognitive scale) Report no spe

significantly impaired. 
C-35

Evidence Table C-1: References 

 1. Ancoli-Israel S, Roth T. Characteristics of insomnia 

in the United States: results of the 1991 National 

Sleep Foundation Survey. Sleep 1999; 22(Suppl 

2):S347-53. 

 2. Bastien CH, Fortier-Brochu E, Rioux I et al. 

Cognitive performance and sleep quality in the 

elderly suffering from chronic insomnia. 

Relationship between objective and subjective 

measures. [erratum appears in J Psychosom Res. 

2003 Nov;55(5):475]. J Psychosom Res 2003; 

54(1):39-49. 

 3. Bixler EO, Kales A, Soldatos CR et al. Prevalence 

of sleep disorders in the Los Angeles metropolitan 

area. Am J Psychiatry 1979; 136(10):1257-62. 

 4. Bixler EO, Vgontzas AN, Lin HM et al. Insomnia in 

Central Pennsylvania. J Psychosom Res 2002; 

53(1):589-92. 

 5. Bliwise NG. Factors related to sleep quality in 

healthy elderly women. Psychol Aging 1992; 

7(1):83-8. 

 6. Bonnet MH, Arand DL. 24-Hour metabolic rate in 

insomniacs and matched normal sleepers. Sleep 

1995; 18(7):581-8. 

 7. Braga-Neto P, Da Silva FP, Monte FS et al. Snoring 

and excessive daytime sleepiness in Parkinson's 

Disease. J Neurol Sci 2004; 217(1):41-5. 

 8. Broman JE, Lundh LG, Aleman K et al. Subjective 

and objective performance in patients with 

persistent insomnia. Scand J Behav Ther 1992; 

21(3):115-26. 

 9. Broman JE, Lundh LG, Hetta J. Insufficient sleep in 

the general population. Neurophysiol Clin 1996; 

26(1):30-9. 

 10. Chambers MJ, Kim JY. The role of state-trait 

anxiety in insomnia and daytime restedness. Behav 

Med 1993; 19(1):42-6. 

 11. Coursey RD, Buchsbaum M, Frankel BL. 

Personality measures and evoked responses in 

chronic insomniacs. J Abnorm Psychol 1975; 

84(3):239-49. 

 12. Crenshaw MC, Edinger JD. Slow-wave sleep and 

waking cognitive performance among older adults 

with and without insomnia complaints. Physiol 

Behav 1999; 66(3):485-92. 

 13. Dorsey CM, Bootzin RR. Subjective and 

psychophysiologic insomnia: an exmaination of 

sleep tendency and personality. Biol Psychiatry 

1997; 41(2):209-16. 

 14. Edinger JD, Glenn DM, Bastian LA et al. Slowwave sleep and waking cognitive performance II: 

findings among middle-aged adults with and 

without insomnia complaints. Physiol Behav 2000; 

70(1-2):127-34. 

 15. Edinger JD, Fins AI, Glenn DM et al. Insomnia and 

the eye of the beholder: are there clinical markers of 

objective sleep disturbances among adults with and 

without insomnia complaints? J Consult Clin 

Psychol 2000; 68(4):586-93. 

 16. Fichtenberg NL, Zafonte RD. Putnam S et al. 

Insomnia in a post-acute brain injury sample. Brain 

Inj 2002; 16(3):197-206. 

 17. Hajak G, SINE Study Group, Study of Insomnia in 

Europe. Epidemiology of severe insomnia and its 

consequences in Germany. Eur Arch Psychiatry 

Clin Neurosci 2001; 251(2):49-56. 

 18. Han SY, Yoon JW, Jo SK et al. Insomnia in 

diabetic hemodialysis patients: Prevalence and risk 

factors by a multicenter study. Nephron 2002; 

92(1):127-32. 

 19. Harvey AG, Greenall E. Catastrophic worry in 

primary insomnia. J Behav Ther Exp Psychiatry 

2003; 34(1):11-23. 

 20. Hauri PJ. Cognitive deficits in insomnia patients. 

Acta Neurol Belg 1997; 97(2):113-7. 

 21. Healey ES, Kales A, Monroe LJ et al. Onset of 

insomnia: role of life-stress events. Psychosom Med 

1981; 43(5):439-51. 

 22. Hetta J, Broman JE, Mallon L. Evaluation of severe 

insomnia in the general population--implications for 

the management of insomnia: insomnia, quality of 

life and healthcare consumption in Sweden. J 

Psychopharmacol 1999; 13(4 Suppl 1):S35-6. 

 23. Hidalgo MP, Caumo W. Sleep disturbances 

associated with minor psychiatric disorders in 

medical students. Neurol Sci 2002; 23(1):35-9. 

 24. Hohagen F, Kappler C, Schramm E et al. Sleep 

onset insomnia, sleep maintaining insomnia and 

insomnia with early morning awakening--temporal 

stability of subtypes in a longitudinal study on 

general practice attenders. Sleep 1994; 17(6):551-4. 
C-36

 25. Hohagen F, Kappler C, Schramm E et al. 

Prevalence of insomnia in elderly general practice 

attenders and the current treatment modalities. Acta 

Psychiatr Scand 1994; 90(2):102-8. 

 26. Hohagen F, Rink K, Kaeppler C et al. Prevalence 

and treatment of insomnia in general practice: A 

longitudinal study. Eur Arch Psychiatry Clin 

Neurosci 1993; 242(6):329-36. 

 27. Ishigooka J, Suzuki M, Isawa S et al. 

Epidemiological study on sleep habits and insomnia 

of new outpatients visiting general hospitals in 

Japan. Psychiatry Clin Neurosci 1999; 53(4):515-

22. 

 28. Kageyama T, Kabuto M, Nitta H et al. A population 

study on risk factors for insomnia among adult 

Japanese women: a possible effect of road traffic 

volume. Sleep 1997; 20(11):963-71. 

 29. Kageyama T, Nishikido N, Kobayashi T et al. 

Cross-sectional survey on risk factors for insomnia 

in Japanese female hospital nurses working rapidly 

rotating shift systems. J Hum Ergol 2001; 30(1-

2):149-54. 

 30. Kales A, Caldwell AB, Soldatos CR et al. 

Biopsychobehavioral correlates of insomnia. II. 

Pattern specificity and consistency with the 

Minnesota Multiphasic Personality Inventory. 

Psychosom Med 1983; 45(4):341-56. 

 31. Kales A, Bixler EO , Soldatos CR. et al. 

Biopsychobehavioral correlates of insomnia: I. Role 

of sleep apnea and nocturnal myoclonus. 

Psychosomat J Consult Liais Psychiatry 1982; 

23(6):589-600. 

 32. Kales JD, Kales A, Bixler EO et al. 

Biopsychobehavioral correlates of insomnia, V: 

Clinical characteristics and behavioral correlates. 

Am J Psychiatry 1984; 141(11):1371-6. 

 33. Kappler C, Hohagen F. Psychosocial aspects of 

insomnia: Results of a study in general practice. Eur 

Arch Psychiatry Clin Neurosci 2003; 253(1):49-52. 

 34. Kawada T, Yosiaki S, Yasuo K et al. Population 

study on the prevalence of insomnia and insomniarelated factors among Japanese women. Sleep Med 

2003; 4(6):563-7. 

 35. Leger D, Guilleminault C, Dreyfus JP et al. 

Prevalence of insomnia in a survey of 12,778 adults 

in France. J Sleep Res 2000; 9(1):35-42. 

 36. Leppavuori A, Pohjasvaara T, Vataja R et al. 

Insomnia in ischemic stroke patients. Cerebrovasc 

Dis 2002; 14(2):90-7. 

 37. Levitt H, Wood A, Moul DE et al. A pilot study of 

subjective daytime alertness and mood in primary 

insomnia participants using ecological momentary 

assessment. [References]. Behav Sleep Med 2004; 

2(2):113-31. 

 38. Lichstein KL, Durrence HH, Bayen UJ et al. 

Primary versus secondary insomnia in older adults: 

subjective sleep and daytime functioning. Psychol 

Aging 2001; 16(2):264-71. 

 39. Linzmayer L, Arnold O, Saletu-Zyhlarz GM et al. 

Daytime noopsychic and thymopsychic 

dysfunctions in nonorganic insomnia related to 

different mental disorders. Somnologie 2002; 

6(4):141-8. 

 40. Lopes Rocha F , Guerra HL, Lima-Costa MFF. 

Prevalence of insomnia and associated sociodemographic factors in a Brazilian community: The 

Bambui study. Sleep Med 2002; 3(2):121-6. 

 41. Lundh L-G, Froeding A, Gyllenhammar L et al. 

Cognitive bias and memory performance in patients 

with persistent insomnia. Scand J Behav Ther 1997; 

26(1):27-35. 

 42. Martikainen K, Partinen M, Hasan J et al. The 

impact of somatic health problems on insomnia in 

middle age. Sleep Med 2003; 4(3):201-6. 

 43. Mendelson WB, Garnett D, Gillin JC et al. The 

experience of insomnia and daytime and nighttime 

functioning. Psychiatry Res 1984; 12(3):235-50. 

 44. Millar A, Espie CA, Scott J. The sleep of remitted 

bipolar outpatients: a controlled naturalistic study 

using actigraphy. J Affect Disord 2004; 80(2-

3):145-53. 

 45. Niemcewicz S, Szelenberger W. 

Psychophysiological correlates of primary 

insomnia. Arch Hellenic Med 2001; 18(1):64-8. 

 46. Ohayon MM. Prevalence of DSM-IV diagnostic 

criteria of insomnia: distinguishing insomnia related 

to mental disorders from sleep disorders. J Psychiatr 

Res 1997; 31(3):333-46. 

 47. Ohayon MM, Hong SC. Prevalence of insomnia and 

associated factors in South Korea. J Psychosom Res 

2002; 53(1):593-600. 

 48. Ohayon MM, Partinen M. Insomnia and global 

sleep dissatisfaction in Finland. J Sleep Res 2002; 

11(4):339-36. 
C-37

 49. Ohayon MM, Roberts RE. Comparability of sleep 

disorders diagnoses using DSM-IV and ICSD 

 classifications with adolescents. Sleep 2001; 

24(8):920-5. 

 50. Ohayon MM, Roberts RE, Zulley J et al. Prevalence 

and patterns of problematic sleep among older 

adolescents. J Am Acad Child Adolesc Psychiatry 

2000; 39(12):1549-56. 

 51. Ohayon MM, Roth T. Place of chronic insomnia in 

the course of depressive and anxiety disorders. J 

Psychiatric Res 2003; 37(1):9-15. 

 52. Ohayon MM, Roth T. What are the contributing 

factors for insomnia in the general population? J 

Psychosom Res 2001; 51(6):745-55. 

 53. Ohayon MM, Smirne S. Prevalence and 

consequences of insomnia disorders in the general 

population of Italy. Sleep Med 2002; 3(2):115-20. 

 54. Ohayon MM, Zulley J, Guilleminault C et al. How 

age and daytime activities are related to insomnia in 

the general population: consequences for older 

people. J Am Geriatr Soc 2001; 49(4):360-6. 

 55. Ohayon MM, Caulet M, Arbus L et al. Are 

prescribed medications effective in the treatment of 

insomnia complaints? J Psychosom Res 1999; 

47(4):359-68. 

 56. Pallesen S, Nordhus IH, Kvale G et al. 

Psychological characteristics of elderly insomniacs. 

Scand J Psychol 2002; 43(5):425-32. 

 57. Pavlova M, Berg O, Gleason R et al. Self-reported 

hyperarousal traits among insomnia patients. J 

Psychosom Res 2001; 51(2):435-41. 

 58. Perlis ML, Smith MT, Orff HJ et al. The mesograde 

amnesia of sleep may be attenuated in subjects with 

primary insomnia. Physiol Behav 2001; 74(1-2):71-

6. 

 59. Riedel BW, Durrence H, Lichstein KL et al. The 

relation between smoking and sleep: the influence 

of smoking level, health, and psychological 

variables. [References]. Behav Sleep Med 2004; 

2(1):63-78. 

 60. Robbins L. Anxiety, depression, and insomnia in 

migraine: A retrospective review of 494 patients. 

Headache Q 1995; 6(4):303-5. 

 61. Rocha FL, Uchoa E, Guerra HL et al. Prevalence of 

sleep complaints and associated factors in 

community-dwelling order people in Brazil: The 

 Bambui health and ageing study (BHAS). Sleep 

Med 2002; 3(3):231-8. 

 62. Roth T, Ancoli-Israel S. Daytime consequences and 

correlates of insomnia in the United States: Results 

of the 1991 National Sleep Foundation Survey. II. 

Sleep 1999; 22(Suppl 2):S354-8. 

 63. Sabbatini M, Minale B, Crispo A et al. Insomnia in 

maintenance haemodialysis patients. Nephrol Dial 

Transplant 2002; 17(5):852-6. 

 64. Saletu-Zhylarz G, Saletu B, Anderer P et al. 

Nonorganic insomnia in generalized anxiety 

disorder. Neuropsychobiol 1997; 36(3):117-29. 

 65. Savard J, Simard S, Blanchet J et al. Prevalence, 

clinical characteristics, and risk factors for insomnia 

in the context of breast cancer. Sleep 2001; 

24(5):583-90. 

 66. Schneider-Helmert D. Twenty-four-hour sleepwake function and personality patterns in chronic 

insomniacs and healthy controls. Sleep 1987; 

10(5):452-62. 

 67. Seidel WF, Ball S, Cohen S et al. Daytime alertness 

in relation to mood, performance, and nocturnal 

sleep in chronic insomniacs and noncomplaining 

sleepers. Sleep 1984; 7(3):230-8. 

 68. Sharpley AL, Attenburrow ME, Cowen PJ. 

Assessment and treatment of insomnia (including a 

case control study of patients with primary 

insomnia). Int J Psychiatry Clin Pract 1997; 

1(2):107-17. 

 69. Shaver JL, Johnston SK, Lentz MJ et al. Stress 

exposure, psychological distress, and physiological 

stress activation in midlife women with insomnia. 

Psychosom Med 2002; 64(5):793-802. 

 70. Shochat T, Umphress J, Israel AG et al. Insomnia in 

primary care patients. Sleep 1999; 22(Suppl 

2):S359-65. 

 71. Sugerman JL, Stern JA, Walsh JK. Daytime 

alertness in subjective and objective insomnia: some 

preliminary findings. Biol Psychiatry 1985; 

20(7):741-50. 

 72. Taylor DJ. A cross-sectional analysis of depression, 

anxiety, and insomnia [dissertation]. Memphis 

(TN): University of Memphis; 2003. 
C-38

 73. Terzano MG, Parrino L, Cirignotta F et al. Studio 

Morfeo: insomnia in primary care, a survey 

conducted on the Italian population. Sleep Med 

2004; 5(1):67-75. 

 74. Vgontzas AN, Kales A, Bixler EO et al. Usefulness 

of polysomnographic studies in the differential 

 diagnosis of insomnia. Int J Neurosci 1995; 82(1-

2):47-60. 

 75. Vignola A, Lamoureux C, Bastien CH et al. Effects 

of chronic insomnia and use of benzodiazepines on 

daytime performance in older adults. J Gerontol 

Series B Psychol Sci Soc Sci 2000; 55(1):P54-62. 

 76. Vincent NK, Walker JR. Perfectionism and chronic 

insomnia. J Psychosom Res 2000; 49(5):349-54. 

 77. Wang W, Zhu SZ, Pan LC et al. Mismatch 

negativity and personality traits in chronic primary 

insomniacs. Funct Neurol 2001; 16(1):3-10. 

 78. Yeo BK, Perera IS, Kok LP et al. Insomnia in the 

community. Singapore Med J 1996; 37(3):282-4. 

 79. Zammit GK, Weiner J, Damato N et al. Quality of 

life in people with insomnia. Sleep 1999; 22(Suppl 

2):S379-85. 
C-39
C-40

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults Abbreviations: CBT = cognitive behavioural therapy; CT = control; d = day; f = flunitrazepam; GOV = government; hr = hour; min. = minute; mg = milligrams; NA = not applicplacebo; q = quazepam; RCT = randomized controlled trial; RT = relaxation therapy; SD = standard deviation; Tr = treatment (drug): wk = week: wks = weeks; yr(s) = year(s). 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Aden, GC Moderate (2/5) 

Private (funds and materials) 

RCT Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

47 (NS) 23 – 59 29 / 21 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Allain, H / 2001 Moderate (3/5) 

Private RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

45.6 (9.6) - Tr 46.7 (11.5) - Pl 25 – 64 188 / 57 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 6.7 (8.0) – Tr 6.6 (7.3) – Pl NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Allain, H / 1998 High (4/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

54.3 (11.0) 32 – 84 67.9% / 32.1% 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 19.5% < 1 yr 80.5% > 1 yr NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Ascher, LM / 1979 Low (1/5) 

NS RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

39 (NS) 24 – 67 15 / 10 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 8 (NS) NS 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Asnis, GM / 1999 Moderate (3/5) 

Private RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

41.6 (1.2) Tr 41.6 (1.0) Pl 18 – 66 150 / 40 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

secondary various psychiatric conditions NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 
C-41

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued) 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Beary, MD / 1984 Moderate (3/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 23 – 35 6 / 0 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS 0.3 – 2 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Botter PA / 1983 High (4/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

Part 1: 44.3 (8) Tr 1mg 40.6 (7.7) Pl Part 2: 46.1 (7.2) Tr 2mg 44.8 (7.1) Pl NS 25 / 15 

Type: Co-morbidity: Duration (months)Mean (SD): Range: 

secondary anxiety neuroses Part 1: 1.3 (0.2) Tr 1mg 1.3 (0.2) Pl Part 2: 1.1 (0.2) Tr 2mg 1.1 (0.1) Pl NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Bowen, AJ / 1978 Moderate (3/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 18 – 60 13 / 5 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Brown, CC / 1979 High (4/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS NS 18 / 0 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Campbell, RD / 1987 High (4/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

38 (2) NS 25 / 31 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 
C-42

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Carr-Kaffashan, L / 1979 Moderate (2/5) 

NS RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

40.1 (NS) 18 – 76 18 / 12 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 11.48 (NS) NS 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Chaudoir, PJ / 1983 Moderate (3/5) 

Private (prepacked drugs) 

RCT Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

50 (NS) 35 – 65 18 / 7 

Type: Co-morbidity: Duration:Mean (SD): Range: 

primary NA 6 months – Tr1 9 months – Tr2 NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Choliz, M / 1995 Moderate (2/5) 

NS RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS NS NS / NS 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Cohn, JB / 1991 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 18 – 65 NS / NS 

Type: Co-morbidity: Duration: Mean (SD): Range: 

primary NA 3 months or more NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Cohn, JB / 1984 Moderate (3/5) 

Private RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

41.4 (10.2) 18 – 61 18 / 12 

Type: Co-morbidity: Duration:Mean (SD): Range: 

primary various medical and psychiatric conditions 6 months or more (all but 1 patient) NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 
C-43

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Cohn, JB / 1983 High (4/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

41.5 (NS) 18 – 60 38 / 15 

Type: Co-morbidity: DurationMean (SD): Range: 

secondary depression 1 month or more (all but 1 subject) NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Coxeter, PD / 2003 High (5/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

54 (15) 22 – 75 12 / 10 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Davies, R / 1986 Moderate (2/5) 

GOV RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

58.59 (10.98) 35 – 78 16 / 18 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Dawson, D / 1998 Moderate (2/5) 

Private (supported research) 

RCT Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

65.67 (1.68) NS NS / NS 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Declerk, A / 1999 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

54 (NS) NS 17 / 5 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Dominguez, RA / 1986 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

46.6 (NS) 21 – 65 46% / 54% 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 
C-44

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Dominguez, RA / 1985 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 20 – 60 NS / NS 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Donath, F / 2000 Moderate (2/5) 

Private RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

49 (NS) 22 – 55 12 / 4 

Type: Co-morbidity: Duration:Mean (SD): Range: 

primary NA 3 months to several yrs NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Drake, CL / 2000 High (4/5) 

Private RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

41.6 (9.5) study 1 38.1 (11.1) study 2 21-60 38 / 45 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 5.7 (7.2) study 1 9.9 (9.8) study 2 NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Dujardin, K / 1998 Moderate (3/5) 

Private RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 40 – 62 0 / 12 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Edinger, JD / 2003 Moderate (2/5) 

GOV RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

51.0 (13.7) NS 2 / 18 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary various medical conditions NS NS 

Type/Description: Frequency / Duration
C-45

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Edinger, JD / 2001 High (4/5) 

GOV RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

55.8 (12.1) CBT 54.5 (10.2) RT 55.7 (9.5) Pl 40-80 35 / 40 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 13.6 (NS) NS 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Elie, R / 1999 Moderate (3/5) 

Private RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

42.5 - 44.3 (12.0 - 12.9) Tr 42.1 (12.0) Pl 18–65 370 / 204 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Elie, R / 1990 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

76 (1.3) 60 – 90 33 / 11 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 7 >= 1 yr 17 > 10 yrs NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Ellis, CM / 1996 High (4/5) 

GOV RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

46 (11) 32 – 67 6 / 9 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 21.7 (13) 1-45 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Espie, CA / 1989 Moderate (2/5) 

NS RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

44.9 (15.3) NS 47 / 23 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 12.4 (12.2) NS 

Type/Description: Frequency / Duration
C-46

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Farag NH / 2003 High (4/5) 

Private RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

37 (13) 21 – 63 20 / 5 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Ferguson, JM / 1991 High (4/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

43.4 (10.9) 18 – 65 56% / 44% 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

secondary major depression NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Fillingim, JM / 1982 High (5/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

81 (NS) NS 89% / 11% 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 1 yr or more NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Fleming, J / 1995 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

33 – 37 (NS) 21 – 60 48% / 52% 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 7 – 10 (NS) NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Fry, J / 2000 Moderate (3/5) 

Private RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

40 - 43 (10 - 13) Tr 43 (12) Pl 18 – 65 342 / 244 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 
C-47

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Garfinkel, D / 1997 High (4/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

79 (5.2) 68 – 93 8 / 13 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary exhibiting various medical conditions NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Garfinkel, D / 1995 High (4/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

76 (8) 68 – 93 5 / 7 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Gelinas, B / 1985 High (4/5) 

Private RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

40.9 (2.19) 18 – 60 16 / 10 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Goethe, JW / 1982 Moderate (2/5) 

Private (provided materials & funding) 

RCT Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 19 – 60 50 / 19 

Type: Co-morbidity: Duration:Mean (SD): Range: 

primary NA 6 months or more (all but 3 patients) NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Goldenberg, F / 1994 High (4/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

42.5 (8.6) Tr 43.3 (9.2) Pl 25 – 60 291 / 167 

Type: Co-morbidity: Duration (months)Mean (SD): Range: 

primary NA 1.6 (0.8) Tr 1.7 (1.1) Pl NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 
C-48

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Haffmans, PMJ High (4/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

44 (NS) NS 3 / 4 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

secondary previous severe major depression NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Haimov, I / 1995 High (4/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

73.1 (3.9) independent living 81.1 (8.9) institutionalized NS 16 / 10 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Hajak, G / 2000 Moderate (3/5) 

Private (grantsupported) 

RCT Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

47.6 (11.3) Tr 47.4 (16.8) Pl NS 36 / 11 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 11.2 (9.7) NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Hajak, G / 1996 Moderate (3/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

41.3 (9.5) NS 3 / 7 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 10.7 (7.9) NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Hajak, G / 1994 High (5/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

51 (11) NS 939 / 566 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description, Do

Frequency / DurationTiming: Route of Delivery: 
C-49

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Hartmann, E / 1983 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

38 - 46 (NS) 39 (NS) Pl 18–71 48 / 48 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 13 (NS) NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Harvey, AG / 2003 Low (1/5) 

NS RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

21.1 (3.7) CBT 18.6 (5.1) CT NS 15 / 11 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary various psychiatric conditions (n=13) 6.4 (3.9) CBT 6.2 (5.8) CT NS 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Haynes, SN / 1977 Low (1/5) 

NS RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

29.3 (NS) NS 15 / 9 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 7.1 (NS) NS 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Haynes, SN / 1974 Low (1/5) 

Academic RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 18–21 5 / 9 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 5.3 (NS) NS 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Hedner, J / 2000 Moderate (3/5) 

Private RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

72.5 (5.9 – 6.8) Tr 72.5 (6.8) Pl 59 – 91 Tr 63 – 95 Pl 285 / 137 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 
C-50

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Heidrich, H / 1981 High (4/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

44.6 (2) Tr 46 (2) Pl 64 – 21 Tr 63 – 28 Pl 67% / 33% 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 2.5 (NS) NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Hernandez, RL / 1983 Moderate (3/5) 

Private RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 22 – 65 24 / 12 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Herrmann, WM / 1993 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 25 – 65 9 / 12 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Hughes, RC / 1978 Low (1/5) 

NS RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

34.2 (NS) NS 24 / 12 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Jacobson, AF / 1986 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

72 (NS) Tr 69 (NS) Pl 60 – 82 slightly more than half female NS / NS 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 16 (16.4) Tr 14.5 (11.9) Pl 1 – 65 Tr 1 – 40 Pl 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 
C-51

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

James, SP / 1990 Moderate (2/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

33.4 (NS) 20 – 57 6 / 4 

Type: Co-morbidity: Duration:Mean (SD): Range: 

primary NA > 6 months NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Krystal, AD / 2003 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

44 (11) 21 – 69 498 / 290 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Lacks, P / 1983 Moderate (2/5) 

Private (supported research) 

RCT Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

40.6 (NS) NS 48 / 16 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 13.8 (NS) NS 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Lacks, P / 1983 Moderate (2/5) 

GOV RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

43.0 (NS) 31 – 59 9 / 6 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 11.7 (NS) NS 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Lahmeyer, H / 1997 High (4/5) 

Private (grantsupported) 

RCT Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

44.9 (NS) 19 – 61 81 / 64 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Lamphere, JK / 1989 Moderate (2/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

36 (10) NS 3 / 9 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 
C-52

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Leppik, IE / 1997 Moderate (3/5) 

Private RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

69 (NS) 59 – 85 63% / 37% 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Lichstein, KL / 2001 Moderate (2/5) 

GOV RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

68.03 (7.04) 59 – 92 53 / 21 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 8.93 (11.54) 0.5-51 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Mamelak, M / 1989 Moderate (2/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 60 – 72 NS / NS 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Mamelak, M / 1987 High (4/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

50 (NS) 32 – 60 21 / 9 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

McAlpine, CJ / 1984 High (4/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 18 – 94 90 / 57 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 72 > 1 yr NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 
C-53

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Melo de Paula, A / 1984 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

28 – 31 (NS) 19 – 55 42 / 16 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 1.3 – 2.1 (NS) 0.2-10 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Mendels, J / 1983 Moderate (3/5) 

Private RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

47 (NS) Tr 45 (NS) Pl 20 – 58 Tr 22 – 60 Pl 19 / 41 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 36 < 10 yrs 24 > 10 yrs NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Milby, JB / 1993 Low (1/5) 

Private RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: Gender Female / Male: 

30.4 (5.68) women 35 (6.13) men NS 8 / 7 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Minnekeer, RJ / 1988 High (4/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

53.2 (14.5) Tr (q) 55.4 (12.5) Tr (f) 54.9 (13.7) Pl NS 130 / 74 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 30% > 5 yrs Tr (q) 32% > 5 yrs Tr (f) 34% > 5 yrs Pl NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 
C-54

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Mitchell, KR / 1979 Low (1/5) 

NS RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

37.4 (NS) 28 – 51 9 / 15 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 6.3 (NS) 2.1 – 8.1 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Mitler, MM / 1984 Moderate (3/5) 

Private (grantsupported) 

RCT Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

37.7 – 45.4 (NS) 27 – 61 17 / 4 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary or secondary personality disorder or sleep-related myoclonus NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Monchesky, TC / 1986 High (4/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

47.1 (1.7) Tr 46.6 (1.8) Pl NS 65 / 26 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary various medical conditions 7.0 (1.2) Tr 6.4 (0.8) Pl NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Montes, LGA / 2003 Moderate (3/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

50 (12.7) 30 – 72 4 / 6 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 12.8 (12.1) 0.5 – 32 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Monti JM / 2000 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

53.8 (1.8) Tr 50.0 (5.3) Pl 27 – 59 12 / 0 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 12.6 (4.9) Tr 17.7 (6.5) Pl NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 
C-55

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Monti, JM / 1996 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

41.2 (3.9) Tr 47.3 (5.7) Pl NS 10 / 2 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 9.5 (3.5) Tr 9.3 (4.7) Pl NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Morin, CM / 1999 Moderate (2/5) 

GOV RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

65 (7) 55 or older 50 / 28 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 16.8 (16.9) NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Nair, NPV / 1990 Moderate (3/5) 

Private (grantsupported) 

RCT Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

46.9 (1.4) 18 – 65 28 / 32 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 9.8 (1.2) NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Negri, L / 1997 Moderate (2/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

42.95 (13.22) 15 – 68 70 / 30 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

secondary anxiety alone + mild depressive symptoms NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Nicassio, P / 1974 Low (1/5) 

GOV RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

45.1 (14.57) 22 – 71 21 / 9 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Frequency / Duration
C-56

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Pasche, E / 1996 Low (1/5) 

Private RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

39.0 (0.7) 21 – 55 59 / 47 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: 

Frequency / Duratio

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Perlis, ML / 2004 Moderate (3/5) 

Private (primary investigatorinitiated project) 

RCT Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

41.3 (13.4) 25 – 60 70.4% / 29.6% 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: 

Dose (mg):

Frequency / DuratioTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Poyares, DR / 2002 Moderate (3/5) 

Academic RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

43.3 (10.6) NS 15 / 4 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: 

Dose (mg): Frequency / DuratioTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Reeves, RL / 1977 High (4/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

68.6 (NS) Tr (t) 69.6 (NS) Tr (f) 70.4 (NS) Pl NS 27 / 14 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: 

Dose (mg):

Frequency / DuratioTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Rickles, K / 1986 High (4/5) 

Private (grantsupported) 

RCT Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

46 (12) NS 63% / 37% 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 8.6 (9.2) NS 

Type/Description: 

Dose (mg):

Frequency / DuratioTiming: Route of Delivery: 
C-57

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Riemann, D / 2002 Moderate (3/5) 

Private RCT 

Double-blind Unclear 

Age (years)Mean (SD): Range: GenderFemale / Male: 

45.3 (10.3) Tr (l) 47.0 (10.8) Tr (t) 48.8 (11.6) Pl NS 23 / 32 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Rodenbeck, A Moderate (3/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

41.3 (9.5) NS 3 / 7 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 10.7 (7.9) NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Roehrs, T / 1999 Low (1/5) 

Unclear RCT 

Not reported as doubleblind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

34.1 (8.8) 21 – 55 5 / 6 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose: Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Roehrs, T / 1983 Moderate (3/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

33.3 (8.0) NS 8 / 4 

Type: Co-morbidity: Duration:Mean (SD): Range: 

primary NA > 6 months NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Roth, TG / 1997 Moderate (2/5 

Private RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

65.9 (4.6) NS 15 / 15 

Type: Co-morbidity: Duration:Mean (SD): Range: 

primary NA > 3 months NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 
C-58

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Roth, T / 1979 High (4/5) 

Private (provided drugs and funding) 

RCT Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 18 – 65 0 / 16 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

unclear unclear NS NS 

Type/Description: Dose (mg):

Frequency / DuratioTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Saletu-Zyhlarz, G / 2003 Moderate (2/5) 

Private (funded pharmacological part of study) 

RCT Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

58 (5) 46 – 67 49 / 0 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary related to postmenopausal syndrome NS NS 

Type/Description: Dose (mg): Frequency / DuratioTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Sanavio, E / 1990 Low (1/5) 

NS RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

39.6 (NS) 25 – 50 24 / 16 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 11.8 (NS) 5 - 25 

Type/Description: Frequency / Duratio

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Sastre-yHernandez, M / 1988 High (4/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 20 – 76 36 / 24 

Type: Co-morbidity: Duration:Mean (SD): Range: 

primary NA 53% > 1 yr 20% 3-12 months 27% < 3 months NS NS 

Type/Description: Dose (mg):

Frequency / DuratioTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Scharf, MB / 1994 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

38 (NS) 22 – 60 48 / 27 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DuratioTiming: Route of Delivery: 
C-59

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Scharf, MB / 1990 High (4/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

40.4 (13.5) Tr (e) 42.8 (13.9) Tr (f) 41.3 (13.0) Pl 21-65 NS / NS 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Shaw, SH / 1992 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

74.9 (1.0) Tr 10mg 72.9 (1.0) Tr 20mg 75.7 (0.8) Pl 65-85 81 / 38 

Type: Co-morbidity: Duration (months)Mean (SD): Range: 

secondary various psychiatric conditions 23 (4) Tr 10mg 2.9 (4.6) Tr 20mg 2.6 (4.9) Pl NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Shealy, RC / 1979 Low (1/5) 

NS RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

19.8 (NS) 17 – 30 70 / 0 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Stanton, HE / 1989 Low (1/5) 

NS RCT 

Not reported as doubleblind Parallel (with option to crossover after Tr) 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 23 – 67 26 / 19 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

unclear NS NS NS 

Type/Description: Frequency / Duration

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Steens, RD / 1993 Moderate (3/5) 

Private RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

58.2 (5.5) 35 – 69 9 / 15 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary mild to moderate chronic obstructive pulmonary disease 7.8 (6.9) 1 - 25 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 
C-60

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Stip, E / 1999 High (4/5) 

NS RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

42.6 (1.6) 20 – 64 21 / 29 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary or secondary mild non-psychotic disorders 10.1 (NS) Tr (z) 9.7 (NS) Tr (t) 12.4 (NS) Pl NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Tietz, EI / 1981 Moderate (3/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

41.2 (16.8) 18 – 60 0 / 15 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Tuk, B / 1997 Moderate (3/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 18 – 78 15 / 6 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Vallieres, A / 2004 Moderate (2/5) 

GOV RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

47.5 (7.92) 34 – 50 3 / 3 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 15.5 (9.2) NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Viukari, M / 1983 High (4/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

73.2 (2.9) group A 75.1 (1.5) group B NS 20 / 17 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary various medical and psychiatric conditions NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 
C-61

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

 Walsh, JK / 2002 Moderate (3/5) 

NS RCT 

Double-blind Parallel 

Age (years)

Mean (SD): Range: GenderFemale / Male: 

43.2 (1.2) Tr 45.0 (1.3) Pl NS 115 / 48 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DuratioTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Walsh, JK / 2000 Moderate (3/5) 

Private (data analysis) 

RCT Double-blind Crossover 

Age (years)

Mean (SD): Range: GenderFemale / Male: 

67.5 (NS) 60 – 79 17 / 31 

Type: Co-morbidity: Duration (years)

Mean (SD): Range:

primary NA NS NS 

Type/Description: 

Dose (mg): Frequency / DuratioTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Walsh, JK / 2000 High (4/5) 

Private (research design, selection of investigators, data analysis) 

RCT Double-blind Parallel 

Age (years)

Mean (SD): Range: GenderFemale / Male: 

43.2 (1.2) Tr 45.0 (1.3) Pl 21 – 65 115 / 48 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DuratioTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Walsh, JK / 1998 High (4/5) 

Private RCT 

Double-blind Parallel 

Age (years)

Mean (SD): Range: GenderFemale / Male: 

38.9 – 39.6 (10 – 11.7) Tr 43.1 (9.0) Pl 18 – 60 77 / 55 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA 7.4 – 11.8 (6.3 – 10.2) Tr 7.4 (7.3) Pl NS 

Type/Description: Dose (mg):

Frequency / DuratioTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Walsh, JK / 1998 Moderate (3/5) 

Private RCT 

Double-blind Parallel 

Age (years)

Mean (SD): Range: GenderFemale / Male: 

42 (NS) 21 – 65 193 / 85 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DuratioTiming: Route of Delivery: 
C-62

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Walsh, JK / 1984 Moderate (3/5) 

Private RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

41.1 (NS) 19 – 65 52% / 48% 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Wang, RIH / 1977 Moderate (3/5) 

NS RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS NS NS / NS 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Waters, WF / 2003 Low (1/5) 

Foundation RCT 

Not reported as doubleblind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

44.1 (NS) 18 – 59 37 / 16 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Winsauer, HJ / 1984 Moderate (3/5) 

Private RCT 

Double-blind Parallel 

Age (years)Mean (SD): Range: GenderFemale / Male: 

NS 60 – 90 39 / 21 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg):

Frequency / DurationTiming: Route of Delivery: 
C-63

Evidence Table C-2: Efficacy and safety of treatments used in the management of chronic insomnia in adults (continued)

AUTHOR / YEAR QUALITY (score) 

FUNDING SOURCE 

STUDY DESIGN POPULATION CHARACTERISTICS INSOMNIA CHARACTERISTICS INTERVENTIONS 

Zhdanova, IV / 2001 Moderate (2/5) 

GOV RCT 

Double-blind Crossover 

Age (years)Mean (SD): Range: GenderFemale / Male: 

over 50 yrs NS NS NS / NS 

Type: Co-morbidity: Duration (years)Mean (SD): Range: 

primary NA NS NS 

Type/Description: Dose (mg): Frequency / DurationTiming: Route of Delivery: 
C-64

Evidence Table C-2: References 

 1. Aden GC, Thatcher C. Quazepam in the short-term 

treatment of insomnia in outpatients. J Clin 

Psychiatry 1983; 44(12):454-6. 

 2. Allain H, Arbus L, Schuck S. Efficacy and safety of 

zolpidem administered as needed in primary 

insomnia: results of a double-blind, placebocontrolled study. Clin Drug Invest 2001; 21(6):391-

400. 

 3. Allain H, Le Coz F, Borderies P et al. Use of 

zolpidem 10 mg as a benzodiazepine substitute in 

84 patients with insomnia. Hum Psychopharmacol 

1998; 13(8):551-9. 

 4. Ascher LM, Turner RM. Paradoxical intention and 

insomnia: an experimental investigation. Behav Res 

Ther 1979; 17(4):408-11. 

 5. Asnis GM, Chakraburtty A, DuBoff EA et al. 

Zolpidem for persistent insomnia in SSRI-treated 

depressed patients. J Clin Psychiatry 1999; 

60(10):668-76. 

 6. Beary MD, Lacey JH, Crutchfield MB et al. 

Psycho-social stress, insomnia and temazepam: a 

sleep laboratory evaluation in a "general practice" 

sample. Psychopharmacol 1984; 83(1):17-9. 

 7. Botter PA. Comparative double blind study of 

loprazolam, 1 mg and 2 mg, versus placebo in 

anxiety induced insomnia. Curr Med Res Opin 

1983; 8(9):626-30. 

 8. Bowen AJ. Comparative efficacy of triazolam, 

flurazepam and placebo in out-patient insomniacs. J 

Int Med Res 1978; 6(4):337-42. 

 9. Brown CC, Horrom NJ, Wagman AM. Effects of ltryptophan on sleep onset insomniacs. Waking 

Sleeping 1979; 3(2):101-8. 

 10. Campbell RD, Grace MGA, Bourgouin J et al. 

Efficacy and safety of zopiclone in the treatment of 

insomnia. Curr Ther Res 1987; 42(4):665-70. 

 11. Carr-Kaffashan L, Woolfolk RL. Active and 

placebo effects in treatment of moderate and severe 

insomnia. J Consult Clin Psychol 1979; 47(6):1072-

80. 

 12. Chaudoir PJ, Jarvie NC, Wilcox GJ. The 

acceptability of a non-benzodiazepine hypnotic 

(zopiclone) in general practice. J Int Med Res 1983; 

11(6):333-7. 

 13. Choliz M. A breathing-retraining procedure in 

treatment of sleep-onset insomnia: theoretical basis 

and experimental findings. Percept Mot Skills 1995; 

80(2):507-13. 

 14. Cohn JB, Wilcox CS, Bremner J et al. Hypnotic 

efficacy of estazolam compared with flurazepam in 

outpatients with insomnia. J Clin Pharmacol 1991; 

31:747-50. 

 15. Cohn JB. Double-blind crossover comparison of 

triazolam and lorazepam in the posthypnotic state. J 

Clin Psychiatry 1984; 45(3):104-7. 

 16. Cohn JB. Triazolam treatment of insomnia in 

depressed patients taking tricyclics. J Clin 

Psychiatry 1983; 44(11):401-6. 

 17. Coxeter PD, Schluter PJ, Eastwood HL et al. 

Valerian does not appear to reduce symptoms for 

patients with chronic insomnia in general practice 

using a series of randomised N-of-I trials. 

Complement Ther Med 2003; 11(4):215-22. 

 18. Davies R, Lacks P, Storandt M et al. Countercontrol 

treatment of sleep-maintenance insomnia in relation 

to age. Psychol Aging 1986; 1(3):233-8. 

 19. Dawson D, Rogers NL, van den Heuvel CJ et al. 

Effect of sustained nocturnal transbuccal melatonin 

administration on sleep and temperature in elderly 

insomniacs. J Biol Rhythms 1998; 13(6):532-8. 

 20. Declerck A, Smits M. Zolpidem, a valuable 

alternative to benzodiazepine hypnotics for chronic 

insomnia? J Int Med Res 1999; 27(6):253-63. 

 21. Dominguez RA, Goldstein BJ, Jacobson AF et al. 

Brotizolam in the treatment of insomnia. 

Psychopharmacol Bull 1985; 21(1):97-100. 

 22. Dominguez RA, Goldstein BJ, Jacobson AF et al. 

Comparative efficacy of estazolam, flurazepam, and 

placebo in outpatients with insomnia. J Clin 

Psychiatry 1986; 47(7):362-5. 

 23. Donath F, Quispe S, Diefenbach K et al. Critical 

evaluation of the effect of valerian extract on sleep 

structure and sleep quality. Pharmacopsychiatry 

2000; 33(2):47-53. 

 24. Drake CL, Roehrs TA, Mangano RM et al. Doseresponse effects of zaleplon as compared with 

triazolam (0.25 mg) and placebo in chronic primary 

insomnia. Hum Psychopharmacol 2000; 15(8):595-

604. 
C-65

 25. Dujardin K, Guieu JD, Leconte-Lambert C et al. 

Comparison of the effects of zolpidem and 

flunitrazepam on sleep structure and daytime 

cognitive functions. A study of untreated 

insomniacs. Pharmacopsychiatry 1998; 31(1):14-8. 

 26. Edinger JD, Sampson WS. A primary care 

"friendly" cognitive behavioral insomnia therapy. 

Sleep 2003; 26(2):177-182. 

 27. Edinger JD, Wohlgemuth W, Radtke R et al. 

Cognitive behavioral therapy for treatment of 

chronic primary insomnia: A randomized controlled 

trial. [References]. J Am Med Assoc 2001; 

285(14):1856-64. 

 28. Elie R, Frenay M, Le Morvan P et al. Efficacy and 

safety of zopiclone and triazolam in the treatment of 

geriatric insomniacs. Int Clin Psychopharmacol 

1990; 5(Suppl 2):39-46. 

 29. Elie R, Ruther E, Farr I et al. Sleep latency is 

shortened during 4 weeks of treatment with 

zaleplon, a novel nonbenzodiazepine hypnotic. J 

Clin Psychiatry 1999; 60(8):536-44. 

 30. Ellis CM, Lemmens G, Parkes JD. Melatonin and 

insomnia. J Sleep Res 1996; 5(1):61-5. 

 31. Espie CA, Lindsay WR, Brooks DN et al. A 

controlled comparative investigation of 

psychological treatments for chronic sleep-onset 

insomnia. Behav Res Ther 1989; 27(1):79-88. 

 32. Farag NH, Mills PJ. A randomised-controlled trial 

of the effects of a traditional herbal supplement on 

sleep onset insomnia. Complement Thera Med 

2003; 11(4):223-5. 

 33. Ferguson JM, Bielski RJ, Houston J et al. 

Comparison of estazolam and placebo in the 

outpatient treatment of insomnia associated with 

major depression. Curr Ther Res 1991; 49(5):898-

907. 

 34. Fillingim JM. Double blind evaluation of 

temazepam, flurazepam, and placebo in geriatric 

insomniacs. Clin Ther 1982; 4(5):369-80. 

 35. Fleming J, Moldofsky H, Walsh JK et al. 

Comparison of the residual effects and efficacy of 

short term zolpidem, flurazepam and placebo in 

patients with chronic insomnia. Clin Drug Invest 

1995; 9:303-13. 

 36. Fry J, Scharf M, Mangano R et al. Zaleplon 

improves sleep without producing rebound effects 

in outpatients with insomnia. Zaleplon Clinical 

Study Group. Int Clin Psychopharmacol 2000; 

15(3):141-52. 

 37. Garfinkel D, Laudon M, Nof D et al. Improvement 

of sleep quality in elderly people by controlledrelease melatonin. Lancet 1995; 346:541-4. 

 38. Garfinkel D, Laudon M, Zisapel N. Improvement of 

sleep quality by controlled-release melatonin in 

benzodiazepine-treated elderly insomniacs. Arch 

Gerontol Geriatr 1997; 24(2):223-31. 

 39. Gelinas B, Thorsteinson L, Lapierre YD et al. 

Zopiclone in the treatment of insomniacs of family 

practice. Psychiatr J Univ Ottawa 1985; 10(3):165-

8. 

 40. Goethe JW, Kader G. Short-term clinical study of 

quazepam 15 mg in outpatient insomniacs. Curr 

Ther Res 1982; 32:150-6. 

 41. Goldenberg F, Hindmarch I, Joyce CRB et al. 

Zopiclone, sleep and health-related quality of life. 

Hum Psychopharmacol 1994; 9(4):245-51. 

 42. Haffmans PMJ, Vos MS. The effects of trazodone 

on sleep disturbances induced by brofaromine. Eur 

Psychiatry 1999; 14(3):167-71. 

 43. Haimov I, Lavie P, Laudon M et al. Melatonin 

replacement therapy of elderly insomniacs. Sleep 

1995; 18(7):598-603. 

 44. Hajak G, Clarenbach P, Fischer W et al. Zopiclone 

improves sleep quality and daytime well-being in 

insomniac patients: comparison with triazolam, 

flunitrazepam and placebo. Int Clin 

Psychopharmacol 1994; 9(5):251-61. 

 45. Hajak G, Rodenbeck A, Adler L et al. Nocturnal 

melatonin secretion and sleep after doxepin 

administration in chronic primary insomnia. 

Pharmacopsychiatry 1996; 29(5):187-92. 

 46. Hajak G, Rodenbeck A, Voderholzer U et al. 

Doxepin in the treatment of primary insomnia - a 

placebo-controlled, double-blind, 

polysomnographic study [abstract]. In: J Eur Coll 

Neuropsychopharmacol. Proceedings of the 13th 

ECNP Congress; 2000 Sep 9-13; Munich, Germany. 

(Suppl 3), S248. 

 47. Hartmann E, Lindsley JG, Spinweber C. Chronic 

insomnia effects of tryptophan, flurazepam, seco 

bartibal and placebo. Psychopharmacol 1983; 

80(2):138-42. 

 48. Harvey AG. The attempted suppression of presleep 

cognitive activity in insomnia. Cognit Ther Res 

2003; 27(6):593-602. 
C-66

 49. Haynes SN, Sides H, Lockwood G. Relaxation 

instructions and frontalis electromyographic 

feedback intervention with sleep-onset insomnia. 

Behav Ther 1977; 8(4):644-52. 

 50. Haynes SN, Woodward S, Moran R et al. 

Relaxation treatment of insomnia. Behav Ther 

1974; 5(4):555-8. 

 51. Hedner J, Yaeche R, Emilien G et al. Zaleplon 

shortens subjective sleep latency and improves 

subjective sleep quality in elderly patients with 

insomnia. The Zaleplon Clinical Investigator Study 

Group. Int J Geriatr Psychiatry 2000; 15(8):704-12. 

 52. Heidrich H, Ott H, Beach RC. Lormetazepam A 

benzodiazepine derivative without hangover effect. 

A double-blind study with chronic insomniacs in a 

general practice setting. Int J Clin Pharmacol Ther 

Toxicol 1981; 19(1):11-17. 

 53. Hernandez LR, Del Rosal PL, Ponce MC. Shortterm study of quazepam 15 milligrams in the 

treatment of insomnia. J Inte Med Res 1983; 

11(3):162-6. 

 54. Herrmann WM, Kubicki ST, Boden S et al. Pilot 

controlled double-blind study of the hypnotic 

effects of zolpidem in patients with chronic 'learned' 

insomnia: Psychometric and polysomnographic 

evaluation. J Int Med Res 1993; 21(6):306-22. 

 55. Hughes RC, Hughes HH. Insomnia: effects of EMG 

biofeedback, relaxation training, and stimulus 

control. Behav Eng 1978; 5(2):67-72. 

 56. Jacobson AF, Dominguez RA, Goldstein BJ et al. 

Efficacy of brotizolam in geriatric patients with 

insomnia. Curr Ther Res 1986; 39:528-36. 

 57. James S, Sack D, Rosenthal N et al. Melatonin 

administration in insomnia. Neuropsychopharmacol 

1990; 3(1):19-24. 

 58. Krystal AD, Walsh JK, Laska E et al. Sustained 

efficacy of eszopiclone over 6 months of nightly 

treatment: results of a randomized, double-blind, 

placebo-controlled study in adults with chronic 

Iisomnia. Sleep 2003; 26(7):793-9. 

 59. Lacks P, Bertelson AD, Sugerman J et al. Treatment 

of sleep maintenance insomnia with stimulus 

control techniques. Behav Res Ther 1983; 

21(3):291-6. 

 60. Lacks P, Bertelson AD, Gans L et al. The 

effectiveness of three behavioral treatments for 

different degrees of sleep onset insomnia. Behav 

Ther 1983; 14(5):593-605. 

 61. Lahmeyer H, Wilcox CS, Kann J et al. Subjective 

efficacy of zolpidem in outpatients with chronic 

insomnia: double blind comparison with placebo. 

Clin Drug Invest 1997; 13:134-44. 

 62. Lamphere JK, Roehrs TA, Zorick FJ et al. The dose 

effects of zopiclone. Hum Psychopharmacol 1989; 

4(1):41-6. 

 63. Leppik IE, Roth-Schechter GB, Gray GW et al. 

Double blind, placebo controlled comparison of 

zolpidem, triazolam, and temazepam in elderly 

patients with insomnia. Drug Dev Res 1997; 

40:230-8. 

 64. Lichstein KL, Riedel BW, Wilson NM et al. 

Relaxation and sleep compression for late-life 

insomnia: a placebo-controlled trial. J Consult Clin 

Psychol 2001; 69(2):227-39. 

 65. Mamelak M, Buck L, Csima A et al. Effects of 

flurazepam and zopiclone on the performance of 

chronic insomniac patients: a study of ethanol-drug 

interaction. Sleep 1987; 10(Suppl 1):79-87. 

 66. Mamelak M, Csima A, Buck L et al. A comparative 

study on the effects of brotizolam and flurazepam 

on sleep and performance in the elderly. J Clin 

Psychopharmacol 1989; 9(4):260-7. 

 67. McAlpine CJ, Ankier SI, Elliott CS. A multicentre 

hospital study to compare the hypnotic efficacy of 

loprazolam and nitrazepam. J Int Med Res 1984; 

12(4):229-37. 

 68. Melo de Paula AJ. Comparative study of 

lormetazepam and flurazepam in the treatment of 

insomnia. Clin Ther 1984; 6(4):500-8. 

 69. Mendels J, Stern S. Evaluation of the short-term 

treatment of insomnia in out patients with 15 

milligrams of quazepam. J Int Med Res 1983; 

11(3):155-61. 

 70. Milby JB, Williams V, Hall JN et al. Effectiveness 

of combined triazolam-behavioral therapy for 

primary insomnia. Am J Psychiatry 1993; 

150:1259-60. 

 71. Minnekeer R, Marchal J, Van de Velde L et al. A 

double-blind study comparing the efficacy and 

safety of quazepam with flunitrazepam and placebo 

in patients with chronic insomnia. Acta Ther 1988; 

14(2):159-70. 

 72. Mitchell KR. Behavioral treatment of presleep 

tension and intrusive cognitions in patients with 

severe predormital insomnia. J Behav Med 1979; 

2(1):57-69. 
C-67

 73. Mitler MM, Seidel WF, van den Hoed J et al. 

Comparative hypnotic effects of flurazepam, 

triazolam, and placebo: a long-term simultaneous 

nighttime and daytime study. J Clin 

Psychopharmacol 1984; 4(1):2-13. 

 74. Monchesky TC, Billings BJ, Phillips R. Zopiclone: 

a new nonbenzodiazepine hypnotic used in general 

practice. Clin Ther 1986; 8(3):283-91. 

 75. Montes LG, Uribe MP, Sotres JC et al. Treatment of 

primary insomnia with melatonin: A double-blind, 

placebo-controlled, crossover study. [References]. J 

Psychiatry Neurosci 2003; 28(3):191-6. 

 76. Monti JM, Monti D, Estevez F et al. Sleep in 

patients with chronic primary insomnia during longterm zolpidem administration and after its 

withdrawal. Int Clin Psychopharmacol 1996; 

114(255-63). 

 77. Monti JM, Alvarino F, Monti D. Conventional and 

power spectrum analysis of the effects of zolpidem 

on sleep EEG in patients with chronic primary 

insomnia. Sleep 2000; 23(8):1075-84. 

 78. Morin CM, Colecchi C, Stone J et al. Behavioral 

and pharmacological therapies for late-life 

insomnia: a randomized controlled trial.[comment]. 

J Am Med Assoc 1999; 281(11):991-9. 

 79. Nair NP, Schwartz G, Dimitri R et al. A dose-range 

finding study of zopiclone in insomniac patients. Int 

Clin Psychopharmacol 1990; 5(Suppl 2):1-10. 

 80. Negri L. Evaluation of the efficacy of pivagabine on 

insomnia associated with mood disorders. 

Arzneimittel Forschung 1997; 47(11 Suppl a):1322-

5. 

 81. Nicassio P, Bootzin R. A comparison of progressive 

relaxation and autogenic training as treatments for 

insomnia. J Abnorm Psychol 1974; 83(3):253-60. 

 82. Pasche B, Erman M, Hayduk R et al. Effects of low 

energy emission therapy in chronic 

psychophysiological insomnia. Sleep 1996; 

19(4):327-36. 

 83. Perlis ML, Smith MT, Orff H et al. The effects of 

modafinil and cognitive behavior therapy on sleep 

continuity in patients with primary insomnia. Sleep 

2004; 27(4):715-25. 

 84. Poyares DR, Guilleminault C, Ohayon MM et al. 

Can valerian improve the sleep of insomniacs after 

benzodiazepine withdrawal? Prog 

NeuroPsychopharmacol Biol Psychiatry 2002; 

26(3):539-45. 

 85. Reeves RL. Comparison of triazolam, flurazepam 

and placebo as hypnotics in geriatric patients with 

insomnia. J Clin Pharmacol 1977; 17:319-23. 

 86. Rickels K, Morris RJ, Mauriello R et al. 

Brotizolam, a triazolothienodiazepine, in insomnia. 

Clin Pharmacol Ther 1986; 40:293-9. 

 87. Riemann D, Voderholzer U, Cohrs S et al. 

Trimipramine in Primary Insomnia: Results of a 

Polysomnographic Double-Blind Controlled Study. 

Pharmacopsychiatry 2002; 35(5):165-74. 

 88. Rodenbeck A, Cohrs S, Jordan W et al. The sleepimproving effects of doxepin are paralleled by a 

normalized plasma cortisol secretion in primary 

iInsomnia - a placebo-controlled, double-blind, 

randomized, cross-over study followed by an open 

treatment over 3 weeks. Psychopharmacol 2003; 

170(4):423-8. 

 89. Roehrs T, Papineau K, Rosenthal L et al. Ethanol as 

a hypnotic in insomniacs: self administration and 

effects on sleep and mood. Neuropsychopharmacol 

1999; 20(3):279-86. 

 90. Roehrs T, Zorick F, Koshorek GL et al. Effects of 

acute administration of brotizolam in subjects with 

disturbed sleep. Br J Clin Pharmacol 1983; 

16(Suppl 2):S371-6. 

 91. Roth T, Tietz EI, Kramer M et al. The effect of a 

single dose of quazepam (Sch-16134) on the sleep 

of chronic insomniacs. J Int Med Res 1979; 

7(6):583-7. 

 92. Roth TG, Roehrs TA, Koshorek GL et al. Hypnotic 

effects of low doses of quazepam in older 

insomniacs. J Clin Psychopharmacol 1997; 

17(5):401-6. 

 93. Saletu-Zyhlarz G, Anderer P, Gruber G et al. 

Insomnia related to postmenopausal syndrome and 

hormone replacement therapy: sleep laboratory 

studies on baseline differences between patients and 

controls and double-blind, placebo-controlled 

investigations on the effects of a novel estrogenprogestogen combination (Climodien [R], Lafamme 

[R]) versus estrogen alone. J Sleep Res 2003; 

12(3):239-54. 

 94. Sanavio E, Vidotto G, Bettinardi O et al. Behaviour 

therapy for DIMS: Comparison of three treatment 

procedures with follow-up. Behav Psychother 1990; 

18(3):151-67. 

 95. Sastre-y-Hernandez M, Visser P, Schutt B et al. 

Sublingual lormetazepam in the treatment of sleep 

disorders in general practice patients. Hum 

Psychopharmacol 1988; 3(2):139-44. 
C-68

 96. Scharf MB, Roth PB, Dominguez RA et al. 

Estazolam and flurazepam: multicenter, placebocontrolled comparative study in outpatients with 

insomnia. J Clin Pharmacol 1990; 30:461-7. 

 97. Scharf MB, Roth T, Vogel GW et al. A multicenter, 

placebo-controlled study evaluating zolpidem in the 

treatment of chronic insomnia. J Clin Psychiatry 

1994; 55(5):192-9. 

 98. Shaw SH, Curson H, Coquelin JP. A double-blind, 

comparative study of zolpidem and placebo in the 

treatment of insomnia in elderly psychiatric inpatients.[erratum appears in J Int Med Res 1992 

Nov; 20(6):following 494] . J Int Med Res 1992; 

20(2):150-61. 

 99. Shealy R. The effectiveness of various treatment 

techniques on different degrees and durations of 

sleep onset insomnia. Behav Res Ther 1979; 

17(6):541-6. 

 100. Stanton HE. Hypnotic relaxation and the reduction 

of sleep onset insomnia. Int J Psychosom 1989; 

36(1-4):64-8. 

 101. Steens RD, Pouliot Z, Millar TW et al. Effects of 

zolpidem and triazolam on sleep and respiration in 

mild to moderate chronic obstructive pulmonary 

disease. Sleep 1993; 16(4):318-26. 

 102. Stip E, Furlan M, Lussier I et al. Double-blind, 

placebo-controlled study comparing effects of 

zopiclone and temazepam on cognitive functioning 

of insomniacs. Hum Psychopharmacol 1999; 

14(4):253-61. 

 103. Tietz EI, Roth T, Zorick FJ et al. The acute effect of 

quazepam on the sleep of chronic insomniacs. A 

dose-response study. Arzneimittel-orschung 1981; 

31(11):1963-6. 

 104. Tuk B, Oberye JJ, Pieters MS et al. 

Pharmacodynamics of temazepam in primary 

insomnia: assessment of the value of quantitative 

electroencephalography and saccadic eye 

movements in predicting improvement of sleep. 

Clin Pharmacol Ther 1997; 62:444-52. 

 105. Vallieres A, Morin CM, Guay B et al. Sequential 

treatment for chronic insomnia: A pilot study. 

Behav Sleep Med 2004; 2(2):94-112. 

 106. Viukari M, Jaatinen P, Kylmamaa T. Flunitrazepam 

and nitrazepam as hypnotics in psychogeriatric 

inpatients. Clin Ther 1983; 5(6):662-70. 

 107. Walsh JK. Zolpidem "as needed" for the treatment 

of primary insomnia: a double-blind, placebocontrolled study. Sleep Med Rev 2002; 6:S7-11. 

 108. Walsh JK, Fry J, Erwin CW et al. Efficacy and 

tolerability of 14-day administration of zaleplon 5 

mg and 10 mg for the treatment of primary 

insomnia. Clin Drug Invest 1998; 16:347-54. 

 109. Walsh JK, Fry J, Richardson GS et al. Short term 

efficacy of zaleplon in older patients with chronic 

insomnia. Clin Drug Invest 2000; 20:143-9. 

 110. Walsh JK, Targum SD, Pegram V et al. Multicenter 

clinical investigation of estazolam: short term 

efficacy. Curr Ther Res 1984; 36:866-74. 

 111. Walsh JK, Erman M, Erwin CW et al. Subjective 

hypnotic efficacy of trazodone and zolpidem in 

DSMIII-R primary insomnia. Hum 

Psychopharmacol 1998; 13(3):191-8. 

 112. Walsh JK, Roth T, Randazzo A et al. Eight weeks 

of non-nightly use of zolpidem for primary 

insomnia. Sleep 2000; 23(8):1087-96. 

 113. Wang RIH, Stockdale SL. Subjective and objective 

method assessing the efficacy of hypnotic 

medications in insomniacs. J Clin Pharmacol 1977; 

17:728-33. 

 114. Waters WF, Hurry MJ, Binks PG et al. Behavioral 

and hypnotic treatments for insomnia subtypes. 

Behav Sleep Med 2003; 1(2):81-101. 

 115. Winsauer HJ, O'Hair DE, Valero R. Quazepam: 

short term treatment of insomnia in geriatric 

outpatients. Curr Ther Res 1984; 35:228-34. 

 116. Zhdanova IV, Wurtman RJa, Regan MM et al. 

Melatonin treatment for age-related insomnia. J 

Clin Endocrinol Metab 2001; 86(10):4727-30. 
D-1

Appendix D: Technical Expert Panel 

 The Technical Experts for this review are outlined below. Some of their professional 

affiliations are briefly described. The panel was consulted for their opinion regarding the 

definition of chronic insomnia used in the review, the inclusion criteria for the review and data 

analysis. They were also asked to provide feedback on the draft report. 

J. Todd Arnedt, Ph.D. 

Clinical Assistant Professor 

Sleep and Chronophysiology Laboratory 

Departments of Psychiatry and Neurology 

University of Michigan, Ann Arbor, MI 

Richard R. Bootzin, PhD 

Professor, University of Arizona, Department of Psychology; 

Professor, University of Arizona, Department of Psychiatry, 

College of Medicine; Director, Sleep Disorders Center, Insomnia Program, 

University of Arizona, College of Medicine 

Irvin Mayers, MD 

Professor, University of Alberta, Pulmonary Medicine; 

Director, University of Alberta, Pulmonary Medicine Division. 

Parameswaran Nair, MD, PhD 

Assistant Professor of Medicine, 

McMaster University, Division of Respirology. 

Larry Pawluk, MD 

Associate Professor, 

University of Alberta, Department of Psychiatry; 

Director, Sleep Medicine Program, 

University of Alberta, Department of Psychiatry. 
D-2

Arthur J. Spielman, PhD 

Professor, The City College of CUNY, Department of Psychology; 

Associate Director, Center for Sleep Disorders Medicine and Research, New York Methodist 

Hospital, Brooklyn, NY; 

Associate Director, Center for Sleep Medicine, Neurology, New York Presbyterian HospitalCornell, NY/Weill Medical College, Cornell University. 
E-1

Appendix E: Excluded Studies 

Four hundred and forty-nine studies were excluded for the questions on manifestations of 

chronic insomnia. The reasons for exclusion of studies potentially relevant to these questions are 

as follows: (1) the study was reported in a language other than English (n=9), (2) the report was a 

review (n=38), (3) the study was not relevant to the review topic (n=71), (4) the study was a case 

report (n=9), (5) the study did not have a control group (n=47), (6) the study did not examine an 

adult population (n=8), (7) the study population did not have chronic insomnia as defined in this 

report (208), (8) the study did not report on any of the outcomes of this review (n=58) and (9) 

data relevant to the study outcomes were not adequately reported (n=1). 

Excluded - Non-English 

The following studies were excluded because they were reported in a language other than 

English. 

 1. Blais FC, Morin CM, Boisclair A et al. Insomnia - 

Prevalence and Treatment in the General Practice. Can 

Fam Phys 2001; 47:759-67. 

 2. De Almeida CAV, Lins OG, Lins SG et al. Sleep 

Disorders in Temporal Lobe Epilepsy. Arq 

NeuroPsiquiatr 2003; 61(4):979-87. 

 3. Horiguchi J, Inami Y, Nishimatsu O et al. Sleep-wake 

complaints in Parkinson's disease. Clin Neurol 1990; 

30(2):214-6. 

 4. Jakoubkova M, Sonka K, Roth J et al. Sleep in 

Parkinson's Disease - a Questionnaire Study. Cesk 

Neurol Neurochir 2001; 64(5):268-72. 

 5. Kamenski G, Pichler I, Zohrer B et al. Insomnia and 

sleeping disorders in the elderly in general practice 

(Germ). Wien Med Wochenschr 2004; 154(1-2):27-

31. 

 6. Leger D, Stal V, Guilleminault C et al. Daily 

Consequences of Insomnia: Impact on Quality of Life. 

Rev Neurol 2001; 157( 10):1270-8. 

 7. Ohayon MM, Lemoine P. [Daytime consequences of 

insomnia complaints in the French general 

population]. Encephale 2004; 30(3):222-7. 

 8. Ohayon MM, Lemoine P. [Sleep and insomnia 

markers in the general population]. Encephale 2004; 

30(2):135-40. 

 9. Wittchen HU, Krause P, Hofler M et al. The 

Nationwide Insomnia Screening and Awareness Study 

(Nisas) 2000. Nervenheilkunde 2001; 20(1):4-16. 

Excluded - Review 

The following studies were excluded because they were reviews. 

 1. Nighttime pain: a major problem for one out of three 

adults J Pract Nurs 1996; 46(2):27-9. 

 2. Aguzzi A, Weissmann C, Tateishi J. Sleepless in 

Bologna: Transmission of fatal familial insomnia. 

Trends Microbiol 1996; 4(4):129-32. 

 3. Akerstedt T. Sleepiness as a consequence of shift 

work. Sleep 1988; 11(1):17-34. 

 4. Alley PM. Helping individuals with sleep 

disturbances: Some behavior therapy techniques. Pers 

Guid J 1983; 61(10):606-8. 

 5. Ancoli-Israel S . Epidemiology of sleep disorders. 

Clin Geriatr Med 1989; 5(2):347-62. 
E-2

 6. Anonymous. Insomnia may lead to depression later in 

life . J Psychosoc Nurs Ment Health Serv 1998; 

36(2):13. 

 7. Anonymous. Management of anxiety and insomnia. 

Int Pharm J 1996; 10(2):58-60. 

 8. Asplund R. Sleep disorders in the elderly. Drugs 

Aging 1999; 14(2):91-103. 

 9. Avidan AY. Insomnia in the geriatric patient. Clin 

Cornerstone 2003; 5(3):51-8. 

10. Ball J, Koloian B. Sleep patterns among ADHD 

children. Clin Psychol Rev 1995; 15(7):681-91. 

11. Bannerman C. Sleep disorders in the later years. 

Postgrad Med 1988; 84(1):265-6, 271-2, 274. 

12. Baratte-Beebe KR, Lee K. Sources of midsleep 

awakenings in childbearing women. Clin Nurs Res 

1999; 8(4):386-97. 

13. Barthlen GM, Stacy C. Dyssomnias, parasomnias, and 

sleep disorders associated with medical and 

psychiatric diseases. Mt Sinai J Med 1994; 61(2):139-

59. 

14. Chilcott LA, Shapiro CM. The socioeconomic impact 

of insomnia: An overview. Pharmacoeconomics 1996; 

10 (Suppl 1):1-14. 

15. Chung KF. Relationships between insomnia and sleepdisordered breathing. Chest 2003; 123(1):310-3. 

16. Crowe C. Evaluation of severe insomnia in the general 

population--implications for the management of 

insomnia: focus on results from Ireland. J 

Psychopharmacol 1999; 13(4 Suppl 1):S29. 

17. Culebras A, Magana R. Neurologic disorders and 

sleep disturbances. Seminars Neurol 1987; 7(3):277-

85. 

18. Daly MP. Insomnia in the elderly. Am Fam Phys 

1992; 45(2):445-6. 

19. Finucane TE. Insomnia and cognitive decline. J Am 

Geriatr Soc 2002; 50(9):1604-5. 

20. Ford DE, Cooper-Patrick L. Sleep disturbances and 

mood disorders: An epidemiologic perspective. 

Depress Anxiety 2001; 14(1):3-6. 

21. Gaillard J-M, Merica H, Blois R. Clinical presentation 

and psychopathology in chronic insomnia. I. Int J 

Short-Term Psychother 1996; 11(1):41-54. 

 

22. Gambetti P, Parchi P. Insomnia in prion diseases: 

sporadic and familial. N Engl J Med 1999; 

340(21):1675-7. 

23. Giesecke ME. The symptom of insomnia in university 

students. J Am Coll Health 1987; 35(5):215-21. 

24. Gillin JC, Spinweber CL, Johnson LC. Rebound 

insomnia: A critical review. J Clin Psychopharmacol 

1989; 9(3):161-72. 

25. Holm KJ, Goa KL. Zolpidem: an update of its 

pharmacology, therapeutic efficacy and tolerability in 

the treatment of insomnia. Drugs 2000; 59(4):865-89. 

26. Howard GF. Evaluation of insomnia. Hosp Pract 

(Office Ed) 1986; 21(1A):16, 21-2, 24. 

27. Hudson JI, Pope HG, Sullivan LE et al. Good sleep, 

bad sleep: a meta-analysis of polysomnographic 

measures in insomnia, depression, and narcolepsy. 

Biol Psychiatry 1992; 32(11):958-75. 

28. Idzikowski C. Impact of insomnia on health-related 

quality of life. Pharmacoecon 1996; 10(Suppl 1):15-

24. 

29. Kales A, Soldatos CR, Bixler EO et al. Rebound 

insomnia and rebound anxiety: a review. Pharmacol 

1983; 26(3):121-37. 

30. Kales A, Vgontzas AN. Predisposition to and 

development and persistence of chronic insomnia: 

importance of psychobehavioral factors. Arch Int Med 

1992; 152(8):1570-2. 

31. Kales JD, Kales A. Nocturnal psychophysiological 

correlates of somatic conditions and sleep disorders. 

Int J Psychiatry Med 1975; 6(1-2):43-62. 

32. Locsin RC. Sleeplessness among the elderly. Rehab 

Nurs 1988; 13(6):340-1. 

33. McDowell Anderson W, Falestiny M. Women and 

sleep. Prim Care Update Obstet Gynecol 2000; 

7(4):131-7. 

34. Roth T. Social and economic consequences of sleep 

disorders. Sleep 1996; 19(8 Suppl):S46-7. 

35. Stoller MK. Economic effects of insomnia. Clin Ther 

1994; 16(5):873-97; 854. 

36. Verster JC, Veldhuijzen DS, Volkerts ER. Residual 

effects of sleep medication on driving ability. Sleep 

Med Rev 2004; 8(4):309-25. 

37. Walsh J, Ustun TB. Prevalence and health 

consequences of insomnia. Sleep 1999; 22(Suppl 

3):S427-36. 
E-3

38. Walsh JK. Clinical and socioeconomic correlates of 

insomnia. J Clin Psychiatry 2004; 65 Suppl 8:13-9. 

Excluded - Topic 

The following studies were excluded because they were not relevant to the review topic. 

 1. Adam K, Oswald I. Can a rapidly-eliminated hypnotic 

cause daytime anxiety? Pharmacopsychiatry 1989; 

22(3):115-9. 

 2. Ancolio C, Tardieu S, Soubrouillard C et al. A 

Randomized Clinical Trial Comparing Doses and 

Efficacy of Lormetazepam Tablets or Oral Solution 

for Insomnia in a General Practice Setting. Hum 

Psychopharmacol Clin Exper 2004; 19(2):129-34. 

 3. Arnulf I, Konofal E, Gauthier C et al. Severe restless 

legs syndrome presenting as intractable insomnia. 

Neurol 2004; 62(8):E19. 

 4. Backhaus J, Hohagen F, Voderholzer U et al. Longterm effectiveness of a short-term cognitivebehavioral group treatment for primary insomnia . Eur 

Arch Psychiatry Clin Neurosci 2001; 251(1):35-41. 

 5. Baskett JJ, Broad JB, Wood PC et al. Does melatonin 

improve sleep in older people? A randomised 

crossover trial. Age Ageing 2003; 32(2):164-70. 

 6. Bastien CH, Vallieres A, Morin CM. Validation of the 

insomnia severity index as an outcome measure for 

insomnia research. Sleep Med 2001; 2(4):297-307. 

 7. Belcher TL. Environmental changes affect sleep 

patterns: a case study. Percept Mot Skills 1995; 80(3 

Pt 2):1089-90. 

 8. Bonnet MH, Arand DL. Situational insomnia: 

Consistency, predictors, and outcomes. Sleep 2003; 

26(8):1029-36. 

 9. Braun WA. High blood pressure and insomnia: not a 

good combination. Med Update 1999; 23(1):2. 

10. Broman JE, Hetta J. Electrodermal activity in patients 

with persistent insomnia. J Sleep Res 1994; 3 (3):165-

70. 

11. Bucci L. Migraine, insomnia, reactive depression due 

to brain serotonin deficiency. Br J Psychiatry 1988; 

152:867-8. 

 

12. Buysse DJ, Reynolds III CF, Kupfer DJ et al. Clinical 

diagnoses in 216 insomnia patients using the 

International Classification of Sleep Disorders (ICSD), 

DSM-IV and ICD-10 categories: A report from the 

APA/NIMH DSM-IV field trial. Sleep 1994; 

17(7):630-7. 

13. Carr-Kaffashan L, Woolfolk RL. Active and placebo 

effects in treatment of moderate and severe insomnia. 

J Consult Clin Psychol 1979; 47(6 ):1072-80. 

14. Chung KF, Lee CK. Over-the-counter sleeping pills: a 

survey of use in Hong Kong and a review of their 

constituents. Gen Hosp Psychiatry 2002; 24(6):430-5. 

15. Clapin-French E. Sleep patterns of aged persons in 

long-term care facilities. J Adv Nurs 1986; 11(1):57-

66. 

16. Cluydts R, Heyde K, De Volder I. Polysomnographic 

findings during non-continuous administration of 

zolpidem. Sleep Med Rev 2002; 6(Suppl 1):S13-9. 

17. Coates TJ, Thoresen CE. Assessing daytime thoughts 

and behavior associated with good and poor sleep: 

Two exploratory case studies. Behav Assess 1984; 

6(2):153-67. 

18. Cohen M, Oksenberg A, Snir D et al. Temporally 

related changes of sleep complaints in traumatic brain 

injured patients. J Neurol Neurosurg Psychiatry 1992; 

55(4):313-5. 

19. Coren S, Searleman A. Left sidedness and sleep 

difficulty: the alinormal syndrome. Brain Cogn 1987; 

6(2):184-92. 

20. Davies R, Lacks P, Storandt M et al. Countercontrol 

treatment of sleep-maintenance insomnia in relation to 

age. Psychol Aging 1986; 1(3):233-8. 

21. de Jonghe F, Ameling EH, Jonkers F et al. Flurazepam 

and temazepam in the treatment of insomnia in a 

general hospital population. Pharmacopsychiatry 

1984; 17(4):133-5. 

22. deVries MW, Peeters FP. Melatonin as a therapeutic 

agent in the treatment of sleep disturbance in 

depression. J Nerv Ment Dis 1997; 185(3):201-2. 

 
E-4

23. Doi Y, Minowa M, Okawa M et al. Prevalence of 

sleep disturbance and hypnotic medication use in 

relation to sociodemographic factors in the general 

Japanese adult population. J Epidemiol 2000; 

10(2):79-86. 

24. Drake CL, Roehrs TA, Mangano RM et al. Doseresponse effects of zaleplon as compared with 

triazolam (0.25 mg) and placebo in chronic primary 

insomnia. Hum Psychopharmacol 2000; 15(8):595-

604. 

25. Edinger JD, Hoelscher TJ, Marsh GR et al. A 

cognitive-behavioral therapy for sleep-maintenance 

insomnia in older adults. Psychol Aging 1992; 

7(2):282-9. 

26. Edinger JD, Wohlgemuth WK, Radtke RA et al. 

Cognitive behavioral therapy for treatment of chronic 

primary insomnia: a randomized controlled trial. J Am 

Med Assoc 2001; 285(14):1856-64. 

27. Ellison ZR, Asplund R. Sleep and cardiac diseases 

amongst elderly people. J Int Med 1995; 237(2):215-6. 

28. Espie CA, Inglis SJ, Harvey L. Predicting clinically 

significant response to cognitive behavior therapy for 

chronic insomnia in general medical practice: analysis 

of outcome data at 12 months posttreatment. J Consult 

Clin Psychol 2001; 69(1):58-66. 

29. Franklin J. The measurement of sleep onset latency in 

insomnia. Behav Res Ther 1981; 19(6):547-9. 

30. Franklin LM. Sleep and hypnotics in a psychiatric 

admission ward. N Z Med J 1969; 69(445):353-6. 

31. Fulda S, Schulz H. Cognitive dysfunction in sleep 

disorders. Sleep Med Rev 2001; 5(6):423-45. 

32. Gallassi R, Morreale A, Montagna P et al. Fatal 

familial insomnia: behavioral and cognitive features. 

Neurol 1996; 46(4):935-9. 

33. Garfinkel D, Laudon M, Zisapel N. Improvement of 

sleep quality by controlled-release melatonin in 

benzodiazepine-treated elderly insomniacs. Arch 

Gerontol Geriatr 1997; 24(2):223-31. 

34. Goldenberg F, Hindmarch I, Joyce CRB et al. 

Zopiclone, sleep and health-related quality of life. 

Hum Psychopharmacol 1994; 9(4):245-51. 

35. Guilleminault C, Clerk A, Black J et al. Nondrug 

treatment trials in psychophysiologic insomnia. Arch 

Int Med 1995; 155(8):838-44. 

 

36. Hajak G, Bandelow B. Safety and tolerance of 

zolpidem in the treatment of disturbed sleep: A postmarketing surveillance of 16,944 cases. Int Clin 

Psychopharmacol 1998; 13(4):157-67. 

37. Hajak G, Bandelow B, Zulley J et al. "As needed" 

pharmacotherapy combined with stimulus control 

treatment in chronic insomnia--assessment of a novel 

intervention strategy in a primary care setting. Ann 

Clin Psychiatry 2002; 14(1):1-7. 

38. Hajak G, Clarenbach P, Fischer W et al. Effects of 

hypnotics on sleep quality and daytime well-being. 

Data from a comparative multicentre study in 

outpatients with insomnia. Eur Psychiatry J Assoc Eur 

Psychiatrists 1995; 10(Suppl 3):173S-9. 

39. Hajak G, Clarenbach P, Fischer W et al. Zopiclone 

improves sleep quality and daytime well-being in 

insomniac patients: Comparison with triazolam, 

flunitrazepam and placebo. Int Clin Psychopharmacol 

1994; 9(4):251-61. 

40. Hajak G, Cluydts R, Declerck A et al. Continuous 

versus non-nightly use of zolpidem in chronic 

insomnia: results of a large-scale, double-blind, 

randomized, outpatient study.[erratum appears in Int 

Clin Psychopharmacol 2002 Jul;17(4):206]. Int Clin 

Psychopharmacol 2002; 17(1):9-17. 

41. Hartz AJ, Bentler S, Noyes R et al. Randomized 

controlled trial of Siberian ginseng for chronic fatigue. 

Psychol Med 2004; 34(1):51-61. 

42. Harvey AG. The attempted suppression of presleep 

cognitive activity in insomnia. Cognitive Therapy & 

Research 27(6), 593-602. 2003. 

43. Harvey AG. Pre-sleep cognitive activity: A 

comparison of sleep-onset insomniacs and good 

sleepers. Br J Clin Psychol 2000; 39(3):275-86. 

44. Hedner J, Yaeche R, Emilien G et al. Zaleplon 

shortens subjective sleep latency and improves 

subjective sleep quality in elderly patients with 

insomnia. The Zaleplon Clinical Investigator Study 

Group. Int J Geriatr Psychiatry 2000; 15(8):704-12. 

45. Hulisz DT. OTC sleep aids and the elderly. U.S. 

Pharm 1995; 20(1):24-31. 

46. Hynes SN, Fitzgerald SG, Shute GE et al. The utility 

and validity of daytime naps in the assessment of 

sleep-onset insomnia. J Behav Med 1985; 8(3):237-47. 

47. Johnson LC, Chernik DA, Hauri P. A multicenter 14-

day study of flurazepam and midazolam in chronic 

insomniacs: general discussion and conclusions. J Clin 

Psychopharmacol 1990; 10(4 Suppl):76S-90S. 
E-5

48. Jones HM. In vivo serotonin 5-HT2A receptor 

occupancy and quetiapine. Am J Psychiatry 2000; 

157(1):148. 

49. Karacan I, Williams R, Salis P et al. New approaches 

to the evaluation and treatment of insomnia. 

Psychosom J Consult Liaison Psychiatry 1971; 

12(2):81-8. 

50. Lamphere JK, Roehrs TA, Zorick FJ et al. The dose 

effects of zopiclone. Hum Psychopharmacol 1989; 

4(1):41-6. 

51. Leppik IE, Roth-Schechter GB, Gray GW et al. 

Double-blind, placebo-controlled comparison of 

zolpidem, triazolam, and temazepam in elderly 

patients with insomnia. Drug Devel Res 1997; 

40(3):230-8. 

52. Levin Y. "Brain music" in the treatment of patients 

with insomnia. Neurosci Behav Physiol 1998; 

28(3):330-5. 

53. Li Pi Shan RS, Ashworth NL. Comparison of 

lorazepam and zopiclone for insomnia in patients with 

stroke and brain injury: a randomized, crossover, 

double-blinded trial. Am JPhys Med Rehab 2004; 

83(6):421-7. 

54. Lichstein KL, Riedel BW, Lester KW et al. Occult 

sleep apnea in a recruited sample of older adults with 

insomnia. J Consult Clin Psychol 1999; 67(3):405-10. 

55. Mahendran R. Characteristics of patients referred to an 

insomnia clinic. Singapore Med J 2001; 42(2):064-7. 

56. Margolis N. Prevalence, costs, and consequences of 

insomnia. Reference bibliography: 1993-1998. Sleep 

1999; 22(Suppl 2):S409-12. 

57. Mashiko H, Niwa S, Kumashiro H et al. Effect of 

trazodone in a single dose before bedtime for sleep 

disorders accompanied by a depressive state: dosefinding study with no concomitant use of hypnotic 

agent. Psychiatry Clin Neurosci 1999; 53(2):193-4. 

58. Morawetz D. Behavioral self-help treatment for 

insomnia: A controlled evaluation. Behav Ther 1989; 

20(3):365-79. 

59. Nelson J, Harvey AG. An exploration of pre-sleep 

cognitive activity in insomnia: Imagery and verbal 

thought. Br J Clin Psychol 2003; 42(3):271-88. 

60. Reynolds CF, Kupfer DJ, Thase ME et al. Sleep, 

gender, and depression: an analysis of gender effects 

on the electroencephalographic sleep of 302 depressed 

outpatients. Biol Psychiatry 1990; 28(8):673-84. 

61. Riemann D, Klein T, Rodenbeck A et al. Nocturnal 

cortisol and melatonin secretion in primary insomnia. 

Psychiatry Res 2002; 113(1-2):17-27. 

62. Saletu B, Prause W, Loffler-Stastka H et al. Quality of 

life in nonorganic and organic sleep disorders: I. 

Comparison with normative data. Wien Klin 

Wochenschr 2003; 115(7-8):246-54. 

63. Savard J, Laroche L, Simard S et al. Chronic insomnia 

and immune functioning. Psychosom Med 2003; 65(2 

):211-21. 

64. Smith MT, Perils ML, Chengazi VU et al. 

Neuroimaging of NREM sleep in primary insomnia: A 

Tc-99-HMPAO single photon emission computed 

tomography study. Sleep 2002; 25(3):325-35. 

65. Stepanski E, Zorick F, Roehrs T et al. Effects of sleep 

deprivation on daytime sleepiness in primary 

insomnia. Sleep 2000; 23(2):215-9. 

66. Stoller MK. The socio-economics of insomnia: The 

materials and the methods. Eur Psychiatry 1997; 

12(Suppl 1):41S-8. 

67. Tachibana H, Izumi T, Honda S et al. The prevalence 

and pattern of insomnia in Japanese industrial 

workers: relationship between psychosocial stress and 

type of insomnia. Psychiatry Clin Neurosci 1998; 

52(4):397-402. 

68. Van Egeren L, Haynes SN, Franzen M et al. Presleep 

cognitions and attributions in sleep-onset insomnia. J 

Behav Med 1983; 6(2):217-32. 

69. Vgontzas AN, Bixler EO, Kales A et al. Validity and 

clinical utility of sleep laboratory criteria for insomnia. 

Int J Neurosci 1994; 77(1-2):11-21. 

70. Waters WF, Adams Jr SG, Binks P et al. Attention, 

stress and negative emotion in persistent sleep-onset 

and sleep-maintenance insomnia. Sleep 1993; 

16(2):128-36. 

71. Wittig RM, Zorick FJ, Blumer D et al. Disturbed sleep 

in patients complaining of chronic pain. J Nerv Ment 

Dis 1982; 170( 7):429-31. 
E-6

Excluded - Design (Case Report) 

The following studies were excluded because they were case reports. 

 1. Aguglia U, Gambardella A, Quattrone A. Sleepinduced masticatory myoclonus: A rare parasomnia 

associated with insomnia. Sleep 1991; 14(1):80-2. 

 2. Allan Hobson J. Sleep and dream suppression 

following a lateral medullary infarct: a first-person 

account. Conscious Cogn 2002; 11(3):377-90. 

 3. Bricolo A. Insomnia after bilateral stereotactic 

thalamotomy in man. J Neurol Neurosurg Psychiatry 

1967; 30(2):154-8. 

 4. Cordeiro QJ, de Araujo Medrado Faria M, Fraguas RJ. 

Depression, insomnia, and memory loss in a patient 

with chronic intoxication by inorganic mercury. J 

Neuropsychiatry Clin Neurosci 2003; 15(4):457-8. 

 5. Hayter J. Insomnia in an older person. Clin Gerontol 

1983; 1(3):96-7. 

 6. Jones ME, Withey S, Harrison DH. 'Clicking-brain 

syndrome': A curious cause of insomnia. Br J Plast 

Surg 2001; 54(8):714-6. 

 7. Kayukawa Y, Okada T, Hayakawa T et al. Rapid eye 

movement-localized apnea in a female patient with 

chronic insomnia. Psychiatry Clin Neurosci 2002; 

56(3):321-2. 

 8. Mendelson WB, Garnett D, Gillin JC. Flurazepaminduced sleep apnea syndrome in a patient with 

insomnia and mild sleep-related respiratory changes. J 

Nerv Ment Dis 1981; 169(4):261-4. 

 9. Taratuto AL, Piccardo P, Reich EG et al. Insomnia 

associated with thalamic involvement in E200K 

Creutzfeldt-Jakob disease. Neurol 2002; 58(3):362-7. 

Excluded - Design (No Control Group) 

The following studies were excluded because they did not have a control group. 

1. Agargun MY, Kara H. Recurrent sleep panic, 

insomnia, and suicidal behavior in patients with panic 

disorder. Compr Psychiatry 1998; 39(3):149-51. 

 2. Aikens JE, Vanable PA, Tadimeti L et al. Differential 

rates of psychopathology symptoms in periodic limb 

movement disorder, obstructive sleep apnea, 

psychophysiological insomnia, and insomnia with 

psychiatric disorder. Sleep 1999; 22(6):775-80. 

 3. Allaert FA, Urbinelli R. Sociodemographic profile of 

insomniac patients across national surveys. CNS 

Drugs 2004; 18(Suppl 1):3-7. 

 4. Bastien CH, Vallieres A, Morin CM. Precipitating 

factors of insomnia. Behav Sleep Med 2004; 2(1):50-

62. 

 5. Bliwise N, Bliwise DL, Dement WC. Age and 

psychopathology in insomnia. Clin Gerontol 1985; 

4(2):3-9. 

 6. Bonnet MH, Kramer M. The interaction of age, 

performance and hypnotics in the sleep of insomniacs. 

J Am Geriatr Soc 1981; 29(11):508-12. 

 7. Broughton R, Tolentino MA, Krelina M. Excessive 

fragmentary myoclonus in NREM sleep: a report of 38 

cases. Electroencephalogr Clin Neurophysiol 1985; 

61(2):123-33. 

 8. Buda FB. Sleep disorders in HIV-positive patients. 

Curable causes of daytime fatigue and sleepiness. Int 

Conf AIDS 1996; 11(1):107 (abstr Mo.B.1301). 

 9. Chapman J, Arlazoroff A, Goldfarb LG et al. Fatal 

insomnia in a case of familial Creutzfeldt-Jakob 

disease with the codon 200(Lys) mutation. Neurol 

1996; 46(3):758-61. 

10. Chemerinski E, Ho B, Flaum M et al. Insomnia as a 

predictor for symptom worsening following 

antipsychotic withdrawal in schizophrenia. Compr 

Psychiatry 2002; 43(5):393-6. 

11. de Carvalho LB , Lopes EA, Silva L et al. Personality 

features in a sample of psychophysiological insomnia 

patients. Arq NeuroPsiquiatr Sep; 61(3A):588-90. 

12. Edinger JD, Stout AL, Hoelscher TJ. Cluster analysis 

of insomniacs' MMPI profiles: relation of subtypes to 

sleep history and treatment outcome. Psychosom Med 

1988; 50(1):77-87. 

 
E-7

13. Guilleminault C, Lin CM, Goncalves MA et al. A 

prospective study of nocturia and the quality of life of 

elderly patients with obstructive sleep apnea or sleep 

onset insomnia. J Psychosom Res 2004; 56(5):511-15. 

14. Guilleminault C, Palombini L, Poyares D et al. 

Chronic insomnia, postmenopausal women, and sleep 

disordered breathing: part 1. Frequency of sleep 

disordered breathing in a cohort. J Psychosom Res 

2002; 53(1):611-5. 

15. Hall M, Buysse DJ, Nowell PD et al. Symptoms of 

stress and depression as correlates of sleep in primary 

insomnia. Psychosom Med 2000; 62(2):227-30. 

16. Hart RP, Morin CM, Best AM. Neuropsychological 

performance in elderly insomnia patients. Aging Cogn 

1995; 2(4):268-78. 

17. Hattori T. Clinical study of insomnia, a common 

disorder in primary care: from a viewpoint of 

consultation-liaison psychiatry. Jpn J Psychiatry 

Neurol 1991; 45(4):775-8. 

18. Kales A, Caldwell AB, Preston TA et al. Personality 

patterns in insomnia. Theoretical implications. Arch 

Gen Psychiatry 1976; 33(9):1128-24. 

19. Kalimo R, Tenkanen L, Harma M et al. Job stress and 

sleep disorders: Findings from the Helsinki Heart 

Study. Stress Med 2000; 16(2):65-75. 

20. Kalogjera-Sackellares D, Cartwright RD. Comparison 

of MMPI profiles in medically and psychologically 

based insomnias. Psychiatry Res 1997; 70(1):49-56. 

21. Morin CM, Rodrigue S, Ivers H. Role of stress, 

arousal, and coping skills in primary insomnia. 

Psychosom Med 2003; 65(2):259-67. 

22. Ohayon MM, Caulet M, Lemoine P. Comorbidity of 

mental and insomnia disorders in the general 

population. Compr Psychiatry 1998; 39(4):185-97. 

23. Philip P, Guilleminault C. Adult psychophysiologic 

insomnia and positive history of childhood insomnia. 

Sleep 1996; 19(3 Suppl):S16-22. 

24. Prause W, Saletu B, Anderer P et al. Quality of life in 

nonorganic and organic sleep disorders: II. Correlation 

with objective and subjective quality of sleep and 

awakening. Wien Klin Wochenschr 2003; 

115(10):326-33. 

25. Radecki SE, Brunton SA. Management of insomnia in 

office-based practice. National prevalence and 

therapeutic patterns. Arch Fam Med 1993; 

2(11):1129-34. 

 

26. Riedel BW, Winfield CF, Lichstein KL. First night 

effect and reverse first night effect in older adults with 

primary insomnia: Does anxiety play a role? Sleep 

Med 2001; 2(2):125-33. 

27. Roehrs T, Conway W, Wittig R et al. Sleep-wake 

complaints in patients with sleep-related respiratory 

disturbances. Am Rev Resp Dis 1985; 132(3):520-3. 

28. Roehrs T, Zorick F, Sicklesteel J et al. Age-related 

sleep-wake disorders at a sleep disorder center. J Am 

Geriatr Soc 1983; 31(6):364-70. 

29. Rosenthal L, Roehrs T. , Sicklesteel J. et al. Periodic 

movements during sleep, sleep fragmentation, and 

sleep-wake complaints. Sleep 1984; 7(4):326-30. 

30. Rossini SRG, Reimao R, Lefevre BH. Chronic 

insomnia in senior citizens: A psychological 

assessment. Rev Bras Neurol Psiquiatr 1999; 3(2):49-

52. 

31. Rotenberg V, Tsetlin M. Clinicophysiological analysis 

of sleep disorders in patients with borderline states. 

Sov Neurol Psychiatry 1985; 18(1):24-35. 

32. Schneider-Helmert D, Kumar A. Sleep, its subjective 

perception, and daytime performance in insomniacs 

with a pattern of alpha sleep. Biol Psychiatry 1995; 

37(2):99-105. 

33. Schramm E, Hohagen F, Kappler C et al. Mental 

comorbidity of chronic insomnia in general practice 

attenders using DSM-III-R. Acta Psychiatr Scand 

1995; 91(1):10-7. 

34. Skaer TL, Robison LM, Sclar DA et al. Psychiatric 

comorbidity and pharmacological treatment patterns 

among patients presenting with insomnia. An 

assessment of office-based encounters in the USA in 

1995 and 1996. Clin Drug Invest 1999; 18(2):161-7. 

35. Smith MT, Perlis ML, Haythornthwaite JA. Suicidal 

ideation in outpatients with chronic musculoskeletal 

pain: an exploratory study of the role of sleep onset 

insomnia and pain intensity. Clin J Pain 2004; 

20(2):111-8. 

36. Specchio LM, Prudenzano MP, De Tommaso M et al. 

Insomnia, quality of life and psychopathological 

features. Brain Res Bull 2004; 63(5):385-91. 

37. Stephanski E, Koshorek G, Zorick F et al. 

Characteristics of individuals who do or do not seek 

treatment for chronic insomnia. Psychosom 1989; 

30(4):421-7. 

 
E-8

38. Stone J, Morin CM, Hart RP et al. Neuropsychological 

functioning in older insomniacs with or without 

obstructive sleep apnea. Psychol Aging 1994; 

9(2):231-6. 

39. Tabloski PA, Church OM. Insomnia, alcohol and drug 

use in community-residing elderly persons. J Subst 

Use 1999; 4(3):147-54. 

40. Tan T, et al. Biopsychobehavioral correlates of 

insomnia: IV. Diagnosis based on DSM-III. Am J 

Psychiatry 1984; 141(3):357-62. 

41. Vandeputte M, de Weerd A. Sleep disorders and 

depressive feelings: A global survey with the Beck 

depression scale. Sleep Med 2003; 4(4):343-5. 

42. Vincent N, Walker J. Anxiety sensitivity: predictor of 

sleep-related impairment and medication use in 

chronic insomnia. Depress Anxiety 2001; 14(4):238-

43. 

 

43. Vlasov N, Yadgarov I. The structure of nocturnal 

sleep in sleep disorders in middle-aged and elderly 

people. Sov Neurol Psychiatry 1986; 19(3):71-9. 

44. Vollrath M, Wicki W, Angst J. The Zurich study. VIII. 

Insomnia: association with depression, anxiety, 

somatic syndromes, and course of insomnia. Eur Arch 

Psychiatry Neurol Sci 1989; 239(2):113-24. 

45. Wilson KG, Eriksson MY, D'Eon JL et al. Major 

depression and insomnia in chronic pain. Clin J Pain 

2002; 18(2):77-83. 

46. Wilson KG, Watson ST, Currie SR. Daily dairy and 

ambulatory activity monitoring of sleep in patients 

with insomnia associated with chronic 

musculoskeletal pain. Pain 1998; 75(1):75-84. 

47. Zucconi M, Ferini-Strambi L, Gambini O et al. 

Structured psychiatric interview and ambulatory sleep 

monitoring in young psychophysiological insomniacs. 

J Clin Psychiatry 1996; 57(8):364-70. 

Excluded - Population (Non-Adult) 

The following studies were excluded because they did not examine an adult population. 

 1. Abdel-Khalek AM . Epidemiologic study of sleep 

disorders in Kuwaiti adolescents. Percept Mot Skills 

2001; 93(3):901-10. 

 2. Abdel-Khalek AM . Prevalence of reported insomnia 

and its consequences in a survey of 5,044 adolescents 

in Kuwait. Sleep 2004; 27(4):726-31. 

 3. Ando K, Hayakawa T, Ohta T et al. Long-term followup study of 10 adolescent patients with sleep-wake 

schedule disorders. Jpn J Psychiatry Neurol 1994; 

48(1):37-41. 

 4. Bertelson AD, Monroe LJ. Personality patterns of 

adolescent poor and good sleepers. J Abnorm Child 

Psychol 1979; 7(2):191-7. 

 5. Bruni O, Ferri R, D'Agostino G et al. Sleep 

disturbances in Angelman syndrome: a questionnaire 

study. Brain Devel 2004; 26(4):233-40. 

 6. Dollinger SJ, Horn JL, Boarini D. Disturbed sleep and 

worries among learning disabled adolescents. Am J 

Orthopsychiatry 1988; 58(3):428-34. 

 7. Leger D, Guilleminault C, Bader G et al. Medical and 

socio-professional impact of insomnia. Sleep 2002; 

25(6):625-9. 

 8. Okuji Y, Matsuura M, Kawasaki N et al. Prevalence of 

insomnia in various psychiatric diagnostic categories. 

Psychiatry Clin Neurosci 2002; 56(3):239-40. 
E-9

Excluded - Population (Not Chronic Insomnia) 

The following studies were excluded because the participants did not suffer from chronic 

insomnia as defined in this report. 

 1. Abe K, Suzuki T. Age trends of early awakening 

and feeling worse in the morning than in the 

evening in apparently normal people. J Nerv Ment 

Dis 1985; 173(8):495-8. 

 2. Agarguen MY, Kara H, Solmaz M. Sleep 

disturbances and suicidal behavior in patients with 

major depression. J Clin Psychiatry 1997; 

58(6):249-51. 

 3. Alapin I, Fichten CS, Libman E et al. How is good 

and poor sleep in older adults and college students 

related to daytime sleepiness, fatigue, and ability to 

concentrate? J Psychosom Res 2000; 49(5):381-90. 

 4. Aldrich MS, Foster NL, White RF et al. Sleep 

abnormalities in progressive supranuclear palsy. 

Ann Neurol 1989; 25(6):577-81. 

 5. Aldrich MS, Shipley JE. Alcohol use and periodic 

limb movements of sleep. Alcohol Clin Exp Res 

1993; 17 (1):192-6. 

 6. Allen RP. Article reviewed: Mortality associated 

with sleep duration and insomia. Sleep Med 2002; 

3(4 ):373-5. 

 7. Allgulander C, Borg S, Vikander B. A 4-6 year 

follow-up of 50 patients with primary dependence 

on sedative and hypnotic drugs. Am J Psychiatry 

1984; 141(12):1580-2. 

 8. Almeida OP, Tamai S, Garrido R. Sleep complaints 

among the elderly: results from a survey in a 

psychogeriatric outpatient clinic in Brazil. Int 

Psychogeriatr 1999; 11(1):47-56. 

 9. Almer G, Hainfellner JA, Brucke T et al. Fatal 

familial insomnia: a new Austrian family. Brain 

1999; 122 ( Pt 1):5-16. 

 10. Alster J, Shemesh Z, Ornan M et al. Sleep 

disturbance associated with chronic tinnitus. Biol 

Psychiatry 1993; 34(1-2):84-90. 

 11. Althuis MD, Fredman L, Langenberg PW et al. The 

relationship between insomnia and mortality among 

community-dwelling older women. J Am Geriatr 

Soc 1998; 46(10):1270-3. 

 12. Amagai Y, Ishikawa S, Gotoh T et al. Sleep 

Duration and Mortality in Japan: the Jichi Medical 

School Cohort Study. J Epidemiol 2004; 14(4):124-

8. 

 13. Andrews HB, Davis N. Sleeping disorders among 

West Australian tertiary students. Community 

Health Stud 1988; 12(2):208-11. 

 14. Angle HV. Sleep problems and sleep medication 

involvement of psychiatric patients. J Nerv Ment 

Dis 1979; 167(12):752-7. 

 15. Angst J, Vollrath M, Koch R et al. The Zurich 

Study: VII. Insomnia: Symptoms, classification and 

prevalence. Eur Arch Psychiatry Neurol Sci 1989; 

238(5-6):285-93. 

 16. Arriaga F, Paiva T, Matos-Pires A et al. The sleep 

of non-depressed patients with panic disorder: A 

comparison with normal controls. Acta Psychiatr 

Scand 1996; 93(3):191-4. 

 17. Asplund R. Sleep and cardiac diseases amongst 

elderly people. J Int Med 1994; 236(1):65-71. 

 18. Asplund R. Sleepiness and sleep in elderly persons 

with tinnitus. Arch Gerontol Geriatri 2003; 

37(2):139-45. 

 19. Astrom C, Lunde I, Ortmann J et al. Sleep 

disturbances in torture survivors. Acta Neurol 

Scand 1989; 79(2 ):150-4. 

 20. Atkinson JH, Ancoli-Israel S, Slater MA et al. 

Subjective sleep disturbance in chronic back pain. 

Clin J Pain 1988; 4(4):225-32. 

 21. Aversa Lopes E , Coin De Carvalho LB, Bernal Da 

Costa Seguro P et al. Sleep disorders in pregnancy. 

Arq NeuroPsiquiatr 2004; 62(2 A):217-21. 

 22. Avoni P, Cortelli P, Montagna P et al. Circadian 

hormonal rhythms in two new cases of fatal familial 

insomnia. Acta Neurol 1991; 13(6):574-6. 

 23. Baker FC, Driver HS. Self-reported sleep across the 

menstrual cycle in young, healthy women. J 

Psychosom Res 2004; 56(2):239-43. 
E-10

 24. Baldwin CM, Bell IR, Guerra S et al. Associations 

between chemical odor intolerance and sleep 

disturbances in community-living adults. Sleep Med 

2004; 5(1):53-9. 

 25. Baldwin CM, Griffith KA, Nieto FJ et al. The 

association of sleep-disordered breathing and sleep 

symptoms with quality of life in the Sleep Heart 

Health Study. Sleep 2001; 24(1):96-105. 

 26. Ban DJ, Lee TJ. Sleep Duration, Subjective Sleep 

Disturbances and Associated Factors Among 

University Students in Korea. J Korean Med Sci 

2001; 16(4):475-80. 

 27. Barak Y, Achiron A, Kimh R et al. Health risks 

among shift workers: a survey of female nurses. 

Health Care Women Int 1996; 17(6):527-33. 

 28. Barbe F, Quera-Salva MA, McCann C et al. Sleeprelated respiratory disturbances in patients with 

Duchenne muscular dystrophy. Eur Resp J 1994; 

7(8):1403-8. 

 29. Barthlen GM, Lange DJ. Unexpectedly severe sleep 

and respiratory pathology in patients with 

amyotrophic lateral sclerosis. Eur J Neurol 2000; 

7(3):299-302. 

 30. Bassetti CL, Mauerhofer D, Gugger M et al. 

Restless legs syndrome: a clinical study of 55 

patients. Eur Neurol 2001; 45(2):67-74. 

 31. Beetar JT, Guilmette TJ, Sparadeo FR. Sleep and 

pain complaints in symptomatic traumatic brain 

injury and neurologic populations. Arch Phys Med 

Rehab 1996; 77(12):1298-302. 

 32. Bell IR, Bootzin RR, Ritenbaugh C et al. A 

polysomnographic study of sleep disturbance in 

community elderly with self-reported environmental 

chemical odor intolerance. Biol Psychiatry 1996; 

40(2):123-33. 

 33. Bellia V, Catalano F, Scichilone N et al. Sleep 

disorders in the elderly with and without chronic 

airflow obstruction: the SARA study. Sleep 2003; 

26(3):318-23. 

 34. Bellows JG. One genetic mutation, two diseases: 

fatal familial insomnia and Creutzfeldt-Jakob 

disease. Compr Ther 1993; 19(1):3. 

 35. Beshwari MMM, Bener A, Ameen A et al. 

Pesticide-related health problems and diseases 

among farmers in the United Arab Emirates. Int J 

Environ Health Res 1999; 9(3):213-21. 

 36. Bliwise DL. Historical change in the report of 

daytime fatigue. Sleep 1996; 19(6):462-4. 

 37. Bonati MT, Ferini-Strambi L, Aridon P et al. 

Autosomal dominant restless legs syndrome maps 

on chromosome 14q. Brain 2003; 126(Pt 6):1485-

92. 

 38. Brabbins CJ, Dewey ME, Copeland JRM et al. 

Insomnia in the elderly: Prevalence, gender 

differences and relationships with morbidity and 

mortality. Int J Geriatr Psychiatry 1993; 8(6):473-

80. 

 39. Brassington GS , King AC, Bliwise DL. Sleep 

problems as a risk factor for falls in a sample of 

community-dwelling adults aged 64-99 years. J Am 

Geriatr Soc 2000; 48(10):1234-40. 

 40. Brower KJ, Aldrich MS, Robinson EA et al. 

Insomnia, self-medication, and relapse to 

alcoholism. Am J Psychiatry 2001; 158( 3):399-

404. 

 41. Brown S, Atkinson H, Gutierrez R et al. Subjective 

sleep disturbance in HIV illness. Int Conf AIDS 

1990; 6(2):397 (abstr 2173). 

 42. Buboltz WCJ, Brown F, Soper B. Sleep habits and 

patterns of college students: a preliminary study. J 

Am Coll Health 2001; 50(3):131-5. 

 43. Budka H. Fatal familial insomnia around the world. 

Brain Pathol 1998; 8(3):553-70. 

 44. Buzzi G, Mostacci B, Sancisi E et al. Sleep 

complaints in periodic paralyses: A web survey. 

Funct Neurol 2001; 16(3):245-52. 

 45. Byles JE, Mishra GD, Harris MA et al. The 

problems of sleep for older women: changes in 

health outcomes. Age Ageing 2003; 32(2):154-63. 

 46. Caap-Ahlgren M, Dehlin O. Insomnia and 

depressive symptoms in patients with Parkinson's 

disease: Relationship to health-related quality of 

life. An interview study of patients living at home. 

Arch Gerontol Geriatr 2001; 32(1):23-33. 

 47. Call-Schmidt TA, Richardson SJ. Prevalence of 

sleep disturbance and its relationship to pain in 

adults with chronic pain. Pain Manag Nurs 2003; 

4(3):124-33. 

 48. Carney RM, Freedland KE, Jaffe AS. Insomnia and 

depression prior to myocardial infarction. 

Psychosom Med 1990; 52(6):603-9. 

 49. Carpenter BD, Strauss ME, Patterson MB. Sleep 

disturbances in community-dwelling patients with 

Alzheimer's disease. Clin Gerontol 1995; 16(2):35-

49. 
E-11

 50. Cartwright RD, Wood E. Adjustment disorders of 

sleep: The sleep effects of a major stressful event 

and its resolution. Psychiatry Res 1991; 39(3 ):199-

209. 

 51. Cernovsky ZZ. Life stress measures and reported 

frequency of sleep disorders. Percept Mot Skills 

1984; 58(1):39-49. 

 52. Chang PP, Ford DE, Mead LA et al. Insomnia in 

young men and subsequent depression. The Johns 

Hopkins Precursors Study. Am J Epidemiol 1997; 

146(2):105-14. 

 53. Charon F, Dramaix M, Mendlewicz J. 

Epidemiological survey of insomniac subjects in a 

sample of 1,761 outpatients. Neuropsychobiol 1989; 

21(3):109-10. 

 54. Chen CC, Yeh TL, Yang YK et al. Psychiatric 

morbidity and post-traumatic symptoms among 

survivors in the early stage following the 1999 

earthquake in Taiwan. Psychiatry Res 2001; 105(1-

2):13-22. 

 55. Chiu HF, Leung T, Lam LC et al. Sleep problems in 

Chinese elderly in Hong Kong. Sleep 1999; 

22(6):717-26. 

 56. Cirignotta F, Mondini S, Zucconi M et al. Insomnia: 

an epidemiological survey. Clin Neuropharmacol 

1985; 8(Suppl 1):S49-54. 

 57. Cohen D, Eisdorfer C, Prinz P et al. Sleep 

disturbances in the institutionalized aged. J Am 

Geriatr Soc 1983; 31(2):79-82. 

 58. Coren S. The prevalence of self-reported sleep 

disturbances in young adults. Int J Neurosci 1994; 

79(1-2):67-73. 

 59. Cortelli P, Gambetti P, Montagna P et al. Fatal 

familial insomnia: clinical features and molecular 

genetics. J Sleep Res 1999; 8(Suppl 1):23-9. 

 60. Cortelli P, Parchi P, Contin M et al. Cardiovascular 

dysautonomia in fatal familial insomnia. Clin Auton 

Res 1991; 1(1):15-21. 

 61. Cricco M, Simonsick EM, Foley DJ. The impact of 

insomnia on cognitive functioning in older adults. J 

Am Geriatr Soc 2001; 49(9):1185-9. 

 62. Crum RM, Storr CL, Chan YF et al. Sleep 

Disturbance and Risk for Alcohol-Related 

Problems. Am J Psychiatry 2004; 161(7):1197-203. 

 63. Curless R, French JM, James OF et al. Is caffeine a 

factor in subjective insomnia of elderly people? Age 

Ageing 1993; 22(1):41-5. 

 64. Dahlitz M, Parkes JD. Sleep paralysis. Lancet 1993; 

341(8842):406-7. 

 65. Daly RJ, Hassall C. Reported sleep on maintenance 

haemodialysis. British Medical Journal 2[708], 508-

9. 1970 May 30. 

 66. Davidson JR, MacLean AW, Brundage MD et al. 

Sleep disturbance in cancer patients. Soc Sci Med 

2002; 54(9):1309-21. 

 67. Davidson LM, Fleming R, Baum A. Chronic stress, 

catecholamines, and sleep disturbance at Three Mile 

Island. J Hum Stress 1987; 13(2):75-83. 

 68. De Souza J. Quality of life and insomnia in 

university psychology students. Hum 

Psychopharmacol 1996; 11(3):169-84. 

 69. De Vecchi A, Finazzi S, Padalino R et al. Sleep 

disorders in peritoneal and haemodialysis patients 

as assessed by a self-administered questionnaire. Int 

J Artif Organs 2000; 23(4):237-42. 

 70. DeViva JC, Zayfert C, Mellman TA. Factors 

associated with insomnia among civilians seeking 

treatment for PTSD: An exploratory study. Behav 

Sleep Med 2004; 2(3):162-76. 

 71. Dodge R, Cline MG, Quan SF. The natural history 

of insomnia and its relationship to respiratory 

symptoms. Arch Int Med 1995; 155(16):1797-800. 

 72. Doi Y, Minowa M. Gender differences in excessive 

daytime sleepiness among Japanese workers. Soc 

Sci Med 2003; 56(4):883-94. 

 73. Domenighetti G , D'Avanzo B, Bisig B. Health 

effects of job insecurity among employees in the 

Swiss general population. Int J Health Serv 2000; 

30(3):477-90. 

 74. Dorandeu A, Wingertsmann L, Chretien F et al. 

Neuronal apoptosis in fatal familial insomnia. Brain 

Pathol 1998; 8(3):531-7. 

 75. Douchez J, Droz JP, Desclaux B et al. Quality of 

life in long-term survivors of nonseminomatous 

germ cell testicular tumors. J Urol 1993; 

149(3):498-501. 

 76. Drake C, Richardson G, Roehrs T et al. 

Vulnerability to stress-related sleep disturbance and 

hyperarousal. Sleep 2004; 27(2):285-91. 

 77. Drummond SP, Gillin JC, Smith TL et al. The sleep 

of abstinent pure primary alcoholic patients: natural 

course and relationship to relapse. Alcohol Clin Exp 

Res 1998; 22(8):1796-802. 
E-12

 78. Dryman A, Eaton WW. Affective symptoms 

associated with the onset of major depression in the 

community: Findings from the US National Institute 

of Mental Health Epidemiologic Catchment Area 

Program. Acta Psychiatr Scand 1991; 84(1):1-5. 

 79. Dumont M, Montplaisir J, Infante-Rivard C. Sleep 

quality of former night-shift workers... XIIth 

International Symposium on Night and Shiftwork. 

Foxwoods symposium series, June 1995. Int J 

Occupat Environ Health 1997; 3(3):Suppl: S10-4. 

 80. Elger BS. Prevalence, Types and Possible Causes of 

Insomnia in a Swiss Remand Prison. Eur J 

Epidemiol 2004; 19(7):665-77. 

 81. Elsenbruch S, Thompson JJ, Hamish MJ et al. 

Behavioral and physiological sleep characteristics 

in women with irritable bowel syndrome. Am J 

Gastroenterol 2002; 97(9):2306-14. 

 82. Eriksen W, Natvig B, Bruusgaard D. Sleep 

Problems: a Predictor of Long-Term Work 

Disability? A Four-Year Prospective Study. Scand J 

Public Health 2001; 29(1):23-31. 

 83. Factor SA, McAlarney T, Sanchez-Ramos JR et al. 

Sleep disorders and sleep effect in Parkinson's 

disease. Mov Disord 1990; 5(4):280-5. 

 84. Fetveit A, Bjorvatn B. Sleep disturbances among 

nursing home residents. Int J Geriatr Psychiatry 

2002; 17(7):604-9. 

 85. Fichten CS, Libman E, Creti L et al. Role of 

thoughts during nocturnal awake times in the 

insomnia experience of older adults. Cogn Ther Res 

2001; 25(6):665-92. 

 86. Fichtenberg NL, Millis SR, Mann NR et al. Factors 

associated with insomnia among post-acute 

traumatic brain injury survivors. Brain Inj 2000; 

14(7):659-67. 

 87. Fischler B, Le Bon O, Hoffmann G et al. Sleep 

anomalies in the chronic fatigue syndrome. A 

comorbidity study. Neuropsychobiol 1997; 

35(3):115-22. 

 88. Foley D, Ancoli-Israel S, Britz P et al. Sleep 

disturbances and chronic disease in older adults: 

Results of the 2003 National Sleep Foundation 

Sleep in America Survey. J Psychosom Res 2004; 

56(5):497-502. 

 89. Foley DJ, Monjan AA, Brown SL et al. Sleep 

complaints among elderly persons: an 

epidemiologic study of three communities. Sleep 

1995; 18(6):425-32. 

 90. Foley DJ, Monjan AA, Izmirlian G et al. Incidence 

and remission of insomnia among elderly adults in a 

biracial cohort. Sleep 1999; 22 Suppl 2:S373-8. 

 91. Folmer RL, Griest SE. Tinnitus and insomnia. Am J 

Otolaryngol Head Neck Med Surg 2000; 21(5):287-

93. 

 92. Frisoni GB, de Leo D, Rozzini R et al. Psychic 

correlates of sleep symptoms in the elderly. Int J 

Geriatr Psychiatry 1992; 7(12):891-8. 

 93. Fukunishi I, Kawamura N, Ishikawa T et al. Sleep 

characteristics of Japanese working men who score 

alexithymic on the Toronto Alexithymia Scale. 

Percept Mot Skills 1997; 84(3, Pt 1):859-65. 

 94. Gallassi R, Morreale A, Montagna P et al. "Fatal 

familial insomnia": neuropsychological study of a 

disease with thalamic degeneration. Cortex 1992; 

28(2):175-87. 

 95. Ganguli M, Reynolds CF, Gilby JE. Prevalence and 

persistence of sleep complaints in a rural older 

community sample: the MoVIES project. J Am 

Geriatr Soc 1996; 44(7):778-84. 

 96. Garbarino S, De Carli F, Mascialino B et al. 

Sleepiness in a population of Italian shiftwork 

policemen. J Hum Ergol 2001; 30(1-2):211-6. 

 97. Garbarino S, De Carli F, Nobili L et al. Sleepiness 

and sleep disorders in shift workers: a study on a 

group of Italian police officers. Sleep 2002; 

25(6):648-53. 

 98. Garbarino S, Nobili L, Beelke M et al. Sleep 

disorders and daytime sleepiness in state police 

shiftworkers. Arch Environ Health 2002; 57(2):167-

73. 

 99. Gering RC, Mahrer AR. Difficulty falling asleep. 

Psychol Rep 1972; 30(2):523-8. 

 100. Gigli GL, Moroni M, Visani L et al. A 

pharmacoepidemiologic Italian multicenter study on 

the treatment of unselected insomniac patients with 

brotizolam. Curr Ther Res Clin Exp 1991; 

50(5):652-66. 

 101. Gislason T, Almqvist M. Somatic diseases and 

sleep complaints. An epidemiological study of 

3,201 Swedish men. Acta Med Scand 1987; 

221(5):475-81. 

 102. Gislason T, Reynisdottir H, Kristbjarnarson H et al. 

Sleep habits and sleep disturbances among the 

elderly--an epidemiological survey. J Int Med 1993; 

234(1):31-9. 
E-13

 103. Goldfarb LG, Petersen RB, Tabaton M et al. Fatal 

familial insomnia and familial Creutzfeldt-Jakob 

disease: disease phenotype determined by a DNA 

polymorphism. Science 1992; 258(5083):806-8. 

 104. Haermae M, Tenkanen L, Sjoeblom T et al. 

Combined effects of shift work and life-style on the 

prevalence of insomnia, sleep deprivation and 

daytime sleepiness. Scand J Work Environ Health 

1998; 24(4):300-7. 

 105. Haider I. Patterns of insomnia in depressive illness: 

a subjective evaluation. Br J Psychiatry 1968; 

114(514):1127-32. 

 106. Hansotia P, Wall R, Berendes J. Sleep disturbances 

and severity of Huntington's disease. Neurol 1985; 

35(11):1672-4. 

 107. Hatoum HT, Kania CM, Kong SX et al. Prevalence 

of insomnia: a survey of the enrollees at five 

managed care organizations. Am J Manage Care 

1998; 4(1):79-86. 

 108. Hatoum HT, Kong SX, Kania CM et al. Insomnia, 

health-related quality of life and healthcare resource 

consumption. A study of managed-care organisation 

enrollees. Pharmacoecon 1998; 14(6 ):629-37. 

 109. Hauri P, Chernik D, Hawkins D et al. Sleep of 

depressed patients in remission. Arch Gen 

Psychiatry 1974; 31(3):386-91. 

 110. Hayer CA, Hicks RA. Type A-B scores and 

insomnia among college students: A replication and 

extension of earlier studies. Percept Mot Skills 

1993; 77(3, Pt 2):1265-6. 

 111. Heath AC, Eaves LJ, Kirk KM et al. Effects of 

lifestyle, personality, symptoms of anxiety and 

depression, and genetic predisposition on subjective 

sleep disturbance and sleep pattern. Twin Res 1998; 

1(4):176-88. 

 112. Heath AC, Kendler KS, Eaves LJ et al. Evidence for 

genetic influences on sleep disturbance and sleep 

pattern in twins. Sleep 1990; 13(4):318-35. 

 113. Henderson S, Jorm AF, Scott LR et al. Insomnia in 

the elderly: its prevalence and correlates in the 

general population. Med J Aust 1995; 162(1):22-4. 

 114. Hoffmann G. Evaluation of severe insomnia in the 

general population--implications for the 

management of insomnia: focus on results from 

Belgium. J Psychopharmacol 1999; 13(4 Suppl 

1):S31-2. 

 115. Hugel H, Ellershaw JE, Cook L et al. The 

prevalence, key causes and management of 

insomnia in palliative care patients. J Pain Symptom 

Manage 2004; 27(4):316-21. 

 116. Hui DS, Wong TY, Ko FW et al. Prevalence of 

sleep disturbances in chinese patients with endstage renal failure on continuous ambulatory 

peritoneal dialysis. Am J Kidney Dis 2000; 

36(4):783-8. 

 117. Hyyppa MT, Kronholm E. Sleep movements and 

poor sleep in patients with non-specific somatic 

complaints--II. Affective disorders and sleep 

quality. J Psychosom Res 1987; 31(5):631-7. 

 118. Infante-Rivard C, Dumont M, Montplaisir J. Sleep 

disorder symptoms among nurses and nursing aides. 

Int Arch Occupat Environ Health 1989; 61(5):353-

8. 

 119. Janson C, Gislason T, De Backer W et al. 

Prevalence of sleep disturbances among young 

adults in three European countries. Sleep 1995; 

18(7):589-97. 

 120. Janson C, Lindberg E, Gislason T et al. Insomnia in 

men - A 10-year prospective population based 

study. Sleep 2001; 24(4):425-30. 

 121. Jensen E, Dehlin O, Hagberg B et al. Insomnia in an 

80-year-old population: relationship to medical, 

psychological and social factors. J Sleep Res 1998; 

7(3):183-9. 

 122. Johns MW. Factor analysis of subjectively reported 

sleep habits, and the nature of insomnia. Psychol 

Med 1975; 5(1):83-8. 

 123. Johnson JE. Insomnia, alcohol, and over-thecounter drag use in old-old urban women. J 

Commun Health Nurs 1997; 14(3):181-8. 

 124. Johnston SK, Landis CA, Lentz MJ et al. Selfreported nap behavior and polysomnography at 

home in midlife women with and without insomnia. 

Sleep 2001; 24(8):913-9. 

 125. Kapur VK, Redline S, Nieto FJ et al. The 

relationship between chronically disrupted sleep 

and healthcare use. Sleep 2002; 25(3):289-96. 

 126. Katz DA, McHorney CA. Clinical correlates of 

insomnia in patients with chronic illness. Arch Int 

Med 1998; 158(10):1099-1107. 
E-14

 127. Kawada T, Kiryu Y, Sasazawa Y et al. Prevalence 

of insomnia and its relationship to the health habits 

or status of women living along a city road part 1. 

Epidemiologic study. Environ Health Prevent Med 

1997; 1(4):211-15. 

 128. Kiejna A, Wojtyniak B, Rymaszewska J et al. 

Prevalence of insomnia in Poland - Results of the 

National Health Interview Survey. Acta 

Neuropsychiatri 2003; 15(2):68-73. 

 129. Kim K, Uchiyama M, Liu X et al. Somatic and 

psychological complaints and their correlates with 

insomnia in the Japanese general population. 

Psychosom Med 2001; 63(3):441-6. 

 130. Kim K, Uchiyama M, Okawa M et al. An 

epidemiological study of insomnia among the 

Japanese general population. Sleep 2000; 23(1):41-

7. 

 131. Klink ME, Quan SF, Kaltenborn WT et al. Risk 

factors associated with complaints of insomnia in a 

general adult population. Influence of previous 

complaints of insomnia. Arch Int Med 1992; 

152(8):1634-7. 

 132. Krakow B, Haynes PL, Warner TD et al. 

Nightmares, insomnia, and sleep-disordered 

breathing in fire evacuees seeking treatment for 

posttraumatic sleep disturbance. J Traumatic Stress 

2004; 17(3):257-68. 

 133. Krakow B, Melendrez D, Ferreira E et al. 

Prevalence of insomnia symptoms in patients with 

sleep-disordered breathing. Chest 2001; 

120(6):1923-9. 

 134. Krakow B, Melendrez D, Pedersen B et al. 

Complex insomnia: insomnia and sleep-disordered 

breathing in a consecutive series of crime victims 

with nightmares and PTSD. Biol Psychiatry 2001; 

49(11):948-53. 

 135. Kripke DF, Garfinkel L, Wingard DL et al. 

Mortality associated with sleep duration and 

insomnia. Arch Gen Psychiatry 2002; 59(2):131-6. 

 136. Kupfer D, Harrow M, Detre T. Sleep patterns and 

psychopathology. Acta Psychiatr Scand 1969; 

45(1):75-89. 

 137. Leger D, Levy E, Paillard M. The direct costs of 

insomnia in France. Sleep 1999; 22(Suppl 2):S394-

401. 

 138. Li RH, Wing YK, Ho SC et al. Gender differences 

in insomnia--a study in the Hong Kong Chinese 

population. J Psychosom Res 2002; 53(1):601-9. 

 139. Liljenberg B, Almqvist M, Hetta J et al. Age and 

the prevalence of insomnia in adulthood. European 

Journal of Psychiatry 3(1), 5-12. 1989. 

 140. Liljenberg B, Almwvist M, Hetta J et al. Affective 

disturbance and insomnia: A population study. Eur J 

Psychiatry 1989; 3(2):91-8. 

 141. Livingston G, Blizard B, Mann A. Does sleep 

disturbance predict depression in elderly people? A 

study in inner London. Br J Gen Pract 1993; 

43(376):445-8. 

 142. Loayza H MP, Ponte TS, Carvalho CG et al. 

Association between mental health screening by 

self-report questionnaire and insomnia in medical 

students. Arq NeuroPsiquiatr 2001; 59(2-A):180-5. 

 143. Lobbezoo F, Visscher CM, Naeije M. Impaired 

health status, sleep disorders, and pain in the 

craniomandibular and cervical spinal regions. Eur J 

Pain 2004; 8(1):23-30. 

 144. Maggi S, Langlois JA, Minicuci N et al. Sleep 

complaints in community-dwelling older persons: 

prevalence, associated factors, and reported causes. 

J Am Geriatr Soc 1998; 46(2):161-8. 

 145. Manabe K, Matsui T, Yamaya M et al. Sleep 

patterns and mortality among elderly patients in a 

geriatric hospital. Gerontol 2000; 46(6):318-22. 

 146. Mant A, Eyland EA. Sleep patterns and problems in 

elderly general practice attenders: an Australian 

survey. Community Health Stud 1988; 12(2):192-9. 

 147. McCall WV, Reboussin BA, Cohen W. Subjective 

measurement of insomnia and quality of life in 

depressed inpatients. J Sleep Res 2000; 9(1):43-8. 

 148. McCarren M, Goldberg J, Ramakrishnan V et al. 

Insomnia in Vietnam era veteran twins: influence of 

genes and combat experience. Sleep 1994; 

17(5):456-61. 

 149. Medori R, Montagna P, Tritschler HJ et al. Fatal 

familial insomnia: a second kindred with mutation 

of prion protein gene at codon 178. Neurol 1992; 

42(3 Pt 1):669-70. 

 150. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia 

and its treatment. Prevalence and correlates. Arch 

Gen Psychiatry 1985; 42(3):225-32. 

 151. Morgan K. Daytime activity and risk factors for 

late-life insomnia. J Sleep Res 2003; 12(3):231-8. 

 152. Morgan K, Clarke D. Longitudinal trends in latelife insomnia: Implications for prescribing. Age 

Ageing 1997; 26(3):179-84. 
E-15

 153. Morgan K, Clarke D. Risk factors for late-life 

insomnia in a representative general practice 

sample. Br J Gen Pract 1997; 47(416):166-9. 

 154. Morgan K, Dallosso H, Ebrahim S et al. 

Characteristics of subjective insomnia in the elderly 

living at home. Age Ageing 1988; 17(1):1-7. 

 155. Morgan K, Healey DW, Healey PJ. Factors 

influencing persistent subjective insomnia in old 

age: a follow-up study of good and poor sleepers 

aged 65 to 74. Age Ageing 1989; 18(2):117-22. 

 156. Morin CM, Gramling SE. Sleep patterns and aging: 

Comparison of older adults with and without 

insomnia complaints. Psychol Aging 1989; 

4(3):290-4. 

 157. Moul DE, Nofzinger EA, Pilkonis PA et al. 

Symptom reports in severe chronic insomnia. Sleep 

2002; 25(5):553-63. 

 158. Nakata A, Haratani T, Kawakami N et al. Sleep 

problems in white-collar male workers in an electric 

equipment manufacturing company in Japan . Ind 

Health 2000; 38(1):62-8. 

 159. Nakata A, Haratani T, Takahashi M et al. Job stress, 

social support, and prevalence of insomnia in a 

population of Japanese daytime workers . Soc Sci 

Med 2004; 59(8):1719-30. 

 160. Newman AB, Enright PL, Manolio TA et al. Sleep 

disturbance, psychosocial correlates, and 

cardiovascular disease in 5201 older adults: the 

Cardiovascular Health Study... abstract presented at 

the November 1993 meeting of American Geriatrics 

Society. J Am Geriatr Soc 1997; 45(1):1-7. 

 161. Neylan TC, Marmar CR, Metzler TJ et al. Sleep 

disturbances in the Vietnam generation: findings 

from a nationally representative sample of male 

Vietnam veterans. Am J Psychiatry 1998; 

155(7):929-33. 

 162. Novak M, Mucsi I, Shapiro CM et al. Increased 

utilization of health services by insomniacs - An 

epidemiological perspective. J Psychosom Res 

2004; 56(5):527-36. 

 163. Ogunremi O. The subjective sleep patterns and 

dreams of Nigerians. Afr J Psychiatry 1978; 4(3 

Suppl 4):113-9. 

 164. Ohayon M. Epidemiological study on insomnia in 

the general population. Sleep 1996; 19(3 Suppl):S7-

15. 

 165. Ohayon MM, Caulet M, Guilleminault C. How a 

general population perceives its sleep and how this 

relates to the complaint of insomnia. Sleep 1997; 

20(9):715-23. 

 166. Ohayon MM, Caulet M, Philip P et al. How sleep 

and mental disorders are related to complaints of 

daytime sleepiness. Arch Int Med 1997; 

157(22):2645-52. 

 167. Ohayon MM, Caulet M, Priest RG et al. DSM-IV 

and ICSD-90 insomnia symptoms and sleep 

dissatisfaction. Br J Psychiatry 1997; 171:382-8. 

 168. Ohida T, Kamal AMM, Uchiyama M et al. The 

Influence of Lifestyle and Health Status Factors on 

Sleep Loss Among the Japanese General 

Population. Sleep 2001; 24(3):333-8. 

 169. Olson LG. A community survey of insomnia in 

Newcastle. Aust N Z J Pub Health 1996; 20(6):655-

7. 

 170. Owens JF, Matthews KA. Sleep disturbance in 

healthy middle-aged women. Maturitas 1998; 

30(1):41-50. 

 171. Pallesen S, Nordhus IH, Nielsen GH et al. 

Prevalence of insomnia in the adult Norwegian 

population. Sleep 2001; 24(7):771-9. 

 172. Partinen M, Eskelinen L, Tuomi K. Complaints of 

insomnia in different occupations. Scand J Work 

Environ Health 1984; 10(6):467-9. 

 173. Piani A, Brotini S, Dolso P et al. Sleep disturbances 

in elderly: A subjective evaluation over 65. Arch 

Gerontol Geriatr 2004; 38(Suppl):325-31. 

 174. Piccione P, Tallarigo R, Zorick F et al. Personality 

differences between insomniac and non-insomniac 

psychiatry outpatients. J Clin Psychiatry 1981; 

42(7):261-3. 

 175. Pollak CP, Perlick D, Linsner JP et al. Sleep 

problems in the community elderly as predictors of 

death and nursing home placement. J Community 

Health 1990; 15(2):123-35. 

 176. Quera-Salva MA, Orluc A, Goldenberg F et al. 

Insomnia and use of hypnotics: Study of a French 

population. Sleep 14(5), 386-391. 1991. 

 177. Redeker NS, Lev EL, Ruggiero J. Insomnia, fatigue, 

anxiety, depression, and quality of life of cancer 

patients undergoing chemotherapy. Sch Inq Nurs 

Pract 2000; 14(4):275-90; 291-8. 
E-16

 178. Reimao R, Souza JC, Gaudioso CE et al. Nocturnal 

sleep pattern in Native Brazilian Terena adults. Arq 

NeuroPsiquiatr 2000; 58(2A):233-8. 

 179. Reynolds CTL, Sewitch DE, Restifo K et al. 

Persistent psychophysiologic insomnia: Preliminary 

research diagnostic criteria and EEG sleep data. Am 

J Psychiatry 1984; 141(6):804-5. 

 180. Roberts RE, Shema SJ, Kaplan GA. Prospective 

data on sleep complaints and associated risk factors 

in an older cohort. Psychosom Med 1999; 

61(2):188-96. 

 181. Roberts RE, Shema SJ, Kaplan GA et al. Sleep 

complaints and depression in an aging cohort: A 

prospective perspective. Am J Psychiatry 2000; 

157(1):81-8. 

 182. Robinson E, Richardson-Robinson F. Effects of 

Loss of Sleep (2). J Exp Psychol 1922; 5:93-100. 

 183. Roehrs T, Lineback W, Zorick F et al. Relationship 

of psychopathology to insomnia in the elderly. J 

Am Geriatr Soc 1982; 30(5):312-5. 

 184. Rubinstein ML, Selwyn PA. High prevalence of 

insomnia in an outpatient population with HIV 

infection. J Acquir Immune Defic Syndr Hum 

Retrovirol 1998; 19(3):260-5. 

 185. Rumble R, Morgan K. Hypnotics, sleep, and 

mortality in elderly people. J Am Geriatr Soc 1992; 

40(8):787-91. 

 186. Sadler M. Lamotrigine associated with insomnia. 

Epilepsia 1999; 40(3):322-5. 

 187. Schubert CR, Cruickshanks KJ, Dalton DS et al. 

Prevalence of sleep problems and quality of life in 

an older population. Sleep 2002; 25(8):889-93. 

 188. Seppala M, Hyyppa MT, Impivaara O et al. 

Subjective quality of sleep and use of hypnotics in 

an elderly urban population. Aging Clin Exp Res 

1997; 9(5):327-34. 

 189. Shute GE, Fitzgerald SG. Cognitive developmental 

level and sleep-onset insomnia. Percept Mot Skills 

1988; 67(2):470. 

 190. Simon GE, VonKorff M. Prevalence, burden, and 

treatment of insomnia in primary care. Am J 

Psychiatry 1997; 154(10):1417-23. 

 191. Sukying C, Bhokakul V, Udomsubpayakul U. An 

epidemiological study on insomnia in an elderly 

Thai population. J Med Assoc Thai 2003; 

86(4):316-24. 

 192. Sutton DA, Moldofsky H, Badley EM. Insomnia 

and health problems in Canadians. Sleep 2001; 

24(6):665-70. 

 193. Sweetwood HL, et al. Sleep disorder over time: 

Psychiatric correlates among males. Br J Psychiatry 

1980; 136:456-62. 

 194. Tabernero C, Polo JM, Sevillano MD et al. Fatal 

familial insomnia: clinical, neuropathological, and 

genetic description of a Spanish family. J Neurol 

Neurosurg Psychiatry 2000; 68(6):774-7. 

 195. Tachibana H, Izumi T, Honda S et al. A study of the 

impact of occupational and domestic factors on 

insomnia among industrial workers of a 

manufacturing company in Japan. Occup Med 

(Oxford) 1996; 46(3):221-7. 

 196. Tandberg E, Larsen JP, Karlsen K. A communitybased study of sleep disorders in patients with 

Parkinson's disease. Mov Disord 1998; 13(6):895-9. 

 197. Tani P, Lindberg N, Nieminen-von Wendt T et al. 

Insomnia is a frequent finding in adults with 

Asperger syndrome. BMC Psychiatry 2003; 

3(1):12. 

 198. Unger ER, Nisenbaum R, Moldofsky H et al. Sleep 

assessment in a population-based study of chronic 

fatigue syndrome. BMC Neurol 2004; 4(1):6. 

 199. Walker S, Fine A, Kryger MH. Sleep complaints 

are common in a dialysis unit. Am J Kidney Dis 

1995; 26(5):751-6. 

 200. Walsh JK, Engelhardt CL. The direct economic 

costs of insomnia in the United States for 1995. 

Sleep 1999; 22(Suppl 2):S386-93. 

 201. Watts FN, Coyle K, East MP. The contribution of 

worry to insomnia. Br J Clin Psychol 1994; 

33(2):211-20. 

 202. Weissman MM, Greenwald S, Nino-Murcia G et al. 

The morbidity of insomnia uncomplicated by 

psychiatric disorders. Gen Hosp Psychiatry 1997; 

19(4):245-20. 

 203. Weyerer S, Dilling H. Prevalence and treatment of 

insomnia in the community: results from the Upper 

Bavarian Field Study. Sleep 1991; 14(5):392-8. 

 204. Wiegand M, Moller AA, Lauer CJ et al. Nocturnal 

sleep in Huntington's disease. J Neurol 1991; 

238(4):203-8. 

 205. Wilson C, Lack L. Sleeping habits of people living 

in the Adelaide metropolitan area: A telephone 

survey. Aust Psychol 1983; 18(3):369-76. 
E-17

 206. Yasuma F, Okada T. Sleep disturbances 

complicated with surgical stress. A questionnaire 

survey in 50 patients. Jpn J Anesthesiol 1989; 

38(1):66-70. 

 207. Yee B, Campbell A, Beasley R et al. Sleep 

disorders: A potential role in New Zealand motor 

vehicle accidents. Int Med J 2002; 32(7):297-304. 

 208. Young T, Rabago D, Zgierska A et al. Objective 

and subjective sleep quality in premenopausal, 

perimenopausal, and postmenopausal women in the 

Wisconsin Sleep Cohort Study. Sleep 2003; 

26(6):667-72. 

Excluded - Outcomes (Irrelevant) 

The following studies were excluded because they did not report on any of the outcomes of 

this review. 

 1. Agnew H, Webb WB. Sleep latencies in human 

subjects: Age, prior wakefulness, and reliability. 

Psychon Sci 1971; 24(6):253-4. 

 2. Alapin I, Libman E, Bailes S et al. Role of nocturnal 

cognitive arousal in the complaint of insomnia among 

older adults. Behav Sleep Med 2003; 1(3):155-70. 

 3. Asplund R, Aberg H. Sleep complaints in women of 

ages 40-64 years in relation to sleep in their parents. 

Sleep Med 2001; 2(3):233-7. 

 4. Azad N, Byszewski A, Sarazin FF-A et al. 

Hospitalized patients' preference in the treatment of 

insomnia: Pharmacological versus nonpharmacological. Can J Clin Pharmacol 2003; 

10(2):89-92. 

 5. Backhaus J, Junghanns K, Hohagen F. Sleep 

disturbances are correlated with decreased morning 

awakening salivary cortisol. Psychoneuroendocrinol 

2004; 29(9):1184-91. 

 6. Barnas C, Whitworth AB, Fleischhacker WW. Are 

patterns of benzodiazepine use predictable? A followup study of benzodiazepine users. Psychopharmacol 

1993; 111(3):301-5. 

 7. Bastien CH, LeBlanc M, Carrier J et al. Sleep EEG 

power spectra, insomnia, and chronic use of 

benzodiazepines. Sleep 2003; 26(3):313-7. 

 8. Bastien CH, Morin CM. Familial incidence of 

insomnia. J Sleep Res 2000; 9(1):49-54. 

 9. Bonato RA. Electroencephalographic correlates of 

sleep onset in chronic psychophysiological insomniacs 

and normal sleepers. Ottawa (ON): Carleton 

University; 1998. 

 

10. Brassington GS . Insomnia and styles of parental 

authority in college students. Psychol Rep 1994; 74(3, 

Pt 1):712-14. 

11. Buhr A, Bianchi MT, Baur R et al. Functional 

characterization of the new human GABA(A) receptor 

mutation beta3(R192H). Hum Genet 2002; 111 

(2):154-60. 

12. Cheek RE, Shaver JK, Lentz MJ. Lifestyle practices 

and sleep in women with and without insomnia... 35th 

Annual Communicating Nursing Research 

Conference/16th Annual WIN Assembly, "Health 

Disparities: Meeting the Challenge," held April 18-20, 

2002, Palm Springs, California. Commun Nurs Res 

2002; 35(10):393. 

13. Cheek RE, Shaver JL, Lentz MJ. Variations in sleep 

hygiene practices of women with and without 

insomnia. Res Nurs Health 2004; 27(4):225-36. 

14. Chevalier H, Los F, Boichut D et al. Evaluation of 

severe insomnia in the general population: results of a 

European multinational survey. J Psychopharmacol 

1999; 13(4 Suppl 1):S21-4. 

15. Cortelli P, Perani D, Parchi P et al. Cerebral 

metabolism in fatal familial insomnia: relation to 

duration, neuropathology, and distribution of proteaseresistant prion protein. Neurol 1997; 49(1):126-33. 

16. Cortelli P, Polinsky R, Montagna P et al. Alteration of 

the serotoninergic system in fatal familial insomnia 

[1]. Ann Neurol 2001; 50(3):421-2. 

17. Coursey RD, Frankel BL. Novelty-seeking, fantasy, 

and sensitization in chronic insomniacs. Percept Mot 

Skills 1977; 44(3 Pt 1):795-8. 

 
E-18

18. Currie SR, Clark S, Rimac S et al. Comprehensive 

Assessment of Insomnia in Recovering Alcoholics 

Using Daaily Sleep Diaries and Ambulatory 

Monitoring. Alcohol -Clin Exp Res 2003; 27(8):1262-

9. 

19. Ellis J, Hampson SE, Cropley M. Sleep hygiene or 

compensatory sleep practices: An examination of 

behaviours affecting sleep in older adults. Psychol 

Health Med 2002; 7(2):157-62. 

20. Fast A, Hertz G. Nocturnal low back pain in 

pregnancy: Polysomnographic correlates. Am J 

Reprod Immunol 1992; 28(3-4):251-3. 

21. Gaillard JM. Chronic primary insomnia: possible 

physiopathological involvement of slow wave sleep 

deficiency. Sleep 1978; 1(2):133-47. 

22. Gaillard JM. Is insomnia a disease of slow-wave 

sleep? Eur Neurol 1976; 14(6):473-84. 

23. Goder R, Friege L, Fritzer G et al. Morning headaches 

in patients with sleep disorders: A systematic 

polysomnographic study. Sleep Med 2003; 4(5):385-

91. 

24. Harvey AG. Beliefs about the utility of presleep 

worry: An investigation of individuals with insomnia 

and good sleepers. Cogn Ther Res 2003; 27(4):403-

14. 

25. Harvey AG. Sleep hygiene and sleep-onset insomnia. 

J Nerv Ment Dis 2000; 188(1):53-5. 

26. Harvey L, Inglis SJ, Espie CA. Insomniacs' reported 

use of CBT components and relationship to long-term 

clinical outcome. Behav Res Ther 2002; 40(1):75-83. 

27. Hauri PJ. A cluster analysis of insomnia. Sleep 1983; 

6(4):326-38. 

28. Irwin M, Clark C, Kennedy B et al. Nocturnal 

catecholamines and immune function in insomniacs, 

depressed patients, and control subjects. Brain Behav 

Immun 2003; 17(5):365-72. 

29. Kales A, Bixler EO, Tan TL et al. Chronic hypnoticdrug use. Ineffectiveness, drug-withdrawal insomnia, 

and dependence. J Am MedAssoc 1974; 227(5):513-7. 

30. Kales A, Bixler EO, Vela-Bueno A et al. 

Biopsychobehavioral correlates of insomnia, III: 

Polygraphic findings of sleep difficulty and their 

relationship to psychopathology. Int J Neurosci 1984; 

23(1):43-55. 

31. Kales A, Scharf MB, Kales JD. Rebound insomnia: a 

new clinical syndrome. Science 1978; 

201(4360):1039-41. 

32. Karadeniz D, Ondze B, Besset A et al. Are periodic 

leg movements during sleep (PLMS) responsible for 

sleep disruption in insomnia patients? Eur J Neurol 

2000; 7(3):331-6. 

33. Mariotti P, Della Marca G, Iuvone L et al. Sleep 

disorders in Sanfilippo syndrome: a polygraphic study. 

Clin Electroencephal 2003; 34(1):18-22. 

34. Medori R, Tritschler HJ, LeBlanc A et al. Fatal 

familial insomnia, a prion disease with a mutation at 

codon 178 of the prion protein gene. N Engl J Med 

1992; 326(7):444-9. 

35. Mendelson WB. Long-term follow-up of chronic 

insomnia. Sleep 1995; 18(8):698-701. 

36. Mendelson WB. Are periodic leg movements 

associated with clinical sleep disturbance? Sleep 1996; 

19(3):219-23. 

37. Mendelson WB, Garnett D, Linnoila M. Do 

insomniacs have impaired daytime functioning? Biol 

Psychiatry 1984; 19(8):1261-4. 

38. Morin CM, Stone J, Trinkle D et al. Dysfunctional 

beliefs and attitudes about sleep among older adults 

with and without insomnia complaints . Psychol Aging 

1993; 8(3):463-7. 

39. Morris M, Lack L, Dawson D. Sleep-onset insomniacs 

have delayed temperature rhythms. Sleep 1990; 

13(1):1-14. 

40. Nowell PD, Buysse DJ, Reynolds CF 3rd et al. 

Clinical factors contributing to the differential 

diagnosis of primary insomnia and insomnia related to 

mental disorders. Am J Psychiatry 1997; 

154(10):1412-6. 

41. Ohayon MM, Zulley J. Correlates of global sleep 

dissatisfaction in the German population. Sleep 2001; 

24(7):780-7. 

42. Perlis ML, Kehr EL, Smith MT et al. Temporal and 

stagewise distribution of high frequency EEG activity 

in patients with primary and secondary insomnia and 

in good sleeper controls. J Sleep Res 2001; 10(2):93-

104. 

43. Perlis ML, Smith MT, Andrews PJ et al. Beta/Gamma 

EEG activity in patients with primary and secondary 

insomnia and good sleeper controls. Sleep 2001; 

24(1):110-7. 

44. Pollak CP, Perlick D, Linsner JP. Daily sleep reports 

and circadian rest-activity cycles of elderly 

community residents with insomnia. Biol Psychiatry 

1992; 32(11):1019-27. 
E-19

45. Riedel BW, Lichstein KL. Objective sleep measures 

and subjective sleep satisfaction: how do older adults 

with insomnia define a good night's sleep? Psychol 

Aging 1998; 13(1):159-63. 

46. Saletu-Zyhlarz GM, Anderer P, Berger P et al. 

Nonorganic insomnia in panic disorder: Comparative 

sleep laboratory studies with normal controls and 

placebo-controlled trials with alprazolam. Hum 

Psychopharmacol 2000; 15(4):241-54. 

47. Schneider-Helmert D, Whitehouse I, Kumar A et al. 

Insomnia and alpha sleep in chronic non-organic pain 

as compared to primary insomnia. Neuropsychobiol 

2001; 43(1):54-8. 

48. Souza JC, Magna LA, Reimao R. Insomnia and 

hypnotic use in Campo Grande general population, 

Brazil. Arq Neuropsiquiatr 2002; 60(3-B):702-7. 

49. Staner L, Cornette F, Maurice D et al. Sleep 

microstructure around sleep onset differentiates major 

depressive insomnia from primary insomnia. J Sleep 

Res 2003; 12(4):319-30. 

50. Stepanski E, Zorick F, Roehrs T et al. Daytime 

alertness in patients with chronic insomnia compared 

with asymptomatic control subjects. Sleep 1988; 

11(1):54-60. 

 

51. Takekawa H, Kubo J, Miyamoto T et al. Amyotrophic 

lateral sclerosis associated with insomnia and the 

aggravation of sleep-disordered breathing. Psychiatry 

Clin Neurosci 2001; 55(3):263-4. 

52. Terashima K, Mikami A, Tachibana N et al. Sleep 

characteristics of menopausal insomnia: a 

polysomnographic study. Psychiatry Clin Neurosci 

2004; 58(2):179-85. 

53. Vallieres A, Morin CM. Actigraphy in the assessment 

of insomnia. Sleep 2003; 26(7):902-6. 

54. Vanable PA, Aikens JE, Tadimeti L et al. Sleep 

latency and duration estimates among sleep disorder 

patients: variability as a function of sleep disorder 

diagnosis, sleep history, and psychological 

characteristics. Sleep 2000; 23(1):71-9. 

55. Vgontzas AN, Tsigos C, Bixler EO et al. Chronic 

insomnia and activity of the stress system: a 

preliminary study. J Psychosom Res 1998; 45(1 Spec 

No):21-31. 

56. Voderholzer U, Al-Shajlawi A, Weske G et al. Are 

there gender differences in objective and subjective 

sleep measures? A study of insomniacs and healthy 

controls. Depress Anxiety 2003; 17(3):162-72. 

57. Walsh JK, Schweitzer PK. Ten-year trends in the 

pharmacological treatment of insomnia. Sleep 1999; 

22(3):371-5. 

58. Zorick FJ, Roth T, Hartze KM et al. Evaluation and 

diagnosis of persistent insomnia. Am J Psychiatry 

1981; 138(6):769-73. 

Excluded - Outcomes (Inadequate Reporting) 

The following study was excluded because data relevant to the outcomes of interest were 

inadequately reported. 

 1. Winett CA. The mediating role of insomnia in the relation between life events and depression and mania. Miami (FL): 

University of Miami; 2001. 
E-20

Five hundred and fifty six studies were excluded for the question on management of chronic 

insomnia. The reasons for exclusion of studies were as follows: (1) the study was reported in a 

language other than English (n=27), (2) the report was a review/commentary/practice parameter 

(n=32), (3) the study report was a duplicate publication (n=3) (4) the study did not examine an 

adult population (n=17), (5) the study population did not suffer from chronic insomnia as defined 

in this report (n=221), (6) the study was not a randomized controlled trial (n=160), (7) the study 

did not have a placebo arm (n=48), (8) the study was not double-blind (n=15), (9) the study did 

not report on any of the outcomes of this review (n=18) and (10) the study outcomes were not 

adequately reported (n=15). 

Excluded - Non-English 

The following studies were excluded because they were reported in a language other than 

English. 

 1. Altamura AC, Colacurcio F, Mauri MC et al. 

Controlled clinical study on the effect of quazepam 

versus triazolam in patients with sleep disorders [Ital]. 

Minerva Psichiatr 1989; 30(3):159-64. 

 2. Bourin M, Andre-David F. Triazolam 0.25 mg versus 

loprazolam 1 mg in common insomnia treated by 

general practitioners (double blind cross-over 

randomized study). [Fr]. Therapie 1989; 44(2):107-14. 

 3. Buscaino GA, Steardo L. [Efficacy of the oral 

treatment with L-tryptophan in subjects with 

insomnia. Preliminary results]. [Italian]. Acta 

Neurologica 30(4), 411-5. 1975 Jul-Aug. 

 4. Carlini EA, Braz S, Troncone LR et al. [Hypnotic 

effect of homeopathic medication and placebo. 

Evaluation by double-blind and crossing technics]. 

[Portuguese]. Amb; Revista Da Associacao Medica 

Brasileira 33[5-6], 83-8. 1987 May-Jun. 

 5. Castellani A, Lescovelli M, Perbellini D. Clinical and 

EEG changes in sleep patterns after administration of 

N-demethyldiazepam to 25 psychiatric patients 

affected by insomnia. [Italian]. Lav Neuropsichiatr 

1975; 56(1, Suppl 3):155-83. 

 6. de Anna M, Zucconi M, Baruzzi A et al. Double blind 

trial of lormetazepam and flurazepam in the treatment 

of insomniacs. Farmaco Ed Prat 1982; 37:275-81. 

 7. Duriez R, Barthelemy C, Rives H et al. Clinical trial 

of zopiclone in insomnia. Therapie London Paris 

1979; 34(3):317-26. 

 8. Estivill-Sancho E, Jaraba G. The treatment of chronic 

insomnia: A program of creative relaxation and body 

consciousness as adjuvant of pharmacotherapy. 

[Spanish]. Psiquis: Revista de Psiquiatria, Psicologia y 

Psicosomatica. Vol 12(9) 1991, 52-57. Alpe Editores 

SA, Spain 12(9), 52-57. 1991. 

 9. Ferrero F, Zahnd J. [Tryptophan in the treatment of 

insomnia in hospitalized psychiatric patients]. 

[French]. Encephale 13(1), 35-7. 1987 Jan-Feb. 

10. Friede M, Liske E, Woelk H et al. Herbal agent for the 

treatment of insomnia. [German]. Tw Neurologie 

Psychiatrie 11(10), 697-700. 1997. 

11. Herberg KW, Laux G, Fischer W. Analysis of the 

effects of a 14 days treatment with zopiclone 7.5mg/d 

on performance capability, actual well-being, and 

quality of sleep of patients with primary insomnia. 

[Germ]. Psychopharmakother 2002; 9(1):25-34. 

12. Huang GG, Chen Q, Li L. Comparison between the 

effect of behavioral and drug therapy on the treatment 

of insomnia in patients with schizophrenia in 

rehabilitation period. [Chin]. Zhongguo Linchuang 

Kangfu 2004; 8(9):1628-9. 

13. Ito E, Matsui T, Okada T et al. A double-blind 

controlled trial of s-1530 in patients with insomnia . 

Rinsyoyakuri 1973; 4(2):61-75. 

14. Ito H, Yagi G, Tateyama M et al. Clinical evaluation 

of flunitrazepam on insomnia in neuropsychiatric 

field: a comparative double-blind cross-over study 

with nitrazepam. Rinsho Hyoka (Clin Eval) 1981; 

9(3):733-67. 

15. Kobayashi R, Ito K, Hirabayashi Y et al. Effectiveness 

of zopiclone (27 267 r so:p.) In insomnia: multi-center 

double-blind study in comparison with flurazepam 

(the second report). Rinsho Hyoka (Clin Eval) 1986; 

14(77-108). 

16. Kurihara M, Jinbo M, Hirose T et al. A study of the 

clinical efficacy of triazolam on insomnia -Doubleblind cross-over study among the smaller and larger 

doses of triazolam, and flurazepam. Rinsho Hyoka 

(Clin Eval) 1980; 8(1):79-110. 
E-21

17. Lan S, Deng M, Zhu X et al. Relaxation training and 

sleep related behavior modification in patients with 

insomnia. [Chin]. Chin Ment Health J 2002; 

16(9):625-7. 

18. Levin I. "Music of the Brain" in the treatment of 

insomnia patients. [Rus]. Zh Nevropatol Psikhiatr Im 

S S Korsakova 1997; 97(4):39-43. 

19. Li LH, Chen JD, Zhao JP et al. Zaleplon vs zolpidem 

in treatment of insomnia: a multicenter, randomized, 

double-blind controlled clinical trial. Zhongguo 

Xinyao Yu Linchuang Zazhi 2003; 22(11):667-70. 

20. Massot JE, Toblli JE. Double-blind study by 

comparing the effect of triazolam and nitrazepam on 

the sleep of usual insomniac patients. Prensa Med 

Argent 1983; 70(8):340-5. 

21. Montakab H. [Acupuncture and insomnia]. [German]. 

Forschende Komplementarmedizin. 6 Suppl 1:29-31, 

1999 Feb 1(6), 29-31. 

22. Rocha FL, Paprocki J, Bustamante LS et al. Doubleblind, randomized, comparative study between 

zopiclone (Imovane) and flunitrazepam (Rohypnol) in 

chronic insomniac patients. [Portuguese]. J Brasil 

Psiquiatr 1991; 40(4):199-215. 

23. Ruther E, Clarenbach P, Hajak G et al. Zopiclone in 

patients with disturbed sleep. Impact on sleep quality 

and day-time wellbeing in comparison of 

flunitrazepam, triazolam and placebo. [German]. 

Munch Med Wochenschr 1992; 134(46):59-65. 

24. Schadeck B, Chelly M, Amsellem D et al. 

Comparative efficacy of doxylamine (15 mg) and 

zolpidem (10 mg) for the treatment of common 

insomnia. A placebo-controlled study. [Fr]. Semaine 

Hopitaux 1996; 72(13-14):428-39. 

25. Yamamura Y, Kokubu T, Ueda E et al. Clinical effects 

of lorazepam on insomnia in the field of internal 

medicine -evaluated by double blind study using 

nitrazepam and placebo as control drugs. Rinsho 

Hyoka (Clin Eval) 1978; 6(2):201-21. 

26. Zhang H, Shen Y, Liu N et al. Effect and reliability of 

zaleplon on treatment of insomnia: A randomized, 

double-blind, control study. [Chin]. Zhongguo 

Linchuang Kangfu 2004; 8(18):3488-90. 

27. Zhou CL, Xie HJ, Wang LQ. Paroxetine in treatment 

of primary insomnia. Zhongguo Xinyao Yu Linchuang 

Zazhi 2002; 21(8):481-4. 

Excluded - Review/Commentary/Practice Parameter 

The following studies were excluded because they were reviews/commentaries/practice 

parameters. 

 1. Agargun MY, Kara H, Ozbek H et al. Restless legs 

syndrome induced by mirtazapine. J Clin Psychiatry 

2002; 63(12):1179. 

 2. Allain H, Milon D, van den Driessche J. Clinical 

pharmacology of hypnotics. Therapie - London Paris 

1984; 39(1):13-6. 

 3. Barker MJ, Jackson M, Greenwood KM et al. 

Cognitive effects of benzodiazepine use: A review. 

Aust Psychol 2003; 38(3):202-13. 

 4. Belleville G, Morin CM. Cognitive-behavioral 

treatment of insomnia secondary to chronic pain. [Fr]. 

Doul Analg 2003; 16(2):111-16. 

 5. Berger M, Van Calker D, Riemann D. Sleep and 

manipulations of the sleep-wake rhythm in depression. 

Acta Psychiatr Scand 2003; 108(418, Suppl):83-91. 

 6. Bootzin RR, Perlis ML. Nonpharmacologic treatments 

of insomnia. J Clin Psychiatry 1992; 53(6 Suppl):37-

41. 

 7. Campbell SS, Terman M, Lewy A et al. Light 

treatment for sleep disorders: Consensus report. V. 

Age-related disturbances. J Biol Rhythms 1995; 

10(2):151-4. 

 8. Chesson ALJ, Littner M, Davila D et al. Practice 

parameters for the use of light therapy in the treatment 

of sleep disorders. Sleep 1999; 22(5):641-60. 

 9. Dall JV. Promoting sleep with therapeutic touch. 

Addict Nurs Network 1993; 5(1):23-4. 

10. Doan RJ. Risperidone for insomnia in PDDs. Can J 

Psychiatry 1998; 43(10):1050-1. 

 
E-22

11. Dundar Y, Dodd S, Strobl J et al. Comparative 

efficacy of newer hypnotic drugs for the short-term 

management of insomnia: a systematic review and 

meta-analysis. Hum Psychopharmacol 2004; 

19(5):305-22. 

12. Garfinkel D. For insomniacs: A way to break 

tranquilizer addiction. Health Facts 1999; 24(12):3. 

13. Gillin JC, Mendelson WB, Dement WC et al. 

Flurazepam and insomnia. Science 1979; 

205(4410):954-5. 

14. Grad RM. Benzodiazepines for insomnia in 

community-dwelling elderly: a review of benefit and 

risk. J Fam Pract 1995; 41(5):473-81. 

15. Hajak G, Cluydts R, Allain H et al. The challenge of 

chronic insomnia: Is non-nightly hypnotic treatment a 

feasible alternative? Eur Psychiatry 2003; 18(5):201-8. 

16. Hirst A, Sloan R. Benzodiazepines and related drugs 

for insomnia in palliative care. The Cochrane 

Database of Systematic Reviews 2001 2001; 

4(CD003346. DOI: 10.1002/14651853. CD003346). 

17. Israel AG, Kramer JA. Safety of zaleplon in the 

treatment of insomnia. Ann Pharmacother 2002; 

36:852-9. 

18. James SP, Mendelson WB. The use of trazodone as a 

hypnotic: a critical review. J Clin Psychiatry 2004; 

65(6):752-5. 

19. Jonas JM, Coleman BS, Sheridan AQ et al. 

Comparative clinical profiles of triazolam versus other 

shorter-acting hypnotics. J Clin Psychiatry 1992; 53 

Suppl:19-31. 

20. Jones CR, Czajkowski L. Evaluation and management 

of insomnia in menopause. Clin Obstet Gynecol 2000; 

43(1):184-97. 

21. Kales A, Bixler EO, Scharf M et al. Sleep laboratory 

studies of flurazepam: a model for evaluating hypnotic 

drugs. Clin Pharmacol Ther 1976; 19(5 Pt 1):576-83. 

22. Kales A, Soldatos CR, Bixler EO et al. Rebound 

insomnia and rebound anxiety: a review. Pharmacol 

1983; 26(3):121-37. 

23. Kales JD, Kales A, Soldatos CR. Quazepam: sleep 

laboratory studies of effectiveness and withdrawal. 

Clin Neuropharmacol 1985; 8(Suppl 1):S55-62. 

24. Krystal AD, Walsh JK, Laska E et al. The sustained 6-

month efficacy of eszopiclone in the treatment of 

chronic insomnia. Sleep 2004; 27(2):346-7. 

25. Larzelere MM, Wiseman P. Anxiety, depression, and 

insomnia. Prim Care 2002; 29(2):339-60. 

26. Lee YJ. Overview of the therapeutic management of 

insomnia with zolpidem. CNS Drugs 2004; 18(41, 

Suppl 1):17-23; 43-5. 

27. McCall WV, D'agostino R, Dunn A. A Meta-Analysis 

of Sleep Changes Associated With Placebo in 

Hypnotic Clinical Trials. Sleep Med 2003; 4(1):57-62. 

28. Nicholson AN. Brotizolam: studies of effects on sleep 

and on performance in young adulthood and in middle 

age. Br J Clin Pharmacol 1983; 16(Suppl 2):S365-9. 

29. Nishino S, Mignot E. Drug treatment of patients with 

insomnia and excessive daytime sleepiness: 

pharmacokinetic considerations.[erratum appears in 

Clin Pharmacokinet 2000 Jan;38(1):40]. Clin 

Pharmacokinet 1999; 37(4):305-30. 

30. Pierce MW, Shu VS, Groves LJ. Safety of estazolam. 

The United States clinical experience. Am J Med 

1990; 88(3A):12S-7S. 

31. Stahl SM, Mendels J, Schwartz GE. Effects of 

reboxetine on anxiety, agitation, and insomnia: results 

of a pooled evaluation of randomized clinical trials. J 

Clin Psychopharmacol 2002; 22(4):388-92. 

32. Trevena L. Sleepless in Sydney--is valerian an 

effective alternative to benzodiazepines in the 

treatment of insomnia? ACP J Club 2004; 

141(1):A14-6. 
E-23

Excluded - Duplicate Publication 

The following studies were excluded because the report was a duplicate publication. 

1. Demisch K, Bauer J, Georgi K et al. Treatment of 

severe chronic insomnia with L-tryptophan: Results 

of a double-blind cross-over study. 

Pharmacopsychiatry 1987; 20(6):242-4. 

2. Dominguez RA, Goldstein BJ, Jacobson AF et al. 

Estazolam in the treatment of insomnia. 

Psychopharmacol Bull 1986; 22(1):278-80. 

 3. Dorn M. [Efficacy and tolerability of Baldrian versus 

oxazepam in non-organic and non-psychiatric 

insomniacs: a randomised, double-blind, clinical, 

comparative study]. [German]. Forschende 

Komplementarmedizin und Klassische 

Naturheilkunde. 2000; 7(2), 79-84. 

Excluded - Population (Non-Adult) 

The following studies were excluded because they did not examine an adult population. 

 1. Cartwright RD, Weiss MF. The effects of electrosleep 

on insomnia revisited. J Nerv Ment Dise 1975; 

161(2):134-7. 

 2. Cloos F, Creteur R, Defesche C et al. Randomized 

double blind cross over patient preference studies 

comparing triazolam versus nitrazepam in insomnia. 

Acta Ther 1977; 3(1):73-89. 

 3. Cluydts R, Heyde K, De Volder I. Polysomnographic 

findings during non-continuous administration of 

zolpidem. Sleep Med Rev 2002; 6(Suppl 1):S13-9. 

 4. Gifford SD. A comparison of drug treatment for 

insomnia and the effect of causal attribution. Dallas 

(TX): North Texas State University. 1979. 

 5. Heffron WA, Roth P. Double-blind evaluation of the 

safety and hypnotic efficacy of temazepam in 

insomniac outpatients. Br J Clin Pharmacol 1979; 

8(1):S69-72. 

 6. Jasovic G M, Nikolic B G., Kuzmanovic V et al. The 

effects of benzodiazepines uhypnotics on performance 

and recent memory during the therapy of insomnia in 

schizophrenic patients. Proceedings of the 9th ECNP 

(European-College-of-Neuropsychopharmacology) 

Congress; 1996 Sep 23; Amsterdam, The Netherlands. 

Oxford University Press, New York 1996:S4-113-4. 

 7. Kales A, Kales JD, Bixler EO et al. Hypnotic efficacy 

of triazolam: sleep laboratory evaluation of 

intermediate-term effectiveness. J Clin Pharmacol 

1976; 16(8-9):399-406. 

 8. Kales A, Scharf MB, Kales JD. Rebound insomnia: a 

new clinical syndrome. Science 1978; 

201(4360):1039-41. 

 9. Kudo Y, Kurihara M. Clinical evaluation of 

diphenhydramine hydrochloride for the treatment of 

insomnia in psychiatric patients: double blind study. J 

Clin Pharmacol 1990; 30:1041-8. 

10. Levin Y. "Brain music" in the treatment of patients 

with insomnia. Neurosci Behav Physiol 1998; 

28(3):330-5. 

11. Minzi A, Celeste M, Ciampini M. Lormetazepam as a 

hypnoinducing drug: A multicenter national survey. 

Curr Ther Res 1985; 38(2):183-95. 

12. Scharf MB. Feasibility of an every-other-night 

regimen in insomniac patients: subjective hypnotic 

effectiveness of quazepam, triazolam, and placebo. J 

Clin Psychiatry 1993; 54(1):33-8. 

13. Schoicket S. Meditation training and stimulus control 

as treatments for sleep-maintenance insomnia. St. 

Louis (MO) Washington University. 1987. 

14. Seigenberg R. Combined treatment approach to sleep 

onset insomnia: Objective measurement by subject 

monitoring of recorded sounds. Salt Lake City (UT) 

Brigham Young University. 1985. 

15. Uhthoff H, Brunet J, Aggerwal A et al. A clinical 

study of Quazepam in hospitalized patients with 

insomnia. J Int Med Res 1981; 9(4):288-91. 

16. Weiss MF. The treatment of insomnia through the use 

of electrosleep: an EEG study. J Nerv Ment Dis 1973; 

157(2):108-20. 

17. Willis CS. Effects of problem-solving and relaxation 

treatments for insomnia on sleep-onset latency and 

cognitive arousal prior to sleep. Panama City (FL): 

Florida State University. 1991. 
E-24

Excluded - Population (Not Chronic Insomnia) 

The following studies were excluded because the participants did not suffer from chronic 

insomnia as defined in this report. 

 1. Adam K, Oswald I. Can a rapidly-eliminated 

hypnotic cause daytime anxiety? 

Pharmacopsychiatry 1989; 22(3):115-9. 

 2. Aivazian G. Clinical evaluation of diazepam. Dis 

Nerv Syst 1964; 25:491-6. 

 3. Akpinar S. Restless legs syndrome treatment with 

dopaminergic drugs. Clin Neuropharmacol 1987; 

10(1):69-79. 

 4. Alberts MS, Anderson RH, Greaves DW et al. 

Affective-state changes during short-term treatment 

of insomnia with triazolam. Curr Ther Res 

 1987; 41:746-50. 

 5. Alexander N, Baldwin RJJ, Cranfield R et al. 

Comparison of triazolam (Halcion) and flurazepam 

(Dalmane) for the treatment of insomnia in general 

practice. A United Kingdom multicentre study. Clin 

Trials J 1984; 21(6):371-7. 

 6. Allain H, Bentue-Ferrer D, Le Breton S et al. 

Preference of Insomniac Patients Between a Single 

Dose of Zolpidem 10 Mg Versus Zaleplon 10 Mg. 

Hum Psychopharmacol - Clin Exp 2003; 18(5):369-

74. 

 7. Allain H, Bentue-Ferrer D, Tarral A et al. Effects on 

postural oscillation and memory functions of a 

single dose of zolpidem 5 mg, zopiclone 3.75 mg 

and lormetazepam 1 mg in elderly healthy subjects. 

A randomized, cross-over, double-blind study 

versus placebo. Eur J Clin Pharmacol 2003; 

59(3):179-88. 

 8. Alperson J, Biglan A. Self administered treatment 

of sleep onset insomnia and the importance of age. 

Behav Ther 1979; 10(3):347-56. 

 9. Ananth JV, Bronheim LA, Klingner A et al. 

Diazepam in the treatment of insomnia in 

psychiatric patients. Curr Ther Res 1973; 15:217-

22. 

 10. Ancolio C, Tardieu S, Soubrouillard C et al. A 

Randomized Clinical Trial Comparing Doses and 

Efficacy of Lormetazepam Tablets or Oral Solution 

for Insomnia in a General Practice Setting. Hum 

Psychopharmacol Clin Exper 2004; 19(2):129-34. 

 11. Andersen T, Lingjaerde O. Nitrazepam (Mogadon) 

as a sleep-inducing agent. An analysis based on a 

double-blind comparison with phenobarbitone. Br J 

Psychiatry 1969; 115(529):1393-7. 

 12. Anderson AA. Zopiclone and nitrazepam: a 

multicenter placebo controlled comparative study of 

efficacy and tolerance in insomniac patients in 

general practice. Sleep 1987; 10(Suppl 1):54-62. 

 13. Andrade CS. Melatonin in medically ill patients 

with insomnia: a double-blind, placebo-controlled 

study. J Clin Psychiatry 2001; 62 (1):41-5. 

 14. Anonymous. Clinical evaluation of flurazepam. J 

Clin Pharmacol New Drugs 1972; 12:217-20. 

 15. Anonymous. A randomized controlled trial of 

amantadine in fatigue associated with multiple 

sclerosis. The Canadian MS Research Group. Can J 

Neurol Sci Aug; 14(3):273-8. 

 16. Ansfield ME, Wegner DM, Bowser R. Ironic effects 

of sleep urgency. Behav Res Ther 1996; 34(7):523-

31. 

 17. Ansoms S, Lebon O, Pelc I et al. Zopiclone or 

lormetazepam in the treatment of insomnia and the 

effect on behavior and mood in patients during the 

postalcoholism withdrawal period. Curr Ther Res 

1991; 49(154-64). 

 18. Ansseau M, Diricq S. Lormetazepam and 

amobarbital sodium in the outpatient treatment of 

insomnia: a controlled trial. Clin Ther 1983; 

5(4):365-76. 

 19. Armitage R, Yonkers K, Cole D et al. A 

multicenter, double-blind comparison of the effects 

of nefazodone and fluoxetine on sleep architecture 

and quality of sleep in depressed outpatients. J Clin 

Psychopharmacol 1997; 17(3):161-8. 

 20. Armitage R, Yonkers K, Rush A et al. No pub 

Comparison of the effects of nefazodone and 

fluoxetine on sleep architecture and sleep efficiency 

in depressed patients. Conf Abstr. Proceedings of 

the 8th Eur Coll Neuropsychopharmacol Congress. 

1995 Sep 30 - Oct 4; Venice, Italy. 1995; 5(3):?? 
E-25

 21. Arriaga F, Cavaglia F, Pires A et al. Effects of 

trazodone on insomnia and anxiety in depressed 

patients: A clinical and sleep EEG study. Int J 

Psychiatry Clin Prac 1997; 1(4):281-86. 

 22. Ascher L, Michael E, Jay S. Use of paradoxical 

intention in a behavioral program for sleep onset 

insomnia. J Consult Clin Psychol 1978; 46(3):547-

50. 

 23. Baiotti G. Comparative trial of a new hypnotic 

(Finorgal) with nitrazepam and triclofos sodium. J 

Int Med Res 1979; 7(5):383-6. 

 24. Bamford CR, Sandyk R. Failure of clonidine to 

ameliorate the symptoms of restless legs syndrome. 

Sleep 1987; 10(4):398-99. 

 25. Barabasz AF. Treatment of insomnia in depressed 

patients by hypnosis and cerebral electrotherapy. 

Am J Clin Hypnosis 1976; 19(2):120-22. 

 26. Baskett JJ, Broad JB, Wood PC et al. Does 

melatonin improve sleep in older people? A 

randomised crossover trial. Age Ageing 2003; 

32(2):164-70. 

 27. Bersani G, Garavini A. Melatonin add-on in manic 

patients with treatment resistant insomnia. Prog 

NeuroPsychopharmacol Biol Psychiatry 2000; 

24(2):185-91. 

 28. Biondi F, Casadei GL. Results of a multicenter trial 

with the hypnotic zolpidem in 1152 insomniac 

patients. Curr Ther Res 1994; 55(3):262-74. 

 29. Bixler EO, Kales A, Tan TL et al. The effects of 

hypnotic drugs on performance. Curr Ther Res Clin 

Exper 1973; 15(1):13-24. 

 30. Bongenaar TCT, Danhof G, Doesborgh HLW et al. 

Results of a multicentre, double-blind study under 

general practice conditions with the new hypnotic, 

lormetazepam. Curr Ther Res Clin Exper 1985; 

38(2):204-14. 

 31. Bonnet MH, Arand DL. Situational insomnia: 

Consistency, predictors, and outcomes. Sleep 2003; 

26(8):1029-36. 

 32. Bonnet MH, Kramer M. The interaction of age, 

performance and hypnotics in the sleep of 

insomniacs. J Am Geriatr Soc 1981; 29(11):508-12. 

 33. Borkovec TD, Fowles DC. Controlled investigation 

of the effects of progressive and hypnotic relaxation 

on insomnia. J Abnorm Psychol 1973; 82(1):153-8. 

 34. Borkovec TD, Grayson JB, O'Brien GT et al. 

Relaxation treatment of pseudoinsomnia and 

idiopathic insomnia: an electroencephalographic 

evaluation. J Appl Behav Anal 1979; 12(1):37-54. 

 35. Borkovec T, Steinmark SW, Nau SD. Relaxation 

training and single-item desensitization in the group 

treatment of insomnia. J Behav Ther Exper 

Psychiatry 1973; 4(4):401-3. 

 36. Boyd DH, Ankier SI. A clinical trial of a new 

hypnotic--loprazolam. Br J Clin Pract 1983; 

37(4):143-8. 

 37. Brusca D. Clinical study of 

cycloheptenylethylbarbiturate (medomin) for 

insomnia. J Nerv Ment Dis 1955; 121:67-71. 

 38. Buguet AG, Roussel BH, Watson WJ et al. Coldinduced diminution of paradoxical sleep in man. 

Electroencephal Clin Neurophysiol 1979; 46(1):29-

32. 

 39. Buysse DJ, Reynolds CF 3rd, Houck PR et al. Does 

lorazepam impair the antidepressant response to 

nortriptyline and psychotherapy? J Clin Psychiatry 

1997; 58(10):426-32. 

 40. Carrera RN, Elenewski JJ. Implosive therapy as a 

treatment for insomnia. J Clin Psychol 1980; 

36(3):729-34. 

 41. Carskadon MA, Dement WC. Effects of total sleep 

loss on sleep tendency. Percept Mot Skills 1979; 

48(2):495-506. 

 42. D'Cruz IA, Ramamoorthy K, Shanbhag SK et al. 

Comparison of two non-barbiturate hypnotics--

methaqualone hydrochloride and meprobamate; a 

double-blind controlled clinical trial. J Assoc Phys 

India 1966; 14(12):727-30. 

 43. Davies C, Levine S. A controlled comparison of 

nitrazepam ('mogadon') with sodium 

amylobarbitone as a sleep-inducing agent. Br J 

Psychiatry 1967; 113(502):1005-8. 

 44. Davison GC, Tsujimoto RN, Glaros AG. 

Attribution and the maintenance of behavior change 

in falling asleep. J Abnorm Psychol 1973; 

82(1):124-33. 

 45. Day BH, Davis H, Parsons DW. An assessment of 

two hypnotics in the elderly. Clin Trials J 1981; 

18(4 ):273-9. 

 46. de Jonghe F, Ameling EH, Jonkers F et al. 

Flurazepam and temazepam in the treatment of 

insomnia in a general hospital population. 

Pharmacopsychiatry 1984; 17(4):133-5. 
E-26

 47. Declerck AC, Ruwe F, O'Hanlon JF et al. Effects of 

zolpidem and flunitrazepam on nocturnal sleep of 

women subjectively complaining of insomnia 

[published erratum appears in ogy (Berl) 

1992;109(1-2):254]. Psychopharmacol 1992; 

106(4):497-501. 

 48. Dehlin O, Bjornson G. Triazolam as a hypnotic for 

geriatric patients. A double-blind cross-over 

comparison of nitrazepam and triazolam regarding 

effects on sleep and psychomotor performance. 

Acta Psychiatr Scand 1983; 67(5):290-6. 

 49. deVries MW, Peeters FP. Melatonin as a 

therapeutic agent in the treatment of sleep 

disturbance in depression. J Nerv Ment Dis 1997; 

185(3):201-2. 

 50. Disayavanish C , Srisurapanont M, Disayavanish P. 

Zopiclone in the treatment of insomnia: An open 

clinical trial. J Med Assoc Thai 1998; 81(6):393-6. 

 51. Dockhorn RJ, Dockhorn DW. Zolpidem in the 

treatment of short-term insomnia: a randomized, 

double-blind, placebo-controlled clinical trial. Clin 

Neuropharmacol 1996; 19(4):333-40. 

 52. Dominguez RA, Jacobson AF, Goldstein BJ et al. 

Comparison of triazolam and placebo in the 

treatment of insomnia in depressed patients. Curr 

Ther Res 1984; 36:856-65. 

 53. Dorsey CM, Lukas SE, Teicher MH et al. Effects of 

passive body heating on the sleep of older female 

insomniacs. J Geriatr Psychiatry Neurol 1996; 

9(2):83-90. 

 54. Elie R, Caille G, Levasseur FA et al. Comparative 

hypnotic activity of single doses of loprazolam, 

flurazepam, and placebo. J Clin Pharmacol 1983; 

23:32-6. 

 55. Engle-Friedman M, Bootzin RR, Hazlewood L et al. 

An evaluation of behavioral treatments for insomnia 

in the older adult. J Clin Psychol 1992; 48(1):77-90. 

 56. Erman MK, Loewy D, Scharf MB. Comparison of 

temazepam 7.5 mg with temazepam 15 mg for the 

treatment of transient insomnia. Curr Med Res Opin 

2004; 20(4):441-9. 

 57. Evans JI, Lewis SA, Gibb IA et al. Sleep and 

birbiturates: some experiments and observations. Br 

Med J 1968; 4(626):291-3. 

 58. Fabre LF, Metzler CM. Comparison of 0.25 mg of 

triazolam with 30 mg of flurazepam in the treatment 

of insomnia. Clin Ther 1978; 1(5):339-47. 

 59. Fabre LFJ, Gainey A, Kemple S et al. Pilot openlabel study of triazolam in the treatment of insomnia 

following alcohol withdrawal. J Stud Alcohol 1977; 

38(11):2188-92. 

 60. Fabre LJ, McLendon D, Harris R. Preference 

studies of triazolam with standard hypnotics in out 

patients with insomnia. J Int Med Res 1976; 

4(4):247-54. 

 61. Fabre LF Jr, Smith WT. Multi-clinic cross-over 

comparison of triazolam (Halcion) and placebo in 

the treatment of co-existing insomnia and anxiety in 

anxious out-patients. Dis Nerv Syst 1977; 

38(6):487-91. 

 62. Fabre LF, et al. Multi-clinic double-blind 

comparison of triazolam (Halcion(R)) and placebo 

administered for 14 consecutive nights in 

outpatients with insomnia. J Clin Psychiatry 1978; 

39(8):679-82. 

 63. Fischbach R. Efficacy and safety of midazolam and 

vesparax in treatment of sleep disorders. Br J Clin 

Pharmacol 1983; 16(Suppl 1):S167-171. 

 64. Fisher S, Gal P. Flurazepam versus amobarbital as a 

sedative-hypnotic for geriatric patients: doubleblind study. J Am Geriatr Soc 1969; 17(4):397-9. 

 65. Fontaine R, Beaudry P, Le Morvan P et al. 

Zopiclone and triazolam in insomnia associated 

with generalized anxiety disorder: a placebocontrolled evaluation of efficacy and daytime 

anxiety. Int Clin Psychopharmacol 1990; 5(3):173-

83. 

 66. Frost JD, DeLucchi MR. Insomnia in the elderly: 

treatment with flurazepam hydrochloride. J Am 

Geriatr Soc 1979; 27:541-6. 

 67. Gallais H, Casanova P, Fabregat H. Midazolam and 

oxazepam in the treatment of insomnia in 

hospitalized patients. Br J Clin Pharmacol 1983; 

16(Suppl 1):S145-149. 

 68. Garcia HF, Figueroa E, De La Canal A et al. 

Evaluation of a single daily dose of theophylline in 

asthmatic volunteers. [Sp]. Prensa Med Argent 

1993; 80(8):610-15. 

 69. Garfinkel D, Zisapel Na, Wainstein J et al. 

Facilitation of benzodiazepine discontinuation by 

melatonin: A new clinical approach. Arch Int Med 

1999; 159(20):2456-60. 

 70. Gelinas B, Thorsteinson L, Lapierre YD. Placebo 

controlled assessment of quazepam as a hypnotic. 

Curr Ther Res 1982; 31(Sec 1):992-8. 
E-27

 71. Ghosh AK. Four-week tolerance study of 

chlormezanone for the treatment of insomnia in the 

elderly. J Int Med Res 1982; 10(6):431-6. 

 72. Gigli GL, Maschio MCE, Diomedi M et al. 

Brotizolam and cognitive performance: A doubleblind, crossover study versus placebo in a 

population of shift workers. Curr Ther Res 1993; 

53(2):129-36. 

 73. Gigli GL, Moroni M, Visani L et al. A 

pharmacoepidemiologic Italian multicenter study on 

the treatment of unselected insomniac patients with 

brotizolam. Curr Ther Res Clin Exp 1991; 

50(5):652-66. 

 74. Gillin JC, Rapaport M, Erman MK et al. A 

comparison of nefazodone and fluoxetine on mood 

and on objective, subjective, and clinician-rated 

measures of sleep in depressed patients: a doubleblind, 8-week clinical trial.[erratum appears in J 

Clin Psychiatry 1997 Jun;58(6):275]. J Clin 

Psychiatry 1997; 58(5):185-92. 

 75. Globus G, Phoebus E, Humphries J et al. The effect 

of lorazepam on anxious insomniacs' sleep as 

recorded in the home environment. J Clin 

Pharmacol 1974; 14(4):192-201. 

 76. Gnirss F, Schneider HD, Schenker J. L-tryptophan 

+ oxprenolol: A new approach to the treatment of 

insomnia. Pharmakopsychiatr 

Neuropsychopharmakol 1978; 11(4):180-5. 

 77. Gossop M, Bradley B. Insomnia among addicts 

during supervised withdrawal from opiates: a 

comparison of oral methadone and 

electrostimulation. Drug Alcohol Dep 1984; 

13(2):191-8. 

 78. Gotestam KG, Oppoyen F, Berntzen D. Treatment 

of insomnia with two benzodiazepines: a doubleblind crossover study. Eur J Clin Pharmacol 1991; 

41(2):137-40. 

 79. Graham KR, Wright GW, Toman WJ et al. 

Relaxation and hypnosis in the treatment of 

insomnia. Am J Clin Hypnosis 1975; 18(1):39-42. 

 80. Greenblatt DJ, Harmatz JS, Zinny MA et al. Effect 

of gradual withdrawal on the rebound sleep disorder 

after discontinuation of triazolam. New Engl J Med 

1987; 317:722-8. 

 81. Hardy M, Kirk-Smith MD, Stretch DD. 

Replacement of drug treatment for insomnia by 

ambient odour. Lancet 1995; 346(8976):701. 

 82. Hartmann E, Chung R, Chien C. L-tryptophan and 

sleep. Psychopharmacol 1971; 19(2):114-27. 

 83. Hartmann E, Elion R. The insomnia of 'sleeping in a 

strange place': effects of l-tryptophan. 

Psychopharmacol 1977; 53(2):131-3. 

 84. Hartmann E, Spinweber CL. Sleep induced by Ltryptophan: effect of dosages within the normal 

dietary intake. J Nerv Ment Dis 1979; 167:497-9. 

 85. Hartz AJ, Bentler S, Noyes R et al. Randomized 

controlled trial of Siberian ginseng for chronic 

fatigue. Psychol Med 2004; 34(1):51-61. 

 86. Hartz AJ, Bentler SE, Brake KA et al. The 

effectiveness of citalopram for idiopathic chronic 

fatigue. J Clin Psychiatry 2003; 64(8):927-35. 

 87. Harvey AG, Farrell C. The efficacy of a 

Pennebaker-Like writing intervention for poor 

sleepers. Behav Sleep Med 2003; 1(2):115-24. 

 88. Hauri P, Wisbey J. Wrist actigraphy in insomnia. 

Sleep 1992; 15(4):293-301. 

 89. Haynes SN, Price M, Simons JP. Stimulus control 

treatment of insomnia. J Behav Ther Exp Psychiatry 

1975; 6(4):279-82. 

 90. Hayoun G, Bagot C. Comparative efficacy and 

safety of triazolam and zopiclone in insomniacs 

seen in general practice. Curr Ther Res 1989; 

46:1236-44. 

 91. Hearst ED, Cloninger CR, Crews EL et al. 

Electrosleep therapy: a double-blind trial. Arch Gen 

Psychiatry 1974; 30(4):463-6. 

 92. Heffler D, Lisman S. Attribution and insomnia A 

replication failure. Psychol Rec 1978; 28(1):123-8. 

 93. Hegelbach F, Tschopp J, Christeller S et al. 

Comparison of the short-acting benzodiazepines 

Midazolam and Triazolam with placebo. 

Arzneimittel Forschung. 1988; 38(3):387-92. 

 94. Helcl I, Lupolover R, Buch JP et al. Evaluation of 

the efficacy and tolerance of orally administered 

midazolam as a hypnotic agent compared with 

oxazepam in the treatment of insomnia of mild to 

moderate severity. Arzneimittel Forschung 1981; 

31(12a):2284-7. 

 95. Hemmeter U, Seifritz E, Hatzinger M et al. Serial 

partial sleep deprivation as adjuvant treatment of 

depressive insomnia. Prog NeuroPsychopharmacol 

Biol Psychiatry 1995; 19(4):593-602. 
E-28

 96. Hindmarch I. Effects of hypnotic and sleepinducing drugs on objective assessments of human 

psychomotor performance and subjective appraisals 

of sleep and early morning behaviour. Br J Clin 

Pharmacol 1979; 8(1):S43-6. 

 97. Hindmarch I. Psychopharmacological aspects of 

idiopathic and transient insomnia. Acta Psychiatr 

Scand 1986; 332(Suppl):47-54. 

 98. Hinton J, Marley E. The effects of meprobamate 

and pentobarbitone sodium on sleep and motility 

during sleep: A controlled trial with psychiatric 

patients. J Neurol Neurosurg Psychiatry 1959;(137-

40). 

 99. Hohenthal TT. Comparative clinical studies of a 

new somnifacient combination of methaqualone and 

etodroxizine versus glutethimide and placebo. 

Cross-over double-blind control test with sequential 

analysis. Arzneimittel Forschung 1969; 19(9):1527-

9. 

 100. Holborn SW, Hiebert DE, Bell CL. Computerinterfaced operant measurement in treating 

insomnia. J Behavior Ther Exp Psychiatry 1987; 

18(4):365-72. 

 101. Hughes RJ, Sack RL, Lewy AJ. The role of 

melatonin and circadian phase in age-related sleepmaintenance insomnia: Assessment in a clinical trial 

of melatonin replacement. Sleep 1998; 21(1):52-68. 

 102. Hunter GM. Two-dose comparison of 

chlormezanone in sleep disturbance due to anxiety. 

Curr Med Res Opin 1982; 8(1):22-7. 

 103. Itil TM, Bozak M, Polvan N et al. Effects of 

supidimide (CG-3033) on objective and subjective 

sleep parameters (a sleep laboratory study) . Curr 

Ther Res Clin Exp 1980; 27:442-57. 

 104. Jean-Louis G, von Gizycki H, Zizi F. Melatonin 

effects on sleep, mood, and cognition in elderly 

with mild cognitive impairment. J Pineal Res 1998; 

25(3):177-83. 

 105. Jobert M, Poiseau E, Jahnig P et al. ECG activity in 

the sleep of insomniac patients under the influence 

of lormetazepam and zopiclone. Neuropsychobiol 

1995; 31(4):204-9. 

 106. Johnson LC, Church MW, Seales DM et al. 

Auditory arousal thresholds of good sleepers and 

poor sleepers with and without flurazepam. Sleep 

1979; 1(3):259-70. 

 107. Kales A, Allen C, Scharf MB et al. Hypnotic drugs 

and their effectiveness. All-night EEG studies of 

insomniac subjects. Arch Gen Psychiatry 1970; 

23(3):226-32. 

 108. Kales A, Kales JD, Scharf MB et al. Hypnotics and 

altered sleep-dream patterns. II. All-night EEG 

studies of chloral hydrate, flurazepam, and 

methaqualone. Arch Gen Psychiatry 1970; 

23(3):219-25. 

 109. Kales A, Manfredi RL, Vgontzas AN et al. 

Rebound insomnia after only brief and intermittent 

use of rapidly eliminated benzodiazepines. Clin 

Pharmacol Ther 1991; 49(4):468-76. 

 110. Kales J, Kales A, Bixler E et al. Effects of placebo 

and flurazepam on sleep patterns in insomniac 

subjects. Clin Pharmacol Ther 1971; 12(4):691-7. 

 111. Kales J, Tjiauw-Ling T, Swearingen C et al. Are 

over-the-counter sleep medications effective? Allnight EEG studies. Curr Ther Res 1971; 13:143-51. 

 112. Kanba S, Miyaoka H, Terada H et al. Triazolam 

accumulation in the elderly after prolonged use. Am 

J Psychiatry 1991; 148(9):1264-5. 

 113. Kangas L, Kanto J, Lehtinen V et al. Long-term 

nitrazepam treatment in psychiatric out-patients 

with insomnia. Psychopharmacol 1979; 63(1):63-6. 

 114. Karacan I, Thornby JI, Anch M et al. Dose-related 

sleep disturbances induced by coffee and caffeine. 

Clin Pharmacol Ther 1976; 20(6):682-9. 

 115. Katsunuma H, Shimizu T, Ogawa K et al. 

Treatment of insomnia by concomitant therapy with 

zopiclone and aniracetam in patients with cerebral 

infarction, cerebroatrophy, Alzheimer's disease and 

Parkinson's disease. Psychiatry Clin Neurosci 1998; 

52(2):198-200. 

 116. Kaynak H, Kaynak D, Gozukirmizi E et al. The 

effects of trazodone on sleep in patients treated with 

stimulant antidepressants. Sleep Med 2004; 5(1):15-

20. 

 117. Kesson CM, Gray JM, Lawson DH et al. Long-term 

efficacy and tolerability of a new hypnoticloprazolam. Br J Clin Pract 1984; 38(9):306-12. 

 118. King A, Oman R, Brassington G et al. Moderateintensity exercise and self-rated quality of sleep in 

older adults. A randomized controlled trial. J Am 

Med Assoc 1997; 277(1):32-7. 

 119. Kolber M, Spooner GR, Szafran O. Adverse events 

with Zyban (buproprion) [2]. Can Med Assoc J 

2003; 169(2 ):103-4. 
E-29

 120. Koves P. Placebo-controlled clinical trial of 

dormicum 15-mg tablet. Ther Hungarica 1993; 

41(3):89-99. 

 121. Kramer M, Bonnet M, Schoen LS et al. Efficacy 

and safety of midazolam 7.5 mg. in geriatric 

insomniacs. Curr Ther Res Clin Exp 1985; 

38(3):414-22. 

 122. Kramer M, Schoen LS, Scharf M. Effects of 

alprazolam on sleep and performance in geriatric 

insomniacs. Curr Ther Res 1984; 36:67-76. 

 123. Kudo Y. Hypnotic effects of a benzodiazepine 

derivative: a clinical observation. Int 

Pharmacopsychiatry 1982; 17(1):49-64. 

 124. Kullander NE. A double-blind clinical trial of a new 

sleep-inducing combination of methaqualone and 

etodroxizine compared with nitrazepam and 

placebo. Arzneimittel Forschung 1969; 19(9):1530-

2. 

 125. Leathwood P, Chauffard F. Aqueous extract of 

valerian reduces latency to fall asleep in man. 

Planta Med 1985;(2):144-8. 

 126. Leigh TJ, Bird HA, Hindmarch I et al. The 

evaluation of a nonsteroidal anti-inflammatory drug 

(Tenoxicam) in the treatment of sleep disturbance in 

osteoarthritic patients. Clin Rheumatol 1989; 

8(4):489-93. 

 127. Li Pi Shan RS, Ashworth NL. Comparison of 

lorazepam and zopiclone for insomnia in patients 

with stroke and brain injury: a randomized, 

crossover, double-blinded trial. Am JPhys Med 

Rehab 2004; 83(6):421-7. 

 128. Lingjaerde O, Berglund J, Bratland SZ et al. 

Alimemazine (trimeprazine; Vallegran) as a 

hypnotic in general practice patients: controlled 

comparison with nitrazepam. Curr Ther Res Clin 

Exp 1978; 24(4):388-96. 

 129. Lingjaerde O, Bratlid T. Triazolam (Halcion) versus 

flunitrazepam (Rohypnol) against midwinter 

insomnia in Northern Norway. Acta Psychiatr 

Scand 1981; 64(3):260-9. 

 130. Lingjaerde O, Bratlid T, Westby OC et al. Effect of 

midazolam, flunitrazepam, and placebo against 

midwinter insomnia in northern Norway. Acta 

Psychiatr Scand 1983; 67(2):118-29. 

 131. Linnoila M, Erwin CW, Brendle A. Efficacy and 

side effects of flunitrazepam and pentobarbital in 

severely insomniac patients. J Clin Pharmacol 1982; 

22(1):14-9. 

 132. Linnoila M, Erwin C, Logue P. Efficacy and side 

effects of flurazepam and a combination of amo 

barbital and seco barbital in insomniac patients. J 

Clin Pharmacol 1980; 20(2-3):117-23. 

 133. Lipani JA. Preference study of the hypnotic efficacy 

of triazolam 0.125 mg compared to placebo in 

geriatric patients with insomnia. Curr Ther Res Clin 

Exp 1978; 24:397-402. 

 134. Loew F, Pawlak C, Benaroyo L et al. Comparison 

of midazolam and oxazepam as hypnotics in elderly 

hospitalized patients. A double-blind clinical trial. 

Arzneimittel Forschung 1988; 38(4):563-7. 

 135. Lohmann H, von Delbruck O, Findeisen P. 

Comparative studies on the efficacy of brotizolam 

and nitrazepam: a multi-centre study. Br J Clin 

Pharmacol 1983; 16(Suppl 2):S403-6. 

 136. Lorizio A, Salsa F. Effectiveness of oral midazolam 

as a hypnotic compared with lorazepam. 

Pharmather 1986; 4(7):463-71. 

 137. Lupolover R, Ballmer U, Helcl J et al. Efficacy and 

safety of midazolam and oxazepam in insomniacs. 

Br J Clin Pharmacol 1983; 16(Suppl 1):139S-43S. 

 138. Lupolover R, Buch JP. Evaluation of efficacy and 

safety of midazolam administered orally in sleep 

disorders. A dose-finding study. Arzneimittel 

Forschung 1981; 31(12a):2281-3. 

 139. MacPhail I, Ogilvie WA, Purvis CR. Comparison of 

diazepam and flurazepam in the treatment of 

insomnia in general practice. J Int Med Res 1979; 

7(5):401-3. 

 140. Maggini C, Murri M, Sacchetti G. Evaluation of the 

effectiveness of temazepam on the insomnia of 

patients with neurosis and endogenous depression. 

Arzneimittel Forschung 1969; 19(10 ):1647-52. 

 141. Maiman DJ. Effect of short term quazepam 

treatment on outpatients with insomnia. Current 

Therapeutic Research 30[Dec], 1005-1013. 1981. 

 142. Mamelak M, Csima A, Price V. The effects of a 

single night's dosing with triazolam on sleep the 

following night. J Clin Pharmacol 1990; 30(6):549-

555. 

 143. Manber R, Rush A, Thase M et al. The effects of 

psychotherapy, nefazodone, and their combination 

on subjective assessment of disturbed sleep in 

chronic depression. Sleep 2003; 26(2):130-6. 

 144. Marino A. Treating chronic insomnia: A cognitivebehavioural group therapy approach. Toronto (ON): 

University of Toronto . 2002. 
E-30

 145. Martinez HT, Serna CT. Short term treatment with 

quazepam for insomnia in geriatric patients. Clin 

Ther 1982; 5(2):174-8. 

 146. Mashiko H, Niwa S, Kumashiro H et al. Effect of 

trazodone in a single dose before bedtime for sleep 

disorders accompanied by a depressive state: dosefinding study with no concomitant use of hypnotic 

agent. Psychiatry Clin Neurosci 1999; 53(2):193-4. 

 147. Mendels J. Evaluation of the safety and efficacy of 

quazepam for the treatment of insomnia in 

psychiatric outpatients. J Clin Psychiatry 1994; 

55(2):60-5. 

 148. Meyer JA, Kurland KZ. Controlled evaluation of 

flurazepam hydrochloride, a new nonbarbiturate 

hypnotic. Mil Med 1973; 138(8):471-4. 

 149. Mitchell JL. The efficacy of short-term group 

cognitive-behavioral therapy in the treatment of 

insomnia in the severely and persistently mentally 

ill. New York (NY): City University of New York. 

2002. 

 150. Mitler MM, Browman CP, Menn SJ et al. Nocturnal 

myoclonus: Treatment efficacy of clonazepam and 

temazepam. Sleep 1986; 9(3):385-92. 

 151. Moja EA, Scamonatti L, Maxia D et al. Doubleblind evaluation of the safety and hypnotic efficacy 

of lormetazepam in general practice. Clin Ther 

1983; 5(6):580-4. 

 152. Montgomery I, Oswald I, Morgan K et al. 

Trazodone enhances sleep in subjective quality but 

not in objective duration. Br J Clin Pharmacol 1983; 

16(2):139-44. 

 153. Monti JM, Alterwain P, Debellis J et al. Short-term 

sleep laboratory evaluation of midazolam in chronic 

insomniacs: preliminary results. Arzneimittel 

Forschung 1987; 37(1):54-7. 

 154. Monti JM, Boussard M, Olivera S et al. The effect 

of midazolam on transient insomnia. Eur J Clin 

Pharmacol 1993; 44(6):525-7. 

 155. Monti J, Debellis J, Gratadoux E et al. Sleep 

laboratory study of the effects of Midazolam in 

insomniac patients. Eur J Clin Pharmacol 1982; 

21(6):479-84. 

 156. Morgan K, Thompson J, Dixon S et al. Predicting 

longer-term outcomes following psychological 

treatment for hypnotic-dependent chronic insomnia. 

J Psychosom Res 2003; 54(1):21-9. 

 157. Morgan VC. Effects of progressive muscle 

relaxation and stimulus control procedures in the 

treatment of insomnia. Louisiana (MS): Mississippi 

State University. 1981. 

 158. Nair N, Schwartz G. Triazolam in insomnia: A 

standard-controlled trial. Curr Ther Res 1978; 23(3, 

Pt 2):388-92. 

 159. Ngen CC, Hassan R. A double-blind placebocontrolled trial of zopiclone 7.5 mg and temazepam 

20 mg in insomnia. Int Clin Psychopharmacol 1990; 

5(3):165-71. 

 160. Nierenberg AA, Adler LA, Peselow E et al. 

Trazodone for antidepressant-associated insomnia. 

Am J Psychiatry 1994; 151:1069-72. 

 161. Norman T, Fulton A, Burrows GD et al. An open 

evaluation of midazolam as a hypnotic. Curr Ther 

Res 1984; 36(3):461-7. 

 162. O'Hair DE, Winsauer HJ. Evaluation of short-term 

treatment with 30 mg of quazepam in insomniac 

outpatients. Clin Ther 1981; 4(4):291-301. 

 163. Okawa KK. Comparison of triazolam 0.25 mg and 

flurazepam 15 mg in treating geriatric insomniacs. 

Curr Ther Res Clin Exp 1978; 23(Sec 2):381-7. 

 164. Pagot R, Cramer P, L' HC et al. Comparison of the 

efficacy and tolerability of zolpidem 20 mg and 

triazolam 0.5 mg in anxious or depressed insomniac 

patients. Curr Ther Res 1993; 53(1):88-97. 

 165. Palomaki H, Berg A, Meririnne E et al. Complaints 

of poststroke insomnia and its treatment with 

mianserin. Cerebrovasc Dis 2003; 15(1-2):56-62. 

 166. Pegram V, Hyde P, Linton P. Chronic use of 

triazolam: the effects on the sleep patterns of 

insomniacs. J Int Med Res 1980; 8(3):224-31. 

 167. Pelka RB, Jaenicke C, Gruenwald J. Impulse 

magnetic-field therapy for insomnia: A doubleblind, placebo-controlled study. Adv Ther 2001; 

18(4):174-80. 

 168. Philipp E, Kapp W. Comparative study of 

midazolam and vesparax in moderate or severe 

insomnia in female surgical patients. Br J Clin 

Pharmacol 1983; 16(Suppl 1):S161-6. 

 169. Piccione P, Zorick F, Lutz T et al. The efficacy of 

triazolam and chloral hydrate in geriatric 

insomniacs. J Int Med Res 1980; 8(5):361-7. 
E-31

 170. Pines A, Rooney JF, Arenillas L. Flurazepam 

('Dalmane') in the treatment of insomnia in patients 

with respiratory disorders. Practitioner 1976; 

217(1298):281-4. 

 171. Polacek J. Confirmation of safety and effect of 

zolpidem on sleep disturbances and well-being 

score in insomniac patients. Homeost Health Dis 

1997; 38(1):14-5. 

 172. Polo-Kantola P, Erkkola R, Helenius H et al. When 

does estrogen replacement therapy improve sleep 

quality? Am J Obstet Gynecol 1998; 178(5):1002-9. 

 173. Ponciano E, Freitas F, Camara J et al. A comparison 

of the efficacy, tolerance and residual effects of 

zopiclone, flurazepam and placebo in insomniac 

outpatients. Int Clin Psychopharmacol 1990; 

5(Suppl 2):69-77. 

 174. Post G, Patrick R, Crowder J et al. Estazolam 

treatment of insomnia in generalized anxiety 

disorder A placebo-controlled study. J Clin 

Psychopharmacol 1991; 11(4):249-53. 

 175. Roehrs T, Zorick F, Lord N et al. Dose-related 

effects of estazolam on sleep of patients with 

insomnia. J Clin Psychopharmacol 1983; 3(3):152-

6. 

 176. Roehrs T, Zorick F, Wittig R et al. Efficacy of a 

reduced triazolam dose in elderly insomniacs. 

Neurobiol Aging 1985; 6(4):293-6. 

 177. Roger M, Attali P, Coquelin JP. Multicenter, 

double-blind, controlled comparison of zolpidem 

and triazolam in elderly patients with insomnia. 

Clin Ther 1993; 15(1):127-36. 

 178. Rosenberg J, Ahlstrom F. Randomized, double 

blind trial of zolpidem 10 mg versus triazolam 0.25 

mg for treatment of insomnia in general practice. 

Scand J Prim Health Care 1994; 12(2):88-92. 

 179. Roslund K, Olsen I. Clinical trial of propiomazine 

and placebo in the treatment of insomnia in the 

elderly. Curr Ther Res 1987; 41:6-12. 

 180. Roth T, Roehrs T, Vogel G. Zolpidem in the 

treatment of transient insomnia: a double-blind, 

randomized comparison with placebo. Sleep 1995; 

18(4):246-51. 

 181. Rush JA, Gillin C, Armitage R et al. Comparative 

Effects of Nefazodone and Fluoxetine on Sleep in 

Outpatients with Major Depressive Disorders. 

Proceedings of the 149th Annual Meeting of the 

American Psychiatric Association; 1996 May 4-9; 

New York, NY. Bio Psychiatry 1998; 44:3-14. 

 182. Sakamoto T, Uchimura N, Mukai M et al. Efficacy 

of L-846 in patients with insomnia: evaluation by 

polysomnography. Psychiatry Clin Neurosc 1998; 

52(2):156-7. 

 183. Salkind MR, Silverstone T. The clinical and 

psychometric evaluation of a new hypnotic drug, 

loprazolam, in general practice. Curr Med Res Opin 

1983; 8(5):368-74. 

 184. Sapienza PL. A double-blind comparison of 

methaqualone, pentobarbital and placebo in the 

management of insomnia. Curr Ther Res Clin Exp 

1966; 8(11):523-7. 

 185. Scharf M, Hirschowitz J, Zemlan F et al. 

Comparative effects of Limbitrol and Amitriptyline 

on sleep efficiency and architecture. J Clin 

Psychiatry 1986; 47(12):587-91. 

 186. Schlich D, L'Heritier C, Coquelin JP et al. Longterm treatment of insomnia with zolpidem: A 

multicentre general practitioner study of 107 

patients. J Int Med Res 1991; 19(3):271-9. 

 187. Seno H, Morita Y, Ikehata K et al. Effects of a weak 

diffuse-brain-stimulation on insomniacs with 

vibration syndrome. Acta Neurobiol Exp 1989; 

49(5):289-94. 

 188. Shamsi Z, Stanley N, Yoon J et al. Effects of three 

doses of 3-indole pyruvic acid on subjective and 

objective measures of sleep and early morning 

performance. Hum Psychopharmacol 1996; 

11(3):235-9. 

 189. Silvestri R, Ferrillo F, Murri L et al. Rebound 

insomnia after abrupt discontinuation of hypnotic 

treatment: Double-blind randomized comparison of 

zolpidem versus triazolam. Hum Psychopharmacol 

1996; 11(3):225-33. 

 190. Simon GE, Heiligenstein JH, Grothaus L et al. 

Should anxiety and insomnia influence 

antidepressant selection: a randomized comparison 

of fluoxetine and imipramine. J Clin Psychiatry 

1998; 59(2):49-55. 

 191. Singer C, Tractenberg RE, Kaye J et al. A 

multicenter, placebo-controlled trial of melatonin 

for sleep disturbance in Alzheimer's disease. Sleep 

2003; 26(7):893-901. 

 192. Smith JA, Renshaw DC. Clinical study of insomnia. 

Am Fam Phys 1975; 11:140-1. 

 193. Stevinson C. Study of combined herbal treatment 

for insomnia. Focus AACN 1999; 4(2):73. 
E-32

 194. Sundaresan P, Wardell W, Weintraub M et al. 

Methodology for demonstrating sustained efficacy 

of hypnotics A comparative study of triazaolam and 

flurazepam. Clin Pharmacol Ther 1979; 25(4):391-

8. 

 195. Sunshine A. Comparison of the hypnotic activity of 

triazolam, flurazepam hydrochloride, and placebo. 

Clin Pharmacol Ther 1975; 17(5):573-7. 

 196. Swanson DA. Double-blind evaluation of a new 

hypnotic--flurazepam hydrochloride. S Afr Med J 

1973; 47:1339-41. 

 197. Tang NK, Harvey AG. Correcting distorted 

perception of sleep in insomnia: a novel behavioural 

experiment? Behav Res Ther 2004; 42(1):27-39. 

 198. Thase ME R, ush AJ, Manber R et al. Differential 

effects of nefazodone and cognitive behavioral 

analysis system of psychotherapy on insomnia 

associated with chronic forms of major depression. 

J Clin Psychiatry 2002; 63(6):493-500. 

 199. Thomson J, Oswald I. Effect of oestrogen on the 

sleep, mood, and anxiety of menopausal women. Br 

Med J 1977; 2(6098):1317-9. 

 200. Tosi GC, Tosi EC, Hattab JR. Use of Ndemethyldiazepam in outpatients suffering from 

insomnia. Curr Ther Res 1973; 15:460-4. 

 201. Usui A, Ishizuka Y, Matsushita Y et al. Bright light 

treatment for night-time insomnia and daytime 

sleepiness in elderly people: comparison with a 

short-acting hypnotic. Psychiatry Clin Neurosci 

2000; 54(3):374-6. 

 202. Van Moffaert M, Pilate C. Zopiclone in the 

treatment of insomnia in depressed patients. Eur/ 

Psychiatry J Assoc Eur Psychiatrists 1995; 10(Suppl 

3):S167-72. 

 203. Van Moffaert M, Wilmotte J, Mesters P et al. 

Comparison of Zopiclone and Flunitrazepam in the 

treatment of insomnia in depressed patients. Curr 

Ther Res 1990; 48(1):140-53. 

 204. Van Steenis D. A comparison of chlormezanone 

and temazepam in sleep disturbance. Curr Med Res 

Opin 1982; 8(1):28-32. 

 205. Velasco M, Velasco F, Cepeda C et al. Effect of a 

new thienodiazepine WE 941 on sleep patterns of 

normal and insomniac subjects. Neuropharmacol 

1981; 20(5):461-8. 

 206. Velden M, Wolk C. Baroreceptor activity and the 

induction of sleep. Percept Mot Skills 1996; 

82(1):178. 

 207. Verbeek I, Declerck G, Neven AK et al. Sleep 

information by telephone: Callers indicate positive 

effects on sleep problems. Sleep Hypnosis 2002; 

4(2):47-51. 

 208. Viukari M, Vartio T, Verho E. Low doses of 

brotizolam and nitrazepam as hypnotics in the 

elderly. Neuropsychobiol 1984; 12(2-3):130-3. 

 209. Vogel GW, Barker K, Gibbons P et al. A 

comparison of the effects of flurazepam 30 mg and 

triazolam 0.5 mg on the sleep of insomniacs. 

Psychopharmacol 1976; 47(1):81-6. 

 210. Walsh JK, Pollak CP, Scharf MB et al. Lack of 

residual sedation following middle-of-the-night 

zaleplon administration in sleep maintenance 

insomnia. Clin Neuropharmacol 2000; 23(1):17-21. 

 211. Walsh JK, Schweitzer PK, Sugerman JL et al. 

Transient insomnia associated with a 3-hour phase 

advance of sleep time and treatment with zolpidem. 

J ClinPsychopharmacol 1990; 10(3):184-9. 

 212. Wang RI, Stockdale SL, Hieb E. Hypnotic efficacy 

of lorazepam and flurazepam. Clin Pharmacol Ther 

1976; 19(2):191-5. 

 213. Ware JC, Brown FW, Moorad PJ Jr et al. Effects on 

sleep: a double-blind study comparing trimipramine 

to imipramine in depressed insomniac patients. 

Sleep 1989; 12(6):537-49. 

 214. Warner M. Stimulus control procedures and a 

paradoxical intention instruction in the treatment of 

sleep onset insomnia. Reno (NV): University of 

Nevada. 1977. 

 215. Wheatley D. Zopiclone: a non-benzodiazepine 

hypnotic. Controlled comparison to temazepam in 

insomnia. Br J Psychiatry 1985; 146:312-4. 

 216. Wickstrom E, Godtlibsen OB, Bredesen JE et al. 

Performance and mood following partial sleep 

deprivation: A randomized, double-blind crossover 

study of zopiclone, triazolam, flunitrazepam, 

ethanol and placebo. Hum Psychopharmacol 1988; 

3(1):3-11. 

 217. Winokur A, Demartinis NA, Mcnally DP et al. 

Comparative effects of mirtazapine and fluoxetine 

on sleep physiology measures in patients with major 

depression and insomnia. J Clin Psychiatry 2003; 

64(10):1224-9. 

 218. Wittig R, Zorick F, Roehrs T et al. Effects of 

temazepam soft gelatin capsules on the sleep of 

subjects with insomnia. Curr Ther Res 1985; 38:15-

22. 
E-33

 219. Wojtulewski JA, Walter J. Treatment of sleep 

disturbance in arthritis with chlormezanone. Curr 

Med Res Opin 1983; 8(7):456-60. 

 220. Zwart CA, Lisman SA. Analysis of stimulus control 

treatment of sleep-onset insomnia. J Consult Clin 

Psychol 1979; 47(1):113-8. 

 221. Zyhlarz G, Saletu B, Brandst_tter N et al. Sleep 

studies in insomnia based on generalized anxiety 

disorder with diphenhydramine/lorazepam 

(SomniumR) Conf Abstr. Proceedings of the XXth 

Collegium Internationale Neuropsychopharmacologicum; 1996 Jun 23-27; 

Melbourne, Australia. Eur Neuropsychopharmacol 

1996; 6(Supp 3):1-247. 

Excluded - Design (Not Randomized Controlled Trial) 

The following studies were excluded because they were not randomized-controlled trials. 

 1. Autret E, Maillard F, Autret A. Comparison of the 

clinical hypnotic effects of zopiclone and triazolam. 

Eur J Clin Pharmacol 1987; 31(5):621-23. 

 2. Backhaus J, Hohagen F, Voderholzer U et al. Longterm effectiveness of a short-term cognitivebehavioral group treatment for primary insomnia . 

Eur Arch Psychiatry Clin Neurosci 2001; 

251(1):35-41. 

 3. Bastien CH, Morin CM, Ouellet MC et al. 

Cognitive-behavioral therapy for insomnia: 

Comparison of individual therapy, group therapy, 

and telephone consultations. J Consult Clin Psychol 

2004; 72(4):653-9. 

 4. Beaumont G, Holland RL. A multi-centre open 

study in general practice to evaluate the efficacy 

and acceptability of zopiclone 7.5 mg nocte in 

patients requiring the prescription of an hypnotic. 

Int Clin Psychopharmacol 1990; 5(Suppl 2):11-20. 

 5. Bes F, Hofman W, Schuur J et al. Effects of delta 

sleep-inducing peptide on sleep of chronic 

insomniac patients. A double-blind study. 

Neuropsychobiol 1992; 26(4):193-7. 

 6. Bixler EO, Kales A, Soldatos CR et al. 

Effectiveness of temazepam with shortintermediate-, and long-term use: sleep laboratory 

evaluation . J Clin Pharmacol 1978; 18(2-3):110-8. 

 7. Bliwise DL, Seidel W, Schanfald D et al. Shortterm trial of estrazolam in geriatric insomniacs. 

Curr Ther Res 1983; 34(6):1009-13. 

 8. Bonnet MH. Effect of 64 hours of sleep deprivation 

upon sleep in geriatric normals and insomniacs. 

Neurobiol Aging 1986; 7(2):89-96. 

 9. Bonnet MH, Rosa R. Sleep and performance in 

young adults and older normals and insomniacs 

during acute sleep loss and recovery. Biol Psychol 

1987; 25(2):153-72. 

 10. Broomfield NM, Espie CA. Initial insomnia and 

paradoxical intention: An experimental 

investigation of putative mechanisms using 

subjective and actigraphic measurement of sleep. 

Behav Cognit Psychother 2003; 31(3):313-24. 

 11. Carskadon M, Dement WC, Mitler MM et al. Selfreports versus sleep laboratory findings in 122 drugfree subjects with complaints of chronic insomnia. 

Am J Psychiatry 1976; 133(12):1382-8. 

 12. Cesco G, Giannico S, Fabbruci I et al. Single-blind 

evaluation of hypnotic activity of 

chlordesmethyldiazepam in No-placebo-reactor 

medical patients. Arzneimittel forschung 1977; 

27(1):146-8. 

 13. Childs-Clarke A. Stimulus control techniques for 

sleep onset insomnia. Nurs Times 1990; 86(35):52-

3. 

 14. Choliz Montanes M. Development of a technique of 

breathing for insomnia treatment: Theoretical basis 

and experimental results. [Sp]. Anal Modific 

Conduct 1993; 19(65):421-32. 

 15. Cluydts RJ, De Roeck J M, Jolie AM. A three week 

multicentre general practitioner study of zolpidem 

in 651 patients with insomnia. Acta Ther 1993; 

19(1):73-91. 

 16. Cuanang JR, Limos L. Treatment of insomnia with 

temazepam: double blind placebo controlled 

evaluation. Clin Ther 1982; 4(5):402-12. 

 17. Currie SR, Wilson KG, Curran D. Clinical 

significance and predictors of treatment response to 

cognitive-behavior therapy for insomnia secondary 

to chronic pain. J Behav Med 2002; 25(2 ):135-53. 

 18. Currie SR, Wilson KG, Pontefract AJ et al. 

Cognitive-behavioral treatment of insomnia 

secondary to chronic pain. J Consult Clin Psychol 

2000; 68 (3):407-16. 
E-34

 19. Dahl LE, Dencker SJ, Lundin L et al. Comparison 

of nitrazepam with triazolam in insomniac 

outpatients. Acta Psychiatr Scand 1982; 65(2):86-

92. 

 20. Dahlitz M, Wells P, James R et al. Treatment of 

insomnia with ritanserin. Lancet 1990; 336:379. 

 21. Danjou P, Puech A, Warot D et al. Lack of sleepinducing properties of propranolol (80 mg) in 

chronic insomniacs previously treated by common 

hypnotic medications. Int Clin Psychopharmacol 

1987; 2(2):135-40. 

 22. Dashevsky BA, Kramer M. Behavioral treatment of 

chronic insomnia in psychiatrically ill patients. J 

Clin Psychiatry 1998; 59(12):693-9. 

 23. Davies D. A multiple treatment approach to the 

group treatment of insomnia: a follow-up study. 

Behav Psychother 1989; 17(4):323-31. 

 24. Dominguez RA, Jacobson AF, Goldstein BJ et al. 

Crossover comparison of brotizolam and 

temazepam in the treatment of insomnia. Current 

Therapeutic Research 33[Mar], 372-379. 1983. 

 25. Dopke CA, Lehner RK, Wells AM. Cognitivebehavioral group therapy for insomnia in 

individuals with serious mental illnesses: a 

preliminary evaluation. Psychiatr Rehab J 2004; 

27(3):235-42. 

 26. Edinger JD, Hoelscher TJ, Marsh GR et al. A 

cognitive-behavioral therapy for sleep-maintenance 

insomnia in older adults. Psychol Aging 1992; 

7(2):282-9. 

 27. Ellinwood E, Linnoila M, Marsh G. Plasma 

concentrations of flurazepam and midazolam in 

chronic insomniacs during 14-day use and their 

relationship to therapeutic effects and next-day 

performance and mood. J Clin Psychopharmacol 

1990; 10(4 Suppl):S68-75. 

 28. Espie CA, Inglis SJ, Tessier S et al. The clinical 

effectiveness of cognitive behaviour therapy for 

chronic insomnia: implementation and evaluation of 

a sleep clinic in general medical practice. Behav 

Res Ther 2001; 39(1):45-60. 

 29. Espie C, Brooks D, Lindsay W. An evaluation of 

tailored psychological treatment of insomnia. J 

Behav Ther Exp Psychiatry 1989; 20(2):143-54. 

 30. Evans DR, Bond IK. Reciprocal inhibition therapy 

and classical conditioning in the treatment of 

insomnia. Behav Res Ther 1969; 7(3):323-5. 

 31. Goldstein L, Graedon J, Willard D et al. A 

comparative study of the effects of methaqualone 

and glutethimide on sleep in male chronic 

insomniacs. J Clin Pharmacol J New Drugs 1970; 

10(4):258-68. 

 32. Goldstein L, Stoltzfus NW, Smith RR. An analysis 

of the effects of methaqualone and glutethimide on 

sleep in insomniac subjects. Res Commun Chem 

Pathol Pharmacol 1971; 2(6):927-33. 

 33. Guilleminault C, Clerk A, Black J et al. Nondrug 

treatment trials in psychophysiologic insomnia. 

Arch Int Med 1995; 155(8):838-44. 

 34. Hagenbucher J, Kleh J. Treatment of insomnia in 

geriatric patients: double-blind study with 

methyprylon and pentobarbital. J Am Geriatr Soc 

1962; 10:1038-40. 

 35. Hajak G, Bandelow B. Safety and tolerance of 

zolpidem in the treatment of disturbed sleep: A 

post-marketing surveillance of 16,944 cases. Int 

Clin Psychopharmacol 1998; 13(4):157-67. 

 36. Hajak G, Bandelow B, Zulley J et al. "As needed" 

pharmacotherapy combined with stimulus control 

treatment in chronic insomnia--assessment of a 

novel intervention strategy in a primary care setting. 

Ann Clin Psychiatry 2002; 14(1):1-7. 

 37. Harvey L, Inglis SJ, Espie CA. Insomniacs' reported 

use of CBT components and relationship to longterm clinical outcome. Behav Res Ther 2002; 

40(1):75-83. 

 38. Hauri P. Treating psychophysiologic insomnia with 

biofeedback. Arch Gen Psychiatry 1981; 38(7):752-

8. 

 39. Hauri P, Roth T, Sateia M et al. Sleep laboratory 

and performance evaluation of midazolam in 

insomniacs. Br J Clin Pharmacol 1983; 16(Suppl 

1):109S-14S. 

 40. Hauri PJ, Olmstead EM. Reverse first night effect in 

insomnia. Sleep 1989; 12(2):97-105. 

 41. Hauri PJ, Silberfarb PM. Effects of aspirin on the 

sleep of insomniacs. Curr Ther Res Clin Exper 

1980; 28:867-74. 

 42. Haynes SN, Adams AE, West S et al. The stimulus 

control paradigm in sleep-onset insomnia: a 

multimethod assessment. J Psychosom Res 1982; 

26(3):333-9. 

 43. Hinkle JE, Lutker ER. Insomnia: A new approach. 

Psychother Theory Res Pract 1972; 9(3):236-7. 
E-35

 44. Hryshko-Mullen AS. Behavioral treatment of 

insomnia: the Wilford Hall Insomnia Program. Mil 

Med 2000; 165(3):200-7. 

 45. Jacobs GD, Rosenberg PA, Friedman R et al. 

Multifactor behavioral treatment of chronic sleeponset insomnia using stimulus control and the 

relaxation response. A preliminary study. Behav 

Modif 1993; 17(4):498-509. 

 46. Jason L. Rapid improvement in insomnia following 

self-monitoring. J Behav Ther Exp Psychiatry 1975; 

6(4):349-50. 

 47. Johnson LC, Spinweber CL, Seidel WF et al. Sleep 

spindle and delta changes during chronic use of a 

short-acting and a long-acting benzodiazepine 

hypnotic. Electroencephal Clin Neurophysiol 1983; 

55(6):662-7. 

 48. Kahn M, Baker BL, Weiss JM. Treatment of 

insomnia by relaxation training. J Abnorm Psychol 

1968; 73(6):556-8. 

 49. Kales A, Bixler EO, Kales JD et al. Comparative 

effectiveness of nine hypnotic drugs: Sleep 

laboratory studies. J Clin Pharmacol. 1977; 

17(4):207-13. 

 50. Kales A, Bixler EO, Soldatos CR et al. Quazepam 

and flurazepam: long-term use and extended 

withdrawal. Clin Pharmacol Ther 1982; 32(6):781-

8. 

 51. Kales A, Bixler EO, Soldatos CR et al. Quazepam 

and temazepam: effects of short- and intermediateterm use and withdrawal. Clin Pharmacol Ther 

1986; 39(3):345-52. 

 52. Kales A, Bixler EO, Vela-Bueno A et al. 

Alprazolam: effects on sleep and withdrawal 

phenomena. J Clin Pharmacol 1987; 27(7):508-15. 

 53. Kales A, Bixler EO, Soldatos CR et al. Doseresponse studies of lormetazepam: efficacy, side 

effects, and rebound insomnia. J Clin Pharmacol. 

1982; 22(11-12):520-30. 

 54. Kales A, Hauri P, Bixler EO et al. Effectiveness of 

intermediate-term use of secobarbital. Clin 

Pharmacol Ther 1976; 20(5):541-5. 

 55. Kales A, Masfredi R, Vgontzas A et al. Clonazepam 

sleep laboratory study of efficacy and withdrawal. J 

Clin Psychopharmacol 1991; 11(3):189-93. 

 56. Kales A, Scharf MB, Bixler EO et al. Doseresponse studies of quazepam. Clin Pharmacol Ther 

1981; 30(2):194-200. 

 57. Kales A, Scharf M, Soldatos C et al. Quazepam A 

new benzodiazepine hyponotic intermediate term 

sleep laboratory evaluation. J Clin Pharmacol 1980; 

20(4 Part 1):184-92. 

 58. Kales A, Soldatos CR, Bixler EO et al. Early 

morning insomnia with rapidly eliminated 

benzodiazepines. Science 1983; 220(4592):95-7. 

 59. Kales A, Soldatos C, Bixler E et al. Diazepam 

Effects on sleep and withdrawal phenomena. J Clin 

Psychopharmacol 1988; 8(5):340-6. 

 60. Karam-Hage M, Brower KJ. Open pilot study of 

gabapentin versus trazodone to treat insomnia in 

alcoholic outpatients. Psychiatry Clinl Neurosci 

2003; 57(5):542-544. 

 61. Kirisoglu C, Guilleminault C. Twenty minutes 

versus forty-five minutes morning bright light 

treatment on sleep onset insomnia in elderly 

subjects. J Psychosom Res 2004; 56(5):537-42. 

 62. Krahn LE, Hanson CA, Pileggi TS et al. 

Electroconvulsive therapy and cardiovascular 

complications in patients taking trazodone for 

insomnia. J Clin Psychiatry 2001; 62(2):108-10. 

 63. Kummer J, Guendel L, Linden J et al. Long-term 

polysomnographic study of the efficacy and safety 

of zolpidem in elderly psychiatric in-patients with 

insomnia. J Int Med Res 1993; 21(4):171-84. 

 64. Lamphere J, Roehrs T, Vogel G et al. The chronic 

efficacy of midazolam. Int Clin Psychopharmacol 

1990; 5(1):31-9. 

 65. Lamphere J, Roehrs T, Zorick F et al. Chronic 

hypnotic efficacy of estazolam. Drugs Exp Clin Res 

1986; 12(8):687-91. 

 66. Leger D, Laudon M, Zisapel N. Nocturnal 6-

sulfatoxymelatonin excretion in insomnia and its 

relation to the response to melatonin replacement 

therapy. Am J Med 2004; 116(2):91-5. 

 67. Leger D, Stal V, Guilleminault C et al. Daily 

consequences of insomnia: Impact on quality of life. 

Rev Neurol 2001; 157(10):1270-8. 

 68. Lichstein KL, Wilson NM, Johnson CT. 

Psychological treatment of secondary insomnia. 

Psychol Aging 2000; 15(2):232-40. 

 69. Lick JR, Heffler D. Relaxation training and 

attention placebo in the treatment of severe 

insomnia. J Consult Clin Psychol 1977; 45(2):153-

61. 
E-36

 70. Lingjaerde O, Bratlid T, Hansen T. Insomnia during 

the "dark period" in northern Norway. An 

explorative, controlled trial with light treatment. 

Acta Psychiatr Scand 1985; 71(5):506-12. 

 71. Liu CY, Yang YY, Yeh EK. Efficacy and side 

effects of zopiclone and triazolamin in the treatment 

of Chinese patients with insomnia - A double blind 

cross-over study. Int Med J 1997; 4(1):45-48. 

 72. MacFarlane J, Cleghorn J, Brown G et al. The 

effects of exogenous melatonin on the total sleep 

time and daytime alertness of chronic insomniacs A 

preliminary study. Biol Psychiatry 1991; 30(4):371-

6. 

 73. Maeda K, Okamoto N, Nishimoto M et al. A 

multicenter study of the effects of vitamin B12 on 

sleep-waking rhythm disorders: In Shizuoka 

Prefecture. Jpn J Psychiatry Neurol 1992; 

46(1):229-30. 

 74. Mamelak M, Csima A, Price V. Effects of 

brotizolam on the sleep of chronic insomniacs. Br 

JClin Pharmacol 1983; 16(Suppl 2):S377-82. 

 75. Mamelak M, Scima A, Price V. Effects of zopiclone 

on the sleep of chronic insomniacs. Int 

Pharmacopsychiatry 1982; 17(Suppl 2):156-64. 

 76. Manfredi RL, Kales A, Vgontzas AN et al. 

Buspirone: Sedative or stimulant effect? Am J 

Psychiatry 1991; 148(9):1213-7. 

 77. McClusky HY. Milby JB. Switzer PK. Williams V. 

Wooten V. Efficacy of behavioral versus triazolam 

treatment in persistent sleep-onset insomnia. Am J 

Psychiatry 1991; 148(1):121-6. 

 78. Mendelson WB. Subjective vs objective tolerance 

during long term administration of triazolam. Clin 

Drug Invest 1995; 10(5):276-9. 

 79. Mendelson WB, Garnett D, Gillin JC. Flurazepaminduced sleep apnea syndrome in a patient with 

insomnia and mild sleep-related respiratory 

changes. J Nerv Ment Dis 1981; 169(4):261-4. 

 80. Mendelson WB, Martin JV, Stephens H et al. 

Effects of flurazepam on sleep, arousal threshold, 

and the perception of being asleep. 

Psychopharmacol 1988; 95(2):258-62. 

 81. Mendelson WB, Weingartner H, Greenblatt DJ et 

al. A clinical study of flurazepam. Sleep 1982; 

5(4):350-60. 

 82. Mimeault V, Morin CM. Self-help treatment for 

insomnia: bibliotherapy with and without 

professional guidance. J Consult Clin Psychol 1999; 

67(4):511-9. 

 83. Monaco V, Bonfante A. Long-term use of 

doxefazepam, a new hypnotic benzodiazepine. Curr 

Ther Res 1985; 37(4):626-47. 

 84. Monti JM. Effect of zolpidem on sleep in insomniac 

patients. Eur J Clin Pharmacol 1989; 36(5):461-6. 

 85. Monti JM, Debellis J, Alterwain P et al. Study of 

delta sleep-inducing peptide efficacy in improving 

sleep on short-term administration to chronic 

insomniacs. Int J Clin Pharmacol Res 1987; 

7(2):105-10. 

 86. Morawetz D. Behavioral self-help treatment for 

insomnia: A controlled evaluation. Behav Ther 

1989; 20(3):365-79. 

 87. Morgan K, Dixon S, Mathers N et al. Psychological 

treatment for insomnia in the management of longterm hypnotic drug use: a pragmatic randomised 

controlled trial. Br J Gen Pract 2003; 53(497):923-

8. 

 88. Morin CM, Gaulier B, Bary T et al. Patients' 

acceptance of psychological and pharmacological 

therapies for insomnia. Sleep 1992; 15(4):302-5. 

 89. Morin CM, Kowatch RA, Wade JB. Behavioral 

management of sleep disturbances secondary to 

chronic pain. J Behav Ther Exp Psychiatry 1989; 

20(4):295-302. 

 90. Morin CM, Stone J, McDonald K et al. 

Psychological management of insomnia: A clinical 

replication series with 100 patients. Behav Ther 

1994; 25(2):291-309. 

 91. Morin CM, Colecchi CA, Ling WD et al. Cognitive 

behavior therapy to facilitate benzodiazepine 

discontinuation among hypnotic-dependent patients 

with insomnia. Behav Ther 1995; 26(4):733-45. 

 92. Morin CM, Kowatch RA, Barry T et al. Cognitivebehavior therapy for late-life insomnia. J Consult 

Clin Psychol 1993; 61(1):137-46. 

 93. Morishita S, Sonohara M, Murakami H et al. Longterm treatment of brotizolam and zopiclone in 

elderly insomniacs. Kawasaki Med J 2000; 26(1):9-

11. 

 94. Moskowitz H, Linnoila M, Roehrs T. Psychomotor 

performance in chronic insomniacs during 14-day 

use of flurazepam and midazolam. J Clin 

Psychopharmacol 1990; 10(Suppl 4):S44-55. 
E-37

 95. Murphy PJ, Campbell SS. Enhanced performance in 

elderly subjects following bright light treatment of 

sleep maintenance insomnia. J Sleep Res 1996; 

5(3):165-72. 

 96. Nowell PD, Reynolds CF 3rd, Buysse DJ et al. 

Paroxetine in the treatment of primary insomnia: 

preliminary clinical and electroencephalogram sleep 

data. J Clin Psychiatry 1999; 60(2):89-95. 

 97. Parrino L, Spaggiari M, Boselli M et al. Clinical 

and polysomnographic effects of trazodone CR in 

chronic insomnia associated with dysthymia. 

Psychopharmacol 1994; 116(4):389-95. 

 98. Pat-Horenczyk R. Changes in attitudes toward 

insomnia following cognitive intervention as part of 

a withdrawal treatment from hypnotics. Behav 

Cognit Psychother 1998; 26(4):345-57. 

 99. Pecknold J, Wilson R, le Morvan P. Long term 

efficacy and withdrawal of zopiclone: a sleep 

laboratory study. Int Clin Psychopharmacol 1990; 

5(Suppl 2):57-67. 

 100. Peeters K, Boucau M, De Bouyalsky I et al. 

Efficacy and safety of a one-month treatment with 

zolpidem in middle-aged and elderly insomniacs. 

Acta Ther 1997; 23(1-2):5-19. 

 101. Pillitteri JL , Kozlowski LT, Person DC et al. Overthe-counter sleep aids: widely used but rarely 

studied. J Subst Abuse 1994; 6(3):315-23. 

 102. Poirrier R, Franck G, Scheldewaert R et al. The 

effects of long-term zolpidem treatment on 

nocturnal polysomnography and daytime vigilance 

in patients with psychophysiological insomnia. Acta 

Ther 1994; 20(3-4):77-86. 

 103. Puder R, Lacks P, Bertelson AD et al. Short-term 

stimulus control treatment of insomnia in older 

adults. Behav Ther 1983; 14(3):424-9. 

 104. Quadens OP, Hoffman G, Buytaert G. Effects of 

zopiclone as compared to flurazepam on sleep in 

women over 40 years of age. Pharmacol 1983; 

27(Suppl 2):146-55. 

 105. Quesnel C, Savard J, Simard S et al. Efficacy of 

cognitive-behavioral therapy for insomnia in 

women treated for nonmetastatic breast cancer. J 

Consult Clin Psychol 2003; 71(1):189-200. 

 106. Rani PU, Naidu MUR. Subjective and 

polysomnographic evaluation of a herbal 

preparation in insomnia. Phytomed 1998; 5(4):253-

7. 

 107. Relinger H. Treatment of sleep onset insomnia by 

paradoxical instruction. Missoula 

 (MT): University of Montana. 1978. 

 108. Relinger H, Bronstein PH. Treatment of sleep onset 

insomnia by paradoxical instruction: A multiple 

baseline design. Behav Modif 1979; 3(2):203-22. 

 109. Rickels K, Gingrich RL, Morris RJ et al. Triazolam 

in insomniac family practice patients. Clin 

Pharmacol Ther 1975; 18:315-24. 

 110. Riedel BW, Lichstein KL. Strategies for evaluating 

adherence to sleep restriction treatment for 

insomnia. Behav Res Ther 2001; 39(2):201-12. 

 111. Riemann D, Feige B, Hornyak M et al. The 

tryptophan depletion test: Impact on sleep in 

primary insomnia--a pilot study. Psychiatry Res 

2002; 109(2):129-35. 

 112. Roehrs T, Hollebeek E, Drake C et al. Substance 

use for insomnia in metropolitan Detroit. J 

Psychosom Res 2002; 53(1):571-6. 

 113. Roehrs T, Merlotti L, Zorick F et al. Rebound 

insomnia and hypnotic self administration. 

Psychopharmacol 1992; 107(4):480-4. 

 114. Roehrs T, Pedrosi B, Rosenthal L et al. Hypnotic 

self administration and dose escalation. 

Psychopharmacol 1996; 127(2):150-4. 

 115. Romano SJ, Tepner RG, Basson BR. Changes in 

insomnia during the treatment of depression: An 

analysis of double-blind, placebo-controlled trials of 

fluoxetine hydrochloride. Psychiatr Ann 1999; 

29(10):562-7. 

 116. Roth T, Roehrs T, Linnoila M et al. Characteristics 

of chronic insomniacs examined in a multicenter 

14-day study of flurazepam and midazolam. J Clin 

Psychopharmacol 1990; 10(4 Suppl):S24-7. 

 117. Rybarczyk B, Lopez M, Benson R et al. Efficacy of 

two behavioral treatment programs for comorbid 

geriatric insomnia. Psychol Aging 2002; 17(2):288-

98. 

 118. Saletu B, Anderer P, Brandstatter N et al. Insomnia 

in generalized anxiety disorder: polysomnographic, 

psychometric and clinical investigations before, 

during and after therapy with a long- versus a shorthalf-life benzodiazepine (quazepam versus 

triazolam). Neuropsychobiol 1994; 29(2):69-90. 

 119. Saletu B, Salegu-Zyhlarz G. Sleep laboratory 

studies with trazodone in insomnia related to 

depression and dysthymia. Ceska Slov Psychiatr 

2002; 98(7):369-76. 
E-38

 120. Saletu Z, Abu B, Anderer P et al. Insomnia in 

depression: Differences in objective and subjective 

sleep and awakening quality to normal controls and 

acute effects of trazodone. Prog 

NeuroPsychopharmacol Biol Psychiatry 2002; 

26(2):249-60. 

 121. Saletu Z, Abu B, Anderer P et al. Insomnia related 

to dysthymia: Polysomnographic and psychometric 

comparison with normal controls and acute 

therapeutic trials with trazodone. Neuropsychobiol 

2001; 44(3):139-49. 

 122. Scharf MB, Kales A, Bixler EO et al. Lorazepamefficacy, side effects, and rebound phenomena. Clin 

Pharmacol Ther 1982; 31(2):175-9. 

 123. Scharf MBa, Mendels J, Thorpy M et al. Safety of 

long-term zolpidem treatment in patients with 

insomnia. Curr Ther Res 1994; 55(9):1100-11. 

 124. Schneider H. Interval therapy with L tryptophan in 

severe chronic insomniacs A predictive laboratory 

study. Int Pharmacopsychiatry 1981; 16(3):162-73. 

 125. Schoicket SL, Bertelson AD, Lacks P. Is sleep 

hygiene a sufficient treatment for sleepmaintenance insomnia? Behav Ther 1988; 

19(2):183-90. 

 126. Scholz OB, Ott R. Effect and course of tape-based 

hypnotherapy in subjects suffering from insomnia. 

Aust J Clin Hypnoth Hypnosis 2000; 21(2 ):96-114. 

 127. Schramm E, Hohagen F, Backhaus J et al. 

Effectiveness of a multicomponent group treatment 

for insomnia. Behav Cognit Psychother 1995; 

23(2):109-27. 

 128. Shealy R, Lowe J, Ritzler B. Sleep onset insomnia: 

Personality characteristics and treatment outcomes. 

J Consult Clin Psychol 1980; 48(5):659-61. 

 129. Simeit R, Deck R, Conta-Marx B. Sleep 

management training for cancer patients with 

insomia. Support Care Cancer 2004; 12(3):176-83. 

 130. Smirne S, et al. Intermediate-term hypnotic efficacy 

of doxefazepam: A sleep laboratory study in 

insomniacs. Curr Ther Res 1985; 37(4):648-57. 

 131. Spence DW, Kayumov L, Chen A et al. 

Acupuncture increases nocturnal melatonin 

secretion and reduces insomnia and anxiety: a 

preliminary report. J Neuropsychiatry Clin Neurosci 

2004; 16(1):19-28. 

 132. Spielman AJ, Saskin P, Thorpy MJ. Treatment of 

chronic insomnia by restriction of time in bed. 

Sleep 1987; 10(1):45-56. 

 133. Spinweber CL. L-tryptophan administered to 

chronic sleep-onset insomniacs: late-appearing 

reduction of sleep latency. Psychopharmacol 1986; 

90(2):151-5. 

 134. Stepanski E, Zorick F, Roehrs T et al. Effects of 

sleep deprivation on daytime sleepiness in primary 

insomnia. Sleep 2000; 23(2):215-9. 

 135. Strom L, Pettersson R, Andersson G. Internet-based 

treatment for insomnia: A controlled evaluation. J 

Consult Clin Psychol 2004; 72(1):113-20. 

 136. Suen LKP, Wong TKS, Leung AWN. Effectiveness 

of auricular therapy on sleep promotion in the 

elderly. Am J Chin Med 2002; 30(4):429-49. 

 137. Suen LKP, Wong TKS, Leung AWN et al. The 

Long-Term Effects of Auricular Therapy Using 

Magnetic Pearls on Elderly With Insomnia. 

Complement Ther Med 2003; 11(2):85-92. 

 138. Suhner AG, Murphy PJ, Campbell SS. Failure of 

timed bright light exposure to alleviate age-related 

sleep maintenance insomnia. J Am Geriatr Soc 

2002; 50(4):617-23. 

 139. Tan T, Kales J, Kales A et al. Inpatient 

multidimensional management of treatmentresistant insomnia. Psychosom J Consult Liaison 

Psychiatry 1987; 28(5):266-72. 

 140. Thoresen CE, Coates TJ, Kirmil-Gray K et al. 

Behavioral self-management in treating sleepmaintenance insomnia. J Behav Med 1981; 4(1):41-

52. 

 141. Tilleard-Cole RR. A placebo-controlled, doseranging study comparing 0.5 mg, 1 mg and 2 mg 

flunitrazepam in out-patients. Curr Med Res Opin 

1983; 8(8):543-6. 

 142. Timotijevic I , Tasic A, Vezmar M et al. 

Brotizolame (Lendormin) in treatment of insomnia 

and anxious-depressive disorders. Psihijatr Danas 

1997; 29(1-2):61-77. 

 143. Turner RM, Ascher LM. A within-subject analysis 

of stimulus control therapy with severe sleep-onset 

insomnia. Behav Res Ther 1979; 17(2):107-12. 

 144. Turner RM, Ascher LM. Therapist factor in the 

treatment of insomnia. Behav Res Ther 1982; 

20(1):33-40. 

 145. Verbeek I, Schreuder K, Declerck G. Evaluation of 

short-term nonpharmacological treatment of 

insomnia in a clinical setting. J Psychosom Res 

1999; 47(4):369-83. 
E-39

 146. Vermeeren A, O'Hanlon JF, Declerck AC et al. 

Acute effects of zolpidem and flunitrazepam on 

sleep, memory and driving performance, compared 

to those of partial sleep deprivation and placebo. 

Acta Ther 1995; 21(1):47-64. 

 147. Vgontzas AN, Kales Aa, Bixler EO et al. 

Temazepam 7.5 mg: Effects on sleep in elderly 

insomniacs. Eur J Clin Pharmacol 1994; 46(3):209-

13. 

 148. Viens M, De Koninck J, Mercier P et al. Trait 

anxiety and sleep-onset insomnia: evaluation of 

treatment using anxiety management training. J 

Psychosom Res 2003; 54(1):31-7. 

 149. Vincent N, Lionberg C. Treatment preference and 

patient satisfaction in chronic insomnia. Sleep 2001; 

24(4):411-17. 

 150. Vogel GW. Sleep laboratory study of lormetazepam 

in older insomniacs. Psychopharmacol 1984;(Suppl 

1):69-78. 

 151. Vogel GW, Morris D. The effects of estazolam on 

sleep, performance, and memory: a long-term sleep 

laboratory study of elderly insomniacs. J Clin 

Pharmacol 1992; 32(7):647-51. 

 152. Walsh JK, Schweitzer PK. Ten-year trends in the 

pharmacological treatment of insomnia. Sleep 1999; 

22(3):371-5. 

 153. Walsh J, Schweitzer P, Parwatikar S. Effects of 

lorazepam and its withdrawal on sleep performance 

and subjective state. Clin Pharmacol Ther 1983; 

34(4):496-500. 

 154. Webb M, Kirker JG. Severe post-traumatic 

insomnia treated with L-5-hydroxytryptophan. 

Lancet 1981; 1(8234):1365-6. 

 155. Wheatley D. Kava and valerian in the treatment of 

stress-induced insomnia. Phytother Res 2001; 

15(6):549-51. 

 156. Wheatley D. Stress-induced insomnia treated with 

kava and valerian: Singly and in combination. Hum 

Psychopharmacol 2001; 16(4):353-6. 

 157. Wolsko PM, Eisenberg DM, Davis RB et al. Use of 

mind-body medical therapies. J Gen Int Med 2004; 

19(1):43-50. 

 158. Woolfolk RL, McNulty TF. Relaxation treatment 

for insomnia: a component analysis. J Consult Clin 

Psychol 1983; 51(4):495-503. 

 159. Wu R, Zhang C, Deng J et al. Comparison between 

cognitive-behavior therapy and medication on 

chronic insomnia. [Chinese]. [References]. Chin 

Ment Health J 2002; 16(10):677-80. 

 160. Zung WW, Wilson WP. The treatment of insomnia 

with antidepressant drugs. Psychophysiol 1968; 

5(2):234-5. 
E-40

Excluded - Design (No Placebo Arm) 

The following studies were excluded because they did not have a placebo arm. 

 1. Agnoli A, Manna V, Martucci N. Double blind study 

on the hypnotic and anti-anxiety effects of zopiclone 

compared with nitrazepam in the treatment of 

insomnia. Int J Clin Pharmacol Res 1989; 9(4):277-81. 

 2. Allen R, Mendels J, Nevins D et al. Efficacy without 

tolerance or rebound insomnia for midazolam and 

temazepam after use for one to three months. J Clin 

Pharmacol 1987; 27(10):768-75. 

 3. Bliwise D, Seidel W, Karacan I et al. Daytime 

sleepiness as a criterion in hypnotic medication trials: 

Comparison of triazolam and flurazepam. Sleep 1983; 

6(2):156-63. 

 4. Blumenthal M, Byring R, Koivula K. Comparison of 

nitrazepam 5 mg with triazolam 0.5 mg in young 

psychiatric insomniac inpatients: Double-blind single 

night cross-over study. Acta Psychiatr Scand 1980; 

62(5):519-24. 

 5. Chaudoir PJ, Bodkin NL, O'Donnell J et al. A 

comparative study of zopiclone and triazolam in 

patients with insomnia. Int Clin Psychopharmacol 

1990; 5(Suppl 2):21-7. 

 6. Cluydts R, Peeters K, De Bouyalsky I et al. 

Comparison of continuous versus intermittent 

administration of zolpidem in chronic insomniacs: A 

double-blind, randomized pilot study. J Int Med Res 

1998; 26(13-24). 

 7. Cluydts R, Peeters K, De Bouyalsky I et al. A pilot, 

randomized, double-blind study of zolpidem 10 mg 

comparing intermittent versus continuous 

administration. Proceedings of the Sixth World 

Congress of Biological Psychiatry; 1997 Jun 22-27; 

Nice, France. Biol Psychiatry 1997; 42(1 Suppl):S1-

316. 

 8. Currie SR, Clark S, Hodgins DC et al. Randomized 

controlled trial of brief cognitive-behavioural 

interventions for insomnia in recovering alcoholics. 

Addiction 2004; 99(9):1121-32. 

 9. Dehlin O, Bengtsson C, Rubin B. Comparison of 

zopiclone and propiomazine as hypnotics in 

outpatients: multicenter, double blind, randomized, 

parallel group comparison of zopiclone and 

propiomazine in insomniacs. Curr Med Res Opin 

1997; 13(10):565-72. 

 

10. Dehlin O, Rubin B, Rundgren A. Double-blind 

comparison of zopiclone and flunitrazepam in elderly 

insomniacs with special focus on residual effects. Curr 

Med Res Opin 1995; 13(6):317-24. 

11. Dehlin O, Rundgren A, Borjesson L et al. Zopiclone to 

geriatric patients. A parallel double-blind doseresponse clinical trial of zopiclone as a hypnotic to 

geriatric patients - a study in a geriatric hospital. 

Pharmacol 1983; 27(Suppl 2):173-8. 

12. Dordain G, Puech AJ, Simon P. Triazolam compared 

with nitrazepam and with oxazepam in insomnia: two 

double-blind, crossover studies analyzed sequentially. 

Br J Clin Pharmacol 1981; 11(Suppl 1):S43-9. 

13. Dorn M. Wirksamkeit und Vertraglichkeit von 

Baldrian versus Oxazepam bei Nichtorganischen und 

nichtpsychiatrischen Insomnien: Eine randomisierte, 

doppelblinde, klinische Vergleichsstudie (Germ). 

Forsch Komplementarmed Klass Naturheilkd 2000; 

7(2):79-84. 

14. Fabre LF Jr, Gross L, Pasigajen V et al. Multiclinic 

double-blind comparison of triazolam and flurazepam 

for seven nights in outpatients with insomnia. J Clin 

Pharmacol 1977; 17(7):402-9. 

15. Feighner JP, Brown SL, Olivier JE. Electrosleep 

therapy. A controlled double blind study. J Nerv Ment 

Dis 1973; 157(2):121-8. 

16. Fleming JA, McClure DJ, Mayes C et al. A 

comparison of the efficacy, safety and withdrawal 

effects of zopiclone and triazolam in the treatment of 

insomnia. Int Clin Psychopharmacol 1990; 5(Suppl 

2):29-37. 

17. Frattola L, Maggioni M, Cesana B et al. Double blind 

comparison of zolpidem 20 mg versus flunitrazepam 2 

mg in insomniac inpatients. Drugs Exp Clin Res 1990; 

16(7):371-6. 

18. Fritz OA, Arias OJL, Dorantes JF et al. Brotizolam 

and chronic insomnia: A multi-centre study. Br J Clin 

Pharmacol 1983; 16(Suppl 2):S413-414. 

19. Hajak G, Cluydts R, Declerck A et al. Continuous 

versus non-nightly use of zolpidem in chronic 

insomnia: results of a large-scale, double-blind, 

randomized, outpatient study.[erratum appears in Int 

Clin Psychopharmacol 2002 Jul;17(4):206]. Int Clin 

Psychopharmacol 2002; 17(1):9-17. 

 
E-41

20. Herrera-Arellano A, Luna-Villegas G, CuevasUriostegui M et al. Polysomnographic evaluation of 

the hypnotic effect of Valeriana edulis standardized 

extract in patients suffering from insomnia. Planta 

Med 2001; 67(8):695-9. 

21. Jovanovic UJ , Dreyfus JF. Polygraphical sleep 

recordings in insomniac patients under zopiclone or 

nitrazepam. Pharmacol 1983; 27(Suppl 2):136-45. 

22. Kales A, Bixler EO, Vela-Bueno A et al. Comparison 

of short and long half-life benzodiazepine hypnotics: 

triazolam and quazepam. Clin Pharmacol Ther 1986; 

40(4):378-86. 

23. Kales A, Soldatos C, Bixler E et al. Midazolam dose 

response studies of effectiveness and rebound 

insomnia. Pharmacol Basel. 1983; 26(3):138-49. 

24. Kellner R, Silverberg L, Bennett J et al. First night 

effects of triazolam in insomnia. Curr Ther Res 1985; 

37:619-25. 

25. Klimm HD, Dreyfus JF, Delmotte M. Zopiclone 

versus nitrazepam: a double-blind comparative study 

of efficacy and tolerance in elderly patients with 

chronic insomnia. Sleep 1987; 10(Suppl 1):73-8. 

26. Krakow B, Melendrez D, Sisley BN et al. A 

randomized controlled trial of nasal dilator strip 

therapy for sleep maintenance insomnia. Sleep 2003; 

26:A303. 

27. Leibowitz M, Sunshine A. Long term hypnotic 

efficacy and safety of triazolam and flurazepam. J Clin 

Pharmacol 1978; 18:302-9. 

28. Linet OI, Rudzik AD. Comparison of triazolam and 

methyprylon as a hypnotic in insomniacs. 

Psychopharmacol Commun 1975; 15(473-80). 

29. Lomen P, Linet OI. Hypnotic efficacy of triazolam 

and methyprylon ininsomniac in-patients. J Int Med 

Res 1976; 4(1):55-8. 

30. Lorizio A, Terzano MG, Parrino L et al. Zolpidem: A 

double-blind comparison of the hypnotic activity and 

safety of a 10-mg versus 20-mg dose. Curr Ther Res 

Clin Exp 1990; 47(5):889-98. 

31. Mamelak M, Csima A, Price V. Comparative 25 night 

sleep laboratory study on the effects of quazepam and 

triazolam on chronic insomniacs. J Clin Pharmacol 

1984; 24:65-75. 

32. Mauri MC, Gianetti S, Pugnetti L et al. Quazepam 

versus triazolam in patients with sleep disorders: A 

double-blind study. Int J Clin Pharmacol Res 1993; 

13(3):173-7. 

33. McClure DJ, Walsh J, Chang H et al. Comparison of 

lorazepam and flurazepam as hypnotic agents in 

chronic insomniacs. J Clin Pharmacol 1988; 28(1):52-

63. 

34. Melo de Paula AJ. Comparative study of zopiclone 

and pentobarbitone as hypnotics. Int 

Pharmacopsychiatry 1982; 17(Suppl 2):188-95. 

35. Mouret J, Ruel D, Maillard F et al. Zopiclone versus 

triazolam in insomniac geriatric patients: a specific 

increase in delta sleep with zopiclone. Int Clin 

Psychopharmacol 1990; 5(Suppl 2):47-55. 

36. Richards HH, Valle-Jones CJ. A double-blind 

comparison of two lormetazepam doses in elderly 

insomniacs. Curr Med Res Opin 1988; 11(1):48-55. 

37. Roehrs T, Bonahoom A, Pedrosi B et al. Nighttime 

versus daytime hypnotic self-administration. 

Psychopharmacol 2002; 161( 2):137-42. 

38. Saletu B, Saletu-Zyhlarz G, Anderer P et al. 

Nonorganic insomnia in generalized anxiety disorder. 

2. Comparative studies on sleep, awakening, daytime 

vigilance and anxiety under lorazepam plus 

diphenhydramine (Somnium) versus lorazepam alone, 

utilizing clinical, polysomnographic and EEG 

mapping methods. Neuropsychobiol 1997; 36(3):130-

52. 

39. Scharf M, Sachais B, Mayleben D et al. A 

polysomnographic comparison of temazepam 15 and 

30 mg with triazolam 0.125 and 0.25 mg in chronic 

insomnia. Curr Ther Res 1990; 48(3):555-67. 

40. Singh AN, Bourgouin J. Comparison of zopiclone and 

flurazepam treatments in insomnia. Hum 

Psychopharmacol 1990; 5(3):217-23. 

41. Smirne S, Cassano GB, Ferrillo F et al. Brotizolam 

versus triazolam for the treatment of insomnia in 

anxious patients. Curr Ther Res Clin Exp 1993; 

53(1):9-17. 

42. Tamminen T, Hansen PP. Chronic administration of 

zopiclone and nitrazepam in the treatment of 

insomnia. Sleep 1987; 10(Suppl 1):63-72. 

43. Tsutsui S. A double-blind comparative study of 

zolpidem versus zopiclone in the treatment of chronic 

primary insomnia. J Int Med Res 2001; 29(3):163-77. 

44. Venter CP, Joubert PH, Stahmer SD et al. Zopiclone 

compared with triazolam in insomnia in geriatric 

patients. Curr Ther Res 1986; 40:1062-8. 

45. Vogel GW, Vogel F. Effect of midazolam on sleep of 

insomniacs. Br J Clin Pharmacol 1983; 16(Suppl 

1):S103-108. 
E-42

46. Voshaar RCO, Van Balkom A, Zitman FG. Zolpidem 

Is Not Superior to Temazeparn With Respect to 

Rebound Insomnia: a Controlled Study. Eur 

Neuropsychopharmacol 2004; 14(4):301-6. 

47. Wheatley D. Brotizolam: a new short-acting hypnotic. 

Int Clin Psychopharmacol 1986; 1(1):36-44. 

48. Ziegler G, Ploch M, Miettinen-Baumann A et al. 

Efficacy and tolerability of valerian extract Li 156 

compared with oxazepam in the treatment of nonorganic insomnia - a randomized, double-blind, 

comparative clinical study . Eur J Med Res 2002; 

7(11):480-6. 

Excluded - Design (Not Double-Blind) 

The following studies were excluded because they were not double-blind. 

 1. Bliwise D, Seidel W, Greenblatt DJ et al. Nighttime 

and daytime efficacy of flurazepam and oxazepam in 

chronic insomnia. Am J Psychiatry 1984; 141(2):191-

5. 

 2. Bonnet MH, Arand DL. The use of lorazepam TID for 

chronic insomnia. Int Clin Psychopharmacol 1999; 

14(2):81-9. 

 3. Brown WT. A comparative study of three hypnotics: 

methyprylon, glutethimide and chloral hydrate. Can 

Med Assoc J 1970; 102(5):510-1. 

 4. Chen HC, Hsieh MT. Clinical trial of suanzaorentang 

in the treatment of insomnia. Clin Ther 1985; 

7(3):334-7. 

 5. Hedner J, Emilien G, Salinas E. Zaleplon reduces 

sleep latency and improves sleep quality in elderly 

patients with primary insomnia. No pub Proceedings 

of the XXIst Collegium Internationale Neuropsychopharmacologicum; 1987 Jul 12-16; Glasgow, 

Scotland. 1998;( ):S212-3. 

 6. Johnson LC, Chernik DA, Hauri P. A multicenter 14-

day study of flurazepam and midazolam in chronic 

insomniacs: general discussion and conclusions. J Clin 

Psychopharmacol 1990; 10(4 Suppl):76S-90S. 

 7. Judd L, Ellinwood E, McAdams L. Cognitive 

performance and mood in patients with chronic 

insomnia during 14-day use of flurazepam and 

midazolam. J Clin Psychopharmacol 1990; 10(4 

Suppl):S56-67. 

 8. Kales A, Kales JD, Bixler EO et al. Effectiveness of 

hypnotic drugs with prolonged use: flurazepam and 

pentobarbital. Clin Pharmacol Ther 1975; 18(3):356-

63. 

 9. Kripke D, Hauri P, Ancoli I et al. Sleep evaluation in 

chronic insomniacs during 14-day use of flurazepam 

and midazolam. J Clin Psychopharmacol 1990; 10(4 

Suppl):S32-43. 

10. Mitler MM, Carskadon MA, Phillips RL et al. 

Hypnotic efficacy of temazepam: a long-term sleep 

laboratory evaluation. Br J Clin Pharmacol 1979; 8 

(1):S63-8. 

11. Morin CM, Bastien CH, Brink D et al. Adverse effects 

of temazepam in older adults with chronic insomnia. 

Hum Psychopharmacol Clin Exp 2003; 18(1):75-82. 

12. Roehrs T, Bonahoom A, Pedrosi B et al. Treatment 

regimen and hypnotic self-administration. 

Psychopharmacol 2001; 155( 1):11-17. 

13. Saletu ZGM, Anderer P, Berger P et al. Nonorganic 

insomnia in panic disorder: Comparative sleep 

laboratory studies with normal controls and placebocontrolled trials with alprazolam. Hum 

Psychopharmacol 2000; 15(4):241-54. 

14. Saletu-ZG, Anderer P, Brandstatter N et al. Placebocontrolled sleep laboratory studies on the acute effects 

of zolpidem on objective and subjective sleep and 

awakening quality in nonorganic insomnia related to 

neurotic and stress-related disorder. Neuropsychobiol 

2000; 41(3):139-48. 

15. Sateia MJ, Hauri P, Kripke D et al. Clinical safety of 

flurazepam and midazolam during 14-day use in 

chronic insomniacs. J Clin Psychopharmacol 1990; 

10(Suppl 4):S28-31. 
E-43

Excluded - Outcomes (Irrelevance) 

The following studies were excluded because they did not report on any outcomes of this 

review. 

 1. Baillargeon L, Landreville P, Verreault R et al. 

Discontinuation of benzodiazepines among older 

insomniac adults treated with cognitive-behavioural 

therapy combined with gradual tapering: A 

randomized trial. Can Med Assoc J 2003; 

169(10):1015-20. 

 2. Bliwise D, Seidel W, Cohen S et al. Profile of mood 

states changes during and after 5 weeks of nightly 

triazolam administration. J Clin Psychiatry 1988; 

49(9):349-55. 

 3. Bonnet MH. Recovery of performance during sleep 

following sleep deprivation in older normal and 

insomniac adult males. Percept Mot Skills 1985; 

60(1):323-34. 

 4. Chernik D, Johnson L, Kanitra L. Sleep performance 

and plasma levels in chronic insomniacs during 14-

day use of flurazepam and midazolam methodology. J 

Clin Psychopharmacol 1990; 10(4 Suppl):S10-19. 

 5. Dement W. Objective measurements of daytime 

sleepiness and performance comparing Quazepam 

with Flurazepam in two adult populations using the 

multiple sleep latency test. J Clin Psychiatry 1991; 

52(Suppl):31-7. 

 6. Demisch K, Bauer J, Georgi K. Treatment of severe 

chronic insomnia with L-tryptophan and varying 

sleeping times. Pharmacopsychiatry 1987; 20(6):245-

8. 

 7. Hajak G, Clarenbach P, Fischer W et al. Rebound 

insomnia after hypnotic withdrawal in insomniac 

outpatients. Eur Arch Psychiatry Clin Neurosci 1998; 

248(3):148-56. 

 8. Johnson LC, Chernik DA, Sateia MJ. Sleep, 

performance, and plasma levels in chronic insomniacs 

during 14-day use of flurazepam and midazolam: an 

introduction. J Clin Psychopharmacol 1990; 10(4 

Suppl):S5-9. 

 9. Kales A, Scharf MB, Kales JD et al. Rebound 

insomnia. A potential hazard following withdrawal of 

certain benzodiazepines. J Am Med Assoc 1979; 

241(16):1692-5. 

10. Lemoine P, Allain H, Janus C et al. Gradual 

withdrawal of zopiclone (7.5 mg) and zolpidem (10 

mg) in insomniacs treated for at least 3 months. Eur 

Psychiatry 1995; 10(Suppl 3):S161-5. 

11. Lushington K, Pollard K, Lack L et al. Daytime 

melatonin administration in elderly good and poor 

sleepers: effects on core body temperature and sleep 

latency. Sleep 1997; 20(12):1135-44. 

12. Morin CM, Azrin NH. Stimulus control and imagery 

training in treating sleep-maintenance insomnia. J 

Consult Clin Psychol 1987; 55(2):260-2. 

13. Morin CM, Bastien C, Guay B et al. Randomized 

Clinical Trial of Supervised Tapering and Cognitive 

Behavior Therapy to Facilitate Benzodiazepine 

Discontinuation in Older Adults With Chronic 

Insomnia. Am J Psychiatry 2004; 161(2):332-42. 

14. Morin CM, Blais F, Savard J. Are changes in beliefs 

and attitudes about sleep related to sleep 

improvements in the treatment of insomnia? Behav 

Res Ther 2002; 40(7):741-52. 

15. Nakra BR, Gfeller JD, Hassan R. A double-blind 

comparison of the effects of temazepam and triazolam 

on residual, daytime performance in elderly 

insomniacs. Int Psychogeriatr 1992; 4(1 ):45-53. 

16. Nelson J, Harvey AG. The differential functions of 

imagery and verbal thought in insomnia. J Abnorm 

Psychol 2002; 111(4):665-9. 

17. Poyares D, Guilleminault C, Ohayon MM et al. 

Chronic benzodiazepine usage and withdrawal in 

insomnia patients. J Psychiatr Res 2004; 38(3):327-34. 

18. Scharf MB, Fletcher K, Graham JP. Comparative 

amnestic effects of benzodiazepine hyponotic agents. J 

Clin Psychiatry 1988; 49(4):134-7. 
E-44

Excluded - Outcomes (Inadequate Reporting) 

The following study was excluded because data relevant to the outcomes of interest were 

inadequately reported. 

 1. Chen D, Chernik DA, Ellinwood E et al. A multicenter 

study of sleep, performance, and plasma levels in 

chronic insomniacs during 14-day use of flurazepam 

and midazolam: executive summary. J Clin 

Psychopharmacol 1990; 10(4 Suppl):S3-4. 

 2. Dominguez RA, Goldstein BJ, Jacobson AF et al. 

Hypnotic efficacy of a modified triazolodiazepine, 

brotizolam. Clin Pharmacol Ther 1985; 37:674-9. 

 3. Ebrahim IO, Fisher JP, De Lacy S et al. A Prospective, 

Randomized, Study Comparing Cognitive Behaviour 

Therapy, Pharmacologic Treatment and Combination 

Therapy in Non-Elderly Patients With Primary 

Insomnia. Sleep 2003; 26:A301-A302. 

 4. Elie R, Deschenes JP. Efficacy and tolerance of 

zopiclone in insomniac geriatric patients. Rev Geriatr 

1994; 19(1):45-50. 

 5. Elie R, Lavoie G, Bourgouin J et al. Zopiclone versus 

flurazepam in insomnia: prolonged administration and 

withdrawal. Int Clin Psychopharmacol 1990; 54(279-

86). 

 6. Guilleminault C , Palombini L, Poyares D et al. 

Chronic insomnia, premenopausal women and sleep 

disordered breathing - Part 2. Comparison of nondrug 

treatment trials in normal breathing and UARS post 

menopausal women complaining of chronic insomnia. 

J Psychosom Res 2002; 53(1):617-23. 

 7. Hajak G, Clarenbach P, Fischer W et al. Effects of 

hypnotics on sleep quality and daytime well-being 

data from a comparative multicentre study in 

outpatients with insomnia. Eur Psychiatry 1995; 

10(Suppl 3):S173-9. 

 8. Hindmarch I. Effects of zopiclone on quality of life in 

insomnia. Eur Psychiatry J Assoc Eur Psychiatrists 

1995; 10(Suppl 3):S91-4. 

 9. Johnson RK. Differential treatments for internal and 

external locus of control insomniac clients. Louisville, 

(KY): University of Louisville; 1976. 

10. Ladouceur R, Gros-Louis Y. Paradoxical intention vs 

stimulus control in the treatment of severe insomnia. J 

Behav Ther Exp Psychiatry 1986; 17(4):267-9. 

11. Partinen M, Hirvonen K, Hublin C et al. Effects of 

after-midnight intake of zolpidem and temazepam on 

driving ability in women with non-organic insomnia. 

Sleep Med 2003; 4(6):553-61. 

12. Riedel B, Lichstein K, Peterson BA et al. A 

comparison of the efficacy of stimulus control for 

medicated and nonmedicated insomniacs. Behav 

Modif 1998; 22(1):3-28. 

13. Saletu B. Sleep, vigilance and cognition in 

postmenopausal women: placebo-controlled studies 

with 2 mg estradiol valerate, with and without 3 mg 

dienogest. Climacteric 2003; 6(Suppl 2):37-45. 

14. Sanavio E. Pre-sleep cognitive intrusions and 

treatment of onset-insomnia. Behav Res Ther 1988; 

26(6):451-9. 

15. Seidel WF, Cohen SA, Bliwise NG et al. Buspirone: 

an anxiolytic without sedative effect. 

Psychopharmacol 1985; 87(3):371-3.